

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 September 2002 (06.09.2002)

PCT

(10) International Publication Number
WO 02/068583 A2

- (51) International Patent Classification⁷: C12N [US/US]; 12119 Eleonore Court, San Diego, CA 92131 (US).
- (21) International Application Number: PCT/US01/45337
- (22) International Filing Date: 30 November 2001 (30.11.2001) (74) Agent: HAILE, Lisa, A.; Gary Cary Ware & Friedenrich LLP, Suite 1100, 4365 Executive Drive, San Diego, CA 92121-2133 (US).
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/250,897 1 December 2000 (01.12.2000) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application: US 60/250,897 (CON) Filed on 1 December 2000 (01.12.2000)
- (71) Applicant (for all designated States except US): DIVERSA CORPORATION [US/US]; 4955 Directors Place, San Diego, CA 92121 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SHORT, Jay, M. [US/US]; 6801 Paseo Delicias, Rancho Santa Fe, CA 92067-7214 (US). MATHUR, Eric, J. [US/US]; 2654 Galicia Way, Carlsbad, CA 92009 (US). RICHARDSON, Toby [GB/US]; 11646 Candy Rose Way, San Diego, CA 92131 (US). ROBERTSON, Dan [US/US]; 818 Via Court, Solana Beach, CA 92075 (US). GRAY, Kevin
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/068583 A2

(54) Title: ENZYMES HAVING DEHALOGENASE ACTIVITY AND METHODS OF USE THEREOF

(57) Abstract: The invention relates to haloalkane dehalogenases and to polynucleotides encoding the haloalkane dehalogenases. In addition methods of designing new dehalogenases and method of use thereof are also provided. The dehalogenases have increased activity and stability at increased pH and temperature.

ENZYMES HAVING DEHALOGENASE ACTIVITY AND METHODS OF USE THEREOF

RELATED APPLICATIONS

The present application claims priority to U.S. Serial No. 60/250,897, filed December 1, 2000, now pending, the contents of which are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

This invention relates generally to enzymes, polynucleotides encoding the enzymes, the use of such polynucleotides and polypeptides, and more specifically to enzymes having haloalkane dehalogenase activity.

BACKGROUND

Environmental pollutants consist of a large quantity and variety of chemicals; many of these are toxic, environmental hazards that were designated in 1979 as priority pollutants by the U.S. Environmental Protection Agency. Microbial and enzymatic biodegradation is one method for the elimination of these pollutants. Accordingly, methods have been designed to treat commercial wastes and to bioremediate polluted environments via microbial and related enzymatic processes.

Unfortunately, many chemical pollutants are either resistant to microbial degradation or are toxic to potential microbial-degraders when present in high concentrations and certain combinations.

Haloalkane dehalogenase belongs to the alpha/beta hydrolase fold family in which all of the enzymes share similar topology, reaction mechanisms, and catalytic triad residues (Krooshof *et al.*, Biochemistry **36**(31):9571-9580, 1997). The enzyme cleaves carbon-halogen bonds in haloalkanes and halocarboxylic acids by hydrolysis, thus converting them to their corresponding alcohols. This reaction is important for

detoxification involving haloalkanes such as ethylchloride, methylchloride, and 1,2-dichloroethane, which are considered priority pollutants by the the Environmental Protection Agency (Rozeboom, H., Kingma, J., Janssen, D., Dijkstra, B. Crystallization of Haloalkane Dehalogenase from *Xanthobacter autotrophicus* GJ10 J Mol Biol 200 (3), 611-612 (1988)).

The haloalkane dehalogenases are produced by microorganisms that can grow entirely on chlorinated aliphatic compounds. No metal or oxygen is needed for activity: water is the sole substrate.

Xanthobacter autotrophicus GJ10 is a nitrogen-fixing bacteria that utilizes 1,2-dichloroethane and a few other haloalkane and halocarboxylic acids for growth (Rozeboom *et al.*, J Mol Biol 200 3:611-612, 1988; Keuning *et al.*, J Bacteriol 163(2):635-639, 1985). It is the most well-studied dehalogenase because it has a known catalytic reaction mechanism, activity mechanism and crystal-structure (Schanstra *et al.*, J Biol Chem 271(25):14747-14753, 1996).

The organism produces two different dehalogenases. One dehalogenase is for halogenated alkanes and the other for halogenated carboxylic acids. Most harmful halogenated compounds are industrially produced for use as cleaning agents, pesticides, and solvents. The natural substrate of *Xanthobacter autotrophicus* is 1,2-dichloroethane. This haloalkane is often used in vinyl production.

Enzymes are highly selective catalysts. Their hallmark is the ability to catalyze reactions with exquisite stereo-, regio-, and chemo-selectivities that are unparalleled in conventional synthetic chemistry. Moreover, enzymes are remarkably versatile. They can be tailored to function in organic solvents, operate at extreme pH's and temperatures, and catalyze reactions with compounds that are structurally unrelated to their natural, physiological substrates

Enzymes are reactive toward a wide range of natural and unnatural substrates, thus enabling the modification of virtually any organic lead compound. Moreover, unlike traditional chemical catalysts, enzymes are highly enantio- and

regio-selective. The high degree of functional group specificity exhibited by enzymes enables one to keep track of each reaction in a synthetic sequence leading to a new active compound. Enzymes are also capable of catalyzing many diverse reactions unrelated to their physiological function in nature. For example, peroxidases catalyze the oxidation of phenols by hydrogen peroxide. Peroxidases can also catalyze hydroxylation reactions that are not related to the native function of the enzyme. Other examples are proteases which catalyze the breakdown of polypeptides. In organic solution some proteases can also acylate sugars, a function unrelated to the native function of these enzymes.

The present invention exploits the unique catalytic properties of enzymes. Whereas the use of biocatalysts (i.e., purified or crude enzymes, non-living or living cells) in chemical transformations normally requires the identification of a particular biocatalyst that reacts with a specific starting compound, the present invention uses selected biocatalysts and reaction conditions that are specific for functional groups that are present in many starting compounds.

Each biocatalyst is specific for one functional group, or several related functional groups, and can react with many starting compounds containing this functional group.

The biocatalytic reactions produce a population of derivatives from a single starting compound. These derivatives can be subjected to another round of biocatalytic reactions to produce a second population of derivative compounds. Thousands of variations of the original compound can be produced with each iteration of biocatalytic derivatization.

Enzymes react at specific sites of a starting compound without affecting the rest of the molecule, a process which is very difficult to achieve using traditional chemical methods. This high degree of biocatalytic specificity provides the means to identify a single active compound within the library. The library is characterized by the series of biocatalytic reactions used to produce it, a so called "biosynthetic history". Screening the library for biological activities and tracing the biosynthetic

history identifies the specific reaction sequence producing the active compound. The reaction sequence is repeated and the structure of the synthesized compound determined. This mode of identification, unlike other synthesis and screening approaches, does not require immobilization technologies, and compounds can be synthesized and tested free in solution using virtually any type of screening assay. It is important to note, that the high degree of specificity of enzyme reactions on functional groups allows for the "tracking" of specific enzymatic reactions that make up the biocatalytically produced library.

Many of the procedural steps are performed using robotic automation enabling the execution of many thousands of biocatalytic reactions and screening assays per day as well as ensuring a high level of accuracy and reproducibility. As a result, a library of derivative compounds can be produced in a matter of weeks which would take years to produce using current chemical methods. (For further teachings on modification of molecules, including small molecules, *See* PCT/US94/09174, herein incorporated by reference in its entirety).

The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

SUMMARY OF THE INVENTION

The invention provides an isolated nucleic acid having a sequence as set forth in SEQ ID NO.: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 43, 45, 47 and variants thereof having at least 50% sequence identity to SEQ ID NO.: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 43, 45 or 47 and encoding polypeptides having dehalogenase activity.

One aspect of the invention is an isolated nucleic acid having a sequence as set forth in SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35,

37, 43, 45, 47 (hereinafter referred to as "Group A nucleic acid sequences"), sequences substantially identical thereto, and sequences complementary thereto.

Another aspect of the invention is an isolated nucleic acid including at least 10 consecutive bases of a sequence as set forth in Group A nucleic acid sequences, sequences substantially identical thereto, and the sequences complementary thereto.

In yet another aspect, the invention provides an isolated nucleic acid encoding a polypeptide having a sequence as set forth in SEQ ID NO.: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48 and variants thereof encoding a polypeptide having dehalogenase activity and having at least 50% sequence identity to such sequences.

Another aspect of the invention is an isolated nucleic acid encoding a polypeptide or a functional fragment thereof having a sequence as set forth in SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48 (hereinafter referred to as "Group B amino acid sequences"), and sequences substantially identical thereto.

Another aspect of the invention is an isolated nucleic acid encoding a polypeptide having at least 10 consecutive amino acids of a sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto.

In yet another aspect, the invention provides a purified polypeptide having a sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto.

Another aspect of the invention is an isolated or purified antibody that specifically binds to a polypeptide having a sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto.

Another aspect of the invention is an isolated or purified antibody or binding fragment thereof, which specifically binds to a polypeptide having at least 10

consecutive amino acids of one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto.

Another aspect of the invention is a method of making a polypeptide having a sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto. The method includes introducing a nucleic acid encoding the polypeptide into a host cell, wherein the nucleic acid is operably linked to a promoter, and culturing the host cell under conditions that allow expression of the nucleic acid.

Another aspect of the invention is a method of making a polypeptide having at least 10 amino acids of a sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto. The method includes introducing a nucleic acid encoding the polypeptide into a host cell, wherein the nucleic acid is operably linked to a promoter, and culturing the host cell under conditions that allow expression of the nucleic acid, thereby producing the polypeptide.

Another aspect of the invention is a method of generating a variant including obtaining a nucleic acid having a sequence as set forth in Group A nucleic acid sequences, sequences substantially identical thereto, sequences complementary to the sequences of Group A nucleic acid sequences, fragments comprising at least 30 consecutive nucleotides of the foregoing sequences, and changing one or more nucleotides in the sequence to another nucleotide, deleting one or more nucleotides in the sequence, or adding one or more nucleotides to the sequence.

Another aspect of the invention is a computer readable medium having stored thereon a sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto.

Another aspect of the invention is a computer system including a processor and a data storage device wherein the data storage device has stored thereon a

sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide having a sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto.

Another aspect of the invention is a method for comparing a first sequence to a reference sequence wherein the first sequence is a nucleic acid having a sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide code of Group B amino acid sequences, and sequences substantially identical thereto. The method includes reading the first sequence and the reference sequence through use of a computer program which compares sequences; and determining differences between the first sequence and the reference sequence with the computer program.

Another aspect of the invention is a method for identifying a feature in a sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide having a sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, including reading the sequence through the use of a computer program which identifies features in sequences; and identifying features in the sequence with the computer program.

Another aspect of the invention is an assay for identifying fragments or variants of Group B amino acid sequences, and sequences substantially identical thereto, which retain the enzymatic function of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto. The assay includes contacting the polypeptide of Group B amino acid sequences, sequences substantially identical thereto, or polypeptide fragment or variant with a substrate molecule under conditions which allow the polypeptide fragment or variant to function, and detecting either a decrease in the level of substrate or an increase in the level of the specific reaction product of the reaction between the polypeptide and substrate thereby identifying a fragment or variant of such sequences.

In yet another aspect, the invention provides a method for synthesizing glycerol. The method includes contacting trichloropropane or dichloropropanol with

a polypeptide having at least 70% homology to a sequence selected from the group consisting of Group B amino acid sequences and sequences substantially identical thereto, and having dehalogenase activity, under conditions to synthesize glycerol.

In yet another aspect, the invention provides a method for producing an optically active halolactic acid. The method includes contacting a dihalopropionic acid with a polypeptide having at least 70% homology to a sequence selected from the group consisting of Group B amino acid sequences and sequences substantially identical thereto, and having dehalogenase activity, under conditions to produce optically active halolactic acid.

In yet another aspect, the invention provides a method for bioremediation by contacting an environmental sample with a polypeptide having at least 70% homology to a sequence selected from the group consisting of Group B amino acid sequences and sequences substantially identical thereto, and having dehalogenase activity.

In another aspect, the invention provides a method for removing a halogenated contaminant or halogenated impurity from a sample. The method includes contacting the sample with a polypeptide having at least 70% homology to a sequence selected from the group consisting of Group B amino acid sequences and sequences substantially identical thereto, and having dehalogenase activity.

In yet another aspect, the invention provides a method for synthesizing a diol, by contacting a dihalopropane or monohalopropanol with a polypeptide having at least 70% homology to a sequence selected from the group consisting of Group B amino acid sequences and sequences substantially identical thereto, and having dehalogenase activity, under conditions to synthesize the diol.

In yet another aspect, the invention provides a method for dehalogenating a halo-substituted cyclic hydrocarbyl. The method includes contacting the halo-substituted cyclic hydrocarbyl with a polypeptide having at least 70% homology to a sequence selected from the group consisting of Group B amino acid sequences and

sequences substantially identical thereto, and having dehalogenase activity, under conditions to dehalogenate the halo-substituted cyclic hydrocarbyl.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings are illustrative of embodiments of the invention and are not meant to limit the scope of the invention as encompassed by the claims.

Figure 1 is a block diagram of a computer system.

Figure 2 is a flow diagram illustrating one embodiment of a process for comparing a new nucleotide or protein sequence with a database of sequences in order to determine the homology levels between the new sequence and the sequences in the database.

Figure 3 is a flow diagram illustrating one embodiment of a process in a computer for determining whether two sequences are homologous.

Figure 4 is a flow diagram illustrating one embodiment of an identifier process 300 for detecting the presence of a feature in a sequence.

Figure 5 shows an alignment of the polypeptide sequences of the invention. A=SEQ ID NO:4; B=SEQ ID NO:2; C=SEQ ID NO:6; rhod2=SEQ ID NO:40; myco4=SEQ ID NO:42.

Figure 6 shows sequences of the invention (SEQ ID Nos:9-38 and 43-48)

Figure 7 shows an example of the formation of glycerol using the dehalogenases of the invention as well as the formation of 1,2-propanediol or 1,3-propanediol using the dehalogenases of the invention.

Figure 8 shows an example of the dehalogenation of a halo-substituted cyclic hydrocarbyl using the dehalogenases of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to haloalkane dehalogenase polypeptides and polynucleotides encoding them as well as methods of use of the polynucleotides and polypeptides. As used herein, the terminology "haloalkane dehalogenase" encompasses enzymes having hydrolase activity, for example, enzymes capable of catalyzing the hydrolysis of haloalkanes via an alkyl-enzyme intermediate.

The polynucleotides of the invention have been identified as encoding polypeptides having dehalogenase activity and in particular embodiments haloalkane dehalogenase activity.

The dehalogenases and polynucleotides encoding the dehalogenases of the invention are useful in a number of processes, methods, and compositions. For example, as discussed above, a dehalogenase can be used to remedy an environment contaminated with aliphatic organochlorine, degrade the herbicide dalapon, degrade halogenated organic acids as well as soil and water remediation, and treat by degradation halogenated organic acid in the soil and water. Furthermore, a dehalogenase of the invention can be used to remove impurities in industrial processes, in the environment, and in medicaments. For example, a dehalogenase can be used to decompose haloalkanoic acid impurities in various samples including, for example, surfactants, carboxymethyl cellulose or thioglycolic acid salts. In yet another aspect, the dehalogenases of the invention can be used in the formation of medicines, agrochemical and ferroelectric liquids by allowing oxidative dehalogenation of specific 1,2-diol or racemic halogenohydrins. For example, a dehalogenase can be used in the synthesis of optically active glycidic and lactic acids (e.g., beta halolactic acid) by treating an α , β -dihalopropionic acid (e.g., dichloropropionic acid) with a dehalogenase. The dehalogenases of the invention can also be used in the production of active (S)-(+)-3-halo-1,2-propanediol or (R)-(-)-3-halo-1,2-propanediol from 1,3-dihalo-2-propanol. (S)-(+)-3 halo-1,2-propanediol is useful as a raw material for physiological and medical treatments and medicaments.

For example, a dehalogenase of the invention can be contacted trichloropropanediol (TCP) or dichloropropanediol (DCP) under conditions and for a time sufficient to allow oxidative dehalogenation to form, for example, glycerol (*e.g.*, DCP or TCP to glycerol) (See, for example, Figure 7). Various diols can be produced using the methods of the invention and the enzymes of the invention. In addition, the methods and compositions of the invention can be applied to halogenated aromatic compounds. For example, the compositions of the invention can be used to dehalogenate a halo-substituted cyclic hydrocarbyl as depicted in Figure 8. Examples of cyclic hydrocarbyl compounds include cycloalkyl, cycloalkenyl, cycloalkadienyl, cycloalkatrienyl, cycloalkynyl, cycloalkadiynyl, aromatic compounds, spiro hydrocarbons wherein two rings are joined by a single atom which is the only common member of the two rings (*e.g.*, spiro[3,4]octanyl, and the like), bicyclic hydrocarbons wherein two rings are joined and have at least two atoms in common (*e.g.*, bicyclo[3.2.1]octane, bicyclo[2.2.1]hept-2-ene, and the like), ring assemblies wherein two or more cyclic systems (*i.e.*, single rings or fused systems) are directly joined to each other by single or double bonds, and the number of such ring junctions is one less than the number of cyclic systems involved (*e.g.*, biphenyl, biphenylene, radicals or *p*-terphenyl, cyclohexylbenzyl, and the like), polycyclics, and the like.

Haloalkane Dehalogenase

Overall Structure

Haloalkane dehalogenase from *Xanthobacter autotrophicus* is composed of 310 amino acids and consists of a single polypeptide chain with a molecular weight of 36,000. The monomeric enzyme is spherical and composed of two domains. The main domain has an alpha/beta hydrolase fold structure with a mixed beta sheet of 8 strands order 12435678; strand 2 is antiparallel to the rest. The second domain is an alpha-helical cap which lies on top of the main domain. (Keuning *et al.*, J Bacteriol 163(2):635-639, 1985) As described in further detail herein, mutagenesis have done to

modify the activity of the enzyme, for example, by mutating specific residues of the cap domain (Krooshof et al., *Biochemistry* **36**(31):9571-9580, 1997).

The active site of the enzyme in *Xanthobacter autotrophicus*, consisting of 3 catalytic residues (Asp 124, His 289, and Asp 260), is found between the two domains in an internal hydrophobic cavity. Nucleophilic Asp 124 and the general base His 289, located after beta-strands 5 and 8 respectively, are fully conserved in the alpha/beta hydrolase family, while Asp 260 is not. The active site is lined with 10 hydrophobic residues: 4 phenylalanines; 2 tryptophans; 2 leucines; 1 valine; and 1 proline. (Schanstra et al., *J Biol Chem* **271**(25):14747-14753, 1996).

During enzymatic hydrolysis of a substrate, haloalkane dehalogenase forms a covalent intermediate formed by nucleophilic substitution with Asp124 that is hydrolyzed by a water molecule that is activated by His289. (Verschuere *et al.*, *Nature* **363**(6431):693-698, 1993). The role of Asp260, which is the third member of a catalytic triad common to dehalogenase enzymes, has been studied by site-directed mutagenesis. Mutation of Asp260 to asparagine resulted in a catalytically inactive D260N mutant, which demonstrates that the triad acid Asp260 is essential for dehalogenase activity in the wild-type enzyme. Furthermore, Asp260 has an important structural role, since the D260N enzyme accumulated mainly in inclusion bodies during expression, and neither substrate nor product could bind in the active-site cavity. Activity for brominated substrates was restored to D260N by replacing Asn148 with an aspartic or glutamic acid. Both double mutants D260N+N148D and D260N+N148E had a 10-fold reduced *k_{cat}* and 40-fold higher *K_m* values for 1,2-dibromoethane compared to the wild-type enzyme. Pre-steady-state kinetic analysis of the D260N+N148E double mutant showed that the decrease in *k_{cat}* was mainly caused by a 220-fold reduction of the rate of carbon-bromine bond cleavage and a 10-fold decrease in the rate of hydrolysis of the alkyl-enzyme intermediate. On the other hand, bromide was released 12-fold faster and via a different pathway than in the wild-type enzyme. Molecular modeling of the mutant showed that Glu148 indeed could take over the interaction with His289 and that there was a change in charge

distribution in the tunnel region that connects the active site with the solvent. (Krooshof *et al.*, Biochemistry 36(31):9571-9580, 1997).

The first step in degradation of the harmful halogenated compounds utilizes haloalkane dehalogenase. The dehalogenase catalysis occurs as a two step-mechanism involving an ester intermediate. No energy is required for hydrolytic dehalogenases; therefore, it is a simple way to detoxify organic matter since the halogen, which causes the toxicity, is lost. A catalytic triad (Asp-His-Asp), along with an aspartate carboxylate (Asp 124), are the focal point of the reaction. The substrate binds to the active site cavity and the Cl-alpha complex reacts with the side chain NH groups of Trp 172 and Trp 175. As a first step a halogen from the substrate is displaced by the nucleophilic aspartate, resulting in an intermediate covalent ester. His 289 then activates a water molecule which hydrolyzes the ester. As a result, an alcohol and halide are displaced from the active site. The two step mechanism involving nucleophilic Asp 124 and water hydrolysis of the ester intermediate is consistent with other alpha/beta hydrolase fold enzymes.

Haloalkane dehalogenase breaks carbon-halogen bonds in aliphatic compounds. Results show that the enzyme reaction with C-Cl bond is slower than that of other C-halide bonds, such as C-Br bonds. The ability of the leaving group is the explanation for the difference. The rate limiting step for 1,2-dichloroethane and 1,2-dibromoethane reactions is not the cleavage of the carbon-halogen bond, but rather the ion release out of the active site.

Bioremediation

The present invention provides a number of dehalogenase enzymes useful in bioremediation having improved enzymatic characteristics. The polynucleotides and polynucleotide products of the invention are useful in, for example, groundwater treatment involving transformed host cells containing a polynucleotide or polypeptide of the invention (*e.g.*, the bacteria *Xanthobacter autotrophicus*) and the haloalkane 1,2-dichloroethane as well as removal of polychlorinated biphenyls (PCB's) from soil sediment.

The haloalkane dehalogenase of the invention are useful in carbon-halide reduction efforts. The enzymes of the invention initiate the degradation of haloalkanes. Alternatively, host cells containing a dehalogenase polynucleotide or polypeptide of the invention can feed on the haloalkanes and produce the detoxifying enzyme.

Definitions

The phrases “nucleic acid” or “nucleic acid sequence” as used herein refer to an oligonucleotide, nucleotide, polynucleotide, or to a fragment of any of these, to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent a sense or antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material, natural or synthetic in origin. In one embodiment, a “nucleic acid sequence” of the invention includes, for example, a sequence encoding a polypeptide as set forth in Group B amino acid sequences and variants thereof. In another embodiment, a “nucleic acid sequence” of the invention includes, for example, a sequence as set forth in Group A nucleic acid sequences, sequences complementary thereto, fragments of the foregoing sequences and variants thereof.

A “coding sequence of” or a “nucleotide sequence encoding” a particular polypeptide or protein, is a nucleic acid sequence which is transcribed and translated into a polypeptide or protein when placed under the control of appropriate regulatory sequences.

The term “gene” means the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region (leader and trailer) as well as, where applicable, intervening sequences (introns) between individual coding segments (exons).

“Amino acid” or “amino acid sequence” as used herein refer to an oligopeptide, peptide, polypeptide, or protein sequence, or to a fragment, portion, or subunit of any of these, and to naturally occurring or synthetic molecules. In one embodiment, an “amino acid sequence” or “polypeptide sequence” of the invention

includes, for example, a sequence as set forth in Group B amino acid sequences, fragments of the foregoing sequences and variants thereof. In another embodiment, an "amino acid sequence" of the invention includes, for example, a sequence encoded by a polynucleotide having a sequence as set forth in Group B nucleic acid sequences, sequences complementary thereto, fragments of the foregoing sequences and variants thereof.

The term "polypeptide" as used herein, refers to amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain modified amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Modifications can occur anywhere in the polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also a given polypeptide may have many types of modifications. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of a phosphatidylinositol, cross-linking cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pergylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, and transfer-RNA mediated addition of amino acids to protein such as arginylation. (See Creighton, T.E., *Proteins – Structure and Molecular Properties* 2nd Ed., W.H. Freeman and Company, New York (1993); *Posttranslational Covalent Modification of Proteins*, B.C. Johnson, Ed., Academic Press, New York, pp. 1-12 (1983)).

As used herein, the term "isolated" means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring).

For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.

As used herein, the term "purified" does not require absolute purity; rather, it is intended as a relative definition. Individual nucleic acids obtained from a library have been conventionally purified to electrophoretic homogeneity. The sequences obtained from these clones could not be obtained directly either from the library or from total human DNA. The purified nucleic acids of the invention have been purified from the remainder of the genomic DNA in the organism by at least 104-106 fold. However, the term "purified" also includes nucleic acids which have been purified from the remainder of the genomic DNA or from other sequences in a library or other environment by at least one order of magnitude, typically two or three orders, and more typically four or five orders of magnitude.

As used herein, the term "recombinant" means that the nucleic acid is adjacent to a "backbone" nucleic acid to which it is not adjacent in its natural environment. Additionally, to be "enriched" the nucleic acids will represent 5% or more of the number of nucleic acid inserts in a population of nucleic acid backbone molecules. Backbone molecules according to the invention include nucleic acids such as expression vectors, self-replicating nucleic acids, viruses, integrating nucleic acids, and other vectors or nucleic acids used to maintain or manipulate a nucleic acid insert of interest. Typically, the enriched nucleic acids represent 15% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules. More typically, the enriched nucleic acids represent 50% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules. In a one embodiment, the enriched nucleic acids represent 90% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules.

“Recombinant” polypeptides or proteins refer to polypeptides or proteins produced by recombinant DNA techniques; i.e., produced from cells transformed by an exogenous DNA construct encoding the desired polypeptide or protein.

“Synthetic” polypeptides or protein are those prepared by chemical synthesis. Solid-phase chemical peptide synthesis methods can also be used to synthesize the polypeptide or fragments of the invention. Such method have been known in the art since the early 1960's (Merrifield, R. B., J. Am. Chem. Soc., 85:2149-2154, 1963) (See also Stewart, J. M. and Young, J. D., Solid Phase Peptide Synthesis, 2nd Ed., Pierce Chemical Co., Rockford, Ill., pp. 11-12)) and have recently been employed in commercially available laboratory peptide design and synthesis kits (Cambridge Research Biochemicals). Such commercially available laboratory kits have generally utilized the teachings of H. M. Geysen et al, Proc. Natl. Acad. Sci., USA, 81:3998 (1984) and provide for synthesizing peptides upon the tips of a multitude of “rods” or “pins” all of which are connected to a single plate. When such a system is utilized, a plate of rods or pins is inverted and inserted into a second plate of corresponding wells or reservoirs, which contain solutions for attaching or anchoring an appropriate amino acid to the pin's or rod's tips. By repeating such a process step, i.e., inverting and inserting the rod's and pin's tips into appropriate solutions, amino acids are built into desired peptides. In addition, a number of available FMOC peptide synthesis systems are available. For example, assembly of a polypeptide or fragment can be carried out on a solid support using an Applied Biosystems, Inc. Model 431A automated peptide synthesizer. Such equipment provides ready access to the peptides of the invention, either by direct synthesis or by synthesis of a series of fragments that can be coupled using other known techniques.

A promoter sequence is “operably linked to” a coding sequence when RNA polymerase which initiates transcription at the promoter will transcribe the coding sequence into mRNA.

“Plasmids” are designated by a lower case “p” preceded and/or followed by capital letters and/or numbers. The starting plasmids herein are either commercially available, publicly available on an unrestricted basis, or can be constructed from

available plasmids in accord with published procedures. In addition, equivalent plasmids to those described herein are known in the art and will be apparent to the ordinarily skilled artisan.

“Digestion” of DNA refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements were used as would be known to the ordinarily skilled artisan. For analytical purposes, typically 1 μ g of plasmid or DNA fragment is used with about 2 units of enzyme in about 20 μ l of buffer solution. For the purpose of isolating DNA fragments for plasmid construction, typically 5 to 50 μ g of DNA are digested with 20 to 250 units of enzyme in a larger volume. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer. Incubation times of about 1 hour at 37°C are ordinarily used, but may vary in accordance with the supplier's instructions. After digestion, gel electrophoresis may be performed to isolate the desired fragment.

“Oligonucleotide” refers to either a single stranded polydeoxynucleotide or two complementary polydeoxynucleotide strands which may be chemically synthesized. Such synthetic oligonucleotides have no 5' phosphate and thus will not ligate to another oligonucleotide without adding a phosphate with an ATP in the presence of a kinase. A synthetic oligonucleotide will ligate to a fragment that has not been dephosphorylated.

The phrase “substantially identical” in the context of two nucleic acids or polypeptides, refers to two or more sequences that have at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, and in some aspects 90-95% nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using one of the known sequence comparison algorithms or by visual inspection. Typically, the substantial identity exists over a region of at least about 100 residues, and most commonly the sequences are substantially identical over at

least about 150-200 residues. In some embodiments, the sequences are substantially identical over the entire length of the coding regions.

Additionally a “substantially identical” amino acid sequence is a sequence that differs from a reference sequence by one or more conservative or non-conservative amino acid substitutions, deletions, or insertions, particularly when such a substitution occurs at a site that is not the active site of the molecule, and provided that the polypeptide essentially retains its functional properties. A conservative amino acid substitution, for example, substitutes one amino acid for another of the same class (e.g., substitution of one hydrophobic amino acid, such as isoleucine, valine, leucine, or methionine, for another, or substitution of one polar amino acid for another, such as substitution of arginine for lysine, glutamic acid for aspartic acid or glutamine for asparagine). One or more amino acids can be deleted, for example, from an dehalogenase polypeptide, resulting in modification of the structure of the polypeptide, without significantly altering its biological activity. For example, amino- or carboxyl-terminal amino acids that are not required for dehalogenase biological activity can be removed. Modified polypeptide sequences of the invention can be assayed for dehalogenase biological activity by any number of methods, including contacting the modified polypeptide sequence with an dehalogenase substrate and determining whether the modified polypeptide decreases the amount of specific substrate in the assay or increases the bioproducts of the enzymatic reaction of a functional dehalogenase polypeptide with the substrate.

“Fragments” as used herein are a portion of a naturally occurring protein which can exist in at least two different conformations. Fragments can have the same or substantially the same amino acid sequence as the naturally occurring protein. “Substantially the same” means that an amino acid sequence is largely, but not entirely, the same, but retains at least one functional activity of the sequence to which it is related. In general two amino acid sequences are “substantially the same” or “substantially homologous” if they are at least about 85% identical. Fragments which have different three dimensional structures as the naturally occurring protein are also included. An example of this, is a “pro-form” molecule, such as a low activity

proprotein that can be modified by cleavage to produce a mature enzyme with significantly higher activity.

“Hybridization” refers to the process by which a nucleic acid strand joins with a complementary strand through base pairing. Hybridization reactions can be sensitive and selective so that a particular sequence of interest can be identified even in samples in which it is present at low concentrations. Suitably stringent conditions can be defined by, for example, the concentrations of salt or formamide in the prehybridization and hybridization solutions, or by the hybridization temperature, and are well known in the art. In particular, stringency can be increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature.

For example, hybridization under high stringency conditions could occur in about 50% formamide at about 37°C to 42°C. Hybridization could occur under reduced stringency conditions in about 35% to 25% formamide at about 30°C to 35°C. In particular, hybridization could occur under high stringency conditions at 42°C in 50% formamide, 5X SSPE, 0.3% SDS, and 200 n/ml sheared and denatured salmon sperm DNA. Hybridization could occur under reduced stringency conditions as described above, but in 35% formamide at a reduced temperature of 35°C. The temperature range corresponding to a particular level of stringency can be further narrowed by calculating the purine to pyrimidine ratio of the nucleic acid of interest and adjusting the temperature accordingly. Variations on the above ranges and conditions are well known in the art.

The term “variant” refers to polynucleotides or polypeptides of the invention modified at one or more base pairs, codons, introns, exons, or amino acid residues (respectively) yet still retain the biological activity of an dehalogenase of the invention. The polynucleotides or polypeptides of the invention may also be modified by introduction of a modified base, such as inosine. Additionally, the modifications may, optionally, be repeated one or more times. Variants can be produced by any number of means including methods such as, for example, error-prone PCR,

shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, *in vivo* mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, GSSM and any combination, permutation or iterative process thereof.

Enzymes are highly selective catalysts. Their hallmark is the ability to catalyze reactions with exquisite stereo-, regio-, and chemo- selectivities that are unparalleled in conventional synthetic chemistry. Moreover, enzymes are remarkably versatile. They can be tailored to function in organic solvents, operate at extreme pHs (for example, high pHs and low pHs) extreme temperatures (for example, high temperatures and low temperatures), extreme salinity levels (for example, high salinity and low salinity), and catalyze reactions with compounds that are structurally unrelated to their natural, physiological substrates.

Enzymes are reactive toward a wide range of natural and unnatural substrates, thus enabling the modification of virtually any organic lead compound. Moreover, unlike traditional chemical catalysts, enzymes are highly enantio- and regio-selective. The high degree of functional group specificity exhibited by enzymes enables one to keep track of each reaction in a synthetic sequence leading to a new active compound. Enzymes are also capable of catalyzing many diverse reactions unrelated to their physiological function in nature. For example, peroxidases catalyze the oxidation of phenols by hydrogen peroxide. Peroxidases can also catalyze hydroxylation reactions that are not related to the native function of the enzyme. Other examples are proteases which catalyze the breakdown of polypeptides. In organic solution some proteases can also acylate sugars, a function unrelated to the native function of these enzymes.

The present invention exploits the unique catalytic properties of enzymes. Whereas the use of biocatalysts (i.e., purified or crude enzymes, non-living or living cells) in chemical transformations normally requires the identification of a particular biocatalyst that reacts with a specific starting compound, the present invention uses

selected biocatalysts and reaction conditions that are specific for functional groups that are present in many starting compounds.

Each biocatalyst is specific for one functional group, or several related functional groups, and can react with many starting compounds containing this functional group.

The biocatalytic reactions produce a population of derivatives from a single starting compound. These derivatives can be subjected to another round of biocatalytic reactions to produce a second population of derivative compounds. Thousands of variations of the original compound can be produced with each iteration of biocatalytic derivatization.

Enzymes react at specific sites of a starting compound without affecting the rest of the molecule, a process which is very difficult to achieve using traditional chemical methods. This high degree of biocatalytic specificity provides the means to identify a single active compound within the library. The library is characterized by the series of biocatalytic reactions used to produce it, a so-called "biosynthetic history". Screening the library for biological activities and tracing the biosynthetic history identifies the specific reaction sequence producing the active compound. The reaction sequence is repeated and the structure of the synthesized compound determined. This mode of identification, unlike other synthesis and screening approaches, does not require immobilization technologies, and compounds can be synthesized and tested free in solution using virtually any type of screening assay. It is important to note, that the high degree of specificity of enzyme reactions on functional groups allows for the "tracking" of specific enzymatic reactions that make up the biocatalytically produced library.

Many of the procedural steps are performed using robotic automation enabling the execution of many thousands of biocatalytic reactions and screening assays per day as well as ensuring a high level of accuracy and reproducibility. As a result, a library of derivative compounds can be produced in a matter of weeks which would take years to produce using current chemical methods. (For further teachings

on modification of molecules, including small molecules, see PCT/US94/09174, herein incorporated by reference in its entirety).

In one aspect, the present invention provides a non-stochastic method termed synthetic gene reassembly, that is somewhat related to stochastic shuffling, save that the nucleic acid building blocks are not shuffled or concatenated or chimerized randomly, but rather are assembled non-stochastically.

The synthetic gene reassembly method does not depend on the presence of a high level of homology between polynucleotides to be shuffled. The invention can be used to non-stochastically generate libraries (or sets) of progeny molecules comprised of over 10^{100} different chimeras. Conceivably, synthetic gene reassembly can even be used to generate libraries comprised of over 10^{1000} different progeny chimeras.

Thus, in one aspect, the invention provides a non-stochastic method of producing a set of finalized chimeric nucleic acid molecules having an overall assembly order that is chosen by design, which method is comprised of the steps of generating by design a plurality of specific nucleic acid building blocks having serviceable mutually compatible ligatable ends, and assembling these nucleic acid building blocks, such that a designed overall assembly order is achieved.

The mutually compatible ligatable ends of the nucleic acid building blocks to be assembled are considered to be "serviceable" for this type of ordered assembly if they enable the building blocks to be coupled in predetermined orders. Thus, in one aspect, the overall assembly order in which the nucleic acid building blocks can be coupled is specified by the design of the ligatable ends and, if more than one assembly step is to be used, then the overall assembly order in which the nucleic acid building blocks can be coupled is also specified by the sequential order of the assembly step(s). In a one embodiment of the invention, the annealed building pieces are treated with an enzyme, such as a ligase (e.g., T4 DNA ligase) to achieve covalent bonding of the building pieces.

In a another embodiment, the design of nucleic acid building blocks is obtained upon analysis of the sequences of a set of progenitor nucleic acid templates that serve as a basis for producing a progeny set of finalized chimeric nucleic acid molecules. These progenitor nucleic acid templates thus serve as a source of sequence information that aids in the design of the nucleic acid building blocks that are to be mutagenized, *i.e.* chimerized or shuffled.

In one exemplification, the invention provides for the chimerization of a family of related genes and their encoded family of related products. In a particular exemplification, the encoded products are enzymes. The dehalogenases of the present invention can be mutagenized in accordance with the methods described herein.

Thus according to one aspect of the invention, the sequences of a plurality of progenitor nucleic acid templates (*e.g.*, polynucleotides of Group A nucleic acid sequences) are aligned in order to select one or more demarcation points, which demarcation points can be located at an area of homology. The demarcation points can be used to delineate the boundaries of nucleic acid building blocks to be generated. Thus, the demarcation points identified and selected in the progenitor molecules serve as potential chimerization points in the assembly of the progeny molecules.

Typically a serviceable demarcation point is an area of homology (comprised of at least one homologous nucleotide base) shared by at least two progenitor templates, but the demarcation point can be an area of homology that is shared by at least half of the progenitor templates, at least two thirds of the progenitor templates, at least three fourths of the progenitor templates, and preferably at almost all of the progenitor templates. Even more preferably still a serviceable demarcation point is an area of homology that is shared by all of the progenitor templates.

In a one embodiment, the gene reassembly process is performed exhaustively in order to generate an exhaustive library. In other words, all possible ordered combinations of the nucleic acid building blocks are represented in the set of finalized chimeric nucleic acid molecules. At the same time, the assembly order (*i.e.*

the order of assembly of each building block in the 5' to 3' sequence of each finalized chimeric nucleic acid) in each combination is by design (or non-stochastic). Because of the non-stochastic nature of the method, the possibility of unwanted side products is greatly reduced.

In another embodiment, the method provides that the gene reassembly process is performed systematically, for example to generate a systematically compartmentalized library, with compartments that can be screened systematically, *e.g.*, one by one. In other words the invention provides that, through the selective and judicious use of specific nucleic acid building blocks, coupled with the selective and judicious use of sequentially stepped assembly reactions, an experimental design can be achieved where specific sets of progeny products are made in each of several reaction vessels. This allows a systematic examination and screening procedure to be performed. Thus, it allows a potentially very large number of progeny molecules to be examined systematically in smaller groups.

Because of its ability to perform chimerizations in a manner that is highly flexible yet exhaustive and systematic as well, particularly when there is a low level of homology among the progenitor molecules, the instant invention provides for the generation of a library (or set) comprised of a large number of progeny molecules. Because of the non-stochastic nature of the instant gene reassembly invention, the progeny molecules generated preferably comprise a library of finalized chimeric nucleic acid molecules having an overall assembly order that is chosen by design. In a particularly embodiment, such a generated library is comprised of greater than 10^3 to greater than 10^{1000} different progeny molecular species.

In one aspect, a set of finalized chimeric nucleic acid molecules, produced as described is comprised of a polynucleotide encoding a polypeptide. According to one embodiment, this polynucleotide is a gene, which may be a man-made gene. According to another embodiment, this polynucleotide is a gene pathway, which may be a man-made gene pathway. The invention provides that one or more man-made

genes generated by the invention may be incorporated into a man-made gene pathway, such as pathway operable in a eukaryotic organism (including a plant).

In another exemplification, the synthetic nature of the step in which the building blocks are generated allows the design and introduction of nucleotides (*e.g.*, one or more nucleotides, which may be, for example, codons or introns or regulatory sequences) that can later be optionally removed in an *in vitro* process (*e.g.*, by mutagenesis) or in an *in vivo* process (*e.g.*, by utilizing the gene splicing ability of a host organism). It is appreciated that in many instances the introduction of these nucleotides may also be desirable for many other reasons in addition to the potential benefit of creating a serviceable demarcation point.

Thus, according to another embodiment, the invention provides that a nucleic acid building block can be used to introduce an intron. Thus, the invention provides that functional introns may be introduced into a man-made gene of the invention. The invention also provides that functional introns may be introduced into a man-made gene pathway of the invention. Accordingly, the invention provides for the generation of a chimeric polynucleotide that is a man-made gene containing one (or more) artificially introduced intron(s).

Accordingly, the invention also provides for the generation of a chimeric polynucleotide that is a man-made gene pathway containing one (or more) artificially introduced intron(s). Preferably, the artificially introduced intron(s) are functional in one or more host cells for gene splicing much in the way that naturally-occurring introns serve functionally in gene splicing. The invention provides a process of producing man-made intron-containing polynucleotides to be introduced into host organisms for recombination and/or splicing.

A man-made gene produced using the invention can also serve as a substrate for recombination with another nucleic acid. Likewise, a man-made gene pathway produced using the invention can also serve as a substrate for recombination with another nucleic acid. In a preferred instance, the recombination is facilitated by, or occurs at, areas of homology between the man-made, intron-containing gene and a

nucleic acid, which serves as a recombination partner. In a particularly preferred instance, the recombination partner may also be a nucleic acid generated by the invention, including a man-made gene or a man-made gene pathway. Recombination may be facilitated by or may occur at areas of homology that exist at the one (or more) artificially introduced intron(s) in the man-made gene.

The synthetic gene reassembly method of the invention utilizes a plurality of nucleic acid building blocks, each of which preferably has two ligatable ends. The two ligatable ends on each nucleic acid building block may be two blunt ends (*i.e.* each having an overhang of zero nucleotides), or preferably one blunt end and one overhang, or more preferably still two overhangs.

A useful overhang for this purpose may be a 3' overhang or a 5' overhang. Thus, a nucleic acid building block may have a 3' overhang or alternatively a 5' overhang or alternatively two 3' overhangs or alternatively two 5' overhangs. The overall order in which the nucleic acid building blocks are assembled to form a finalized chimeric nucleic acid molecule is determined by purposeful experimental design and is not random.

According to one preferred embodiment, a nucleic acid building block is generated by chemical synthesis of two single-stranded nucleic acids (also referred to as single-stranded oligos) and contacting them so as to allow them to anneal to form a double-stranded nucleic acid building block.

A double-stranded nucleic acid building block can be of variable size. The sizes of these building blocks can be small or large. Preferred sizes for building block range from 1 base pair (not including any overhangs) to 100,000 base pairs (not including any overhangs). Other preferred size ranges are also provided, which have lower limits of from 1 bp to 10,000 bp (including every integer value in between), and upper limits of from 2 bp to 100, 000 bp (including every integer value in between).

Many methods exist by which a double-stranded nucleic acid building block can be generated that is serviceable for the invention; and these are known in the art and can be readily performed by the skilled artisan.

According to one embodiment, a double-stranded nucleic acid building block is generated by first generating two single stranded nucleic acids and allowing them to anneal to form a double-stranded nucleic acid building block. The two strands of a double-stranded nucleic acid building block may be complementary at every nucleotide apart from any that form an overhang; thus containing no mismatches, apart from any overhang(s). According to another embodiment, the two strands of a double-stranded nucleic acid building block are complementary at fewer than every nucleotide apart from any that form an overhang. Thus, according to this embodiment, a double-stranded nucleic acid building block can be used to introduce codon degeneracy. Preferably the codon degeneracy is introduced using the site-saturation mutagenesis described herein, using one or more N,N,G/T cassettes or alternatively using one or more N,N,N cassettes.

The *in vivo* recombination method of the invention can be performed blindly on a pool of unknown hybrids or alleles of a specific polynucleotide or sequence. However, it is not necessary to know the actual DNA or RNA sequence of the specific polynucleotide.

The approach of using recombination within a mixed population of genes can be useful for the generation of any useful proteins, for example, interleukin I, antibodies, tPA and growth hormone. This approach may be used to generate proteins having altered specificity or activity. The approach may also be useful for the generation of hybrid nucleic acid sequences, for example, promoter regions, introns, exons, enhancer sequences, 3' untranslated regions or 5' untranslated regions of genes. Thus this approach may be used to generate genes having increased rates of expression. This approach may also be useful in the study of repetitive DNA sequences. Finally, this approach may be useful to mutate ribozymes or aptamers.

In one aspect the invention described herein is directed to the use of repeated cycles of reductive reassortment, recombination and selection which allow for the directed molecular evolution of highly complex linear sequences, such as DNA, RNA or proteins thorough recombination.

In vivo shuffling of molecules is useful in providing variants and can be performed utilizing the natural property of cells to recombine multimers. While recombination *in vivo* has provided the major natural route to molecular diversity, genetic recombination remains a relatively complex process that involves 1) the recognition of homologies; 2) strand cleavage, strand invasion, and metabolic steps leading to the production of recombinant chiasma; and finally 3) the resolution of chiasma into discrete recombined molecules. The formation of the chiasma requires the recognition of homologous sequences.

In another embodiment, the invention includes a method for producing a hybrid polynucleotide from at least a first polynucleotide and a second polynucleotide. The invention can be used to produce a hybrid polynucleotide by introducing at least a first polynucleotide and a second polynucleotide which share at least one region of partial sequence homology (*e.g.*, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 43, 45, 47, and combinations thereof) into a suitable host cell. The regions of partial sequence homology promote processes which result in sequence reorganization producing a hybrid polynucleotide. The term "hybrid polynucleotide," as used herein, is any nucleotide sequence which results from the method of the present invention and contains sequence from at least two original polynucleotide sequences. Such hybrid polynucleotides can result from intermolecular recombination events which promote sequence integration between DNA molecules. In addition, such hybrid polynucleotides can result from intramolecular reductive reassortment processes which utilize repeated sequences to alter a nucleotide sequence within a DNA molecule.

The invention provides a means for generating hybrid polynucleotides which may encode biologically active hybrid polypeptides (*e.g.*, hybrid haloalkane

dehalogenase). In one aspect, the original polynucleotides encode biologically active polypeptides. The method of the invention produces new hybrid polypeptides by utilizing cellular processes which integrate the sequence of the original polynucleotides such that the resulting hybrid polynucleotide encodes a polypeptide demonstrating activities derived from the original biologically active polypeptides. For example, the original polynucleotides may encode a particular enzyme from different microorganisms. An enzyme encoded by a first polynucleotide from one organism or variant may, for example, function effectively under a particular environmental condition, *e.g.* high salinity. An enzyme encoded by a second polynucleotide from a different organism or variant may function effectively under a different environmental condition, such as extremely high temperatures. A hybrid polynucleotide containing sequences from the first and second original polynucleotides may encode an enzyme which exhibits characteristics of both enzymes encoded by the original polynucleotides. Thus, the enzyme encoded by the hybrid polynucleotide may function effectively under environmental conditions shared by each of the enzymes encoded by the first and second polynucleotides, *e.g.*, high salinity and extreme temperatures.

Enzymes encoded by the polynucleotides of the invention include, but are not limited to, hydrolases, dehalogenases and haloalkane dehalogenases. A hybrid polypeptide resulting from the method of the invention may exhibit specialized enzyme activity not displayed in the original enzymes. For example, following recombination and/or reductive reassortment of polynucleotides encoding hydrolase activities, the resulting hybrid polypeptide encoded by a hybrid polynucleotide can be screened for specialized hydrolase activities obtained from each of the original enzymes, *i.e.* the type of bond on which the hydrolase acts and the temperature at which the hydrolase functions. Thus, for example, the hydrolase may be screened to ascertain those chemical functionalities which distinguish the hybrid hydrolase from the original hydrolases, such as: (a) amide (peptide bonds), *i.e.*, proteases; (b) ester bonds, *i.e.*, esterases and lipases; (c) acetals, *i.e.*, glycosidases and, for example, the temperature, pH or salt concentration at which the hybrid polypeptide functions.

Sources of the original polynucleotides may be isolated from individual organisms ("isolates"), collections of organisms that have been grown in defined media ("enrichment cultures"), or, uncultivated organisms ("environmental samples"). The use of a culture-independent approach to derive polynucleotides encoding novel bioactivities from environmental samples is most preferable since it allows one to access untapped resources of biodiversity.

"Environmental libraries" are generated from environmental samples and represent the collective genomes of naturally occurring organisms archived in cloning vectors that can be propagated in suitable prokaryotic hosts. Because the cloned DNA is initially extracted directly from environmental samples, the libraries are not limited to the small fraction of prokaryotes that can be grown in pure culture. Additionally, a normalization of the environmental DNA present in these samples could allow more equal representation of the DNA from all of the species present in the original sample. This can dramatically increase the efficiency of finding interesting genes from minor constituents of the sample which may be under-represented by several orders of magnitude compared to the dominant species.

For example, gene libraries generated from one or more uncultivated microorganisms are screened for an activity of interest. Potential pathways encoding bioactive molecules of interest are first captured in prokaryotic cells in the form of gene expression libraries. Polynucleotides encoding activities of interest are isolated from such libraries and introduced into a host cell. The host cell is grown under conditions which promote recombination and/or reductive reassortment creating potentially active biomolecules with novel or enhanced activities.

The microorganisms from which the polynucleotide may be prepared include prokaryotic microorganisms, such as *Eubacteria* and *Archaeobacteria*, and lower eukaryotic microorganisms such as fungi, some algae and protozoa. Polynucleotides may be isolated from environmental samples in which case the nucleic acid may be recovered without culturing of an organism or recovered from one or more cultured organisms. In one aspect, such microorganisms may be

extremophiles, such as hyperthermophiles, psychrophiles, psychrotrophs, halophiles, barophiles and acidophiles. Polynucleotides encoding enzymes isolated from extremophilic microorganisms are particularly preferred. Such enzymes may function at temperatures above 100°C in terrestrial hot springs and deep sea thermal vents, at temperatures below 0°C in arctic waters, in the saturated salt environment of the Dead Sea, at pH values around 0 in coal deposits and geothermal sulfur-rich springs, or at pH values greater than 11 in sewage sludge. For example, several esterases and lipases cloned and expressed from extremophilic organisms show high activity throughout a wide range of temperatures and pHs.

Polynucleotides selected and isolated as hereinabove described are introduced into a suitable host cell. A suitable host cell is any cell which is capable of promoting recombination and/or reductive reassortment. The selected polynucleotides are preferably already in a vector which includes appropriate control sequences. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or preferably, the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis *et al.*, 1986).

As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as *E. coli*, *Streptomyces*, *Salmonella typhimurium*; fungal cells, such as yeast; insect cells such as *Drosophila S2* and *Spodoptera Sf9*; animal cells such as CHO, COS or Bowes melanoma; adenoviruses; and plant cells. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.

With particular references to various mammalian cell culture systems that can be employed to express recombinant protein, examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described in "SV40-transformed simian cells support the replication of early SV40 mutants" (Gluzman, 1981), and other cell lines capable of expressing a compatible vector, for example, the

C127, 3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

Host cells containing the polynucleotides of interest can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying genes. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan. The clones which are identified as having the specified enzyme activity may then be sequenced to identify the polynucleotide sequence encoding an enzyme having the enhanced activity.

In another aspect, it is envisioned the method of the present invention can be used to generate novel polynucleotides encoding biochemical pathways from one or more operons or gene clusters or portions thereof. For example, bacteria and many eukaryotes have a coordinated mechanism for regulating genes whose products are involved in related processes. The genes are clustered, in structures referred to as "gene clusters," on a single chromosome and are transcribed together under the control of a single regulatory sequence, including a single promoter which initiates transcription of the entire cluster. Thus, a gene cluster is a group of adjacent genes that are either identical or related, usually as to their function. An example of a biochemical pathway encoded by gene clusters are polyketides. Polyketides are molecules which are an extremely rich source of bioactivities, including antibiotics (such as tetracyclines and erythromycin), anti-cancer agents (daunomycin), immunosuppressants (FK506 and rapamycin), and veterinary products (monensin). Many polyketides (produced by polyketide synthases) are valuable as therapeutic agents. Polyketide synthases are multifunctional enzymes that catalyze the biosynthesis of an enormous variety of carbon chains differing in length and patterns

of functionality and cyclization. Polyketide synthase genes fall into gene clusters and at least one type (designated type I) of polyketide synthases have large size genes and enzymes, complicating genetic manipulation and *in vitro* studies of these genes/proteins.

Gene cluster DNA can be isolated from different organisms and ligated into vectors, particularly vectors containing expression regulatory sequences which can control and regulate the production of a detectable protein or protein-related array activity from the ligated gene clusters. Use of vectors which have an exceptionally large capacity for exogenous DNA introduction are particularly appropriate for use with such gene clusters and are described by way of example herein to include the f-factor (or fertility factor) of *E. coli*. This f-factor of *E. coli* is a plasmid which affect high-frequency transfer of itself during conjugation and is ideal to achieve and stably propagate large DNA fragments, such as gene clusters from mixed microbial samples. A particularly preferred embodiment is to use cloning vectors, referred to as "fosmids" or bacterial artificial chromosome (BAC) vectors. These are derived from *E. coli* f-factor which is able to stably integrate large segments of genomic DNA. When integrated with DNA from a mixed uncultured environmental sample, this makes it possible to achieve large genomic fragments in the form of a stable "environmental DNA library." Another type of vector for use in the present invention is a cosmid vector. Cosmid vectors were originally designed to clone and propagate large segments of genomic DNA. Cloning into cosmid vectors is described in detail in Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press (1989). Once ligated into an appropriate vector, two or more vectors containing different polyketide synthase gene clusters can be introduced into a suitable host cell. Regions of partial sequence homology shared by the gene clusters will promote processes which result in sequence reorganization resulting in a hybrid gene cluster. The novel hybrid gene cluster can then be screened for enhanced activities not found in the original gene clusters.

Therefore, in a one embodiment, the invention relates to a method for producing a biologically active hybrid polypeptide and screening such a polypeptide for enhanced activity by:

- 1) introducing at least a first polynucleotide in operable linkage and a second polynucleotide in operable linkage, said at least first polynucleotide and second polynucleotide sharing at least one region of partial sequence homology, into a suitable host cell;
- 2) growing the host cell under conditions which promote sequence reorganization resulting in a hybrid polynucleotide in operable linkage;
- 3) expressing a hybrid polypeptide encoded by the hybrid polynucleotide;
- 4) screening the hybrid polypeptide under conditions which promote identification of enhanced biological activity; and
- 5) isolating the a polynucleotide encoding the hybrid polypeptide.

Methods for screening for various enzyme activities are known to those of skill in the art and are discussed throughout the present specification. Such methods may be employed when isolating the polypeptides and polynucleotides of the invention.

As representative examples of expression vectors which may be used, there may be mentioned viral particles, baculovirus, phage, plasmids, phagemids, cosmids, fosmids, bacterial artificial chromosomes, viral DNA (*e.g.*, vaccinia, adenovirus, fowl pox virus, pseudorabies and derivatives of SV40), P1-based artificial chromosomes, yeast plasmids, yeast artificial chromosomes, and any other vectors specific for specific hosts of interest (such as bacillus, aspergillus and yeast). Thus, for example, the DNA may be included in any one of a variety of expression vectors for expressing a polypeptide. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences. Large numbers of suitable vectors are known to those of skill in the art, and are commercially available. The following vectors are provided by way of

example; Bacterial: pQE vectors (Qiagen), pBluescript plasmids, pNH vectors, (lambda-ZAP vectors (Stratagene); ptrc99a, pKK223-3, pDR540, pRIT2T (Pharmacia); Eukaryotic: pXT1, pSG5 (Stratagene), pSVK3, pBPV, pMSG, pSVLSV40 (Pharmacia). However, any other plasmid or other vector may be used so long as they are replicable and viable in the host. Low copy number or high copy number vectors may be employed with the present invention.

The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct RNA synthesis. Particular named bacterial promoters include *lacI*, *lacZ*, *T3*, *T7*, *gpt*, *lambda P_R*, *P_L* and *trp*. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression. Promoter regions can be selected from any desired gene using chloramphenicol transferase (CAT) vectors or other vectors with selectable markers. In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in *E. coli*.

In vivo reassortment is focused on "inter-molecular" processes collectively referred to as "recombination" which in bacteria, is generally viewed as a "RecA-dependent" phenomenon. The invention can rely on recombination processes of a host cell to recombine and re-assort sequences, or the cells' ability to mediate reductive processes to decrease the complexity of quasi-repeated sequences in the cell by deletion. This process of "reductive reassortment" occurs by an "intra-molecular," RecA-independent process.

Therefore, in another aspect of the invention, novel polynucleotides can be generated by the process of reductive reassortment. The method involves the

generation of constructs containing consecutive sequences (original encoding sequences), their insertion into an appropriate vector, and their subsequent introduction into an appropriate host cell. The reassortment of the individual molecular identities occurs by combinatorial processes between the consecutive sequences in the construct possessing regions of homology, or between quasi-repeated units. The reassortment process recombines and/or reduces the complexity and extent of the repeated sequences, and results in the production of novel molecular species. Various treatments may be applied to enhance the rate of reassortment. These could include treatment with ultra-violet light, or DNA damaging chemicals, and/or the use of host cell lines displaying enhanced levels of "genetic instability". Thus the reassortment process may involve homologous recombination or the natural property of quasi-repeated sequences to direct their own evolution.

Repeated or "quasi-repeated" sequences play a role in genetic instability. In the present invention, "quasi-repeats" are repeats that are not restricted to their original unit structure. Quasi-repeated units can be presented as an array of sequences in a construct; consecutive units of similar sequences. Once ligated, the junctions between the consecutive sequences become essentially invisible and the quasi-repetitive nature of the resulting construct is now continuous at the molecular level. The deletion process the cell performs to reduce the complexity of the resulting construct operates between the quasi-repeated sequences. The quasi-repeated units provide a practically limitless repertoire of templates upon which slippage events can occur. The constructs containing the quasi-repeats thus effectively provide sufficient molecular elasticity that deletion (and potentially insertion) events can occur virtually anywhere within the quasi-repetitive units.

When the quasi-repeated sequences are all ligated in the same orientation, for instance head to tail or vice versa, the cell cannot distinguish individual units. Consequently, the reductive process can occur throughout the sequences. In contrast, when for example, the units are presented head to head, rather than head to tail, the inversion delineates the endpoints of the adjacent unit so that deletion formation will favor the loss of discrete units. Thus, it is preferable with the present method that the

sequences are in the same orientation. Random orientation of quasi-repeated sequences will result in the loss of reassortment efficiency, while consistent orientation of the sequences will offer the highest efficiency. However, while having fewer of the contiguous sequences in the same orientation decreases the efficiency, it may still provide sufficient elasticity for the effective recovery of novel molecules. Constructs can be made with the quasi-repeated sequences in the same orientation to allow higher efficiency.

Sequences can be assembled in a head to tail orientation using any of a variety of methods, including the following:

- a) Primers that include a poly-A head and poly-T tail which when made single-stranded would provide orientation can be utilized. This is accomplished by having the first few bases of the primers made from RNA and hence easily removed RNaseH.
- b) Primers that include unique restriction cleavage sites can be utilized. Multiple sites, a battery of unique sequences, and repeated synthesis and ligation steps would be required.
- c) The inner few bases of the primer could be thiolated and an exonuclease used to produce properly tailed molecules.

The recovery of the re-assorted sequences relies on the identification of cloning vectors with a reduced repetitive index (RI). The re-assorted encoding sequences can then be recovered by amplification. The products are re-cloned and expressed. The recovery of cloning vectors with reduced RI can be affected by:

- 1) The use of vectors only stably maintained when the construct is reduced in complexity.
- 2) The physical recovery of shortened vectors by physical procedures. In this case, the cloning vector would be recovered using standard plasmid isolation

procedures and size fractionated on either an agarose gel, or column with a low molecular weight cut off utilizing standard procedures.

3) The recovery of vectors containing interrupted genes which can be selected when insert size decreases.

4) The use of direct selection techniques with an expression vector and the appropriate selection.

Encoding sequences (for example, genes) from related organisms may demonstrate a high degree of homology and encode quite diverse protein products. These types of sequences are particularly useful in the present invention as quasi-repeats. However, while the examples illustrated below demonstrate the reassortment of nearly identical original encoding sequences (quasi-repeats), this process is not limited to such nearly identical repeats.

The following example demonstrates a method of the invention. Encoding nucleic acid sequences (quasi-repeats) derived from three (3) unique species are described. Each sequence encodes a protein with a distinct set of properties. Each of the sequences differs by a single or a few base pairs at a unique position in the sequence. The quasi-repeated sequences are separately or collectively amplified and ligated into random assemblies such that all possible permutations and combinations are available in the population of ligated molecules. The number of quasi-repeat units can be controlled by the assembly conditions. The average number of quasi-repeated units in a construct is defined as the repetitive index (RI).

Once formed, the constructs may, or may not be size fractionated on an agarose gel according to published protocols, inserted into a cloning vector, and transfected into an appropriate host cell. The cells are then propagated and "reductive reassortment" is effected. The rate of the reductive reassortment process may be stimulated by the introduction of DNA damage if desired. Whether the reduction in RI is mediated by deletion formation between repeated sequences by an "intra-molecular" mechanism, or mediated by recombination-like events through "inter-

molecular” mechanisms is immaterial. The end result is a reassortment of the molecules into all possible combinations.

Optionally, the method comprises the additional step of screening the library members of the shuffled pool to identify individual shuffled library members having the ability to bind or otherwise interact, or catalyze a particular reaction (*e.g.*, such as catalytic domain of an enzyme) with a predetermined macromolecule, such as for example a proteinaceous receptor, an oligosaccharide, viron, or other predetermined compound or structure.

The polypeptides that are identified from such libraries can be used for therapeutic, diagnostic, research and related purposes (*e.g.*, catalysts, solutes for increasing osmolarity of an aqueous solution, and the like), and/or can be subjected to one or more additional cycles of shuffling and/or selection.

In another aspect, it is envisioned that prior to or during recombination or reassortment, polynucleotides generated by the method of the invention can be subjected to agents or processes which promote the introduction of mutations into the original polynucleotides. The introduction of such mutations would increase the diversity of resulting hybrid polynucleotides and polypeptides encoded therefrom. The agents or processes which promote mutagenesis can include, but are not limited to: (+)-CC-1065, or a synthetic analog such as (+)-CC-1065-(N3-Adenine (*See* Sun and Hurley, (1992); an N-acetylated or deacetylated 4'-fluoro-4-aminobiphenyl adduct capable of inhibiting DNA synthesis (*See*, for example, van de Poll *et al.* (1992)); or a N-acetylated or deacetylated 4-aminobiphenyl adduct capable of inhibiting DNA synthesis (*See* also, van de Poll *et al.* (1992), pp. 751-758); trivalent chromium, a trivalent chromium salt, a polycyclic aromatic hydrocarbon (PAH) DNA adduct capable of inhibiting DNA replication, such as 7-bromomethyl-benz[*a*]anthracene (“BMA”), tris(2,3-dibromopropyl)phosphate (“Tris-BP”), 1,2-dibromo-3-chloropropane (“DBCP”), 2-bromoacrolein (2BA), benzo[*a*]pyrene-7,8-dihydrodiol-9-10-epoxide (“BPDE”), a platinum(II) halogen salt, N-hydroxy-2-amino-3-methylimidazo[4,5-*f*]-quinoline (“N-hydroxy-IQ”), and N-hydroxy-2-amino-1-

methyl-6-phenylimidazo[4,5-f]pyridine ("N-hydroxy-PhIP"). Especially preferred means for slowing or halting PCR amplification consist of UV light (+)-CC-1065 and (+)-CC-1065-(N3-Adenine). Particularly encompassed means are DNA adducts or polynucleotides comprising the DNA adducts from the polynucleotides or polynucleotides pool, which can be released or removed by a process including heating the solution comprising the polynucleotides prior to further processing.

In another aspect the invention is directed to a method of producing recombinant proteins having biological activity by treating a sample comprising double-stranded template polynucleotides encoding a wild-type protein under conditions according to the invention which provide for the production of hybrid or re-assorted polynucleotides.

The invention also provides for the use of proprietary codon primers (containing a degenerate N,N,N sequence) to introduce point mutations into a polynucleotide, so as to generate a set of progeny polypeptides in which a full range of single amino acid substitutions is represented at each amino acid position (gene site saturated mutagenesis (GSSM)). The oligos used are comprised contiguously of a first homologous sequence, a degenerate N,N,N sequence, and preferably but not necessarily a second homologous sequence. The downstream progeny translational products from the use of such oligos include all possible amino acid changes at each amino acid site along the polypeptide, because the degeneracy of the N,N,N sequence includes codons for all 20 amino acids.

In one aspect, one such degenerate oligo (comprised of one degenerate N,N,N cassette) is used for subjecting each original codon in a parental polynucleotide template to a full range of codon substitutions. In another aspect, at least two degenerate N,N,N cassettes are used – either in the same oligo or not, for subjecting at least two original codons in a parental polynucleotide template to a full range of codon substitutions. Thus, more than one N,N,N sequence can be contained in one oligo to introduce amino acid mutations at more than one site. This plurality of N,N,N sequences can be directly contiguous, or separated by one or more additional

nucleotide sequence(s). In another aspect, oligos serviceable for introducing additions and deletions can be used either alone or in combination with the codons containing an N,N,N sequence, to introduce any combination or permutation of amino acid additions, deletions, and/or substitutions.

In a particular exemplification, it is possible to simultaneously mutagenize two or more contiguous amino acid positions using an oligo that contains contiguous N,N,N triplets, *i.e.* a degenerate (N,N,N)_n sequence.

In another aspect, the present invention provides for the use of degenerate cassettes having less degeneracy than the N,N,N sequence. For example, it may be desirable in some instances to use (*e.g.* in an oligo) a degenerate triplet sequence comprised of only one N, where said N can be in the first second or third position of the triplet. Any other bases including any combinations and permutations thereof can be used in the remaining two positions of the triplet. Alternatively, it may be desirable in some instances to use (*e.g.* in an oligo) a degenerate N,N,N triplet sequence, N,N,G/T, or an N,N, G/C triplet sequence.

It is appreciated, however, that the use of a degenerate triplet (such as N,N,G/T or an N,N, G/C triplet sequence) as disclosed in the instant invention is advantageous for several reasons. In one aspect, this invention provides a means to systematically and fairly easily generate the substitution of the full range of possible amino acids (for a total of 20 amino acids) into each and every amino acid position in a polypeptide. Thus, for a 100 amino acid polypeptide, the invention provides a way to systematically and fairly easily generate 2000 distinct species (*i.e.*, 20 possible amino acids per position times 100 amino acid positions). It is appreciated that there is provided, through the use of an oligo containing a degenerate N,N,G/T or an N,N, G/C triplet sequence, 32 individual sequences that code for 20 possible amino acids. Thus, in a reaction vessel in which a parental polynucleotide sequence is subjected to saturation mutagenesis using one such oligo, there are generated 32 distinct progeny polynucleotides encoding 20 distinct polypeptides. In contrast, the use of a non-

degenerate oligo in site-directed mutagenesis leads to only one progeny polypeptide product per reaction vessel.

This invention also provides for the use of nondegenerate oligos, which can optionally be used in combination with degenerate primers disclosed. It is appreciated that in some situations, it is advantageous to use nondegenerate oligos to generate specific point mutations in a working polynucleotide. This provides a means to generate specific silent point mutations, point mutations leading to corresponding amino acid changes, and point mutations that cause the generation of stop codons and the corresponding expression of polypeptide fragments.

Thus, in a preferred embodiment of this invention, each saturation mutagenesis reaction vessel contains polynucleotides encoding at least 20 progeny polypeptide molecules such that all 20 amino acids are represented at the one specific amino acid position corresponding to the codon position mutagenized in the parental polynucleotide. The 32-fold degenerate progeny polypeptides generated from each saturation mutagenesis reaction vessel can be subjected to clonal amplification (*e.g.*, cloned into a suitable *E. coli* host using an expression vector) and subjected to expression screening. When an individual progeny polypeptide is identified by screening to display a favorable change in property (when compared to the parental polypeptide), it can be sequenced to identify the correspondingly favorable amino acid substitution contained therein.

It is appreciated that upon mutagenizing each and every amino acid position in a parental polypeptide using saturation mutagenesis as disclosed herein, favorable amino acid changes may be identified at more than one amino acid position. One or more new progeny molecules can be generated that contain a combination of all or part of these favorable amino acid substitutions. For example, if 2 specific favorable amino acid changes are identified in each of 3 amino acid positions in a polypeptide, the permutations include 3 possibilities at each position (no change from the original amino acid, and each of two favorable changes) and 3 positions. Thus, there are $3 \times 3 \times 3$ or 27 total possibilities, including 7 that were previously examined

- 6 single point mutations (*i.e.*, 2 at each of three positions) and no change at any position.

In yet another aspect, site-saturation mutagenesis can be used together with shuffling, chimerization, recombination and other mutagenizing processes, along with screening. This invention provides for the use of any mutagenizing process(es), including saturation mutagenesis, in an iterative manner. In one exemplification, the iterative use of any mutagenizing process(es) is used in combination with screening.

Thus, in a non-limiting exemplification, this invention provides for the use of saturation mutagenesis in combination with additional mutagenization processes, such as process where two or more related polynucleotides are introduced into a suitable host cell such that a hybrid polynucleotide is generated by recombination and reductive reassortment.

In addition to performing mutagenesis along the entire sequence of a gene, the instant invention provides that mutagenesis can be used to replace each of any number of bases in a polynucleotide sequence, wherein the number of bases to be mutagenized is preferably every integer from 15 to 100,000. Thus, instead of mutagenizing every position along a molecule, one can subject every or a discrete number of bases (preferably a subset totaling from 15 to 100,000) to mutagenesis. Preferably, a separate nucleotide is used for mutagenizing each position or group of positions along a polynucleotide sequence. A group of 3 positions to be mutagenized may be a codon. The mutations are preferably introduced using a mutagenic primer, containing a heterologous cassette, also referred to as a mutagenic cassette. Preferred cassettes can have from 1 to 500 bases. Each nucleotide position in such heterologous cassettes be N, A, C, G, T, A/C, A/G, A/T, C/G, C/T, G/T, C/G/T, A/G/T, A/C/T, A/C/G, or E, where E is any base that is not A, C, G, or T (E can be referred to as a designer oligo).

In a general sense, saturation mutagenesis is comprised of mutagenizing a complete set of mutagenic cassettes (wherein each cassette is preferably about 1-500 bases in length) in defined polynucleotide sequence to be mutagenized (wherein the

sequence to be mutagenized is preferably from about 15 to 100,000 bases in length). Thus, a group of mutations (ranging from 1 to 100 mutations) is introduced into each cassette to be mutagenized. A grouping of mutations to be introduced into one cassette can be different or the same from a second grouping of mutations to be introduced into a second cassette during the application of one round of saturation mutagenesis. Such groupings are exemplified by deletions, additions, groupings of particular codons, and groupings of particular nucleotide cassettes.

Defined sequences to be mutagenized include a whole gene, pathway, cDNA, an entire open reading frame (ORF), and entire promoter, enhancer, repressor/transactivator, origin of replication, intron, operator, or any polynucleotide functional group. Generally, a "defined sequences" for this purpose may be any polynucleotide that a 15 base-polynucleotide sequence, and polynucleotide sequences of lengths between 15 bases and 15,000 bases (this invention specifically names every integer in between). Considerations in choosing groupings of codons include types of amino acids encoded by a degenerate mutagenic cassette.

In a particularly preferred exemplification a grouping of mutations that can be introduced into a mutagenic cassette, this invention specifically provides for degenerate codon substitutions (using degenerate oligos) that code for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20 amino acids at each position, and a library of polypeptides encoded thereby.

One aspect of the invention is an isolated nucleic acid comprising one of the sequences of Group A nucleic acid sequences, and sequences substantially identical thereto, the sequences complementary thereto, or a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive bases of one of the sequences of a Group A nucleic acid sequence (or the sequences complementary thereto). The isolated, nucleic acids may comprise DNA, including cDNA, genomic DNA, and synthetic DNA. The DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand. Alternatively, the isolated nucleic acids may comprise RNA.

As discussed in more detail below, the isolated nucleic acids of one of the Group A nucleic acid sequences, and sequences substantially identical thereto, may be used to prepare one of the polypeptides of a Group B amino acid sequence, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto.

Accordingly, another aspect of the invention is an isolated nucleic acid which encodes one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of one of the polypeptides of the Group B amino acid sequences. The coding sequences of these nucleic acids may be identical to one of the coding sequences of one of the nucleic acids of Group A nucleic acid sequences, or a fragment thereof or may be different coding sequences which encode one of the polypeptides of Group B amino acid sequences, sequences substantially identical thereto, and fragments having at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of one of the polypeptides of Group B amino acid sequences, as a result of the redundancy or degeneracy of the genetic code. The genetic code is well known to those of skill in the art and can be obtained, for example, on page 214 of B. Lewin, Genes VI, Oxford University Press, 1997, the disclosure of which is incorporated herein by reference.

The isolated nucleic acid which encodes one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, may include, but is not limited to: only the coding sequence of one of Group A nucleic acid sequences, and sequences substantially identical thereto, and additional coding sequences, such as leader sequences or proprotein sequences and non-coding sequences, such as introns or non-coding sequences 5' and/or 3' of the coding sequence. Thus, as used herein, the term "polynucleotide encoding a polypeptide" encompasses a polynucleotide which includes only the coding sequence for the

polypeptide as well as a polynucleotide which includes additional coding and/or non-coding sequence.

Alternatively, the nucleic acid sequences of Group A nucleic acid sequences, and sequences substantially identical thereto, may be mutagenized using conventional techniques, such as site directed mutagenesis, or other techniques familiar to those skilled in the art, to introduce silent changes into the polynucleotides of Group A nucleic acid sequences, and sequences substantially identical thereto. As used herein, "silent changes" include, for example, changes which do not alter the amino acid sequence encoded by the polynucleotide. Such changes may be desirable in order to increase the level of the polypeptide produced by host cells containing a vector encoding the polypeptide by introducing codons or codon pairs which occur frequently in the host organism.

The invention also relates to polynucleotides which have nucleotide changes which result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto. Such nucleotide changes may be introduced using techniques such as site directed mutagenesis, random chemical mutagenesis, exonuclease III deletion, and other recombinant DNA techniques. Alternatively, such nucleotide changes may be naturally occurring allelic variants which are isolated by identifying nucleic acids which specifically hybridize to probes comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive bases of one of the sequences of Group A nucleic acid sequences, and sequences substantially identical thereto (or the sequences complementary thereto) under conditions of high, moderate, or low stringency as provided herein.

The isolated nucleic acids of Group A nucleic acid sequences, and sequences substantially identical thereto, the sequences complementary thereto, or a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive bases of one of the sequences of Group A nucleic acid sequences, and sequences substantially identical thereto, or the sequences complementary thereto

may also be used as probes to determine whether a biological sample, such as a soil sample, contains an organism having a nucleic acid sequence of the invention or an organism from which the nucleic acid was obtained. In such procedures, a biological sample potentially harboring the organism from which the nucleic acid was isolated is obtained and nucleic acids are obtained from the sample. The nucleic acids are contacted with the probe under conditions which permit the probe to specifically hybridize to any complementary sequences from which are present therein.

Where necessary, conditions which permit the probe to specifically hybridize to complementary sequences may be determined by placing the probe in contact with complementary sequences from samples known to contain the complementary sequence as well as control sequences which do not contain the complementary sequence. Hybridization conditions, such as the salt concentration of the hybridization buffer, the formamide concentration of the hybridization buffer, or the hybridization temperature, may be varied to identify conditions which allow the probe to hybridize specifically to complementary nucleic acids.

If the sample contains the organism from which the nucleic acid was isolated, specific hybridization of the probe is then detected. Hybridization may be detected by labeling the probe with a detectable agent such as a radioactive isotope, a fluorescent dye or an enzyme capable of catalyzing the formation of a detectable product.

Many methods for using the labeled probes to detect the presence of complementary nucleic acids in a sample are familiar to those skilled in the art. These include Southern Blots, Northern Blots, colony hybridization procedures, and dot blots. Protocols for each of these procedures are provided in Ausubel *et al.* Current Protocols in Molecular Biology, John Wiley 503 Sons, Inc. (1997) and Sambrook *et al.*, Molecular Cloning: A Laboratory Manual 2nd Ed., Cold Spring Harbor Laboratory Press (1989), the entire disclosures of which are incorporated herein by reference.

Alternatively, more than one probe (at least one of which is capable of specifically hybridizing to any complementary sequences which are present in the

nucleic acid sample), may be used in an amplification reaction to determine whether the sample contains an organism containing a nucleic acid sequence of the invention (e.g., an organism from which the nucleic acid was isolated). Typically, the probes comprise oligonucleotides. In one embodiment, the amplification reaction may comprise a PCR reaction. PCR protocols are described in Ausubel and Sambrook, *supra*. Alternatively, the amplification may comprise a ligase chain reaction, 3SR, or strand displacement reaction. (See Barany, F., "The Ligase Chain Reaction in a PCR World", *PCR Methods and Applications* 1:5-16, 1991; E. Fahy *et al.*, "Self-sustained Sequence Replication (3SR): An Isothermal Transcription-based Amplification System Alternative to PCR", *PCR Methods and Applications* 1:25-33, 1991; and Walker G.T. *et al.*, "Strand Displacement Amplification-an Isothermal *in vitro* DNA Amplification Technique", *Nucleic Acid Research* 20:1691-1696, 1992, the disclosures of which are incorporated herein by reference in their entireties). In such procedures, the nucleic acids in the sample are contacted with the probes, the amplification reaction is performed, and any resulting amplification product is detected. The amplification product may be detected by performing gel electrophoresis on the reaction products and staining the gel with an intercalator such as ethidium bromide. Alternatively, one or more of the probes may be labeled with a radioactive isotope and the presence of a radioactive amplification product may be detected by autoradiography after gel electrophoresis.

Probes derived from sequences near the ends of the sequences of Group A nucleic acid sequences, and sequences substantially identical thereto, may also be used in chromosome walking procedures to identify clones containing genomic sequences located adjacent to the sequences of Group A nucleic acid sequences, and sequences substantially identical thereto. Such methods allow the isolation of genes which encode additional proteins from the host organism.

The isolated nucleic acids of Group A nucleic acid sequences, and sequences substantially identical thereto, the sequences complementary thereto, or a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive bases of one of the sequences of Group A nucleic acid sequences,

and sequences substantially identical thereto, or the sequences complementary thereto may be used as probes to identify and isolate related nucleic acids. In some embodiments, the related nucleic acids may be cDNAs or genomic DNAs from organisms other than the one from which the nucleic acid was isolated. For example, the other organisms may be related organisms. In such procedures, a nucleic acid sample is contacted with the probe under conditions which permit the probe to specifically hybridize to related sequences. Hybridization of the probe to nucleic acids from the related organism is then detected using any of the methods described above.

In nucleic acid hybridization reactions, the conditions used to achieve a particular level of stringency will vary, depending on the nature of the nucleic acids being hybridized. For example, the length, degree of complementarity, nucleotide sequence composition (*e.g.*, GC v. AT content), and nucleic acid type (*e.g.*, RNA v. DNA) of the hybridizing regions of the nucleic acids can be considered in selecting hybridization conditions. An additional consideration is whether one of the nucleic acids is immobilized, for example, on a filter.

Hybridization may be carried out under conditions of low stringency, moderate stringency or high stringency. As an example of nucleic acid hybridization, a polymer membrane containing immobilized denatured nucleic acids is first prehybridized for 30 minutes at 45°C in a solution consisting of 0.9 M NaCl, 50 mM NaH₂PO₄, pH 7.0, 5.0 mM Na₂EDTA, 0.5% SDS, 10X Denhardt's, and 0.5 mg/ml polyriboadenylic acid. Approximately 2×10^7 cpm (specific activity $4-9 \times 10^8$ cpm/ug) of ³²P end-labeled oligonucleotide probe are then added to the solution. After 12-16 hours of incubation, the membrane is washed for 30 minutes at room temperature in 1X SET (150 mM NaCl, 20 mM Tris hydrochloride, pH 7.8, 1 mM Na₂EDTA) containing 0.5% SDS, followed by a 30 minute wash in fresh 1X SET at T_m-10°C for the oligonucleotide probe. The membrane is then exposed to autoradiographic film for detection of hybridization signals.

By varying the stringency of the hybridization conditions used to identify nucleic acids, such as cDNAs or genomic DNAs, which hybridize to the detectable probe, nucleic acids having different levels of homology to the probe can be identified and isolated. Stringency may be varied by conducting the hybridization at varying temperatures below the melting temperatures of the probes. The melting temperature, T_m , is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly complementary probe. Very stringent conditions are selected to be equal to or about 5°C lower than the T_m for a particular probe. The melting temperature of the probe may be calculated using the following formulas:

For probes between 14 and 70 nucleotides in length the melting temperature (T_m) is calculated using the formula: $T_m = 81.5 + 16.6(\log [Na^+] + 0.41(\text{fraction G+C}) - (600/N))$ where N is the length of the probe.

If the hybridization is carried out in a solution containing formamide, the melting temperature may be calculated using the equation: $T_m = 81.5 + 16.6(\log [Na^+] + 0.41(\text{fraction G+C}) - (0.63\% \text{ formamide}) - (600/N))$ where N is the length of the probe.

Prehybridization may be carried out in 6X SSC, 5X Denhardt's reagent, 0.5% SDS, 100µg denatured fragmented salmon sperm DNA or 6X SSC, 5X Denhardt's reagent, 0.5% SDS, 100µg denatured fragmented salmon sperm DNA, 50% formamide. The formulas for SSC and Denhardt's solutions are listed in Sambrook *et al.*, *supra*.

Hybridization is conducted by adding the detectable probe to the prehybridization solutions listed above. Where the probe comprises double stranded DNA, it is denatured before addition to the hybridization solution. The filter is contacted with the hybridization solution for a sufficient period of time to allow the probe to hybridize to cDNAs or genomic DNAs containing sequences complementary thereto or homologous thereto. For probes over 200 nucleotides in length, the

hybridization may be carried out at 15-25°C below the T_m . For shorter probes, such as oligonucleotide probes, the hybridization may be conducted at 5-10°C below the T_m . Typically, for hybridizations in 6X SSC, the hybridization is conducted at approximately 68°C. Usually, for hybridizations in 50% formamide containing solutions, the hybridization is conducted at approximately 42°C.

All of the foregoing hybridizations would be considered to be under conditions of high stringency.

Following hybridization, the filter is washed to remove any non-specifically bound detectable probe. The stringency used to wash the filters can also be varied depending on the nature of the nucleic acids being hybridized, the length of the nucleic acids being hybridized, the degree of complementarity, the nucleotide sequence composition (*e.g.*, GC v. AT content), and the nucleic acid type (*e.g.*, RNA v. DNA). Examples of progressively higher stringency condition washes are as follows: 2X SSC, 0.1% SDS at room temperature for 15 minutes (low stringency); 0.1X SSC, 0.5% SDS at room temperature for 30 minutes to 1 hour (moderate stringency); 0.1X SSC, 0.5% SDS for 15 to 30 minutes at between the hybridization temperature and 68°C (high stringency); and 0.15M NaCl for 15 minutes at 72°C (very high stringency). A final low stringency wash can be conducted in 0.1X SSC at room temperature. The examples above are merely illustrative of one set of conditions that can be used to wash filters. One of skill in the art would know that there are numerous recipes for different stringency washes. Some other examples are given below.

Nucleic acids which have hybridized to the probe are identified by autoradiography or other conventional techniques.

The above procedure may be modified to identify nucleic acids having decreasing levels of homology to the probe sequence. For example, to obtain nucleic acids of decreasing homology to the detectable probe, less stringent conditions may be used. For example, the hybridization temperature may be decreased in increments

of 5°C from 68°C to 42°C in a hybridization buffer having a Na⁺ concentration of approximately 1M. Following hybridization, the filter may be washed with 2X SSC, 0.5% SDS at the temperature of hybridization. These conditions are considered to be “moderate” conditions above 50°C and “low” conditions below 50°C. A specific example of “moderate” hybridization conditions is when the above hybridization is conducted at 55°C. A specific example of “low stringency” hybridization conditions is when the above hybridization is conducted at 45°C.

Alternatively, the hybridization may be carried out in buffers, such as 6X SSC, containing formamide at a temperature of 42°C. In this case, the concentration of formamide in the hybridization buffer may be reduced in 5% increments from 50% to 0% to identify clones having decreasing levels of homology to the probe. Following hybridization, the filter may be washed with 6X SSC, 0.5% SDS at 50°C. These conditions are considered to be “moderate” conditions above 25% formamide and “low” conditions below 25% formamide. A specific example of “moderate” hybridization conditions is when the above hybridization is conducted at 30% formamide. A specific example of “low stringency” hybridization conditions is when the above hybridization is conducted at 10% formamide.

For example, the preceding methods may be used to isolate nucleic acids having a sequence with at least about 97%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55% or at least 50% homology to a nucleic acid sequence selected from the group consisting of one of the sequences of Group A nucleic acid sequences, and sequences substantially identical thereto, or fragments comprising at least about 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive bases thereof, and the sequences complementary thereto. Homology may be measured using the alignment algorithm. For example, the homologous polynucleotides may have a coding sequence which is a naturally occurring allelic variant of one of the coding sequences described herein. Such allelic variants may have a substitution, deletion or addition of one or more

nucleotides when compared to the nucleic acids of Group A nucleic acid sequences or the sequences complementary thereto.

Additionally, the above procedures may be used to isolate nucleic acids which encode polypeptides having at least about 99%, 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55% or at least 50% homology to a polypeptide having the sequence of one of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof as determined using a sequence alignment algorithm (*e.g.*, such as the FASTA version 3.0t78 algorithm with the default parameters).

Another aspect of the invention is an isolated or purified polypeptide comprising the sequence of one of Group A nucleic acid sequences, and sequences substantially identical thereto, or fragments comprising at least about 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof. As discussed above, such polypeptides may be obtained by inserting a nucleic acid encoding the polypeptide into a vector such that the coding sequence is operably linked to a sequence capable of driving the expression of the encoded polypeptide in a suitable host cell. For example, the expression vector may comprise a promoter, a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression.

Promoters suitable for expressing the polypeptide or fragment thereof in bacteria include the *E. coli lac* or *trp* promoters, the *lacI* promoter, the *lacZ* promoter, the *T3* promoter, the *T7* promoter, the *gpt* promoter, the *lambda P_R* promoter, the *lambda P_L* promoter, promoters from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), and the acid phosphatase promoter. Fungal promoters include the \forall factor promoter. Eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, heat shock promoters, the early and late SV40 promoter, LTRs from retroviruses, and the mouse

metallothionein-I promoter. Other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses may also be used.

Mammalian expression vectors may also comprise an origin of replication, any necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. In some embodiments, DNA sequences derived from the SV40 splice and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

Vectors for expressing the polypeptide or fragment thereof in eukaryotic cells may also contain enhancers to increase expression levels. Enhancers are cis-acting elements of DNA, usually from about 10 to about 300 bp in length that act on a promoter to increase its transcription. Examples include the SV40 enhancer on the late side of the replication origin bp 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and the adenovirus enhancers.

In addition, the expression vectors typically contain one or more selectable marker genes to permit selection of host cells containing the vector. Such selectable markers include genes encoding dihydrofolate reductase or genes conferring neomycin resistance for eukaryotic cell culture, genes conferring tetracycline or ampicillin resistance in *E. coli*, and the *S. cerevisiae TRP1* gene.

After the expression libraries have been generated one can include the additional step of "biopanning" such libraries prior to screening by cell sorting. The "biopanning" procedure refers to a process for identifying clones having a specified biological activity by screening for sequence homology in a library of clones prepared by (i) selectively isolating target DNA, from DNA derived from at least one microorganism, by use of at least one probe DNA comprising at least a portion of a DNA sequence encoding an biological having the specified biological activity; and (ii) optionally transforming a host with isolated target DNA to produce a library of clones which are screened for the specified biological activity.

The probe DNA used for selectively isolating the target DNA of interest from the DNA derived from at least one microorganism can be a full-length coding region sequence or a partial coding region sequence of DNA for an enzyme of known activity. The original DNA library can be preferably probed using mixtures of probes comprising at least a portion of the DNA sequence encoding an enzyme having the specified enzyme activity. These probes or probe libraries are preferably single-stranded and the microbial DNA which is probed has preferably been converted into single-stranded form. The probes that are particularly suitable are those derived from DNA encoding enzymes having an activity similar or identical to the specified enzyme activity which is to be screened.

The probe DNA should be at least about 10 bases and preferably at least 15 bases. In one embodiment, the entire coding region may be employed as a probe. Conditions for the hybridization in which target DNA is selectively isolated by the use of at least one DNA probe will be designed to provide a hybridization stringency of at least about 50% sequence identity, more particularly a stringency providing for a sequence identity of at least about 70%.

In nucleic acid hybridization reactions, the conditions used to achieve a particular level of stringency will vary, depending on the nature of the nucleic acids being hybridized. For example, the length, degree of complementarity, nucleotide sequence composition (*e.g.*, GC v. AT content), and nucleic acid type (*e.g.*, RNA v. DNA) of the hybridizing regions of the nucleic acids can be considered in selecting hybridization conditions. An additional consideration is whether one of the nucleic acids is immobilized, for example, on a filter.

An example of progressively higher stringency conditions is as follows: 2 x SSC/0.1% SDS at about room temperature (hybridization conditions); 0.2 x SSC/0.1% SDS at about room temperature (low stringency conditions); 0.2 x SSC/0.1% SDS at about 42°C (moderate stringency conditions); and 0.1 x SSC at about 68°C (high stringency conditions). Washing can be carried out using only one of these conditions, *e.g.*, high stringency conditions, or each of the conditions can be

used, *e.g.*, for 10-15 minutes each, in the order listed above, repeating any or all of the steps listed. However, as mentioned above, optimal conditions will vary, depending on the particular hybridization reaction involved, and can be determined empirically.

Hybridization techniques for probing a microbial DNA library to isolate target DNA of potential interest are well known in the art and any of those which are described in the literature are suitable for use herein, particularly those which use a solid phase-bound, directly or indirectly bound, probe DNA for ease in separation from the remainder of the DNA derived from the microorganisms.

Preferably the probe DNA is "labeled" with one partner of a specific binding pair (*i.e.* a ligand) and the other partner of the pair is bound to a solid matrix to provide ease of separation of target from its source. The ligand and specific binding partner can be selected from, in either orientation, the following: (1) an antigen or hapten and an antibody or specific binding fragment thereof; (2) biotin or iminobiotin and avidin or streptavidin; (3) a sugar and a lectin specific therefor; (4) an enzyme and an inhibitor therefor; (5) an apoenzyme and cofactor; (6) complementary homopolymeric oligonucleotides; and (7) a hormone and a receptor therefor. The solid phase is preferably selected from: (1) a glass or polymeric surface; (2) a packed column of polymeric beads; and (3) magnetic or paramagnetic particles.

Further, it is optional but desirable to perform an amplification of the target DNA that has been isolated. In this embodiment the target DNA is separated from the probe DNA after isolation. It is then amplified before being used to transform hosts. The double stranded DNA selected to include as at least a portion thereof a predetermined DNA sequence can be rendered single stranded, subjected to amplification and reannealed to provide amplified numbers of selected double stranded DNA. Numerous amplification methodologies are now well known in the art.

The selected DNA is then used for preparing a library for screening by transforming a suitable organism. Hosts, particularly those specifically identified

herein as preferred, are transformed by artificial introduction of the vectors containing the target DNA by inoculation under conditions conducive for such transformation.

The resultant libraries of transformed clones are then screened for clones which display activity for the enzyme of interest.

Having prepared a multiplicity of clones from DNA selectively isolated from an organism, such clones are screened for a specific enzyme activity and to identify the clones having the specified enzyme characteristics.

The screening for enzyme activity may be effected on individual expression clones or may be initially effected on a mixture of expression clones to ascertain whether or not the mixture has one or more specified enzyme activities. If the mixture has a specified enzyme activity, then the individual clones may be rescreened utilizing a FACS machine for such enzyme activity or for a more specific activity. Alternatively, encapsulation techniques such as gel microdroplets, may be employed to localize multiple clones in one location to be screened on a FACS machine for positive expressing clones within the group of clones which can then be broken out into individual clones to be screened again on a FACS machine to identify positive individual clones. Thus, for example, if a clone mixture has hydrolase activity, then the individual clones may be recovered and screened utilizing a FACS machine to determine which of such clones has hydrolase activity. As used herein, "small insert library" means a gene library containing clones with random small size nucleic acid inserts of up to approximately 5000 base pairs. As used herein, "large insert library" means a gene library containing clones with random large size nucleic acid inserts of approximately 5000 up to several hundred thousand base pairs or greater.

As described with respect to one of the above aspects, the invention provides a process for enzyme activity screening of clones containing selected DNA derived from a microorganism which process includes: screening a library for specified enzyme activity, said library including a plurality of clones, said clones having been prepared by recovering from genomic DNA of a microorganism selected DNA, which DNA is selected by hybridization to at least one DNA sequence which is

all or a portion of a DNA sequence encoding an enzyme having the specified activity; and transforming a host with the selected DNA to produce clones which are screened for the specified enzyme activity.

In one embodiment, a DNA library derived from a microorganism is subjected to a selection procedure to select therefrom DNA which hybridizes to one or more probe DNA sequences which is all or a portion of a DNA sequence encoding an enzyme having the specified enzyme activity by:

- (a) rendering the double-stranded genomic DNA population into a single-stranded DNA population;
- (b) contacting the single-stranded DNA population of (a) with the DNA probe bound to a ligand under conditions permissive of hybridization so as to produce a double-stranded complex of probe and members of the genomic DNA population which hybridize thereto;
- (c) contacting the double-stranded complex of (b) with a solid phase specific binding partner for said ligand so as to produce a solid phase complex;
- (d) separating the solid phase complex from the single-stranded DNA population of (b);
- (e) releasing from the probe the members of the genomic population which had bound to the solid phase bound probe;
- (f) forming double-stranded DNA from the members of the genomic population of (e);
- (g) introducing the double-stranded DNA of (f) into a suitable host to form a library containing a plurality of clones containing the selected DNA; and
- (h) screening the library for the specified enzyme activity.

In another aspect, the process includes a preselection to recover DNA including signal or secretion sequences. In this manner it is possible to select from the genomic DNA population by hybridization as hereinabove described only DNA which includes a signal or secretion sequence. The following paragraphs describe the protocol for this embodiment of the invention, the nature and function of secretion signal sequences in general and a specific exemplary application of such sequences to an assay or selection process.

A particularly embodiment of this aspect further comprises, after (a) but before (b) above, the steps of:

- (ai) contacting the single-stranded DNA population of (a) with a ligand-bound oligonucleotide probe that is complementary to a secretion signal sequence unique to a given class of proteins under conditions permissive of hybridization to form a double-stranded complex;
- (aii) contacting the double-stranded complex of (ai) with a solid phase specific binding partner for said ligand so as to produce a solid phase complex;
- (aiii) separating the solid phase complex from the single-stranded DNA population of (a);
- (aiv) releasing the members of the genomic population which had bound to said solid phase bound probe; and
- (av) separating the solid phase bound probe from the members of the genomic population which had bound thereto.

The DNA which has been selected and isolated to include a signal sequence is then subjected to the selection procedure hereinabove described to select and isolate therefrom DNA which binds to one or more probe DNA sequences derived from DNA encoding an enzyme(s) having the specified enzyme activity.

This procedure is described and exemplified in U.S. Serial No. 08/692,002, filed August 2, 1996, incorporated herein by reference.

In vivo biopanning may be performed utilizing a FACS-based machine. Complex gene libraries are constructed with vectors which contain elements which stabilize transcribed RNA. For example, the inclusion of sequences which result in secondary structures such as hairpins which are designed to flank the transcribed regions of the RNA would serve to enhance their stability, thus increasing their half life within the cell. The probe molecules used in the biopanning process consist of oligonucleotides labeled with reporter molecules that only fluoresce upon binding of the probe to a target molecule. These probes are introduced into the recombinant cells from the library using one of several transformation methods. The probe molecules bind to the transcribed target mRNA resulting in DNA/RNA heteroduplex molecules. Binding of the probe to a target will yield a fluorescent signal which is detected and sorted by the FACS machine during the screening process.

In some embodiments, the nucleic acid encoding one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least about 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof is assembled in appropriate phase with a leader sequence capable of directing secretion of the translated polypeptide or fragment thereof. Optionally, the nucleic acid can encode a fusion polypeptide in which one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof is fused to heterologous peptides or polypeptides, such as N-terminal identification peptides which impart desired characteristics, such as increased stability or simplified purification.

The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is ligated to the desired position in the vector following digestion of the insert and the vector with appropriate restriction endonucleases. Alternatively, blunt ends in both the insert and the vector may be

ligated. A variety of cloning techniques are disclosed in Ausubel *et al.* Current Protocols in Molecular Biology, John Wiley 503 Sons, Inc. 1997 and Sambrook *et al.*, Molecular Cloning: A Laboratory Manual 2nd Ed., Cold Spring Harbor Laboratory Press (1989), the entire disclosures of which are incorporated herein by reference. Such procedures and others are deemed to be within the scope of those skilled in the art.

The vector may be, for example, in the form of a plasmid, a viral particle, or a phage. Other vectors include chromosomal, nonchromosomal and synthetic DNA sequences, derivatives of SV40; bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. A variety of cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor, N.Y., (1989), the disclosure of which is hereby incorporated by reference.

Particular bacterial vectors which may be used include the commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017), pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden), GEM1 (Promega Biotec, Madison, WI, USA) pQE70, pQE60, pQE-9 (Qiagen), pD10, psiX174 pBluescript II KS, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene), ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia), pKK232-8 and pCM7. Particular eukaryotic vectors include pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, and pSVL (Pharmacia). However, any other vector may be used as long as it is replicable and viable in the host cell.

The host cell may be any of the host cells familiar to those skilled in the art, including prokaryotic cells, eukaryotic cells, mammalian cells, insect cells, or plant cells. As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as *E. coli*, *Streptomyces*, *Bacillus subtilis*, *Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, fungal cells, such as yeast, insect cells such as *Drosophila S2* and

Spodoptera Sf9, animal cells such as CHO, COS or Bowes melanoma, and adenoviruses. The selection of an appropriate host is within the abilities of those skilled in the art.

The vector may be introduced into the host cells using any of a variety of techniques, including transformation, transfection, transduction, viral infection, gene guns, or Ti-mediated gene transfer. Particular methods include calcium phosphate transfection, DEAE-Dextran mediated transfection, lipofection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).

Where appropriate, the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes of the invention. Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter may be induced by appropriate means (*e.g.*, temperature shift or chemical induction) and the cells may be cultured for an additional period to allow them to produce the desired polypeptide or fragment thereof.

Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract is retained for further purification. Microbial cells employed for expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Such methods are well known to those skilled in the art. The expressed polypeptide or fragment thereof can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the polypeptide. If desired, high performance liquid chromatography (HPLC) can be employed for final purification steps.

Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts (described by Gluzman, Cell, 23:175, 1981), and other cell lines capable of expressing proteins from a compatible vector, such as the C127, 3T3, CHO, HeLa and BHK cell lines.

The constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence. Depending upon the host employed in a recombinant production procedure, the polypeptides produced by host cells containing the vector may be glycosylated or may be non-glycosylated. Polypeptides of the invention may or may not also include an initial methionine amino acid residue.

Alternatively, the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof can be synthetically produced by conventional peptide synthesizers. In other embodiments, fragments or portions of the polypeptides may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, the fragments may be employed as intermediates for producing the full-length polypeptides.

Cell-free translation systems can also be employed to produce one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof using mRNAs transcribed from a DNA construct comprising a promoter operably linked to a nucleic acid encoding the polypeptide or fragment thereof. In some embodiments, the DNA construct may be linearized prior to conducting an *in vitro* transcription reaction. The transcribed mRNA is then incubated with an appropriate cell-free translation extract, such as a rabbit reticulocyte extract, to produce the desired polypeptide or fragment thereof.

The invention also relates to variants of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising

at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof. The term "variant" includes derivatives or analogs of these polypeptides. In particular, the variants may differ in amino acid sequence from the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, by one or more substitutions, additions, deletions, fusions and truncations, which may be present in any combination.

The variants may be naturally occurring or created *in vitro*. In particular, such variants may be created using genetic engineering techniques such as site directed mutagenesis, random chemical mutagenesis, Exonuclease III deletion procedures, and standard cloning techniques. Alternatively, such variants, fragments, analogs, or derivatives may be created using chemical synthesis or modification procedures.

Other methods of making variants are also familiar to those skilled in the art. These include procedures in which nucleic acid sequences obtained from natural isolates are modified to generate nucleic acids which encode polypeptides having characteristics which enhance their value in industrial or laboratory applications. In such procedures, a large number of variant sequences having one or more nucleotide differences with respect to the sequence obtained from the natural isolate are generated and characterized. Typically, these nucleotide differences result in amino acid changes with respect to the polypeptides encoded by the nucleic acids from the natural isolates.

For example, variants may be created using error prone PCR. In error prone PCR, PCR is performed under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product. Error prone PCR is described in Leung, D.W., *et al.*, Technique, 1:11-15, 1989) and Caldwell, R. C. & Joyce G.F., PCR Methods Applic., 2:28-33, 1992, the disclosure of which is incorporated herein by reference in its entirety. Briefly, in such procedures, nucleic acids to be mutagenized are mixed with PCR primers, reaction buffer, MgCl₂, MnCl₂, Taq polymerase and an appropriate

concentration of dNTPs for achieving a high rate of point mutation along the entire length of the PCR product. For example, the reaction may be performed using 20 fmole of nucleic acid to be mutagenized, 30pmole of each PCR primer, a reaction buffer comprising 50mM KCl, 10mM Tris HCl (pH 8.3) and 0.01% gelatin, 7mM MgCl₂, 0.5mM MnCl₂, 5 units of Taq polymerase, 0.2mM dGTP, 0.2mM dATP, 1mM dCTP, and 1mM dTTP. PCR may be performed for 30 cycles of 94° C for 1 min, 45° C for 1 min, and 72° C for 1 min. However, it will be appreciated that these parameters may be varied as appropriate. The mutagenized nucleic acids are cloned into an appropriate vector and the activities of the polypeptides encoded by the mutagenized nucleic acids is evaluated.

Variants may also be created using oligonucleotide directed mutagenesis to generate site-specific mutations in any cloned DNA of interest. Oligonucleotide mutagenesis is described in Reidhaar-Olson, J.F. & Sauer, R.T., *et al.*, Science, 241:53-57, 1988, the disclosure of which is incorporated herein by reference in its entirety. Briefly, in such procedures a plurality of double stranded oligonucleotides bearing one or more mutations to be introduced into the cloned DNA are synthesized and inserted into the cloned DNA to be mutagenized. Clones containing the mutagenized DNA are recovered and the activities of the polypeptides they encode are assessed.

Another method for generating variants is assembly PCR. Assembly PCR involves the assembly of a PCR product from a mixture of small DNA fragments. A large number of different PCR reactions occur in parallel in the same vial, with the products of one reaction priming the products of another reaction. Assembly PCR is described in U.S. Patent No. 5,965,408, filed July 9, 1996, entitled, "Method of DNA Reassembly by Interrupting Synthesis", the disclosure of which is incorporated herein by reference in its entirety.

Still another method of generating variants is sexual PCR mutagenesis. In sexual PCR mutagenesis, forced homologous recombination occurs between DNA molecules of different but highly related DNA sequence *in vitro*, as a result of random

fragmentation of the DNA molecule based on sequence homology, followed by fixation of the crossover by primer extension in a PCR reaction. Sexual PCR mutagenesis is described in Stemmer, W.P., PNAS, USA, 91:10747-10751, 1994, the disclosure of which is incorporated herein by reference. Briefly, in such procedures a plurality of nucleic acids to be recombined are digested with DNase to generate fragments having an average size of 50-200 nucleotides. Fragments of the desired average size are purified and resuspended in a PCR mixture. PCR is conducted under conditions which facilitate recombination between the nucleic acid fragments. For example, PCR may be performed by resuspending the purified fragments at a concentration of 10-30ng/1 in a solution of 0.2mM of each dNTP, 2.2mM MgCl₂, 50mM KCl, 10mM Tris HCl, pH 9.0, and 0.1% Triton X-100. 2.5 units of Taq polymerase per 100:1 of reaction mixture is added and PCR is performed using the following regime: 94° C for 60 seconds, 94° C for 30 seconds, 50-55° C for 30 seconds, 72° C for 30 seconds (30-45 times) and 72° C for 5 minutes. However, it will be appreciated that these parameters may be varied as appropriate. In some embodiments, oligonucleotides may be included in the PCR reactions. In other embodiments, the Klenow fragment of DNA polymerase I may be used in a first set of PCR reactions and Taq polymerase may be used in a subsequent set of PCR reactions. Recombinant sequences are isolated and the activities of the polypeptides they encode are assessed.

Variants may also be created by *in vivo* mutagenesis. In some embodiments, random mutations in a sequence of interest are generated by propagating the sequence of interest in a bacterial strain, such as an E. coli strain, which carries mutations in one or more of the DNA repair pathways. Such "mutator" strains have a higher random mutation rate than that of a wild-type parent. Propagating the DNA in one of these strains will eventually generate random mutations within the DNA. Mutator strains suitable for use for *in vivo* mutagenesis are described in PCT Publication No. WO 91/16427, published October 31, 1991, entitled "Methods for Phenotype Creation from Multiple Gene Populations" the disclosure of which is incorporated herein by reference in its entirety.

Variants may also be generated using cassette mutagenesis. In cassette mutagenesis a small region of a double stranded DNA molecule is replaced with a synthetic oligonucleotide "cassette" that differs from the native sequence. The oligonucleotide often contains completely and/or partially randomized native sequence.

Recursive ensemble mutagenesis may also be used to generate variants. Recursive ensemble mutagenesis is an algorithm for protein engineering (protein mutagenesis) developed to produce diverse populations of phenotypically related mutants whose members differ in amino acid sequence. This method uses a feedback mechanism to control successive rounds of combinatorial cassette mutagenesis. Recursive ensemble mutagenesis is described in Arkin, A.P. and Youvan, D.C., PNAS, USA, 89:7811-7815, 1992, the disclosure of which is incorporated herein by reference in its entirety.

In some embodiments, variants are created using exponential ensemble mutagenesis. Exponential ensemble mutagenesis is a process for generating combinatorial libraries with a high percentage of unique and functional mutants, wherein small groups of residues are randomized in parallel to identify, at each altered position, amino acids which lead to functional proteins. Exponential ensemble mutagenesis is described in Delegrave, S. and Youvan, D.C., Biotechnology Research, 11:1548-1552, 1993, the disclosure of which incorporated herein by reference in its entirety. Random and site-directed mutagenesis are described in Arnold, F.H., Current Opinion in Biotechnology, 4:450-455, 1993, the disclosure of which is incorporated herein by reference in its entirety.

In some embodiments, the variants are created using shuffling procedures wherein portions of a plurality of nucleic acids which encode distinct polypeptides are fused together to create chimeric nucleic acid sequences which encode chimeric polypeptides as described in U.S. Patent No. 5,965,408, filed July 9, 1996, entitled, "Method of DNA Reassembly by Interrupting Synthesis", and U.S. Patent No.

5,939,250, filed May 22, 1996, entitled, "Production of Enzymes Having Desired Activities by Mutagenesis", both of which are incorporated herein by reference.

The variants of the polypeptides of Group B amino acid sequences may be variants in which one or more of the amino acid residues of the polypeptides of the Group B amino acid sequences are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code.

Conservative substitutions are those that substitute a given amino acid in a polypeptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the following replacements: replacements of an aliphatic amino acid such as Alanine, Valine, Leucine and Isoleucine with another aliphatic amino acid; replacement of a Serine with a Threonine or vice versa; replacement of an acidic residue such as Aspartic acid and Glutamic acid with another acidic residue; replacement of a residue bearing an amide group, such as Asparagine and Glutamine, with another residue bearing an amide group; exchange of a basic residue such as Lysine and Arginine with another basic residue; and replacement of an aromatic residue such as Phenylalanine, Tyrosine with another aromatic residue.

Other variants are those in which one or more of the amino acid residues of the polypeptides of the Group B amino acid sequences includes a substituent group.

Still other variants are those in which the polypeptide is associated with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol).

Additional variants are those in which additional amino acids are fused to the polypeptide, such as a leader sequence, a secretory sequence, a proprotein sequence or a sequence which facilitates purification, enrichment, or stabilization of the polypeptide.

In some embodiments, the fragments, derivatives and analogs retain the same biological function or activity as the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto. In other embodiments, the fragment, derivative, or analog includes a proprotein, such that the fragment, derivative, or analog can be activated by cleavage of the proprotein portion to produce an active polypeptide.

Another aspect of the invention is polypeptides or fragments thereof which have at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or more than about 95% homology to one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or a fragment comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof. Homology may be determined using any of the programs described above which aligns the polypeptides or fragments being compared and determines the extent of amino acid identity or similarity between them. It will be appreciated that amino acid "homology" includes conservative amino acid substitutions such as those described above.

The polypeptides or fragments having homology to one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or a fragment comprising at least about 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof may be obtained by isolating the nucleic acids encoding them using the techniques described above.

Alternatively, the homologous polypeptides or fragments may be obtained through biochemical enrichment or purification procedures. The sequence of potentially homologous polypeptides or fragments may be determined by proteolytic digestion, gel electrophoresis and/or microsequencing. The sequence of the prospective homologous polypeptide or fragment can be compared to one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or a fragment comprising at least about 5, 10, 15, 20, 25, 30, 35, 40, 50, 75,

100, or 150 consecutive amino acids thereof using any of the programs described above.

Another aspect of the invention is an assay for identifying fragments or variants of Group B amino acid sequences, and sequences substantially identical thereto, which retain the enzymatic function of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto. For example the fragments or variants of said polypeptides, may be used to catalyze biochemical reactions, which indicate that the fragment or variant retains the enzymatic activity of the polypeptides in the Group B amino acid sequences.

The assay for determining if fragments of variants retain the enzymatic activity of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto includes the steps of: contacting the polypeptide fragment or variant with a substrate molecule under conditions which allow the polypeptide fragment or variant to function, and detecting either a decrease in the level of substrate or an increase in the level of the specific reaction product of the reaction between the polypeptide and substrate.

The polypeptides of Group B amino acid sequences, and sequences substantially identical thereto or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof may be used in a variety of applications. For example, the polypeptides or fragments thereof may be used to catalyze biochemical reactions. In accordance with one aspect of the invention, there is provided a process for utilizing the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto or polynucleotides encoding such polypeptides for hydrolyzing glycosidic linkages. In such procedures, a substance containing a glycosidic linkage (*e.g.*, a starch) is contacted with one of the polypeptides of Group B amino acid sequences, or sequences substantially identical thereto under conditions which facilitate the hydrolysis of the glycosidic linkage.

The polypeptides of Group B amino acid sequences, and sequences substantially identical thereto or fragments comprising at least 5, 10, 15, 20, 25, 30, 35,

40, 50, 75, 100, or 150 consecutive amino acids thereof, may also be used to generate antibodies which bind specifically to the polypeptides or fragments. The resulting antibodies may be used in immunoaffinity chromatography procedures to isolate or purify the polypeptide or to determine whether the polypeptide is present in a biological sample. In such procedures, a protein preparation, such as an extract, or a biological sample is contacted with an antibody capable of specifically binding to one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof.

In immunoaffinity procedures, the antibody is attached to a solid support, such as a bead or other column matrix. The protein preparation is placed in contact with the antibody under conditions in which the antibody specifically binds to one of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragment thereof. After a wash to remove non-specifically bound proteins, the specifically bound polypeptides are eluted.

The ability of proteins in a biological sample to bind to the antibody may be determined using any of a variety of procedures familiar to those skilled in the art. For example, binding may be determined by labeling the antibody with a detectable label such as a fluorescent agent, an enzymatic label, or a radioisotope. Alternatively, binding of the antibody to the sample may be detected using a secondary antibody having such a detectable label thereon. Particular assays include ELISA assays, sandwich assays, radioimmunoassays, and Western Blots.

Polyclonal antibodies generated against the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof can be obtained by direct injection of the polypeptides into an animal or by administering the polypeptides to an animal, for example, a nonhuman. The antibody so obtained will then bind the polypeptide itself. In this manner, even a sequence encoding only a fragment of the polypeptide can be used to generate antibodies which

may bind to the whole native polypeptide. Such antibodies can then be used to isolate the polypeptide from cells expressing that polypeptide.

For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler and Milstein, *Nature*, 256:495-497, 1975, the disclosure of which is incorporated herein by reference), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* 4:72, 1983, the disclosure of which is incorporated herein by reference), and the EBV-hybridoma technique (Cole, *et al.*, 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96, the disclosure of which is incorporated herein by reference).

Techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778, the disclosure of which is incorporated herein by reference) can be adapted to produce single chain antibodies to the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof. Alternatively, transgenic mice may be used to express humanized antibodies to these polypeptides or fragments thereof.

Antibodies generated against the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof may be used in screening for similar polypeptides from other organisms and samples. In such techniques, polypeptides from the organism are contacted with the antibody and those polypeptides which specifically bind the antibody are detected. Any of the procedures described above may be used to detect antibody binding. One such screening assay is described in "Methods for Measuring Cellulase Activities", *Methods in Enzymology*, Vol 160, pp. 87-116, which is hereby incorporated by reference in its entirety.

As used herein the term "nucleic acid sequence as set forth in SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 43, 45 and 47"

encompasses the nucleotide sequences of Group A nucleic acid sequences, and sequences substantially identical thereto, as well as sequences homologous to Group A nucleic acid sequences, and fragments thereof and sequences complementary to all of the preceding sequences. The fragments include portions of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 43, 45 and 47 comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of Group A nucleic acid sequences, and sequences substantially identical thereto. Homologous sequences and fragments of Group A nucleic acid sequences, and sequences substantially identical thereto, refer to a sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55% or 50% homology to these sequences. Homology may be determined using any of the computer programs and parameters described herein, including FASTA version 3.0t78 with the default parameters. Homologous sequences also include RNA sequences in which uridines replace the thymines in the nucleic acid sequences as set forth in the Group A nucleic acid sequences. The homologous sequences may be obtained using any of the procedures described herein or may result from the correction of a sequencing error. It will be appreciated that the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, can be represented in the traditional single character format (See the inside back cover of Stryer, Lubert. Biochemistry, 3rd Ed., W. H Freeman & Co., New York.) or in any other format which records the identity of the nucleotides in a sequence.

As used herein the term "a polypeptide sequence as set forth in SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46 and 48" encompasses the polypeptide sequence of Group B amino acid sequences, and sequences substantially identical thereto, which are encoded by a sequence as set forth in SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 43, 45 and 47, polypeptide sequences homologous to the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto, or fragments of any of the preceding sequences. Homologous polypeptide sequences refer to a polypeptide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, 75%, 70%, 65%,

60%, 55% or 50% homology to one of the polypeptide sequences of the Group B amino acid sequences. Homology may be determined using any of the computer programs and parameters described herein, including FASTA version 3.0t78 with the default parameters or with any modified parameters. The homologous sequences may be obtained using any of the procedures described herein or may result from the correction of a sequencing error. The polypeptide fragments comprise at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of the polypeptides of Group B amino acid sequences, and sequences substantially identical thereto. It will be appreciated that the polypeptide codes as set forth in Group B amino acid sequences, and sequences substantially identical thereto, can be represented in the traditional single character format or three letter format (See the inside back cover of Stryer, Lubert. Biochemistry, 3rd Ed., W. H Freeman & Co., New York.) or in any other format which relates the identity of the polypeptides in a sequence.

It will be appreciated by those skilled in the art that a nucleic acid sequence as set forth in SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 43, 45 and 47, and a polypeptide sequence as set forth in SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46 and 48 can be stored, recorded, and manipulated on any medium which can be read and accessed by a computer. As used herein, the words "recorded" and "stored" refer to a process for storing information on a computer medium. A skilled artisan can readily adopt any of the presently known methods for recording information on a computer readable medium to generate manufactures comprising one or more of the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, one or more of the polypeptide sequences as set forth in Group B amino acid sequences, and sequences substantially identical thereto. Another aspect of the invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, or 20 nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto.

Another aspect of the invention is a computer readable medium having recorded thereon one or more of the nucleic acid sequences as set forth in Group A

nucleic acid sequences, and sequences substantially identical thereto. Another aspect of the invention is a computer readable medium having recorded thereon one or more of the polypeptide sequences as set forth in Group B amino acid sequences, and sequences substantially identical thereto. Another aspect of the invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, or 20 of the sequences as set forth above.

Computer readable media include magnetically readable media, optically readable media, electronically readable media and magnetic/optical media. For example, the computer readable media may be a hard disk, a floppy disk, a magnetic tape, CD-ROM, Digital Versatile Disk (DVD), Random Access Memory (RAM), or Read Only Memory (ROM) as well as other types of other media known to those skilled in the art.

Embodiments of the invention include systems (e.g., internet based systems), particularly computer systems which store and manipulate the sequence information described herein. One example of a computer system 100 is illustrated in block diagram form in Figure 1. As used herein, "a computer system" refers to the hardware components, software components, and data storage components used to analyze a nucleotide sequence of a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in the Group B amino acid sequences. The computer system 100 typically includes a processor for processing, accessing and manipulating the sequence data. The processor 105 can be any well-known type of central processing unit, such as, for example, the Pentium III from Intel Corporation, or similar processor from Sun, Motorola, Compaq, AMD or International Business Machines.

Typically the computer system 100 is a general purpose system that comprises the processor 105 and one or more internal data storage components 110 for storing data, and one or more data retrieving devices for retrieving the data stored on the data storage components. A skilled artisan can readily appreciate that any one of the currently available computer systems are suitable.

In one particular embodiment, the computer system 100 includes a processor 105 connected to a bus which is connected to a main memory 115 (preferably implemented as RAM) and one or more internal data storage devices 110, such as a hard drive and/or other computer readable media having data recorded thereon. In some embodiments, the computer system 100 further includes one or more data retrieving device 118 for reading the data stored on the internal data storage devices 110.

The data retrieving device 118 may represent, for example, a floppy disk drive, a compact disk drive, a magnetic tape drive, or a modem capable of connection to a remote data storage system (*e.g.*, via the internet) etc. In some embodiments, the internal data storage device 110 is a removable computer readable medium such as a floppy disk, a compact disk, a magnetic tape, etc. containing control logic and/or data recorded thereon. The computer system 100 may advantageously include or be programmed by appropriate software for reading the control logic and/or the data from the data storage component once inserted in the data retrieving device.

The computer system 100 includes a display 120 which is used to display output to a computer user. It should also be noted that the computer system 100 can be linked to other computer systems 125a-c in a network or wide area network to provide centralized access to the computer system 100.

Software for accessing and processing the nucleotide sequences of a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, (such as search tools, compare tools, and modeling tools etc.) may reside in main memory 115 during execution.

In some embodiments, the computer system 100 may further comprise a sequence comparison algorithm for comparing a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences

substantially identical thereto, stored on a computer readable medium to a reference nucleotide or polypeptide sequence(s) stored on a computer readable medium. A "sequence comparison algorithm" refers to one or more programs which are implemented (locally or remotely) on the computer system 100 to compare a nucleotide sequence with other nucleotide sequences and/or compounds stored within a data storage means. For example, the sequence comparison algorithm may compare the nucleotide sequences of a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, stored on a computer readable medium to reference sequences stored on a computer readable medium to identify homologies or structural motifs. Various sequence comparison programs identified elsewhere in this patent specification are particularly contemplated for use in this aspect of the invention. Protein and/or nucleic acid sequence homologies may be evaluated using any of the variety of sequence comparison algorithms and programs known in the art. Such algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85(8):2444-2448, 1988; Altschul *et al.*, J. Mol. Biol. 215(3):403-410, 1990; Thompson *et al.*, Nucleic Acids Res. 22(2):4673-4680, 1994; Higgins *et al.*, Methods Enzymol. 266:383-402, 1996; Altschul *et al.*, J. Mol. Biol. 215(3):403-410, 1990; Altschul *et al.*, Nature Genetics 3:266-272, 1993).

Homology or identity is often measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705). Such software matches similar sequences by assigning degrees of homology to various deletions, substitutions and other modifications. The terms "homology" and "identity" in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same when compared and aligned for maximum correspondence over a comparison window or

designated region as measured using any number of sequence comparison algorithms or by manual alignment and visual inspection.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A "comparison window", as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequence for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482, 1981, by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443, 1970, by the search for similarity method of person & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444, 1988, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection. Other algorithms for determining homology or identity include, for example, in addition to a BLAST program (Basic Local Alignment Search Tool at the National Center for Biological Information), ALIGN, AMAS (Analysis of Multiply Aligned Sequences), AMPS (Protein Multiple Sequence Alignment), ASSET (Aligned Segment Statistical Evaluation Tool), BANDS, BESTSCOR, BIOSCAN (Biological Sequence Comparative Analysis Node), BLIMPS (BLoCKs IMProved Searcher), FASTA, Intervals & Points, BMB, CLUSTAL V, CLUSTAL W, CONSENSUS,

LCONSENSUS, WCONSENSUS, Smith-Waterman algorithm, DARWIN, Las Vegas algorithm, FNAT (Forced Nucleotide Alignment Tool), Framealign, Framesearch, DYNAMIC, FILTER, FSAP (Fristensky Sequence Analysis Package), GAP (Global Alignment Program), GENAL, GIBBS, GenQuest, ISSC (Sensitive Sequence Comparison), LALIGN (Local Sequence Alignment), LCP (Local Content Program), MACAW (Multiple Alignment Construction & Analysis Workbench), MAP (Multiple Alignment Program), MBLKP, MBLKN, PIMA (Pattern-Induced Multiple-sequence Alignment), SAGA (Sequence Alignment by Genetic Algorithm) and WHAT-IF. Such alignment programs can also be used to screen genome databases to identify polynucleotide sequences having substantially identical sequences. A number of genome databases are available, for example, a substantial portion of the human genome is available as part of the Human Genome Sequencing Project (J. Roach, http://weber.u.Washington.edu/~roach/human_genome_progress.2.html) (Gibbs, 1995). At least twenty-one other genomes have already been sequenced, including, for example, *M. genitalium* (Fraser *et al.*, 1995), *M. jannaschii* (Bult *et al.*, 1996), *H. influenzae* (Fleischmann *et al.*, 1995), *E. coli* (Blattner *et al.*, 1997), and yeast (*S. cerevisiae*) (Mewes *et al.*, 1997), and *D. melanogaster* (Adams *et al.*, 2000). Significant progress has also been made in sequencing the genomes of model organism, such as mouse, *C. elegans*, and *Arabidopsis sp.* Several databases containing genomic information annotated with some functional information are maintained by different organization, and are accessible via the internet, for example, <http://www.tigr.org/tdb>; <http://www.genetics.wisc.edu>; <http://genome-www.stanford.edu/~ball>; <http://hiv-web.lanl.gov>; <http://www.ncbi.nlm.nih.gov>; <http://www.ebi.ac.uk>; <http://Pasteur.fr/other/biology>; and <http://www.genome.wi.mit.edu>.

One example of a useful algorithm is BLAST and BLAST 2.0 algorithms, which are described in Altschul *et al.*, Nuc. Acids Res. 25:3389-3402, 1977, and Altschul *et al.*, J. Mol. Biol. 215:403-410, 1990, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves

first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W , T , and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, $M=5$, $N=-4$ and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectations (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915, 1989) alignments (B) of 50, expectation (E) of 10, $M=5$, $N=-4$, and a comparison of both strands.

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, *e.g.*, Karlin & Altschul, Proc. Natl. Acad. Sci. USA 90:5873, 1993). One measure of similarity provided by BLAST algorithm is the smallest sum probability ($P(N)$), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a references sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.

In one embodiment, protein and nucleic acid sequence homologies are evaluated using the Basic Local Alignment Search Tool ("BLAST"). In particular, five specific BLAST programs are used to perform the following task:

- (1) BLASTP and BLAST3 compare an amino acid query sequence against a protein sequence database;
- (2) BLASTN compares a nucleotide query sequence against a nucleotide sequence database;
- (3) BLASTX compares the six-frame conceptual translation products of a query nucleotide sequence (both strands) against a protein sequence database;
- (4) TBLASTN compares a query protein sequence against a nucleotide sequence database translated in all six reading frames (both strands); and
- (5) TBLASTX compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

The BLAST programs identify homologous sequences by identifying similar segments, which are referred to herein as "high-scoring segment pairs," between a query amino or nucleic acid sequence and a test sequence which is preferably obtained from a protein or nucleic acid sequence database. High-scoring segment pairs are preferably identified (*i.e.*, aligned) by means of a scoring matrix, many of which are known in the art. Preferably, the scoring matrix used is the BLOSUM62 matrix (Gonnet *et al.*, Science 256:1443-1445, 1992; Henikoff and Henikoff, Proteins 17:49-61, 1993). Less preferably, the PAM or PAM250 matrices may also be used (see, *e.g.*, Schwartz and Dayhoff, eds., 1978, *Matrices for Detecting Distance Relationships: Atlas of Protein Sequence and Structure*, Washington:

National Biomedical Research Foundation). BLAST programs are accessible through the U.S. National Library of Medicine, *e.g.*, at www.ncbi.nlm.nih.gov.

The parameters used with the above algorithms may be adapted depending on the sequence length and degree of homology studied. In some embodiments, the parameters may be the default parameters used by the algorithms in the absence of instructions from the user.

Figure 2 is a flow diagram illustrating one embodiment of a process 200 for comparing a new nucleotide or protein sequence with a database of sequences in order to determine the homology levels between the new sequence and the sequences in the database. The database of sequences can be a private database stored within the computer system 100, or a public database such as GENBANK that is available through the Internet.

The process 200 begins at a start state 201 and then moves to a state 202 wherein the new sequence to be compared is stored to a memory in a computer system 100. As discussed above, the memory could be any type of memory, including RAM or an internal storage device.

The process 200 then moves to a state 204 wherein a database of sequences is opened for analysis and comparison. The process 200 then moves to a state 206 wherein the first sequence stored in the database is read into a memory on the computer. A comparison is then performed at a state 210 to determine if the first sequence is the same as the second sequence. It is important to note that this step is not limited to performing an exact comparison between the new sequence and the first sequence in the database. Well-known methods are known to those of skill in the art for comparing two nucleotide or protein sequences, even if they are not identical. For example, gaps can be introduced into one sequence in order to raise the homology level between the two tested sequences. The parameters that control whether gaps or other features are introduced into a sequence during comparison are normally entered by the user of the computer system.

Once a comparison of the two sequences has been performed at the state 210, a determination is made at a decision state 210 whether the two sequences are the same. Of course, the term "same" is not limited to sequences that are absolutely identical. Sequences that are within the homology parameters entered by the user will be marked as "same" in the process 200.

If a determination is made that the two sequences are the same, the process 200 moves to a state 214 wherein the name of the sequence from the database is displayed to the user. This state notifies the user that the sequence with the displayed name fulfills the homology constraints that were entered. Once the name of the stored sequence is displayed to the user, the process 200 moves to a decision state 218 wherein a determination is made whether more sequences exist in the database. If no more sequences exist in the database, then the process 200 terminates at an end state 220. However, if more sequences do exist in the database, then the process 200 moves to a state 224 wherein a pointer is moved to the next sequence in the database so that it can be compared to the new sequence. In this manner, the new sequence is aligned and compared with every sequence in the database.

It should be noted that if a determination had been made at the decision state 212 that the sequences were not homologous, then the process 200 would move immediately to the decision state 218 in order to determine if any other sequences were available in the database for comparison.

Accordingly, one aspect of the invention is a computer system comprising a processor, a data storage device having stored thereon a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, a data storage device having retrievably stored thereon reference nucleotide sequences or polypeptide sequences to be compared to a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, and a

sequence comparer for conducting the comparison. The sequence comparer may indicate a homology level between the sequences compared or identify structural motifs in the above described nucleic acid code of Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, or it may identify structural motifs in sequences which are compared to these nucleic acid codes and polypeptide codes. In some embodiments, the data storage device may have stored thereon the sequences of at least 2, 5, 10, 15, 20, 25, 30 or 40 or more of the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or the polypeptide sequences as set forth in Group B amino acid sequences, and sequences substantially identical thereto.

Another aspect of the invention is a method for determining the level of homology between a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, and a reference nucleotide sequence. The method including reading the nucleic acid code or the polypeptide code and the reference nucleotide or polypeptide sequence through the use of a computer program which determines homology levels and determining homology between the nucleic acid code or polypeptide code and the reference nucleotide or polypeptide sequence with the computer program. The computer program may be any of a number of computer programs for determining homology levels, including those specifically enumerated herein, (*e.g.*, BLAST2N with the default parameters or with any modified parameters). The method may be implemented using the computer systems described above. The method may also be performed by reading at least 2, 5, 10, 15, 20, 25, 30 or 40 or more of the above described nucleic acid sequences as set forth in the Group A nucleic acid sequences, or the polypeptide sequences as set forth in the Group B amino acid sequences through use of the computer program and determining homology between the nucleic acid codes or polypeptide codes and reference nucleotide sequences or polypeptide sequences.

Figure 3 is a flow diagram illustrating one embodiment of a process 250 in a computer for determining whether two sequences are homologous. The process 250 begins at a start state 252 and then moves to a state 254 wherein a first sequence to be compared is stored to a memory. The second sequence to be compared is then stored to a memory at a state 256. The process 250 then moves to a state 260 wherein the first character in the first sequence is read and then to a state 262 wherein the first character of the second sequence is read. It should be understood that if the sequence is a nucleotide sequence, then the character would normally be either A, T, C, G or U. If the sequence is a protein sequence, then it is preferably in the single letter amino acid code so that the first and sequence sequences can be easily compared.

A determination is then made at a decision state 264 whether the two characters are the same. If they are the same, then the process 250 moves to a state 268 wherein the next characters in the first and second sequences are read. A determination is then made whether the next characters are the same. If they are, then the process 250 continues this loop until two characters are not the same. If a determination is made that the next two characters are not the same, the process 250 moves to a decision state 274 to determine whether there are any more characters either sequence to read.

If there are not any more characters to read, then the process 250 moves to a state 276 wherein the level of homology between the first and second sequences is displayed to the user. The level of homology is determined by calculating the proportion of characters between the sequences that were the same out of the total number of sequences in the first sequence. Thus, if every character in a first 100 nucleotide sequence aligned with a every character in a second sequence, the homology level would be 100%.

Alternatively, the computer program may be a computer program which compares the nucleotide sequences of a nucleic acid sequence as set forth in the invention, to one or more reference nucleotide sequences in order to determine whether the nucleic acid code of Group A nucleic acid sequences, and sequences

substantially identical thereto, differs from a reference nucleic acid sequence at one or more positions. Optionally such a program records the length and identity of inserted, deleted or substituted nucleotides with respect to the sequence of either the reference polynucleotide or a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto. In one embodiment, the computer program may be a program which determines whether a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, contains a single nucleotide polymorphism (SNP) with respect to a reference nucleotide sequence.

Accordingly, another aspect of the invention is a method for determining whether a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, differs at one or more nucleotides from a reference nucleotide sequence comprising the steps of reading the nucleic acid code and the reference nucleotide sequence through use of a computer program which identifies differences between nucleic acid sequences and identifying differences between the nucleic acid code and the reference nucleotide sequence with the computer program. In some embodiments, the computer program is a program which identifies single nucleotide polymorphisms. The method may be implemented by the computer systems described above and the method illustrated in Figure 3. The method may also be performed by reading at least 2, 5, 10, 15, 20, 25, 30, or 40 or more of the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, and the reference nucleotide sequences through the use of the computer program and identifying differences between the nucleic acid codes and the reference nucleotide sequences with the computer program.

In other embodiments the computer based system may further comprise an identifier for identifying features within a nucleic acid sequence as set forth in the Group A nucleic acid sequences or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto.

An “identifier” refers to one or more programs which identifies certain features within a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto. In one embodiment, the identifier may comprise a program which identifies an open reading frame in a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto.

Figure 5 is a flow diagram illustrating one embodiment of an identifier process 300 for detecting the presence of a feature in a sequence. The process 300 begins at a start state 302 and then moves to a state 304 wherein a first sequence that is to be checked for features is stored to a memory 115 in the computer system 100. The process 300 then moves to a state 306 wherein a database of sequence features is opened. Such a database would include a list of each feature’s attributes along with the name of the feature. For example, a feature name could be “Initiation Codon” and the attribute would be “ATG”. Another example would be the feature name “TAATAA Box” and the feature attribute would be “TAATAA”. An example of such a database is produced by the University of Wisconsin Genetics Computer Group (www.gcg.com). Alternatively, the features may be structural polypeptide motifs such as alpha helices, beta sheets, or functional polypeptide motifs such as enzymatic active sites, helix-turn-helix motifs or other motifs known to those skilled in the art.

Once the database of features is opened at the state 306, the process 300 moves to a state 308 wherein the first feature is read from the database. A comparison of the attribute of the first feature with the first sequence is then made at a state 310. A determination is then made at a decision state 316 whether the attribute of the feature was found in the first sequence. If the attribute was found, then the process 300 moves to a state 318 wherein the name of the found feature is displayed to the user.

The process 300 then moves to a decision state 320 wherein a determination is made whether more features exist in the database. If no more features do exist, then the process 300 terminates at an end state 324. However, if more features do exist in the database, then the process 300 reads the next sequence feature at a state 326 and loops back to the state 310 wherein the attribute of the next feature is compared against the first sequence.

It should be noted, that if the feature attribute is not found in the first sequence at the decision state 316, the process 300 moves directly to the decision state 320 in order to determine if any more features exist in the database.

Accordingly, another aspect of the invention is a method of identifying a feature within a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, comprising reading the nucleic acid code(s) or polypeptide code(s) through the use of a computer program which identifies features therein and identifying features within the nucleic acid code(s) with the computer program. In one embodiment, computer program comprises a computer program which identifies open reading frames. The method may be performed by reading a single sequence or at least 2, 5, 10, 15, 20, 25, 30, or 40 of the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or the polypeptide sequences as set forth in Group B amino acid sequences, and sequences substantially identical thereto, through the use of the computer program and identifying features within the nucleic acid codes or polypeptide codes with the computer program.

A nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto, may be stored and manipulated in a variety of data processor programs in a variety of formats. For example, a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in

Group B amino acid sequences, and sequences substantially identical thereto, may be stored as text in a word processing file, such as MicrosoftWORD or WORDPERFECT or as an ASCII file in a variety of database programs familiar to those of skill in the art, such as DB2, SYBASE, or ORACLE. In addition, many computer programs and databases may be used as sequence comparison algorithms, identifiers, or sources of reference nucleotide sequences or polypeptide sequences to be compared to a nucleic acid sequence as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or a polypeptide sequence as set forth in Group B amino acid sequences, and sequences substantially identical thereto. The following list is intended not to limit the invention but to provide guidance to programs and databases which are useful with the nucleic acid sequences as set forth in Group A nucleic acid sequences, and sequences substantially identical thereto, or the polypeptide sequences as set forth in Group B amino acid sequences, and sequences substantially identical thereto.

The programs and databases which may be used include, but are not limited to: MacPattern (EMBL), DiscoveryBase (Molecular Applications Group), GeneMine (Molecular Applications Group), Look (Molecular Applications Group), MacLook (Molecular Applications Group), BLAST and BLAST2 (NCBI), BLASTN and BLASTX (Altschul et al, J. Mol. Biol. 215: 403, 1990), FASTA (Pearson and Lipman, Proc. Natl. Acad. Sci. USA, 85: 2444, 1988), FASTDB (Brutlag *et al.* Comp. App. Biosci. 6:237-245, 1990), Catalyst (Molecular Simulations Inc.), Catalyst/SHAPE (Molecular Simulations Inc.), Cerius².DBAccess (Molecular Simulations Inc.), HypoGen (Molecular Simulations Inc.), Insight II, (Molecular Simulations Inc.), Discover (Molecular Simulations Inc.), CHARMM (Molecular Simulations Inc.), Felix (Molecular Simulations Inc.), DelPhi, (Molecular Simulations Inc.), QuanteMM, (Molecular Simulations Inc.), Homology (Molecular Simulations Inc.), Modeler (Molecular Simulations Inc.), ISIS (Molecular Simulations Inc.), Quanta/Protein Design (Molecular Simulations Inc.), WebLab (Molecular Simulations Inc.), WebLab Diversity Explorer (Molecular Simulations Inc.), Gene Explorer (Molecular Simulations Inc.), SeqFold (Molecular Simulations Inc.), the

MDL Available Chemicals Directory database, the MDL Drug Data Report data base, the Comprehensive Medicinal Chemistry database, Derwent's World Drug Index database, the BioByteMasterFile database, the Genbank database, and the Genseqn database. Many other programs and data bases would be apparent to one of skill in the art given the present disclosure.

Motifs which may be detected using the above programs include sequences encoding leucine zippers, helix-turn-helix motifs, glycosylation sites, ubiquitination sites, alpha helices, and beta sheets, signal sequences encoding signal peptides which direct the secretion of the encoded proteins, sequences implicated in transcription regulation such as homeoboxes, acidic stretches, enzymatic active sites, substrate binding sites, and enzymatic cleavage sites.

The present invention exploits the unique catalytic properties of enzymes. Whereas the use of biocatalysts (i.e., purified or crude enzymes, non-living or living cells) in chemical transformations normally requires the identification of a particular biocatalyst that reacts with a specific starting compound, the present invention uses selected biocatalysts and reaction conditions that are specific for functional groups that are present in many starting compounds, such as small molecules. Each biocatalyst is specific for one functional group, or several related functional groups, and can react with many starting compounds containing this functional group.

The biocatalytic reactions produce a population of derivatives from a single starting compound. These derivatives can be subjected to another round of biocatalytic reactions to produce a second population of derivative compounds. Thousands of variations of the original small molecule or compound can be produced with each iteration of biocatalytic derivatization.

Enzymes react at specific sites of a starting compound without affecting the rest of the molecule, a process which is very difficult to achieve using traditional chemical methods. This high degree of biocatalytic specificity provides the means to identify a single active compound within the library. The library is characterized by the series of biocatalytic reactions used to produce it, a so called "biosynthetic

history". Screening the library for biological activities and tracing the biosynthetic history identifies the specific reaction sequence producing the active compound. The reaction sequence is repeated and the structure of the synthesized compound determined. This mode of identification, unlike other synthesis and screening approaches, does not require immobilization technologies, and compounds can be synthesized and tested free in solution using virtually any type of screening assay. It is important to note, that the high degree of specificity of enzyme reactions on functional groups allows for the "tracking" of specific enzymatic reactions that make up the biocatalytically produced library.

Many of the procedural steps are performed using robotic automation enabling the execution of many thousands of biocatalytic reactions and screening assays per day as well as ensuring a high level of accuracy and reproducibility. As a result, a library of derivative compounds can be produced in a matter of weeks which would take years to produce using current chemical methods.

In a particular embodiment, the invention provides a method for modifying small molecules, comprising contacting a polypeptide encoded by a polynucleotide described herein or enzymatically active fragments thereof with a small molecule to produce a modified small molecule. A library of modified small molecules is tested to determine if a modified small molecule is present within the library which exhibits a desired activity. A specific biocatalytic reaction which produces the modified small molecule of desired activity is identified by systematically eliminating each of the biocatalytic reactions used to produce a portion of the library, and then testing the small molecules produced in the portion of the library for the presence or absence of the modified small molecule with the desired activity. The specific biocatalytic reactions which produce the modified small molecule of desired activity is optionally repeated. The biocatalytic reactions are conducted with a group of biocatalysts that react with distinct structural moieties found within the structure of a small molecule, each biocatalyst is specific for one structural moiety or a group of related structural moieties; and each biocatalyst reacts with many different small molecules which contain the distinct structural moiety.

The invention will be further described with reference to the following examples; however, it is to be understood that the invention is not limited to such examples.

EXAMPLES

Example 1

Site-Saturation Mutagenesis

To accomplish site-saturation mutagenesis every residue (317) of a dehalogenase enzyme (SEQ ID NO:2) encoded by SEQ ID NO:1 was converted into all 20 amino acids by site directed mutagenesis using 32-fold degenerate oligonucleotide primers, as follows:

A culture of the dehalogenase expression construct was grown and a preparation of the plasmid was made.

Primers were made to randomize each codon - they have the common structure $X_{20}NN(G/T)X_{20}$, wherein X_{20} represents the 20 nucleotides of the nucleic acid sequence of SEQ ID NO:1 flanking the codon to be changed.

A reaction mix of 25 μ l was prepared containing ~50 ng of plasmid template, 125 ng of each primer, 1X native Pfu buffer, 200 μ M each dNTP and 2.5 U native Pfu DNA polymerase.

The reaction was cycled in a Robo96 Gradient Cycler as follows:

Initial denaturation at 95°C for 1 min;

20 cycles of 95°C for 45 sec, 53°C for 1 min and 72°C for 11 min; and

Final elongation step of 72°C for 10 min.

The reaction mix was digested with 10 U of *DpnI* at 37°C for 1 hour to digest the methylated template DNA.

Two μ l of the reaction mix were used to transform 50 μ l of XL1-Blue MRF' cells and the entire transformation mix was plated on a large LB-Amp-Met plate yielding 200-1000 colonies.

Individual colonies were toothpicked into the wells of 384-well microtiter plates containing LB-Amp-IPTG and grown overnight.

The clones on these plates were assayed the following day.

Example 2

Dehalogenase Thermal Stability

This invention provides that a desirable property to be generated by directed evolution is exemplified in a limiting fashion by an improved residual activity (e.g. an enzymatic activity, an immunoreactivity, an antibiotic activity, etc.) of a molecule upon subjection to altered environment, including what may be considered a harsh environment, for a specified time. Such a harsh environment may comprise any combination of the following (iteratively or not, and in any order or permutation): an elevated temperature (including a temperature that may cause denaturation of a working enzyme), a decreased temperature, an elevated salinity, a decreased salinity, an elevated pH, a decreased pH, an elevated pressure, a decreased pressure, and an change in exposure to a radiation source (including uv radiation, visible light, as well as the entire electromagnetic spectrum).

The following example shows an application of directed evolution to evolve the ability of an enzyme to regain or retain activity upon exposure to an elevated temperature.

Every residue (317) of a dehalogenase enzyme was converted into all 20 amino acids by site directed mutagenesis using 32-fold degenerate oligonucleotide primers, as described above. The screening procedure was as follows:

Overnight cultures in 384-well plates were centrifuged and the media removed. To each well was added 0.06 mL 1 mM Tris/SO₄²⁻ pH 7.8.

A robot made 2 assay plates from each parent growth plate consisting of 0.02 mL cell suspension.

One assay plate was placed at room temperature and the other at elevated temperature (initial screen used 55°C) for a period of time (initially 30 minutes).

After the prescribed time 0.08 mL room temperature substrate (TCP saturated 1 mM Tris/SO₄²⁻ pH 7.8 with 1.5 mM NaN₃ and 0.1 mM bromothymol blue) was added to each well. TCP = trichloropropane.

Measurements at 620 nm were taken at various time points to generate a progress curve for each well.

Data were analyzed and the kinetics of the cells heated to those not heated were compared. Each plate contained 1-2 columns (24 wells) of un-mutated 20F12 controls.

Wells that appeared to have improved stability were regrown and tested under the same conditions.

Following this procedure clones having mutations that conferred increased thermal stability on the enzyme were sequenced to determine the exact amino acid changes at each position that were specifically responsible for the improvement. Mutants having a nucleic acid sequence as set forth in SEQ ID NO:5 and 7 and polypeptide sequences as set forth in SEQ ID NO:6 and 8, respectively, were identified. The thermal mutant at position G182V (SEQ ID NO:6) can also be a glutamate (Q) with similar increased thermal stability. Similarly, the P302A mutation could be changed to leucine (L), serine (S), lysine (K) or arginine (R). These variants (as well as those below) are encompassed by the present invention.

Following this procedure nine single site mutations appeared to confer increased thermal stability. Sequence analysis showed that the following changes were beneficial:

D89G; F91S; T159L; G182Q, G182V; I220L; N238T; W251Y; P302A, P302L, P302S, P302K; P302R/S306R. Only two sites (189 and 302) had more than one substitution. The first 5 on the list were combined (using G189Q) into a single gene.

Thermal stability was assessed by incubating the enzyme at the elevated temperature (55°C and 80°C) for some period of time and activity assay at 30°C. Initial rates were plotted vs. time at the higher temperature. The enzyme was in 50 mM Tris/SO₄ pH 7.8 for both the incubation and the assay. Product (Cl⁻) was detected by a standard method using Fe(NO₃)₃ and HgSCN. The dehalogenase of SEQ ID NO:2 was used as the *de facto* wild type. The apparent half-life (T_{1/2}) was calculated by fitting the data to an exponential decay function.

While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid comprising a sequence that encodes a polypeptide having dehalogenase activity, wherein said sequence is selected from the group consisting of:
SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47;
variants having at least about 50% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;
sequences complementary to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47; and
sequences complementary to variants having at least about 50% homology to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection.
2. The isolated nucleic acid as claimed in claim 1, wherein the isolated nucleic acid comprises a complementary sequence that hybridizes under conditions of high stringency to a sequence selected from the group consisting of: SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, and variants having at least about 50% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection.
3. The isolated nucleic acid as claimed in claim 1, wherein the isolated nucleic acid comprises a complementary sequence that hybridizes under conditions of moderate stringency to a sequence selected from the group consisting of: SEQ

ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, and variants having at least about 50% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection.

4. The isolated nucleic acid as claimed in claim 1, wherein the isolated nucleic acid comprises a complementary sequence that hybridizes under conditions of low stringency to a sequence selected from the group consisting of: SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, and variants having at least about 50% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection.
5. The isolated nucleic acid as claimed in claim 1, wherein said variants have at least about 50% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, over a region of at least about 200 residues, as determined by analysis with a sequence comparison algorithm.
6. The isolated nucleic acid according to claim 1, wherein said variants have at least about 50% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47 over the entire sequence.
7. The isolated nucleic acid according to claim 1, 2, 3, 4, 5 or 6, wherein said variants have at least about 55% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.

8. The isolated nucleic acid according to claim 1, 2, 3, 4, 5 or 6, wherein said variants have at least about 60% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.
9. The isolated nucleic acid according to claim 1, 2, 3, 4, 5 or 6, wherein said variants have at least about 65% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.
10. The isolated nucleic acid according to claim 1, 2, 3, 4, 5 or 6, wherein said variants have at least about 70% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.
11. The isolated nucleic acid according to claim 1, 2, 3, 4, 5 or 6, wherein said variants have at least about 75% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.
12. The isolated nucleic acid according to claim 1, 2, 3, 4, 5 or 6, wherein said variants have at least about 80% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.
13. The isolated nucleic acid according to claim 1, 2, 3, 4, 5 or 6, wherein said variants have at least about 85% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.
14. The isolated nucleic acid according to claim 1, 2, 3, 4, 5 or 6, wherein said variants have at least about 90% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.
15. The isolated nucleic acid according to claim 1, 2, 3, 4, 5 or 6, wherein said variants have at least about 95% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.

16. The isolated nucleic acid of claim 1, wherein the sequence comparison algorithm is FASTA version 3.0t78 with the default parameters.
17. An isolated nucleic acid comprising at least 10 consecutive bases of a sequence selected from the group consisting of:
 - SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47;
 - variants having at least about 50% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;
 - sequences complementary to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47; and
 - sequences complementary to variants having at least about 50% homology to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection.
18. The isolated nucleic acid as claimed in claim 17, wherein said sequence has at least about 50% homology to a sequence selected from the group consisting of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, over a region of at least about 200 residues.
19. The isolated nucleic acid as claimed in claim 17, wherein said sequence has at least about 50% homology to a sequence selected from the group consisting of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, over the entire sequence.

20. The isolated nucleic acid as claimed in claim 17, 18 or 19, wherein said sequence has at least about 55% homology to a sequence selected from the group consisting of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.
21. The isolated nucleic acid as claimed in claim 17, 18 or 19, wherein said sequence has at least about 60% homology to a sequence selected from the group consisting of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.
22. The isolated nucleic acid as claimed in claim 17, 18 or 19, wherein said sequence has at least about 65% homology to a sequence selected from the group consisting of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.
23. The isolated nucleic acid as claimed in claim 17, 18 or 19, wherein said sequence has at least about 70% homology to a sequence selected from the group consisting of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.
24. The isolated nucleic acid as claimed in claim 17, 18 or 19, wherein said sequence has at least about 75% homology to a sequence selected from the group consisting of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.
25. The isolated nucleic acid as claimed in claim 17, 18 or 19, wherein said sequence has at least about 80% homology to a sequence selected from the group consisting of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.

26. The isolated nucleic acid as claimed in claim 17, 18 or 19, wherein said sequence has at least about 85% homology to a sequence selected from the group consisting of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.
27. The isolated nucleic acid as claimed in claim 17, 18 or 19, wherein said sequence has at least about 90% homology to a sequence selected from the group consisting of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.
28. The isolated nucleic acid as claimed in claim 17, 18 or 19, wherein said sequence has at least about 95% homology to a sequence selected from the group consisting of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.
29. An isolated nucleic acid encoding a polypeptide selected from the group consisting of:
 - polypeptides having an amino acid sequence selected from the group consisting of:
 - SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48;
 - variants having at least about 50% homology to at least one of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;
 - sequences complementary to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48; and
 - sequences complementary to variants having at least about 50% homology to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48 over a region of at least about 100 residues, as

determined by analysis with a sequence comparison algorithm or by visual inspection; and

polypeptides having at least 10 consecutive amino acids of a polypeptide having a sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48.

30. A purified polypeptide selected from the group consisting of:

polypeptides having an amino acid sequence selected from the group consisting of: SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48;

variants having at least about 50% homology to at least one of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;

sequences complementary to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48; and

sequences complementary to variants having at least about 50% homology to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection; and

polypeptides having at least 10 consecutive amino acids of a polypeptide having a sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48.

31. The purified polypeptide as claimed in claim 30, wherein the amino acid sequence has at least about 50% homology to a sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26,

28, 30, 32, 34, 36, 38, 44, 46, and 48, over a region of at least about 200 residues.

32. The purified polypeptide as claimed in claim 30, wherein the amino acid sequence has at least about 50% homology to a sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48, over the entire sequence.
33. The purified polypeptide as claimed in claim 30, 31 or 32, wherein in the amino acid sequence has at least about 55% homology to a sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48.
34. The purified polypeptide as claimed in claim 30, 31 or 32, wherein the amino acid sequence has at least about 60% homology to a sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48.
35. The purified polypeptide as claimed in claim 30, 31 or 32, wherein the amino acid sequence has at least about 65% homology to a sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48.
36. The purified polypeptide as claimed in claim 30, 31 or 32, wherein the amino acid sequence has at least about 70% homology to a sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48.
37. The purified polypeptide as claimed in claim 30, 31 or 32, wherein the amino acid sequence has at least about 75% homology to a sequence selected from

the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48.

38. The purified polypeptide as claimed in claim 30, 31 or 32, wherein the amino acid sequence has at least about 80% homology to a sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48.
39. The purified polypeptide as claimed in claim 30, 31 or 32, wherein the amino acid sequence has at least about 85% homology to a sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48.
40. The purified polypeptide as claimed in claim 30, 31 or 32, wherein the amino acid sequence has at least about 90% homology to a sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48.
41. The purified polypeptide as claimed in claim 30, 31 or 32, wherein the amino acid sequence has at least about 95% homology to a sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48.
42. A purified polypeptide as claimed in claim 30, having an amino acid sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48; and sequences having at least about 50% homology to at least one of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48, over the entire sequence.

43. A purified antibody that specifically binds to a polypeptide selected from the group consisting of:
polypeptides comprising an amino acid sequence selected from the group consisting of:
SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48;
variants having at least about 50% homology to at least one of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;
sequences complementary to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48; and
sequences complementary to variants having at least about 50% homology to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection; and
polypeptides having at least 10 consecutive amino acids of a polypeptide having a sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48.
44. A purified antibody as claimed in claim 43, that specifically binds to a polypeptide having at least 10 consecutive amino acids of a polypeptide selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48.
45. The antibody of claim 43, wherein the antibodies are polyclonal.
46. The antibody of claim 43, wherein the antibodies are monoclonal.
47. A method of producing a polypeptide selected from the group consisting of:

polypeptides having an amino acid sequence selected from the group consisting of: SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48;

variants having at least about 50% homology to at least one of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;

sequences complementary to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48; and

sequences complementary to variants having at least about 50% homology to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection; and

polypeptides having at least 10 consecutive amino acids of a polypeptide having a sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48; comprising the steps of introducing a nucleic acid encoding the polypeptide into a host cell under conditions that allow expression of the polypeptide, and recovering the polypeptide.

48. A method of producing a polypeptide comprising at least 10 amino acids of a sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48, comprising the steps of: introducing a nucleic acid encoding the polypeptide, operably linked to a promoter, into a host cell under conditions that allow expression of the polypeptide, and recovering the polypeptide.

49. A method of generating a variant comprising:
obtaining a nucleic acid comprising a polynucleotide selected from the group consisting of:

SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47;

variants having at least about 50% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;

sequences complementary to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47; and

sequences complementary to variants having at least about 50% homology to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection; and

fragments comprising at least 30 consecutive nucleotides any of the foregoing sequences; and

modifying one or more nucleotides in said polynucleotide to another nucleotide, deleting one or more nucleotides in said polynucleotide, or adding one or more nucleotides to said polynucleotide.

50. The method of claim 49, wherein the modifications are introduced by a method selected from: error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, *in vivo* mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, gene site saturated mutagenesis or any combination, permutation or iterative process thereof.
51. The method of claim 50, wherein the modifications are introduced by error-prone PCR.
52. The method of claim 50, wherein the modifications are introduced by shuffling.

53. The method of claim 50, wherein the modifications are introduced by oligonucleotide-directed mutagenesis.
54. The method of claim 50, wherein the modifications are introduced by assembly PCR.
55. The method of claim 50, wherein the modifications are introduced by sexual PCR mutagenesis.
56. The method of claim 50, wherein the modifications are introduced by *in vivo* mutagenesis.
57. The method of claim 50, wherein the modifications are introduced by cassette mutagenesis.
58. The method of claim 50, wherein the modifications are introduced by recursive ensemble mutagenesis.
59. The method of claim 50, wherein the modifications are introduced by exponential ensemble mutagenesis.
60. The method of claim 50, wherein the modifications are introduced by site-specific mutagenesis.
61. The method of claim 50, wherein the modifications are introduced by gene reassembly.
62. The method of claim 50, wherein the modifications are introduced by gene site saturated mutagenesis.

63. A computer readable medium having stored thereon a sequence selected from the group consisting of:

nucleic acid sequences of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47;

variants of a nucleic acid sequence having at least about 50% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;

nucleic acid sequences complementary to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47;

nucleic acid sequences complementary to variants of nucleic acid sequences having at least about 50% homology to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;

polypeptide sequences SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48;

variants of polypeptide sequences having at least about 50% homology to at least one of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;

polypeptide sequences complementary to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48; and

polypeptide sequences complementary to variants of polypeptide sequences having at least about 50% homology to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection.

64. A computer system comprising a processor and a data storage device wherein said data storage device has stored thereon a sequence selected from the group consisting of:
- nucleic acid sequences of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47;
 - variants of a nucleic acid sequence having at least about 50% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;
 - nucleic acid sequences complementary to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47;
 - nucleic acid sequences complementary to variants of nucleic acid sequences having at least about 50% homology to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;
 - polypeptide sequences SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48;
 - variants of polypeptide sequences having at least about 50% homology to at least one of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;
 - polypeptide sequences complementary to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48; and
 - polypeptide sequences complementary to variants of polypeptide sequences having at least about 50% homology to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection.

65. The computer system of claim 64, further comprising a sequence comparison algorithm and a data storage device having at least one reference sequence stored thereon.
66. The computer system of claim 65, wherein the sequence comparison algorithm comprises a computer program which indicates polymorphisms.
67. The computer system of claim 64, further comprising an identifier which identifies one or more features in said sequence.
68. A method for comparing a first sequence to a second sequence comprising the steps of:
reading the first sequence and the second sequence through use of a computer program which compares sequences; and
determining differences between the first sequence and the second sequence with the computer program, wherein said first sequence is a sequence selected from the group consisting of:
nucleic acid sequences of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47;
variants of a nucleic acid sequence having at least about 50% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;
nucleic acid sequences complementary to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47;
nucleic acid sequences complementary to variants of nucleic acid sequences having at least about 50% homology to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47 over a

region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;

polypeptide sequences SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48;

variants of polypeptide sequences having at least about 50% homology to at least one of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;

polypeptide sequences complementary to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48; and

polypeptide sequences complementary to variants of polypeptide sequences having at least about 50% homology to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection.

69. The method of claim 68, wherein the step of determining differences between the first sequence and the second sequence further comprises the step of identifying polymorphisms.

70. A method for identifying a feature in a sequence comprising the steps of:
reading the sequence using a computer program which identifies one or more features in a sequence; and

identifying one or more features in the sequence with the computer program,
wherein the sequence is selected from the group consisting of:

nucleic acid sequences of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47;

variants of a nucleic acid sequence having at least about 50% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, over a region of at least about

100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;

nucleic acid sequences complementary to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47;

nucleic acid sequences complementary to variants of nucleic acid sequences having at least about 50% homology to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;

polypeptide sequences SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48;

variants of polypeptide sequences having at least about 50% homology to at least one of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;

polypeptide sequences complementary to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48; and

polypeptide sequences complementary to variants of polypeptide sequences having at least about 50% homology to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection.

71. A method of hydrolyzing a carbon-halogen linkage comprising contacting a substance containing the carbon-halogen linkage with a polypeptide selected from the group consisting of SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto, under conditions which facilitate the hydrolysis of the carbon-halogen linkage.

72. A method of catalyzing the breakdown of a haloalkane or halocarboxylic acid, comprising the step of contacting a sample containing haloalkane or halocarboxylic acid with a polypeptide having a sequence selected from the group consisting of:
- polypeptide sequences SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48;
 - variants of polypeptide sequences having at least about 50% homology to at least one of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;
 - polypeptide sequences complementary to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48; and
 - polypeptide sequences complementary to variants of polypeptide sequences having at least about 50% homology to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;
- under conditions which facilitate the breakdown of the haloalkane or halocarboxylic acid.
73. An assay for identifying functional polypeptide fragments or variants encoded by fragments of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, and sequences having at least about 50% homology to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection, which retain at least one property of the polypeptides of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48, and sequences having at least about 50% homology to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48,

over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection, said assay comprising the steps of:

contacting the polypeptide of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48, and sequences having at least about 50% homology to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection, polypeptide fragments or variants encoded by SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, sequences having at least about 50% homology to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection, and sequences complementary to any of the foregoing sequences, with a substrate molecule under conditions which allow the particular polypeptide to function; and

detecting either a decrease in an amount of a substrate or an increase in an amount of a reaction product which results from a reaction between said polypeptide and said substrate; wherein a decrease in the amount of the substrate or an increase in the amount of the reaction product is indicative of existence of the functional polypeptide.

74. A nucleic acid probe comprising an oligonucleotide from about 10 to 50 nucleotides in length and having a segment of at least 10 contiguous nucleotides that is at least 50% complementary to a nucleic acid target region of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47; and which hybridizes to the nucleic acid target region under moderate to highly stringent conditions to form a detectable target:probe duplex.
75. The probe of claim 74, wherein the oligonucleotide is DNA.

76. The probe of claim 74, wherein the oligonucleotide has a segment of at least 10 contiguous nucleotides that is at least 55% complementary to the nucleic acid target region.
77. The probe of claim 74, wherein the oligonucleotide has a segment of at least 10 contiguous nucleotides that is at least 60% complementary to the nucleic acid target region.
78. The probe of claim 74, wherein the oligonucleotide has a segment of at least 10 contiguous nucleotides that is at least 65% complementary to the nucleic acid target region.
79. The probe of claim 74, wherein the oligonucleotide has a segment of at least 10 contiguous nucleotides that is at least 70% complementary to the nucleic acid target region.
80. The probe of claim 74, wherein the oligonucleotide has a segment of at least 10 contiguous nucleotides that is at least 75% complementary to the nucleic acid target region.
81. The probe of claim 74, wherein the oligonucleotide has a segment of at least 10 contiguous nucleotides that is at least 80% complementary to the nucleic acid target region.
82. The probe of claim 74, wherein the oligonucleotide has a segment of at least 10 contiguous nucleotides that is at least 85% complementary to the nucleic acid target region.

83. The probe of claim 74, wherein the oligonucleotide has a segment of at least 10 contiguous nucleotides that is at least 90% complementary to the nucleic acid target region.
84. The probe of claim 74, wherein the oligonucleotide has a segment of at least 10 contiguous nucleotides that is at least 95% complementary to the nucleic acid target region.
85. The probe of claim 74, wherein the oligonucleotide has a segment of at least 10 contiguous nucleotides that is fully complementary to the nucleic acid target region.
86. The probe of claim 74, wherein the oligonucleotide is 15-50 bases in length.
87. The probe of claim 74, wherein the probe further comprises a detectable isotopic label.
88. The probe of claim 74, wherein the probe further comprises a detectable non-isotopic label selected from the group consisting of a fluorescent molecule, a chemiluminescent molecule, an enzyme, a cofactor, an enzyme substrate, and a hapten.
89. The probe of claim 86, wherein the oligonucleotide has a segment of at least 15 contiguous nucleotides that is at least 90% complementary to the nucleic acid target region, and which hybridizes to the nucleic acid target region under moderate to highly stringent conditions to form a detectable target:probe duplex.
90. The probe of claim 86, wherein the oligonucleotide has a segment of at least 15 contiguous nucleotides that is at least 95% complementary to a nucleic acid target region, and which hybridizes to the nucleic acid target region under

moderate to highly stringent conditions to form a detectable target:probe duplex.

91. The probe of claim 86, wherein the oligonucleotide has a segment of at least 15 contiguous nucleotides that is at least 97% complementary to a nucleic acid target region, and which hybridizes to the nucleic acid target region under moderate to highly stringent conditions to form a detectable target:probe duplex.
92. A polynucleotide probe for isolation or identification of dehalogenase genes having a sequence which is the same as, or fully complementary to at least a fragment of one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47.
93. A protein preparation comprising a polypeptide selected from the group consisting of: polypeptides having an amino acid sequence selected from the group consisting of:
 - SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48;
 - variants having at least about 50% homology to at least one of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;
 - sequences complementary to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48; and
 - sequences complementary to variants having at least about 50% homology to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection; and

polypeptides having at least 10 consecutive amino acids of a polypeptide having a sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48; and

wherein the protein preparation is a liquid.

94. A protein preparation comprising a polypeptide selected from the group consisting of: polypeptides having an amino acid sequence selected from the group consisting of:
- SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48;
 - variants having at least about 50% homology to at least one of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;
 - sequences complementary to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48; and
 - sequences complementary to variants having at least about 50% homology to SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection; and
- polypeptides having at least 10 consecutive amino acids of a polypeptide having a sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, and 48; and
- wherein the polypeptide is a solid.

95. A method for modifying small molecules, comprising the step of mixing at least one polypeptide encoded by a polynucleotide selected from the group consisting of:

SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47;

variants having at least about 50% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;

sequences complementary to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47; and

sequences complementary to variants having at least about 50% homology to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection; and fragments of any of the foregoing polypeptides;

with at least one small molecule to produce at least one modified small molecule via at least one biocatalytic reaction, wherein the at least one polypeptide has dehalogenase activity.

96. The method of claim 95, wherein the at least one polypeptide comprises a plurality of polypeptides and the at least one small molecule comprises a plurality of small molecules, whereby a plurality of modified small molecules are produced via a plurality of biocatalytic reactions to form a library of modified small molecules.

97. The method of 96, further comprising the step of testing the library to determine if a particular modified small molecule, which exhibits a desired activity is present within the library.

98. The method of claim 97 wherein the step of testing the library further comprises the steps of:

systematically eliminating all but one of the biocatalytic reactions used to produce a portion of the plurality of the modified small molecules within the library

by testing the portion of the modified small molecule for the presence or absence of the particular modified small molecule with the desired activity, and identifying a specific biocatalytic reaction which produces the particular modified small molecule of desired activity.

99. The method of claim 98 wherein the specific biocatalytic reaction, which produces the modified small molecule of desired activity is repeated.
100. The method of claim 93 wherein the biocatalytic reactions are conducted with a group of biocatalysts that react with distinct structural moieties found within the at least one small molecule;
each biocatalyst is specific for a particular structural moiety or a group of related structural moieties; and
each biocatalyst reacts with a plurality of small molecules which contain the particular structural moiety specific to the particular biocatalyst.
101. A cloning vector comprising a sequence that encodes a polypeptide having dehalogenase activity, said sequence being selected from the group consisting of:
SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47;
variants having at least about 50% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;
sequences complementary to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47; and
sequences complementary to variants having at least about 50% homology to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection.

102. A host cell comprising a sequence that encodes a polypeptide having dehalogenase activity, said sequence being selected from the group consisting of:

SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47;

variants having at least about 50% homology to at least one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection;

sequences complementary to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47; and

sequences complementary to variants having at least about 50% homology to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47, over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection.

103. An expression vector capable of replicating in a host cell comprising a polynucleotide having a sequence selected from the group consisting of SEQ ID NOS: 1, 3, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47 and 9, variants having at least about 50% homology to SEQ ID NOS: 1, 3, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47 and 9 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection, sequences complementary to SEQ ID NOS: 1, 3, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47 and 9, and sequences complementary to variants having at least about 50% homology to SEQ ID NOS: 1, 3, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 43, 45, and 47 and 9 over a region of at least about 100 residues, as determined by analysis with a sequence comparison algorithm or by visual inspection, and isolated nucleic acids that hybridize to nucleic acids having

any of the foregoing sequences under conditions of low, moderate and high stringency.

104. A vector as claimed in claim 101 or 103, wherein the vector is selected from the group consisting of viral vectors, plasmid vectors, phage vectors, phagemid vectors, cosmids, fosmids, bacteriophages, artificial chromosomes, adenovirus vectors, retroviral vectors, and adeno-associated viral vectors.
105. A host cell comprising an expression vector as claimed in claim 103.
106. A host cell as claimed in claim 47, 102, 103 or 105, wherein the host is selected from the group consisting of prokaryotes, eukaryotes, fungi, yeasts, plants and metabolically rich hosts.
107. The isolated nucleic acid of claim 1, wherein the variant is produced by a method selected from: error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, *in vivo* mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, gene site saturated mutagenesis or any combination, permutation or iterative process thereof.
108. The method of any one of claims 49-62, wherein the modifying of one or more nucleotides is optionally repeated one or more times.
109. The method of claim 49, wherein the modification is introduction of a modified base.
110. The method of claim 64, wherein the modified base is inosine.
111. A method for producing (R)-(\pm)-3-halo-1,2-propanediol comprising contacting a 1,3 dihalo-2-propanol with a polypeptide having at least 70% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences

substantially identical thereto, and having dehalogenase activity, under conditions to produce (R)-(+)-3-halo-1,2-propanediol.

112. The method of claim 111, wherein the polypeptide has at least 80% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.
113. The method of claim 111, wherein the polypeptide has at least 90% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.
114. The method of claim 111, wherein the polypeptide has at least 95% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.
115. The method of claim 111, wherein the polypeptide has a sequence as set forth in the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequence having conservative substitutions, deletions or insertions thereof.
116. A method for synthesizing glycerol, comprising contacting trichloropropane or dichloropropanol with a polypeptide having at least 70% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto, and having dehalogenase activity, under conditions to synthesize glycerol.
117. The method of claim 116, wherein the polypeptide has at least 80% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10,

12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.

118. The method of claim 116, wherein the polypeptide has at least 90% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.
119. The method of claim 116, wherein the polypeptide has at least 95% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.
120. The method of claim 116, wherein the polypeptide has a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequence having conservative substitutions, deletions or insertions thereof.
121. A method for producing an optically active halolactic acid, comprising contacting a dihalopropionic acid with a polypeptide having at least 70% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto, and having dehalogenase activity, under conditions to produce optically active halolactic acid.
122. The method of claim 121, wherein the polypeptide has at least 80% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.
123. The method of claim 121, wherein the polypeptide has at least 90% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10,

12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.

124. The method of claim 121, wherein the polypeptide has at least 95% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.
125. The method of claim 121, wherein the polypeptide has a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequence having conservative substitutions, deletions or insertions thereof.
126. A method for bioremediation, comprising contacting an environmental sample with a polypeptide having at least 70% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto, and having dehalogenase activity.
127. The method of claim 126, wherein the polypeptide has at least 80% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.
128. The method of claim 126, wherein the polypeptide has at least 90% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.
129. The method of claim 126, wherein the polypeptide has at least 95% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.

130. The method of claim 126, wherein the polypeptide has a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequence having conservative substitutions, deletions or insertions thereof.
131. A method of removing a halogenated contaminant or halogenated impurity from a sample comprising contacting the sample with a polypeptide having at least 70% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto, and having dehalogenase activity.
132. The method of claim 131, wherein the polypeptide has at least 80% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.
133. The method of claim 131, wherein the polypeptide has at least 90% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.
134. The method of claim 131, wherein the polypeptide has at least 95% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.
135. The method of claim 131, wherein the polypeptide has a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequence having conservative substitutions, deletions or insertions thereof.

136. A method for synthesizing a diol, comprising contacting a dihalopropane or monohalopropanol with a polypeptide having at least 70% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto, and having dehalogenase activity, under conditions to synthesize the diol.
137. The method of claim 136, wherein the polypeptide has at least 80% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.
138. The method of claim 136, wherein the polypeptide has at least 90% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.
139. The method of claim 136, wherein the polypeptide has at least 95% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.
140. The method of claim 136, wherein the polypeptide has a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequence having conservative substitutions, deletions or insertions thereof.
141. A method for dehalogenating a halo-substituted cyclic hydrocarbyl, comprising contacting the halo-substituted cyclic hydrocarbyl with a polypeptide having at least 70% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto,

and having dehalogenase activity, under conditions to dehalogenate the halo-substituted cyclic hydrocarbyl.

142. The method of claim 141, wherein the polypeptide has at least 80% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.
143. The method of claim 141, wherein the polypeptide has at least 90% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.
144. The method of claim 141, wherein the polypeptide has at least 95% homology to a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequences substantially identical thereto.
145. The method of claim 141, wherein the polypeptide has a sequence selected from the group consisting of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 44, 46, 48, and sequence having conservative substitutions, deletions or insertions thereof.

1/26




FIGURE 1

2/26





FIGURE 2

3/26

**FIGURE 3**

4/26




FIGURE 4

5/26

Summary of the catalytic and thermal amino acid upmutants:

	1	*				50
A	MGDSHHHHHH	GMSEIGTGFP	FDPHYVEVLG	ERMHYVDVGP	RDGTPVLFLH	
B	MGGSHHHHHH	GMSEIGTGFP	FDPHYVEVLG	ERMHYVDVGP	RDGTPVLFLH	
rhod2	-----	-MSEIGTGFP	FDPHYVEVLG	ERMHYVDVGP	RDGTPVLFLH	
C	MGDSHHHHHH	GMSEIGTGFP	FDPHYVEVLG	ERMHYVDVGP	RDGTPVLFLH	
myco4	-----	-MSEIGTGFP	FDPHYVEVLG	ERMHYVDVGP	RDGTPVLFLH	
Consensus	-----	-MSEIGTGFP	FDPHYVEVLG	ERMHYVDVGP	RDGTPVLFLH	
	51			*	*	100
A	GNPTSSYLWR	NIIPHVAPSH	RCIAPDLIGM	GKSDKPDLGY	FFDDHVRYLD	
B	GNPTSSYLWR	NIIPHVAPSH	RCIAPDLIGM	GKSDKPDLGY	FFDDHVRYLD	
rhod2	GNPTSSYLWR	NIIPHVAPSH	RCIAPDLIGM	GKSDKPDLGY	FFDDHVRYLD	
C	GNPTSSYLWR	NIIPHVAPSH	RCIAPDLIGM	GKSDKPDLGY	SFDDHVRYLD	
myco4	GNPTSSYLWR	NIIPHVAPSH	RCIAPDLIGM	GKSDKPDLGY	FFDDHVRYLD	
Consensus	GNPTSSYLWR	NIIPHVAPSH	RCIAPDLIGM	GKSDKPDL-Y	-FDDHVRYLD	
	101					150
A	AFIEALGLEE	VVLVIHDWGS	ALGFHWAKRN	PERVKGIACM	EFIRPIPTWD	
B	AFIEALGLEE	VVLVIHDWGS	ALGFHWAKRN	PERVKGIACM	EFIRPIPTWD	
rhod2	AFIEALGLEE	VVLVIHDWGS	ALGFHWAKRN	PERVKGIACM	EFIRPIPTWD	
C	AFIEALGLEE	VVLVIHDWGS	ALGFHWAKRN	PERVKGIACM	EFIRPIPTWD	
myco4	AFIEALGLEE	VVLVIHDWGS	ALGFHWAKRN	PERVKGIACM	EFIRPIPTWD	
Consensus	AFIEALGLEE	VVLVIHDWGS	ALGFHWAKRN	PERVKGIACM	EFIRPIPTWD	
	151	*		*	*	200
A	EWPEFARETf	QAFRTADVGR	ELIIDQNAFI	EGVLPKFVVR	PLTEVEMDHY	
B	EWPEFARETf	QAFRTADVGR	ELIIDQNAFI	EGVLPKCVVR	PLTEVEMDHY	
rhod2	EWPEFARETf	QAFRTADVGR	ELIIDQNAFI	EGALPKCVVR	PLTEVEMDHY	
C	EWPEFARELF	QAFRTADVGR	ELIIDQNAFI	EVVLPKFVVR	PLTEVEMDHY	
myco4	EWPEFARETf	QAFRTADVGR	ELIIDQNAFI	EGALPKFVVR	PLTEVEMDHY	
Consensus	EWPEFARE-F	QAFRTADVGR	ELIIDQNAFI	E--LPK-VVR	PLTEVEMDHY	
	201		*	*		250
A	REPFLKPVDK	EPLWRFPNEI	PIAGEPANIV	ALVEAYMNWL	HQSPVPKLLF	
B	REPFLKPVDK	EPLWRFPNEI	PIAGEPANIV	ALVEAYMNWL	HQSPVPKLLF	
rhod2	REPFLKPVDK	EPLWRFPNEL	PIAGEPANIV	ALVEAYMNWL	HQSPVPKLLF	
C	REPFLKPVDK	EPLWRFPNEL	PIAGEPANIV	ALVEAYMTWL	HQSPVPKLLF	
myco4	REPFLKPVDK	EPLWRFPNEL	PIAGEPANIV	ALVEAYMNWL	HQSPVPKLLF	
Consensus	REPFLKPVDK	EPLWRFPNE-	PIAGEPANIV	ALVEAYM-WL	HQSPVPKLLF	
	251*					300
A	WGTPGVLIPP	AEAARLAESL	PNCKTVDIGP	GLHYLQEDNP	DLIGSEIARW	
B	WGTPGVLIPP	AEAARLAESL	PNCKTVDIGP	GLHYLQEDNP	DLIGSEIARW	
rhod2	WGTPGVLIPP	AEAARLAESL	PNCKTVDIGP	GLHYLQEDNP	DLIGSEIARW	
C	YGTPGVLIPP	AEAARLAESL	PNCKTVDIGP	GLHYLQEDNP	DLIGSEIARW	
myco4	WGTPGVLISP	AEAARLAESL	PNCKTVDIGP	GLHFLQEDNP	DLIGSEIARW	
Consensus	-GTPGVLI-P	AEAARLAESL	PNCKTVDIGP	GLH-LQEDNP	DLIGSEIARW	
	301	*				319
A	LPGLASGLGD	YKDDDDK*~				
B	LPGLASGLGD	YKDDDDK*~				
rhod2	LPAL-----	-----				
C	LAGLASGLGD	YKDDDDK*~				
myco4	LPALIVGKSI	EFDGGWAT*				
Consensus	L--L-----	-----				

FIG 5

6/26

Figure 6A
124DL6
(SEQ ID NOS:9 and 10)

1
ATG AAC GCA ACG GAA CAC GAC AAG CGC TAC ATC GAG GTG CTG GGT AAG CGA
Met Asn Ala Thr Glu His Asp Lys Arg Tyr Ile Glu Val Leu Gly Lys Arg

ATG GCC TAT GTC GAG ATG GGC GAG GGT GAT CCC ATC ATT TTC CAA CAC GGC
Met Ala Tyr Val Glu Met Gly Glu Gly Asp Pro Ile Ile Phe Gln His Gly

AAT CCG ACC TCA TCG TAC CTG TGG CGC AAC ATC ATG CCC CAT GTG CAA CAG
Asn Pro Thr Ser Ser Tyr Leu Trp Arg Asn Ile Met Pro His Val Gln Gln

CTC GGT CGC TGC ATA GCG CTC GAC CTG ATC GGC ATG GGC GAT TCA GAA AAA
Leu Gly Arg Cys Ile Ala Leu Asp Leu Ile Gly Met Gly Asp Ser Glu Lys

CTC GAG GAC TCC GGA CCC GAG CGC TAC ACG TTC GTC GAG CAC AGC CGG TAT
Leu Glu Asp Ser Gly Pro Glu Arg Tyr Thr Phe Val Glu His Ser Arg Tyr

TTT GAT GCC GCG CTC GAA GCC CTG GGT GTG ACG AGC AAC GTG ACG CTG GTG
Phe Asp Ala Ala Leu Glu Ala Leu Gly Val Thr Ser Asn Val Thr Leu Val

ATC CAC GAT TGG GGT TCA GCG CTG GGC TTC CAC TGG GCT AAC CGC TAT CGT
Ile His Asp Trp Gly Ser Ala Leu Gly Phe His Trp Ala Asn Arg Tyr Arg

GAT GAC GTA AAA GGT ATC TGC TAC ATG GAA GCC ATC GTG TCG CCG CTG ACC
Asp Asp Val Lys Gly Ile Cys Tyr Met Glu Ala Ile Val Ser Pro Leu Thr

TGG GAT ACG TTT CCG GAA GGT GCG CGT GGT GTT TTC CAG GGG TTT CGT TCA
Trp Asp Thr Phe Pro Glu Gly Ala Arg Gly Val Phe Gln Gly Phe Arg Ser

CCG GCT GGC GAA GCA ATG GTG CTT GAG AAC AAT GTG TTC GTC GAA AAC GTA
Pro Ala Gly Glu Ala Met Val Leu Glu Asn Asn Val Phe Val Glu Asn Val

CTT CCC GGG TCG ATA CTC AGA GAC CTC AGC GAG GAA GAA ATG AAC GTC TAC
Leu Pro Gly Ser Ile Leu Arg Asp Leu Ser Glu Glu Glu Met Asn Val Tyr

CGG CGC CCT TTC ACG GAG CCT GGC GAA GGT CGG CGT CCG ACG CTC ACC TGG
Arg Arg Pro Phe Thr Glu Pro Gly Glu Gly Arg Arg Pro Thr Leu Thr Trp

CCA CGG CAG ATT CCG ATC GAT GGC GAA CCT GCA GAC GTC GTC GCC CTG GTA
Pro Arg Gln Ile Pro Ile Asp Gly Glu Pro Ala Asp Val Val Ala Leu Val

GCC GAG TAC GCC GCC TGG TTG CAG AGT GCG GAA GTA CCG AAG TTG TTT GTG
Ala Glu Tyr Ala Ala Trp Leu Gln Ser Ala Glu Val Pro Lys Leu Phe Val

AAT GCT GAA CCA GGG GCG TTG CTC ACG GGA CCG CAG CGC GAG TTC TGC CGG
Asn Ala Glu Pro Gly Ala Leu Leu Thr Gly Pro Gln Arg Glu Phe Cys Arg

AGT TGG ACC AAT CAG AGC GAG GTC ACC GTG TCA GGT AGC CAC TTC ATC CAG
Ser Trp Thr Asn Gln Ser Glu Val Thr Val Ser Gly Ser His Phe Ile Gln

GAA GAT TCA CCG GAT GAG ATC GGT GAA GCA TTG AAA GTG TGG ATG ACT GGA
Glu Asp Ser Pro Asp Glu Ile Gly Glu Ala Leu Lys Val Trp Met Thr Gly

870
TAG
End

7/26

Figure 6B
124DL4
(SEQ ID NOS:11 and 12)

1
 ATG CAG GTG GGG ATC GCC GCT ACG CTC GCC GAA ATG GAC AAG AAA CGT GTC
 Met Gln Val Gly Ile Ala Ala Thr Leu Ala Glu Met Asp Lys Lys Arg Val
 CGT GTG TAC AAC GCG GAG ATG GCC TAT GTC GAC ACG GGC CAG GGT GAT TCC
 Arg Val Tyr Asn Ala Glu Met Ala Tyr Val Asp Thr Gly Gln Gly Asp Ser
 GTT CTG TTT CTT CAC GGC AAC CCG ACG TCG TCG TAT CTG TGG AGG GGC GTA
 Val Leu Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg Gly Val
 ATG CCT TTT GTG ACG GAC GTC GCC CGA TGT GTG GCT CCG GAC CTG ATC GGT
 Met Pro Phe Val Thr Asp Val Ala Arg Cys Val Ala Pro Asp Leu Ile Gly
 ATG GGC GAT TCC GAC AAG CTC GAG TCG TCG ATG TAC CGC TTC GAG GAT CAC
 Met Gly Asp Ser Asp Lys Leu Glu Ser Ser Met Tyr Arg Phe Glu Asp His
 CGG CGG TAC CTG GAT GGT TTC CTC GAT GCG GTG GAC ATC GGA GAC GAT GTG
 Arg Arg Tyr Leu Asp Gly Phe Leu Asp Ala Val Asp Ile Gly Asp Asp Val
 ACG GTT GTG GTG CAC GAC TGG GGC TCT GCA CTC GGC TTC GAC TGG GCG AAC
 Thr Val Val Val His Asp Trp Gly Ser Ala Leu Gly Phe Asp Trp Ala Asn
 CGG CAC CGC GAC CGG GTC AAA GGA ATC GCA TAC ATG GAA GCG ATC GTT CGT
 Arg His Arg Asp Arg Val Lys Gly Ile Ala Tyr Met Glu Ala Ile Val Arg
 CCA TTG AGC TGG GAG GAG TGG CCG GAC GCA TCT CGC CGC CTG TTC GAG GCA
 Pro Leu Ser Trp Glu Glu Trp Pro Asp Ala Ser Arg Arg Leu Phe Glu Ala
 ATG CGC TCA GAC GCG GGG GAG GAG ATC GTT CTC GAA AAG AAT GTC TTC GTC
 Met Arg Ser Asp Ala Gly Glu Glu Ile Val Leu Glu Lys Asn Val Phe Val
 GAG CGG ATT CTG CTC GGC TCG GTC CTT TGT GAT CTG ACC GAG GAG GAA ATG
 Glu Arg Ile Leu Leu Gly Ser Val Leu Cys Asp Leu Thr Glu Glu Glu Met
 GCG GAG TAC CGG CGC CCG TAC CTC GAG CCG GGT GAG TCA CGG CGC CCG ATG
 Ala Glu Tyr Arg Arg Pro Tyr Leu Glu Pro Gly Glu Ser Arg Arg Pro Met
 CTG ACA TGG CCA CGC GAG ATC CCG ATC GAC GGC CAC CCC GCC GAC GTT GCG
 Leu Thr Trp Pro Arg Glu Ile Pro Ile Asp Gly His Pro Ala Asp Val Ala
 AAG ATC GTC GCG GAG TAC TCG TCG TGG CTC TCC GGG TCG GAG GTG CCG AAG
 Lys Ile Val Ala Glu Tyr Ser Ser Trp Leu Ser Gly Ser Glu Val Pro Lys
 CTC TTC GTC GAT GCC GAC CCG GGC GCC ATC CTG ACA GGT CCG AAG CGA GAC
 Leu Phe Val Asp Ala Asp Pro Gly Ala Ile Leu Thr Gly Pro Lys Arg Asp
 TTC TGC AGG GCG TGG CCG AAC CAG GTC GAG ACG ACC GTG GCA GGA ATC CAC
 Phe Cys Arg Ala Trp Pro Asn Gln Val Glu Thr Thr Val Ala Gly Ile His
 TTC ATA CAG GAG GAT TCC TCC GCC GAG ATC GGA GCC GCG ATC AGG ACC TGG
 Phe Ile Gln Glu Asp Ser Ser Ala Glu Ile Gly Ala Ala Ile Arg Thr Trp
 882
 TAC CTG GGA CTC TGA
 Tyr Leu Gly Leu End

8/26

Figure 6C
124DL5
(SEQ ID NOS:13 and 14)

1
 ATG GAG AAA CAC CGC GTA GAA GTT CTC GGT TCG GAG ATG GCC TAC ATC GAC
 Met Glu Lys His Arg Val Glu Val Leu Gly Ser Glu Met Ala Tyr Ile Asp
 GTG GGA GAG GGC GAC CCG ATC GTG TTC CTC CAC GGA AAT CCC ACG TCG TCG
 Val Gly Glu Gly Asp Pro Ile Val Phe Leu His Gly Asn Pro Thr Ser Ser
 TAC CTG TGG CGG AAC GTG ATT CCC CAC GTT GCC GGC TTG GGA CGC TGC ATC
 Tyr Leu Trp Arg Asn Val Ile Pro His Val Ala Gly Leu Gly Arg Cys Ile
 GCC CCG GAT CTG ATC GGC ATG GGA GAC TCG GAT AAG GTC CAT GGT CTC GAG
 Ala Pro Asp Leu Ile Gly Met Gly Asp Ser Asp Lys Val His Gly Leu Glu
 TAC CGC TTC GTT GAT CAC CGC CGG TAC CTC GAC GCC TTC CTT GAA GCG GTC
 Tyr Arg Phe Val Asp His Arg Arg Tyr Leu Asp Ala Phe Leu Glu Ala Val
 GGC GTT GAG GAT GCT GTG ACA TTC ATC GTA CAC GAC TGG GGC TCG GCT CTC
 Gly Val Glu Asp Ala Val Thr Phe Ile Val His Asp Trp Gly Ser Ala Leu
 GGA TTC GAC TGG GCG AAC CGT CAC CGT GAA GCG GTC GAA GGC ATC GCA TAC
 Gly Phe Asp Trp Ala Asn Arg His Arg Glu Ala Val Glu Gly Ile Ala Tyr
 ATG GAG GCG ATC GTG CAC CCG GTT GCT TGG AAC GAC TGG CCG GAG CTC TCT
 Met Glu Ala Ile Val His Pro Val Ala Trp Asn Asp Trp Pro Glu Leu Ser
 CGA CCG ATA TTT CAG GCG ATG AGG TCC TCG TCC GGT GAG AAG ATC GTG CTT
 Arg Pro Ile Phe Gln Ala Met Arg Ser Ser Ser Gly Glu Lys Ile Val Leu
 GAG AAG AAC GTG TTC GTG GAG CGA ATC CTG CCC GCT TCC GTG ATG CGC GAT
 Glu Lys Asn Val Phe Val Glu Arg Ile Leu Pro Ala Ser Val Met Arg Asp
 CTG AGC GAC GAC GAG ATG GAT GAG TAC CGT CGA CCG TTC CAG AAC CCG GGA
 Leu Ser Asp Asp Glu Met Asp Glu Tyr Arg Arg Pro Phe Gln Asn Pro Gly
 GAG GAT CGA AGA CCC ACG CTG ACG TGG CCA CGG GAG ATC CCG ATC GAT GGA
 Glu Asp Arg Arg Pro Thr Leu Thr Trp Pro Arg Glu Ile Pro Ile Asp Gly
 GAA CCG GGG GAC GTC GCC GCC ATC GTC GAT GAC TAC GGG CGA TGG CTC TCG
 Glu Pro Gly Asp Val Ala Ala Ile Val Asp Asp Tyr Gly Arg Trp Leu Ser
 GAG AGC GAT GTC CCA AAG CTC TTC ATC GAC GCG GAT CCG GGA GCG ATC CTC
 Glu Ser Asp Val Pro Lys Leu Phe Ile Asp Ala Asp Pro Gly Ala Ile Leu
 GTG GGT CCA GCG CGT GGG TTC TGC CGC GGC TGG CGG AAC CAG ACC GAA GTG
 Val Gly Pro Ala Arg Gly Phe Cys Arg Gly Trp Arg Asn Gln Thr Glu Val
 AGC GTC ACA GGA ACC CAC TTC ATC CAG GAA GAC TCT CCC GAC GAG ATC GGC
 Ser Val Thr Gly Thr His Phe Ile Gln Glu Asp Ser Pro Asp Glu Ile Gly
 849
 GCT GCG CTG GCT CGA TGG ATC GAG AAC CGG TAA
 Ala Ala Leu Ala Arg Trp Ile Glu Asn Arg End

9/26

Figure 6D
150DL2
(SEQ ID NOS:15 and 16)

1
 ATG GCT AGC GCG CCT ATC GAC CCG ACC GAC CCG CAT CCG AGA AAG CGG ATC
 Met Ala Ser Ala Pro Ile Asp Pro Thr Asp Pro His Pro Arg Lys Arg Ile

GCC GTG CTC GAT TCG GAG ATG AGC TAC GTC GAT ACC GGC GAG GGA GCG CCG
 Ala Val Leu Asp Ser Glu Met Ser Tyr Val Asp Thr Gly Glu Gly Ala Pro

ATC GTG TTC CTT CAC GGC AAC CCG ACT TCC TCC TAT CTT TGG CGC AAC ATC
 Ile Val Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg Asn Ile

ATC CCC TAT CTC GCG GAT CAC GGC AGA TGC CTC GCA CCG GAT CTG GTC GGG
 Ile Pro Tyr Leu Ala Asp His Gly Arg Cys Leu Ala Pro Asp Leu Val Gly

ATG GGC CGC TCC GGA AAA TCG CCG ACC CGG TCC TAT GGC TTT ACC GAT CAC
 Met Gly Arg Ser Gly Lys Ser Pro Thr Arg Ser Tyr Gly Phe Thr Asp His

GCG CGC TAT TTG GAC GCA TGG TTC GAC GCC CTG GAC CTG ACC CGC GAC GTG
 Ala Arg Tyr Leu Asp Ala Trp Phe Asp Ala Leu Asp Leu Thr Arg Asp Val

ACC CTG GTG ATT CAT GAC TGG GGA TCG GCG CTG GGC TTC CAC CGT GCC TTT
 Thr Leu Val Ile His Asp Trp Gly Ser Ala Leu Gly Phe His Arg Ala Phe

CGC TTC CCC GAA CAG ATC AAG GCG ATC GCC TAT ATG GAG GCC ATC GTC CGG
 Arg Phe Pro Glu Gln Ile Lys Ala Ile Ala Tyr Met Glu Ala Ile Val Arg

CCG CTC GTC TGG GCC GAC ATC GCC GGC GCC GAG CAG GCG TTT CGC GCG ATC
 Pro Leu Val Trp Ala Asp Ile Ala Gly Ala Glu Gln Ala Phe Arg Ala Ile

CGA TCC GAG GCC GGC GAA CAC ATG ATT CTG GAC GAG AAC TTT TTC GTC GAA
 Arg Ser Glu Ala Gly Glu His Met Ile Leu Asp Glu Asn Phe Phe Val Glu

GTG CTC CTT CCG GCG AGC ATC CTG CGC AGA TTG AGC GAT CTG GAG ATG GCC
 Val Leu Leu Pro Ala Ser Ile Leu Arg Arg Leu Ser Asp Leu Glu Met Ala

GCC TAC CGC GCA CCG TTC CTC GAC CGG GAG TCG CGA TGG CCG ACC CTG CGC
 Ala Tyr Arg Ala Pro Phe Leu Asp Arg Glu Ser Arg Trp Pro Thr Leu Arg

TGG CCG CGC GAG GTT CCG ATC GAG GGG GAG CCG GCC GAC GTG ACC GCC ATC
 Trp Pro Arg Glu Val Pro Ile Glu Gly Glu Pro Ala Asp Val Thr Ala Ile

GTC GAG GCC TAC GGA CGA TGG ATG GCC GAG AAC ACG CTG CCG AAG CTG CTG
 Val Glu Ala Tyr Gly Arg Trp Met Ala Glu Asn Thr Leu Pro Lys Leu Leu

GTC TTG GGT GAT CCG GGA GTG ATC GCT ACC GGC CGC ACG CGC GAC TTC TGT
 Val Leu Gly Asp Pro Gly Val Ile Ala Thr Gly Arg Thr Arg Asp Phe Cys

CGA AGC TGG AAG AAT CAG CGG GAG GTC ACC GTA TCC GGC AGC CAC TTC CTT
 Arg Ser Trp Lys Asn Gln Arg Glu Val Thr Val Ser Gly Ser His Phe Leu

CAG GAA GAC TCG CCG CAC GAG ATC GGC CTC GCG CTC CCG GAT TTC GTG CGG
 Gln Glu Asp Ser Pro His Glu Ile Gly Leu Ala Leu Arg Asp Phe Val Arg

876
 TCG GCG TAA
 Ser Ala End

10/26

Figure 6E
149DL1
(SEQ ID NOS:17 and 18)

1
 ATG CAA TTA ACG AAT GAA ACA GAA GCC AAC GCG ATC TCT GCG ACA AGT CCC
 Met Gln Leu Thr Asn Glu Thr Glu Ala Asn Ala Ile Ser Ala Thr Ser Pro
 TAC CCA AAA TTT CGG CGG TCG GTC TTC GGC CGC GAG ATG GCG TAC GTG GAA
 Tyr Pro Lys Phe Arg Arg Ser Val Phe Gly Arg Glu Met Ala Tyr Val Glu
 GTG GGA CGG GGC GAC CCC ATC GTA CTC TTG CAC GGC AAC CCC ACC TCG TCG
 Val Gly Arg Gly Asp Pro Ile Val Leu Leu His Gly Asn Pro Thr Ser Ser
 TAC CTC TGG CGC AAC GTG TTG CCG CAC CTG GCG CCG TTA GGC CGC TGT ATC
 Tyr Leu Trp Arg Asn Val Leu Pro His Leu Ala Pro Leu Gly Arg Cys Ile
 GCT CCA GAC CTG ATT GGT ATG GGA GAC TCA GAC AAA CTG CGT GAC AGT GGG
 Ala Pro Asp Leu Ile Gly Met Gly Asp Ser Asp Lys Leu Arg Asp Ser Gly
 CCG GGC TCA TAT CGC TTC GTC GAG CAG CGC CGT TAC CTC GAC GCC CTG CTC
 Pro Gly Ser Tyr Arg Phe Val Glu Gln Arg Arg Tyr Leu Asp Ala Leu Leu
 GAG GCT CTG GAC GTG CAC GAG CGA GTC ACG TTT GTC ATC CAT GAC TGG GGC
 Glu Ala Leu Asp Val His Glu Arg Val Thr Phe Val Ile His Asp Trp Gly
 TCG GCC CTC GGA TTT GAT TGG GCC AAC CGC CAC CGC GAA GCA ATG AGG GGT
 Ser Ala Leu Gly Phe Asp Trp Ala Asn Arg His Arg Glu Ala Met Arg Gly
 ATC GCG TAC ATG GAG GCG ATT GTG CGG CCG CAG GGC GGG GAC CAC TGG GAC
 Ile Ala Tyr Met Glu Ala Ile Val Arg Pro Gln Gly Gly Asp His Trp Asp
 AAC ATC AAC ATG CGT CCA CCC TTG CAG GCG CTG CGT TCA TGG GCC GGC GAG
 Asn Ile Asn Met Arg Pro Pro Leu Gln Ala Leu Arg Ser Trp Ala Gly Glu
 GTG ATG GTC CTG CAA GAC AAC TTC TTT ATC GAG AAG ATG CTG CCA GGG GGC
 Val Met Val Leu Gln Asp Asn Phe Phe Ile Glu Lys Met Leu Pro Gly Gly
 ATC CTG CGC GCC CTC TCC GCA GGG GAG ATG GCA GAA TAC CGG CGG CCG TTT
 Ile Leu Arg Ala Leu Ser Ala Gly Glu Met Ala Glu Tyr Arg Arg Pro Phe
 GCC GAG CCC GGC GAG GGG CGA CGA CCG ACG CTG ACA TGG CCC CGG GAA CTC
 Ala Glu Pro Gly Glu Gly Arg Arg Pro Thr Leu Thr Trp Pro Arg Glu Leu
 CCC ATA GAA GGC GAC CCC GCC GAA GTG GCT GCG ATC GTG GCC GCC TAC GCG
 Pro Ile Glu Gly Asp Pro Ala Glu Val Ala Ala Ile Val Ala Ala Tyr Ala
 GAC TGG TTA GCG ACA AGT GAT GTG CCC AAG CTT TTC CTG AAG GCC GAG CCC
 Asp Trp Leu Ala Thr Ser Asp Val Pro Lys Leu Phe Leu Lys Ala Glu Pro
 GGG GCG CTC ATC GCC GGC GGA GCG AAT CTC GAG ACC GTC CGC AAA TGG CCG
 Gly Ala Leu Ile Ala Gly Gly Ala Asn Leu Glu Thr Val Arg Lys Trp Pro
 GCG CAG ACC GAG GTA ACG GTC GCG GGG ATC CAT TTC ATC CAG GAA GAT TCG
 Ala Gln Thr Glu Val Thr Val Ala Gly Ile His Phe Ile Gln Glu Asp Ser
 918
 CCG GAC GAG ATC GGC CGG GCG ATC GCC GAT TGG ATG AGG GCG TTG AGC TGA
 Pro Asp Glu Ile Gly Arg Ala Ile Ala Asp Trp Met Arg Ala Leu Ser End

11/26

Figure 6F
149d19
(SEQ ID NOS:19 and 20)

1
 ATG CTC GTT GCG CAG ACA AGG AAG CAT CCA ATG ACT GAA ACG CCG CTG ACA
 Met Leu Val Ala Gln Thr Arg Lys His Pro Met Thr Glu Thr Pro Leu Thr
 AAA AAC ACC GTC GAT GTG CTG GGC ACG TCG ATG GCC TAT CAC GCG CGC GGC
 Lys Asn Thr Val Asp Val Leu Gly Thr Ser Met Ala Tyr His Ala Arg Gly
 GAG GGT GCG CCA ATA TTG TTT CTG CAC GGC AAC CCG ACC TCG TCC TAT CTG
 Glu Gly Ala Pro Ile Leu Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu
 TGG CGC GAC GTC ATT CCC GAA CTG GAG GGA CGC GGC CGG CTG ATC GCG CCG
 Trp Arg Asp Val Ile Pro Glu Leu Glu Gly Arg Gly Arg Leu Ile Ala Pro
 GAT CTG ATC GGG ATG GGC GAT TCC GCC AAA TTG CCA GAT CCC GGT GCG GAC
 Asp Leu Ile Gly Met Gly Asp Ser Ala Lys Leu Pro Asp Pro Gly Ala Asp
 ACC TAT CGC TTC ACG ACT CAT CGC AAA TAT CTC GAT GCC TTC GTC GAT GCG
 Thr Tyr Arg Phe Thr Thr His Arg Lys Tyr Leu Asp Ala Phe Val Asp Ala
 GTG ATC GGC CCG GCG CAA TCC ATC GTG ATG GTG GTG CAC GAC TGG GGC TCG
 Val Ile Gly Pro Ala Gln Ser Ile Val Met Val Val His Asp Trp Gly Ser
 GCG CTC GGT TTC GAC TGG GCC AAC CGT CAC CGC AAC CGT ATC CGT GGT ATC
 Ala Leu Gly Phe Asp Trp Ala Asn Arg His Arg Asn Arg Ile Arg Gly Ile
 GCC TAT ATG GAG GGG ATC GTG CGC CCG ATC GCC TCC TGG GAT GAA TGG AGC
 Ala Tyr Met Glu Gly Ile Val Arg Pro Ile Ala Ser Trp Asp Glu Trp Ser
 GCG TCG GCC ACG CCG ATC TTC CAG GGA TTT CGC TCC GAC AAG GGC GAG ACC
 Ala Ser Ala Thr Pro Ile Phe Gln Gly Phe Arg Ser Asp Lys Gly Glu Thr
 ATG ATC CTG GAG CGC AAC ATG TTC GTC GAG CGG GTG CTG CCG GGG TCG GTG
 Met Ile Leu Glu Arg Asn Met Phe Val Glu Arg Val Leu Pro Gly Ser Val
 TTG CGG AAA CTG ACC GAG GCC GAG ATG GCG GAA TAC CGC CGG CCC TAT CCG
 Leu Arg Lys Leu Thr Glu Ala Glu Met Ala Glu Tyr Arg Arg Pro Tyr Pro
 AAA GCC GAG GAC CGC TGG CCG ACG CTG ACC TGG CCG CGC CAG ATC CCG ATC
 Lys Ala Glu Asp Arg Trp Pro Thr Leu Thr Trp Pro Arg Gln Ile Pro Ile
 GCC GGC GAA CCC GCC GAT GTG GTG CAG ATC GCG GCG GAG TAT TCA CGA TGG
 Ala Gly Glu Pro Ala Asp Val Val Gln Ile Ala Ala Glu Tyr Ser Arg Trp
 ATG GCG GAG AAC GAC ATC CCA AAA CTG TTC GTC AAC GCC GAG CCC GGT GCG
 Met Ala Glu Asn Asp Ile Pro Lys Leu Phe Val Asn Ala Glu Pro Gly Ala
 ATC CTG ACC GGC GCG CCC CGG GAT TTC TGC CGA AGC TGG AAA AGC CAG ACC
 Ile Leu Thr Gly Ala Pro Arg Asp Phe Cys Arg Ser Trp Lys Ser Gln Thr
 GAA GTC ACC GTC GCG GGC TCG CAT TTC ATC CAG GAA GAC TCC GGA CCG GCG
 Glu Val Thr Val Ala Gly Ser His Phe Ile Gln Glu Asp Ser Gly Pro Ala
 912
 ATC GGC CGG GCG GTA GCC GCC TGG ATG ACG GCG AAT GGG CTA TAG
 Ile Gly Arg Ala Val Ala Ala Trp Met Thr Ala Asn Gly Leu End

12/26

Figure 6G

151d18

(SEQ ID NOS:21 and 22)

1
 ATG GCT AGC ATG ACC CAG GTT TCC ATC TCG ACC GAG GAC GCT TCC TAC CGG
 Met Ala Ser Met Thr Gln Val Ser Ile Ser Thr Glu Asp Ala Ser Tyr Arg
 AAG CGG GTC CGC GTG CTC GAT ACC GAC ATG GCC TAT GTC GAC GTG GGC GAA
 Lys Arg Val Arg Val Leu Asp Thr Asp Met Ala Tyr Val Asp Val Gly Glu
 GGC GAT CCG ATC GTG TTC CTG CAC GGC AAC CCG ACG CCG TCG TTC CTG TGG
 Gly Asp Pro Ile Val Phe Leu His Gly Asn Pro Thr Pro Ser Phe Leu Trp
 CGC AAC ATC ATC CCC TAC GCC CTG CCC TTC GGC CGC TGC CTC GCG CCC GAC
 Arg Asn Ile Ile Pro Tyr Ala Leu Pro Phe Gly Arg Cys Leu Ala Pro Asp
 TAC GTG GGG ATG GGC AAT TCC GGG CCG GCG CCG GGC GGG TCG TAT CGA TTC
 Tyr Val Gly Met Gly Asn Ser Gly Pro Ala Pro Gly Gly Ser Tyr Arg Phe
 GTC GAT CAC CGG CGC TAT CTC GAC GCC TGG TTC GAG GCC ATG GGC CTG ACG
 Val Asp His Arg Arg Tyr Leu Asp Ala Trp Phe Glu Ala Met Gly Leu Thr
 GAG AAC GTC ATC CTC GTG GTG CAC GAC TGG GGC TCG GCG CTC GGC TTC GAC
 Glu Asn Val Ile Leu Val Val His Asp Trp Gly Ser Ala Leu Gly Phe Asp
 TGG GCG CGG CGT CAC CCC GAT CGG GTC AAG GCC ATC GTC TAT ATG GAA GGG
 Trp Ala Arg Arg His Pro Asp Arg Val Lys Ala Ile Val Tyr Met Glu Gly
 ATC GTC CGG CCG TTC CTG TCC TGG GAC GAA TGG CCG GCC GTC ACG CGC GCC
 Ile Val Arg Pro Phe Leu Ser Trp Asp Glu Trp Pro Ala Val Thr Arg Ala
 TTC TTC CAG GGC CAG CGC ACG GCG GCG GGC GAG GAC CTG ATT CTC CAG AAG
 Phe Phe Gln Gly Gln Arg Thr Ala Ala Gly Glu Asp Leu Ile Leu Gln Lys
 AAC CTG TTC ATC GAG TAT CTC CTG CCG CTG CGC GGC ATC CCC AAG GAG GCG
 Asn Leu Phe Ile Glu Tyr Leu Leu Pro Leu Arg Gly Ile Pro Lys Glu Ala
 ATC GAG GTC TAC CGC CGT CCC TTC CGG AAC CCC GGT GCC TCG CGC CAG CCG
 Ile Glu Val Tyr Arg Arg Pro Phe Arg Asn Pro Gly Ala Ser Arg Gln Pro
 ATG CTG ACC TGG ACC CGC GAA CTG CCG ATC GCC GGC GAG CCC GCC GAC GTC
 Met Leu Thr Trp Thr Arg Glu Leu Pro Ile Ala Gly Glu Pro Ala Asp Val
 GTG GCC ATC GTC GAG GAC TAC GCC CGC TTC CTC TCC ACC AGC CCG ATC CCC
 Val Ala Ile Val Glu Asp Tyr Ala Arg Phe Leu Ser Thr Ser Pro Ile Pro
 AAG CTG TTC ATC GAC GCC GAG CCC GGC GGC TTC CTG ATC GGC GCC CAG CGC
 Lys Leu Phe Ile Asp Ala Glu Pro Gly Gly Phe Leu Ile Gly Ala Gln Arg
 GAA TTC TGC CGC GCC TGG CCC AAC CAG ACC GAG GTG ACG GTC CCA GGC GTC
 Glu Phe Cys Arg Ala Trp Pro Asn Gln Thr Glu Val Thr Val Pro Gly Val
 CAT TTC GTC CAG GAG GAC AGT CCG AGG GCG ATC GGC GAG GCA GTG TCC GCC
 His Phe Val Gln Glu Asp Ser Pro Arg Ala Ile Gly Glu Ala Val Ser Ala
 894
 TTC GTT GTT TCG TTG CGG GGC GCG TAG
 Phe Val Val Ser Leu Arg Gly Ala End

13/26

Figure 6H
757d16
(SEQ ID NOS:23 and 24)

1
 ATG AAT GTG GCG CGA GGC GAC ACG GTC GTC ACC GCC GCG GAG CCT GAT GGC
 Met Asn Val Ala Arg Gly Asp Thr Val Val Thr Ala Ala Glu Pro Asp Gly

CCG GAC CAC CTG CCT CGG CGT CGC GTG AAG GTG ATG GAT ACC GAA ATC AGC
 Pro Asp His Leu Pro Arg Arg Arg Val Lys Val Met Asp Thr Glu Ile Ser

TAT GTC GAT GTC GGT GAA GGT GAG CCC GTC GTC TTT CTG CAC GGC AAT CCC
 Tyr Val Asp Val Gly Glu Gly Glu Pro Val Val Phe Leu His Gly Asn Pro

ACG TGG TCC TAT CAA TGG CGC AAT ATC ATT CCT TAC ATC AGC CCC GTT CGC
 Thr Trp Ser Tyr Gln Trp Arg Asn Ile Ile Pro Tyr Ile Ser Pro Val Arg

CGC TGT CTC GCG CCC GAT CTT GTC GGC ATG GGT TGG TCC GGC AAG TCG CCG
 Arg Cys Leu Ala Pro Asp Leu Val Gly Met Gly Trp Ser Gly Lys Ser Pro

GGC AAA GCC TAT CGT TTC GTC GAT CAG GCC CGC TAC ATG GAT GCC TGG TTC
 Gly Lys Ala Tyr Arg Phe Val Asp Gln Ala Arg Tyr Met Asp Ala Trp Phe

GAG GCG TTG CAG CTG ACC CGG AAC GTT ACG TTG GTG TTG CAC GAC TGG GGC
 Glu Ala Leu Gln Leu Thr Arg Asn Val Thr Leu Val Leu His Asp Trp Gly

GCG GCC ATC GGC TTC TAT CGC GCC CGG CGC CAT CCT GAG CAG ATA AAG GCG
 Ala Ala Ile Gly Phe Tyr Arg Ala Arg Arg His Pro Glu Gln Ile Lys Ala

ATT GCC TAT TAT GAA GCT GTC GCT CAC TCG CGC CGA TGG GAC GAC TTC TCT
 Ile Ala Tyr Tyr Glu Ala Val Ala His Ser Arg Arg Trp Asp Asp Phe Ser

GGC GGC CGC GAC CGC CAA TTC CGC CTA TTA CGC TCG CCC GAC GGA GAA CGC
 Gly Gly Arg Asp Arg Gln Phe Arg Leu Leu Arg Ser Pro Asp Gly Glu Arg

CTC GTC CTC GAC GAG AAC ATG TTC GTG GAA GTC GTC CTG CCG CGC GGC ATT
 Leu Val Leu Asp Glu Asn Met Phe Val Glu Val Val Leu Pro Arg Gly Ile

TTG CGC AAG CTA ACC GAT GAC GAG ATG GAA GCC TAC CGA GCT CCT TAT CGC
 Leu Arg Lys Leu Thr Asp Asp Glu Met Glu Ala Tyr Arg Ala Pro Tyr Arg

GAT CGC GAG CGG CGC CTG CCG ACC CTG ATT TGG CCG CGC GAG GTG CCG ATC
 Asp Arg Glu Arg Arg Leu Pro Thr Leu Ile Trp Pro Arg Glu Val Pro Ile

GAA GGA GAG CCC GCG GAC GTC GTG GCC ATT GTC GAT GAG AAT GCG CGA TGG
 Glu Gly Glu Pro Ala Asp Val Val Ala Ile Val Asp Glu Asn Ala Arg Trp

CTT GCG GCC AGC GAT CGG CTG CCG AAG CTG TTC ATC AAG GGC GAT CCC GGA
 Leu Ala Ala Ser Asp Arg Leu Pro Lys Leu Phe Ile Lys Gly Asp Pro Gly

GCA ATC CAT ACC GGA CGC TTG CTC GAT CTG GTT CGC GCG TTT CCC AAT CAG
 Ala Ile His Thr Gly Arg Leu Leu Asp Leu Val Arg Ala Phe Pro Asn Gln

CGC GAG GTG ACC GTC AAG GGG CTG CAC CAC CTG CAG GAC GAT TCG CCA GAC
 Arg Glu Val Thr Val Lys Gly Leu His His Leu Gln Asp Asp Ser Pro Asp

915

GAA ATC GGC GCT GCG CTG CGG GCA TTC GTG CTC CGC AAA GGG ATT TGA
 Glu Ile Gly Ala Ala Leu Arg Ala Phe Val Leu Arg Lys Gly Ile End

14/26

Figure 6I
664d110
(SEQ ID NOS:25 and 26)

1
 ATG CTG GAC AGG ATT TCT GCC AAA GGC AAT CTT ACT CGT AGC TGC GTA AGC
 Met Leu Asp Arg Ile Ser Ala Lys Gly Asn Leu Thr Arg Ser Cys Val Ser
 GTC CTT GAC AGC GAG ATG AGT TAC GTC GCG ACT GGT CGG GGG CAC CCA ATC
 Val Leu Asp Ser Glu Met Ser Tyr Val Ala Thr Gly Arg Gly His Pro Ile
 GTT TTC CTG CAC GGG AAC CCG ACC TCA TCT TAT CTT TGG CGT AAC GTC ATC
 Val Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg Asn Val Ile
 CCC CAC GTC AGC AAC CTT GGC CGG TGC CTC GCG CCG GAC CTC GTT GGT ATG
 Pro His Val Ser Asn Leu Gly Arg Cys Leu Ala Pro Asp Leu Val Gly Met
 GGC CAG CCG GCC GCC TCT CCA CGG GGC GCC TAT CGC TTT GTG GAC CAT TCA
 Gly Gln Pro Ala Ala Ser Pro Arg Gly Ala Tyr Arg Phe Val Asp His Ser
 CGT TAT CTC GAC GCA TGG TTT GAG GCC CTG GAC TTG CGT AGA AAC GTT ACC
 Arg Tyr Leu Asp Ala Trp Phe Glu Ala Leu Asp Leu Arg Arg Asn Val Thr
 CTG GTG GTG CAC GAT TGG GGA TCG GCG CTC GGC TTT CAT TGG GCT TCC AGG
 Leu Val Val His Asp Trp Gly Ser Ala Leu Gly Phe His Trp Ala Ser Arg
 CAT CCC GAG CGG GTG CGG GCC ATC GCT TAC ATG GAG TCG ATC GTT CAG CCG
 His Pro Glu Arg Val Arg Ala Ile Ala Tyr Met Glu Ser Ile Val Gln Pro
 CGC GAC TGG GAA GAC CTC CCC CCA AGT CGG GCG CCG ATC TTT CGC GAC CTG
 Arg Asp Trp Glu Asp Leu Pro Pro Ser Arg Ala Pro Ile Phe Arg Asp Leu
 CGG TCC AAT AAA GGT GAG CGC ATG ATC CTC GAC GAA AAT GCC TTC ATT GAG
 Arg Ser Asn Lys Gly Glu Arg Met Ile Leu Asp Glu Asn Ala Phe Ile Glu
 ATT CTC TTG CCG AAG CTC GTC ATC CGG ACT CTG ACC AGC GCT GAG ATG GAT
 Ile Leu Leu Pro Lys Leu Val Ile Arg Thr Leu Thr Ser Ala Glu Met Asp
 GCA TAT CGT CGT CCA TTT ATT GAA CCG AAC TCG CGC TGG CCT ACA CTT ATC
 Ala Tyr Arg Arg Pro Phe Ile Glu Pro Asn Ser Arg Trp Pro Thr Leu Ile
 TGG CCG CGC GAG CTA CCG ATC GGT GGC GAA CCT GCC GAC GTG GTG AAA ATT
 Trp Pro Arg Glu Leu Pro Ile Gly Gly Glu Pro Ala Asp Val Val Lys Ile
 GTC GAA GAT TAC GGG CAA TGG CTT CTC AAG ACC CCG TTG CCG AAG TTG TTT
 Val Glu Asp Tyr Gly Gln Trp Leu Leu Lys Thr Pro Leu Pro Lys Leu Phe
 ATC AAC GCC GAG CCA GGG TCG CTG TTG ATC GGA CGG GCA CGT GAA TTC TGC
 Ile Asn Ala Glu Pro Gly Ser Leu Leu Ile Gly Arg Ala Arg Glu Phe Cys
 CGC TCC TGG CCA AAT CAA GAG GAA GTG ACG GTT CGG GGT ATC CAT TTT ATT
 Arg Ser Trp Pro Asn Gln Glu Glu Val Thr Val Arg Gly Ile His Phe Ile
 CAG GAA GAC AGT CCC GAT GAG ATT GGC GCT GCG CTT ACG CGC TTC ATG AGG
 Gln Glu Asp Ser Pro Asp Glu Ile Gly Ala Ala Leu Thr Arg Phe Met Arg
 90 0
 CAA ATA AGT CCA GAT TCC GTG ATC CGA AAC TAA
 Gln Ile Ser Pro Asp Ser Val Ile Arg Asn End

15/26

Figure 6J
664d17
(SEQ ID NOS:27 and 28)

1
ATG ATC TCT GCA GCA TTT CCG TAC CAA AAG AAG CGG CGG CAG GTC CTC GGC
Met Ile Ser Ala Ala Phe Pro Tyr Gln Lys Lys Arg Arg Gln Val Leu Gly

AGC GAG ATG GCA TAC GTC GAG GTA GGA GAG GGC GAC CCC ATC GTG TCG CTG
Ser Glu Met Ala Tyr Val Glu Val Gly Glu Gly Asp Pro Ile Val Ser Leu

CAC GGT AAT CCC ACC TCG TCC TAC CTC TGG CGC AAC ACA TTG CCC TAC CTG
His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg Asn Thr Leu Pro Tyr Leu

CAG CCA CTA GGC CGC TGC ATC GCC CCC GAC CTG ATC GGC ATG GGC GAC TCC
Gln Pro Leu Gly Arg Cys Ile Ala Pro Asp Leu Ile Gly Met Gly Asp Ser

GCC AAG CTG CCT AAC AGT GGC CCC GGC TCG TAT CGA TTC GTC GAG CAC CGC
Ala Lys Leu Pro Asn Ser Gly Pro Gly Ser Tyr Arg Phe Val Glu His Arg

CGC TAC CTC GAC ACC CTG CTC GAG GCC TTA AAT ATG CGC GAG CGG GTC ACC
Arg Tyr Leu Asp Thr Leu Leu Glu Ala Leu Asn Met Arg Glu Arg Val Thr

TTC GTC GCC CAT GAC TGG GGC TCG GCC CTC GCC TTC GAT TGG GCC AAT CGC
Phe Val Ala His Asp Trp Gly Ser Ala Leu Ala Phe Asp Trp Ala Asn Arg

CAC CGC GAG GCA GTG AAG GGT ATC GCG CAC ATG GAG GCG ATC GTG CGG CCG
His Arg Glu Ala Val Lys Gly Ile Ala His Met Glu Ala Ile Val Arg Pro

CAG GAC TGG ACC CAC TGG GAC ACG ATG GGG GCG CGT CCA ATC TTG CAG CAG
Gln Asp Trp Thr His Trp Asp Thr Met Gly Ala Arg Pro Ile Leu Gln Gln

TTG CGT TCC GAG GCT GGC GAG AAG TTG ATG CTG CAA GAA AAC CTC TTC ATC
Leu Arg Ser Glu Ala Gly Glu Lys Leu Met Leu Gln Glu Asn Leu Phe Ile

GAG ACG TTC CTG CCT AAG GCC ATC AAG CGA ACC CTC TCC GCC GAG GAG AAG
Glu Thr Phe Leu Pro Lys Ala Ile Lys Arg Thr Leu Ser Ala Glu Glu Lys

GCG GAG TAT AGA CGG CCG TTC GCC GAG CCG GGC GAG GGG CGA CGG CCG ACG
Ala Glu Tyr Arg Arg Pro Phe Ala Glu Pro Gly Glu Gly Arg Arg Pro Thr

CTG ACG TGG GTC CGG CAG ATC CCC ATC GAC GGC GAG CCC GCC GAC GTG ACT
Leu Thr Trp Val Arg Gln Ile Pro Ile Asp Gly Glu Pro Ala Asp Val Thr

TCG ATC GTA TCC GCC TAT GGG GAG TGG CTG GCG AAA AGC AAT GTG CCC AAG
Ser Ile Val Ser Ala Tyr Gly Glu Trp Leu Ala Lys Ser Asn Val Pro Lys

CTG TTC GTG AAG GCT GAG CCG GGC GTC CTC GTT GCT GGT GGC GCG AAC CTT
Leu Phe Val Lys Ala Glu Pro Gly Val Leu Val Ala Gly Gly Ala Asn Leu

GAC GCC GTC CGC TCA TGG CCA GCA CAG ACC GAG GTG ACG GTC CCG GGA ATC
Asp Ala Val Arg Ser Trp Pro Ala Gln Thr Glu Val Thr Val Pro Gly Ile

CAT TTC ATC CAG GAA GAT TCG CCG GAC GAG ATT GGG CGG GCC ATC GCC GGC
His Phe Ile Gln Glu Asp Ser Pro Asp Glu Ile Gly Arg Ala Ile Ala Gly

888
TGG ATT AAG ACG TTG GGC TAA
Trp Ile Lys Thr Leu Gly End

16/26

Figure 6K
124d148
(SEQ ID NOS:29 and 30)

1
ATG ACG GAG CAG GAG ATA TCA GCG GCG TTT CCC TTC GAG TCG AAG TTC GTG
Met Thr Glu Gln Glu Ile Ser Ala Ala Phe Pro Phe Glu Ser Lys Phe Val

GAT GTG CAA GGC TCC CGC ATG CAC TAC GTG GAG GAG GGC TCG GGC GAC CCG
Asp Val Gln Gly Ser Arg Met His Tyr Val Glu Glu Gly Ser Gly Asp Pro

GTG GTG TTC CTC CAC GGC AAC CCG ACC TCG TCC TAC CTG TGG CGG AAC GTC
Val Val Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg Asn Val

ATC CCT CAC GTG TCC CCG CTT GCG AGG TGC ATC GCG CCG GAC CTC ATC GGC
Ile Pro His Val Ser Pro Leu Ala Arg Cys Ile Ala Pro Asp Leu Ile Gly

ATG GGG AAG TCG GAC AAA CCG GAT ATC GAG TAC CGC TTC TTC GAC CAC GCC
Met Gly Lys Ser Asp Lys Pro Asp Ile Glu Tyr Arg Phe Phe Asp His Ala

GGG TAC GTT GAC GGG TTC ATC GAG GCA CTG GGA CTG CGG AAC ATC ACC TTC
Gly Tyr Val Asp Gly Phe Ile Glu Ala Leu Gly Leu Arg Asn Ile Thr Phe

GTC GCC TAC GAC TGG GGC TCC GCG CTG GCG TTC CAC TAC GCG CGA CGG CAC
Val Ala Tyr Asp Trp Gly Ser Ala Leu Ala Phe His Tyr Ala Arg Arg His

GAG GAT AAC GTA AAG GGG TTG GCG TTC ATG GAG GCC ATC GTG CGA CCG CTC
Glu Asp Asn Val Lys Gly Leu Ala Phe Met Glu Ala Ile Val Arg Pro Leu

ACC TGG GAC GAG TGG CCG GAG CAG GCA AGG CAG ATG TTC CAG GCG TTC CGG
Thr Trp Asp Glu Trp Pro Glu Gln Ala Arg Gln Met Phe Gln Ala Phe Arg

ACG CCG GGC GTC GGG GAG AAG ATG ATC CTG GAG GAA AAC GCC TTC GTG GAG
Thr Pro Gly Val Gly Glu Lys Met Ile Leu Glu Glu Asn Ala Phe Val Glu

CAG GTG TTG CCG GGA GCG ATC CTC CGC AAG CTG TCC GAC GAG GAG ATG GAC
Gln Val Leu Pro Gly Ala Ile Leu Arg Lys Leu Ser Asp Glu Glu Met Asp

CGC TAC CGG GAG CCG TTC CCC GAC CCC ACC AGC CGG AGG CCG ACG TGG CGC
Arg Tyr Arg Glu Pro Phe Pro Asp Pro Thr Ser Arg Arg Pro Thr Trp Arg

TGG CCC AAC GAG ATA CCT GTC GAG GGG AAG CCG CCG GAC GTG GTT GAG GCA
Trp Pro Asn Glu Ile Pro Val Glu Gly Lys Pro Pro Asp Val Val Glu Ala

GTG CAG GCC TAC GCC GAT TGG ATG GGC GAG TCG GAT GTG CCC AAG CTC CTC
Val Gln Ala Tyr Ala Asp Trp Met Gly Glu Ser Asp Val Pro Lys Leu Leu

CTG TAC GCT CAC CCA GGC GCG ATC CTC CGA GAG CCG CTG CTG GAG TGG TGC
Leu Tyr Ala His Pro Gly Ala Ile Leu Arg Glu Pro Leu Leu Glu Trp Cys

CGC AAC AAC ATG CGC AAC CTG AAG ACG GTC GAC ATC GGG CCC GGG GTG CAC
Arg Asn Asn Met Arg Asn Leu Lys Thr Val Asp Ile Gly Pro Gly Val His

TTC GTG CCG GAG GAC CGC CCC CAC GAG ATC GGG GAG GCC ATC GCG GAG TGG
Phe Val Pro Glu Asp Arg Pro His Glu Ile Gly Glu Ala Ile Ala Glu Trp

882
TAC CAG CGG CTG TAG
Tyr Gln Arg Leu End

17/26

Figure 6L
124d149
(SEQ ID NOS:31 and 32)

1
GTG AGC GAG ATC TCC CCG AAA GAG CCC ATG GAC AAG AAG CAC ATC CCC GTA
Met Ser Glu Ile Ser Pro Lys Glu Pro Met Asp Lys Lys His Ile Pro Val

CTC GGA AAA TCG ATG GCG TAC CGG GAC GTA GGT GAG GGA GAC CCG ATC GTC
Leu Gly Lys Ser Met Ala Tyr Arg Asp Val Gly Glu Gly Asp Pro Ile Val

TTC CTG CAC GGC AAC CCC ACC TCG TCG TAT CTC TGG CGC AAC ATC ATC CCC
Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg Asn Ile Ile Pro

CAC CTC GAG CCG CAT GCA CGC TGC ATC GCG CCG GAT CTC ATC GGA ATG GGA
His Leu Glu Pro His Ala Arg Cys Ile Ala Pro Asp Leu Ile Gly Met Gly

GAT TCG GAG AAG CTC GAG CCG AGC GGA CCG GAC CGC TAT CGC TTC ATC GAA
Asp Ser Glu Lys Leu Glu Pro Ser Gly Pro Asp Arg Tyr Arg Phe Ile Glu

CAT CGC GAA TAT CTC GAT GGT TTC TTC GAG GCT CTG GCC CTG CAA CAG AAC
His Arg Glu Tyr Leu Asp Gly Phe Phe Glu Ala Leu Ala Leu Gln Gln Asn

GTC ACC CTC GTC GTC CAC GAC TGG GGC TCC GGG CTG GGC TTC GAT TGG GCC
Val Thr Leu Val Val His Asp Trp Gly Ser Gly Leu Gly Phe Asp Trp Ala

AAC CGG AAT CGG GAG CGC ATC AAG GGG ATC GCT TAT ATG GAG GCC ATC GTT
Asn Arg Asn Arg Glu Arg Ile Lys Gly Ile Ala Tyr Met Glu Ala Ile Val

CGC CCG CTC AGC TGG CAA GAC TGG CCC GAC GAC GCC CGC GCG GTC TTT CAG
Arg Pro Leu Ser Trp Gln Asp Trp Pro Asp Asp Ala Arg Ala Val Phe Gln

GGT TTT CGC TCC GAA GCA GGA GAG TCG ATG GTG ATC GAG AAG AAC GTC TTC
Gly Phe Arg Ser Glu Ala Gly Glu Ser Met Val Ile Glu Lys Asn Val Phe

GTC GAA CGG GTC CTG CCC AGC TCG GTC CTG CGG ACG CTC CGT GAC GAG GAG
Val Glu Arg Val Leu Pro Ser Ser Val Leu Arg Thr Leu Arg Asp Glu Glu

ATG GAG GTC TAT CGC AGA CCG TTT CAA GAC GCC GGA GAA TCA AGG CGC CCG
Met Glu Val Tyr Arg Arg Pro Phe Gln Asp Ala Gly Glu Ser Arg Arg Pro

ACC CTC ACC TGG CCC CGC CAG ATC CCG ATC GAG GGG GAG CCG GAG GAT GTG
Thr Leu Thr Trp Pro Arg Gln Ile Pro Ile Glu Gly Glu Pro Glu Asp Val

ACC GAG ATC GCG AGC GCG TAC AGC GCG TGG ATG GCC GAG AAC GAT CTC CCC
Thr Glu Ile Ala Ser Ala Tyr Ser Ala Trp Met Ala Glu Asn Asp Leu Pro

AAG CTC TTC GTT AAC GCC GAG CCG GGC GCG ATC CTG ATC GGT CCG CAG CGC
Lys Leu Phe Val Asn Ala Glu Pro Gly Ala Ile Leu Ile Gly Pro Gln Arg

GAG TTC TGC CGC ACG TGG AAG AAT CAA CGC GAA GTC ACG GTA AGC GGT AGC
Glu Phe Cys Arg Thr Trp Lys Asn Gln Arg Glu Val Thr Val Ser Gly Ser

CAC TTC ATC CAG GAG GAC TCT CCG CAC GAA ATC GGC GAC GCG ATT GCA GGC
His Phe Ile Gln Glu Asp Ser Pro His Glu Ile Gly Asp Ala Ile Ala Gly

885
TGG TAC GCG GAT CTC TAG
Trp Tyr Ala Asp Leu End

18/26

Figure 6M
124d147
(SEQ ID NOS:33 and 34)

1
ATG ACC ACC GAA ATC TCG GCA GCC GAC CCC TTC GAG CGG CAC CGG GTC ACC
Met Thr Thr Glu Ile Ser Ala Ala Asp Pro Phe Glu Arg His Arg Val Thr

GTG CTC GAC TCA GAG ATG TCG TAC ATC GAC ACC GGC CCC GGC GCC GCA GGC
Val Leu Asp Ser Glu Met Ser Tyr Ile Asp Thr Gly Pro Gly Ala Ala Gly

AGT GAG CCG ATC GTG TTT CTC CAC GGG AAC CCA ACC TCG TCC TAC CTC TGG
Ser Glu Pro Ile Val Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp

CGC AAC ATC ATT CCC CAC GTC CAG CAC CTC GGG CGC TGC CTC GCA CCG GAT
Arg Asn Ile Ile Pro His Val Gln His Leu Gly Arg Cys Leu Ala Pro Asp

CTG ATC GGG ATG GGC AAC TCG GAC CCT TCC CCT AAC GGC AGC TAC CGC TTC
Leu Ile Gly Met Gly Asn Ser Asp Pro Ser Pro Asn Gly Ser Tyr Arg Phe

GTC GAC CAC GTG AAG TAC CTC GAC GCC TGG TTG GAC GCC GTC GGC GTG ACC
Val Asp His Val Lys Tyr Leu Asp Ala Trp Leu Asp Ala Val Gly Val Thr

GAC CAG GTG ACG TTC GTG CAT GAC TGG GGA TCG GCG CTC GGC TTC CAC
Asp Gln Val Thr Phe Val Val His Asp Trp Gly Ser Ala Leu Gly Phe His

TGG GCA GAC CGC CAT CGC GAC GCC ATC CGA GGC TTC GCC TAC ATG GAG GCG
Trp Ala Asp Arg His Arg Asp Ala Ile Arg Gly Phe Ala Tyr Met Glu Ala

ATC GTG CGC CCC GTC GAG TGG GAG GAC TGG CCG CCT GCG GAC GTC TTC CGA
Ile Val Arg Pro Val Glu Trp Glu Asp Trp Pro Pro Ala Asp Val Phe Arg

CGG ATG CGA TCC GAG GAG GGC GAC GAG ATG ATG CTC GAG GGC AAC TTC TTC
Arg Met Arg Ser Glu Glu Gly Asp Glu Met Met Leu Glu Gly Asn Phe Phe

GTC GAG GTG ATC CTG CCC CGC AGC GTC CTC CGC GGC CTC ACT GAC GAA GAG
Val Glu Val Ile Leu Pro Arg Ser Val Leu Arg Gly Leu Thr Asp Glu Glu

ATG GAG GTA TAC CGG CGA CCC TAC CTC GAG CGC GGC GAG TCG CGG CGT CCG
Met Glu Val Tyr Arg Arg Pro Tyr Leu Glu Arg Gly Glu Ser Arg Arg Pro

ACG CTG ACC TGG CCG CGG GAG ATC CCG CTG TCA GGC GAG CCG GCG GAT GTC
Thr Leu Thr Trp Pro Arg Glu Ile Pro Leu Ser Gly Glu Pro Ala Asp Val

GTC GAG ATC GTC AGC GCC TAC AGC AAA TGG CTG TCC GAG ACG ACC GTG CCG
Val Glu Ile Val Ser Ala Tyr Ser Lys Trp Leu Ser Glu Thr Thr Val Pro

AAG CTC CTC GTC ACT GCC GAG CCG GGT GCG ATC CTG AAC GGC CCG CAG CTG
Lys Leu Leu Val Thr Ala Glu Pro Gly Ala Ile Leu Asn Gly Pro Gln Leu

GAG TTC GCT CGC GGG TTT GCC AAC CAG ACC GAG GTC CGA GTC GCC GGC TCG
Glu Phe Ala Arg Gly Phe Ala Asn Gln Thr Glu Val Arg Val Ala Gly Ser

CAC TTC ATC CAG GAG GAC TCG CCA CAC GAG ATC GGC GCC GCC CTC GCC GAG
His Phe Ile Gln Glu Asp Ser Pro His Glu Ile Gly Ala Ala Leu Ala Glu

888
TGG TAC CCG ACG ACG ACC TGA
Trp Tyr Pro Thr Thr Thr End

19/26

Figure 6N

282dl6

(SEQ ID NOS:35 and 36)

1
 ATG TAC GAG AAA CGG TTC GTA TCT GTC CTC GGT CAC CGG ATG GCA TAC GTC
 Met Tyr Glu Lys Arg Phe Val Ser Val Leu Gly His Arg Met Ala Tyr Val

GAG CAA GGA GCC GGG GAC CCG ATC GTG TTC CTA CAT GGC AAC CCC ACC TCG
 Glu Gln Gly Ala Gly Asp Pro Ile Val Phe Leu His Gly Asn Pro Thr Ser

TCC TAC CTG TGG CGG AAG GTC ATC CCC GCG CTA ACG GAG CAG GGA CGA TGC
 Ser Tyr Leu Trp Arg Lys Val Ile Pro Ala Leu Thr Glu Gln Gly Arg Cys

ATC GCT CCC GAC TTG ATC GGC ATG GGC GAC TCC GAG AAG CTG GCT GAC AGC
 Ile Ala Pro Asp Leu Ile Gly Met Gly Asp Ser Glu Lys Leu Ala Asp Ser

GGC CCC GGT AGC TAC CGC TTC GTG GAA CAT CGG CGT TTC CTC GAT GCC TTC
 Gly Pro Gly Ser Tyr Arg Phe Val Glu His Arg Arg Phe Leu Asp Ala Phe

CTC GAA AGG GTT GGG ATC AGC GAG TCG GTG GTC CTG GTG ATC CAC GAC TGG
 Leu Glu Arg Val Gly Ile Ser Glu Ser Val Val Leu Val Ile His Asp Trp

GGT TCG GCC CTC GGC TTC GAC TGG GCC TAC CGC CAC CAA AAC GCC GTC AAG
 Gly Ser Ala Leu Gly Phe Asp Trp Ala Tyr Arg His Gln Asn Ala Val Lys

GGG ATC GCA TAT ATG GAA GCG CTG GTC GGG CCT GTA GGT TGG AGC GAC TGG
 Gly Ile Ala Tyr Met Glu Ala Leu Val Gly Pro Val Gly Trp Ser Asp Trp

CCG GAG TCG GCC CGG TCC ATC TTC CAG GCT TTC CGC TCC GAA GCC GGG GAC
 Pro Glu Ser Ala Arg Ser Ile Phe Gln Ala Phe Arg Ser Glu Ala Gly Asp

AGC CTC ATC CTC GAG AAG AAC TTC TTC GTC GAG CGG GTG CTG CCC GCA TCG
 Ser Leu Ile Leu Glu Lys Asn Phe Phe Val Glu Arg Val Leu Pro Ala Ser

GTG CTC GAT CCC CTG CCA GAA GAA GTG CTC GAC GAG TAT CGA CAG CCG TTT
 Val Leu Asp Pro Leu Pro Glu Glu Val Leu Asp Glu Tyr Arg Gln Pro Phe

CTC GAA CCG GGC GAG TCT CGC CGA CCC ACC CTC ACC TGG CCT AGG GAG ATC
 Leu Glu Pro Gly Glu Ser Arg Arg Pro Thr Leu Thr Trp Pro Arg Glu Ile

CCC ATC GAC GGT GAG CCG GCC GAC GTC CAC GAG ATC GTG TCC GCG TAC AAC
 Pro Ile Asp Gly Glu Pro Ala Asp Val His Glu Ile Val Ser Ala Tyr Asn

CGC TGG ATT GGA TCC TCT CCG GTG CCC AAG CTG TAC GTC AAC GCC GAT CCC
 Arg Trp Ile Gly Ser Ser Pro Val Pro Lys Leu Tyr Val Asn Ala Asp Pro

GGC TTC TTC AGC CCT GGC ATC GTC GAG GCC ACG GCC GCC TGG CCC AAC CAG
 Gly Phe Phe Ser Pro Gly Ile Val Glu Ala Thr Ala Ala Trp Pro Asn Gln

GAA ACA GTC ACG GTC CGT GGC CAC CAT TTC TTG CAG GAA GAC TCT GGT GAA
 Glu Thr Val Thr Val Arg Gly His His Phe Leu Gln Glu Asp Ser Gly Glu

861
 GCG ATC GGT GAT GCC ATC GCC GAC TGG TAC CGG CGT GTC TCG TGA
 Ala Ile Gly Asp Ala Ile Ala Asp Trp Tyr Arg Arg Val Ser End

20/26

Figure 60
151dl17
(SEQ ID NOS:37 and 38)

1
ATG AAT GCA ATC GCC AGT GAG CCC TAT GGG CAA CTG AGG TTC CAA GAG ATC
Met Asn Ala Ile Ala Ser Glu Pro Tyr Gly Gln Leu Arg Phe Gln Glu Ile

GCC GGC AAG CAA ATG GCG TAC ATC GAC GAG GGC GTC GGT GAT GCC ATC GTT
Ala Gly Lys Gln Met Ala Tyr Ile Asp Glu Gly Val Gly Asp Ala Ile Val

TTC CAG CAC GGC AAC CCC ACG TCG TCC TAC CTG TGG CGC AAC GTT ATG CCG
Phe Gln His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg Asn Val Met Pro

CAC CTG GAA GGG CTG GGC CGG CTG GTG GCG TGC GAT CTG ATC GGG ATG GGG
His Leu Glu Gly Leu Gly Arg Leu Val Ala Cys Asp Leu Ile Gly Met Gly

GCG TCG GAG AAG CTC AGC CCA TCG GGC CCC GAC CGC TAT AAC TAT GCC GAG
Ala Ser Glu Lys Leu Ser Pro Ser Gly Pro Asp Arg Tyr Asn Tyr Ala Glu

CAG CGC GAC TAT CTG TTC GCG CTC TGG GAT GCG CTC GAC CTT GGC GAT CAC
Gln Arg Asp Tyr Leu Phe Ala Leu Trp Asp Ala Leu Asp Leu Gly Asp His

GTG GTG CTG GTG CTG CAT GAC TGG GGC TCA GCA TTG GGC TTC GAC TGG GCC
Val Val Leu Val Leu His Asp Trp Gly Ser Ala Leu Gly Phe Asp Trp Ala

AAC CAG CAT CGC GAC CGA GTG CAG GGC ATC GCA TTC ATG GAG GCG ATC GTC
Asn Gln His Arg Asp Arg Val Gln Gly Ile Ala Phe Met Glu Ala Ile Val

AGC CCG ATC ACA TGG GCC GAC TTC CAT CCC AGC GTG CGA GGC GTG TTC CAG
Ser Pro Ile Thr Trp Ala Asp Phe His Pro Ser Val Arg Gly Val Phe Gln

GGG TTC CGG TCG CCC GAG GGT GAG CGG ATG GTG TTG GAG CAG AAC ATC TTT
Gly Phe Arg Ser Pro Glu Gly Glu Arg Met Val Leu Glu Gln Asn Ile Phe

GTC GAA GGG GTA CTG CCC GGG GCG ATC CAG CGC CGA CTG TCT GAC GAG GAG
Val Glu Gly Val Leu Pro Gly Ala Ile Gln Arg Arg Leu Ser Asp Glu Glu

ATG GGC CAT TAC CGG CAG CCA TTC GTC GAA CCC GGC GAG GAC CGG CGA CCG
Met Gly His Tyr Arg Gln Pro Phe Val Glu Pro Gly Glu Asp Arg Arg Pro

ACC TTG TCG TGG CCA CGG AAC ATC CCC ATC GAC GGC GAG CCG GCC GAG GTC
Thr Leu Ser Trp Pro Arg Asn Ile Pro Ile Asp Gly Glu Pro Ala Glu Val

GTC GCG GTC GTC GAC GAG TAC CGT AGC TGG CTC GAG AAG AGC GAC ATT CCA
Val Ala Val Val Asp Glu Tyr Arg Ser Trp Leu Glu Lys Ser Asp Ile Pro

AAG CTG TTC GTG AAC GCC GAG CCG GGC GCG ATC GTC ACC GGC CGC ATC CGC
Lys Leu Phe Val Asn Ala Glu Pro Gly Ala Ile Val Thr Gly Arg Ile Arg

GAC TAT ATC CGG ACG TGG GCG AAC CTC AGC GAA ATC ACG GTT CCC GGA GTG
Asp Tyr Ile Arg Thr Trp Ala Asn Leu Ser Glu Ile Thr Val Pro Gly Val

CAT TTC ATC CAA GAA GAC AGC CCA GAC GGA ATC GGC TCG GCC GTG GCA CAG
His Phe Ile Gln Glu Asp Ser Pro Asp Gly Ile Gly Ser Ala Val Ala Gln

891
TTC CTG CAG CAG CTA CGC GCC TAA
Phe Leu Gln Gln Leu Arg Ala End

21/26

Figure 6P
828DL29-1
(SEQ ID NO: 43 and 44)

1
atg tca gaa atc ggt aca ggc ttc ccc ttc gac ccc cat tat gtg gaa
Met Ser Glu Ile Gly Thr Gly Phe Pro Phe Asp Pro His Tyr Val Glu

gtc ctg ggc gag cgt atg cac tac gtc gat gtt gga ccg cgg gat ggc
Val Leu Gly Glu Arg Met His Tyr Val Asp Val Gly Pro Arg Asp Gly

acg cct gtg ctg ttc ctg cac ggt aac ccg acc tcg tcc tac ctg tgg
Thr Pro Val Leu Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp

cgc aac atc atc ccg cat gta gca ccg agt cat ccg tgc att gct cca
Arg Asn Ile Ile Pro His Val Ala Pro Ser His Arg Cys Ile Ala Pro

gac ctg atc ggg atg gga aaa tcg gac aaa cca gac ctc ggt tat ttc
Asp Leu Ile Gly Met Gly Lys Ser Asp Lys Pro Asp Leu Gly Tyr Phe

ttc gac gac cac gtc cgc tac ctc gat gcc ttc atc gaa gcc ttg ggt
Phe Asp Asp His Val Arg Tyr Leu Asp Ala Phe Ile Glu Ala Leu Gly

ttg gaa gag gtc gtc ttg gtc atc cac gac tgg ggc tca gct ctc gga
Leu Glu Glu Val Val Leu Val Ile His Asp Trp Gly Ser Ala Leu Gly

ttc cac tgg gcc aag cgc aat ccg gaa ccg gtc aaa ggt att gca tgt
Phe His Trp Ala Lys Arg Asn Pro Glu Arg Val Lys Gly Ile Ala Cys

atg gaa ttc atc ccg tct atc ccg acg tgg gac gaa tgg ccg gaa ttc
Met Glu Phe Ile Arg Ser Ile Pro Thr Trp Asp Glu Trp Pro Glu Phe

gcc cgt gag acc ttc cag gcc ttc ccg acc gcc gac gtc ggc cga gag
Ala Arg Glu Thr Phe Gln Ala Phe Arg Thr Ala Asp Val Gly Arg Glu

ttg atc atc gat cag aac gct ttc atc gag cat gtg ctc ccg aaa tac
Leu Ile Ile Asp Gln Asn Ala Phe Ile Glu His Val Leu Pro Lys Tyr

gtc gtc cgt ccg ctt acg gag gtc gag atg gac cac tat cgc gag ccc
Val Val Arg Pro Leu Thr Glu Val Glu Met Asp His Tyr Arg Glu Pro

ttc ctc aag cct gct gac cga gag cca ctg tgg cga ttc ccc aac gag
Phe Leu Lys Pro Ala Asp Arg Glu Pro Leu Trp Arg Phe Pro Asn Glu

ctc ccc atc gcc ggt gag ccc gcg aac atc gtc gcg ctc gtc gag gca
Leu Pro Ile Ala Gly Glu Pro Ala Asn Ile Val Ala Leu Val Glu Ala

tac atg aac tgg ctg cac cag tca cct gtc ccg aag ttg ttg ttc tgg
Tyr Met Asn Trp Leu His Gln Ser Pro Val Pro Lys Leu Leu Phe Trp

ggc aca ccc ggc cta ctg atc ccc ccg gcc gaa gcc tcg aga ctt gcc
Gly Thr Pro Gly Leu Leu Ile Pro Pro Ala Glu Ala Ser Arg Leu Ala

gaa agc ctc ccc aac tgc aag aca gtg gac atc ggc ccg gga ctg cac
Glu Ser Leu Pro Asn Cys Lys Thr Val Asp Ile Gly Pro Gly Leu His

ttc ctc cag gaa gac aac ccg gac ctt atc ggc agt gag atc gcg cgc
Phe Leu Gln Glu Asp Asn Pro Asp Leu Ile Gly Ser Glu Ile Ala Arg

tgg ctc gcc gga ctc gcg agc ggc ctc ggc gac tac cat cat cat cat
Trp Leu Ala Gly Leu Ala Ser Gly Leu Gly Asp Tyr His His His His

921
cat cat taa
His His END

Figure 6Q

22/26

959DL4

(SEQ ID NO:45 and 46)

1
atg agc gaa gaa gcg atc tcg gcc ctc gac ccg cat cca cgc aag aaa
Met Ser Glu Glu Ala Ile Ser Ala Leu Asp Pro His Pro Arg Lys Lys

cag gaa ctg ctc gcc acc tcg atg tct tat gtc gat acc ggg act ggc
Gln Glu Leu Leu Gly Thr Ser Met Ser Tyr Val Asp Thr Gly Thr Gly

gag ccg gtg gtg ttc ctg cac gcc aat cca acc tcc tcg tac ttg tgg
Glu Pro Val Val Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp

cgg aac gtg att cca cat gtc gcg ccg gtc gcc agg tgc atc gct ccc
Arg Asn Val Ile Pro His Val Ala Pro Val Ala Arg Cys Ile Ala Pro

gac ctg atc ggg atg gga gcg tca ggg cct tcc tct agc gcc aac tac
Asp Leu Ile Gly Met Gly Ala Ser Gly Pro Ser Ser Ser Gly Asn Tyr

acg ttc gcc gat cat gcg cga cat ctc gat gcg ctc ctc gac gcg att
Thr Phe Ala Asp His Ala Arg His Leu Asp Ala Leu Leu Asp Ala Ile

ttg cca aag gcc cag ctc agc ttg gtg gtg cac gac tgg gga tgc gcg
Leu Pro Lys Gly Gln Leu Ser Leu Val Val His Asp Trp Gly Ser Ala

ctg gcc ttc cac tgg gcc aat cgc aat cgg gat cgg gta agg gga atc
Leu Gly Phe His Trp Ala Asn Arg Asn Arg Asp Arg Val Arg Gly Ile

gcc tac atg gaa gcg att gtg cga ccg gtg ctg tgg tgc gag tgg ccc
Ala Tyr Met Glu Ala Ile Val Arg Pro Val Leu Trp Ser Glu Trp Pro

gaa cgt gcc cga gac att ttc aag acg ctg cga act ccg gcc gcc gaa
Glu Arg Ala Arg Asp Ile Phe Lys Thr Leu Arg Thr Pro Ala Gly Glu

gag atg att ctc aaa aac aac gta ttc gtg gag cgg atc ctg ccc gcc
Glu Met Ile Leu Lys Asn Asn Val Phe Val Glu Arg Ile Leu Pro Gly

agc gtc ttg cgc aaa ttg agc tcc gaa gaa atg gac aat tat cgc cgg
Ser Val Leu Arg Lys Leu Ser Ser Glu Glu Met Asp Asn Tyr Arg Arg

ccc ttt cgc gac gca gga gaa tcg cgg cgg cca aca ctc acg tgg ccg
Pro Phe Arg Asp Ala Gly Glu Ser Arg Arg Pro Thr Leu Thr Trp Pro

cgt cag att ccg atc gag ggt gag ccg gcc gac gtg gtg gaa atc gtg
Arg Gln Ile Pro Ile Glu Gly Glu Pro Ala Asp Val Val Glu Ile Val

cag aaa tat tcc gag tgg ctg gca cag agc gcg gtg ccc aaa ctg ctc
Gln Lys Tyr Ser Glu Trp Leu Ala Gln Ser Ala Val Pro Lys Leu Leu

gtg aat gcg gag ccg gga gcg att ttg ata ggc gcg cag cgc gag ttt
Val Asn Ala Glu Pro Gly Ala Ile Leu Ile Gly Ala Gln Arg Glu Phe

tgc cac caa tgg ccg aat cag cgc gaa gtc acg gtc aag gcc gta cac
Cys His Gln Trp Pro Asn Gln Arg Glu Val Thr Val Lys Gly Val His

ttc atc cag gaa gat tcc ccg cac gag atc ggg cga gcg atc gca gac
Phe Ile Gln Glu Asp Ser Pro His Glu Ile Gly Arg Ala Ile Ala Asp

882
tgg tac cga gga atc tga
Trp Tyr Arg Gly Ile END

23/26

Figure 6R
959DL2
(SEQ ID NO:47 and 48)

1
atg gct act act gga gaa gcg ata tct tct gca ttt ccg tac gag aag
Met Ala Thr Thr Gly Glu Ala Ile Ser Ser Ala Phe Pro Tyr Glu Lys

cag cgc cgg cgg gtt ctg ggg aga gag atg gcc tat gtg gaa gtg ggg
Gln Arg Arg Arg Val Leu Gly Arg Glu Met Ala Tyr Val Glu Val Gly

gcc gcc gac ccg atc gtg ctg ctg cac gcc aat ccg acc tca tcc tac
Ala Gly Asp Pro Ile Val Leu Leu His Gly Asn Pro Thr Ser Ser Tyr

ctc tgg cgc aat gtc ctg ccg cat ctc caa cta cga gcc cga tgc atc
Leu Trp Arg Asn Val Leu Pro His Leu Gln Leu Arg Gly Arg Cys Ile

gcg ccc gac ctg att gcc atg gcc gac tcc gat aag cta cct gac agc
Ala Pro Asp Leu Ile Gly Met Gly Asp Ser Asp Lys Leu Pro Asp Ser

ggc ccg agc tcg tat cgc ttc gta gat cag cgc cgc tac ctc gat gcg
Gly Pro Ser Ser Tyr Arg Phe Val Asp Gln Arg Arg Tyr Leu Asp Ala

ctg ctg gag gca ttg gac gta cgt gag cgt gtg acg ctc gtc att cat
Leu Leu Glu Ala Leu Asp Val Arg Glu Arg Val Thr Leu Val Ile His

gac tgg gcc tcg gga ctt gcc ttt gac tgg gcc aac cga cac cgc gac
Asp Trp Gly Ser Gly Leu Gly Phe Asp Trp Ala Asn Arg His Arg Asp

gcc gta aag gcc atc gca tac atg gag gcg atc gtg cgc ccg cag gga
Ala Val Lys Gly Ile Ala Tyr Met Glu Ala Ile Val Arg Pro Gln Gly

tgg gac cac tgg gac gta atg aat atg cgt cca ttc cta gag gcg ctg
Trp Asp His Trp Asp Val Met Asn Met Arg Pro Phe Leu Glu Ala Leu

cgt tcc gag gcc gcc gag aag atg gtc ctt gaa gac aac ttt ttc atc
Arg Ser Glu Ala Gly Glu Lys Met Val Leu Glu Asp Asn Phe Phe Ile

gag aag att tta cca gcc gct gtt ctc cgc aag ctc acc gcg gat gaa
Glu Lys Ile Leu Pro Gly Ala Val Leu Arg Lys Leu Thr Ala Asp Glu

atg gcg gag tat cgt cgg ccg ttc gct gaa ccc gcc gag gcg cga cga
Met Ala Glu Tyr Arg Arg Pro Phe Ala Glu Pro Gly Glu Ala Arg Arg

ccg act ctg act tgg cca cgg gag att cct atc gat gcc aaa ccc gcc
Pro Thr Leu Thr Trp Pro Arg Glu Ile Pro Ile Asp Gly Lys Pro Ala

gac gtg aat acg att gtg gcg gcc tat tcg gag tgg ctt gcg acg agc
Asp Val Asn Thr Ile Val Ala Ala Tyr Ser Glu Trp Leu Ala Thr Ser

gat gtg ccc aag cta ttc ata aaa gcc gag ccc gcc gca ctc ctt gcc
Asp Val Pro Lys Leu Phe Ile Lys Ala Glu Pro Gly Ala Leu Leu Gly

agc ggg att aac ctt gaa acc gct cgc tcc tgg cct gcg cag acg gaa
Ser Gly Ile Asn Leu Glu Thr Ala Arg Ser Trp Pro Ala Gln Thr Glu

gta acc gtg gcc gga gtt cat ttt gtg caa gag gat tcg cca gat gag
Val Thr Val Ala Gly Val His Phe Val Gln Glu Asp Ser Pro Asp Glu

att ggg cgc tcg gat tct gcc gac cct tgg ccc gct gcc gga cga aat
Ile Gly Arg Ser Asp Ser Gly Asp Pro Trp Pro Ala Gly Gly Arg Asn

cgc cgt cta ctc gcc ccg tct gcc gca gca tct cga tca cta cag tcc

24/26

Arg Arg Leu Leu Ala Pro Ser Gly Ala Ala Ser Arg Ser Leu Gln Ser

gtt cgc gct cag ctt cgc act gcc ctg caa tac ccc cgg cct gcg gtt
Val Arg Ala Gln Leu Arg Thr Ala Leu Gln Tyr Pro Arg Pro Ala Val

1032
cct gtg ccg cga cag ctt cga tga
Pro Val Pro Arg Gln Leu Arg END

25/26




FIG. 7

26/26




FIG. 8

1

SEQUENCE LISTING

<110> Richardson, Toby H.
Robertson, Dan E.
Gray, Kevin

<120> ENZYMES HAVING DEHALOGENASE ACTIVITY AND METHODS OF USE
THEREOF

<130> DIVER1550-1

<140> Not Yet Known

<141> 2000-12-01

<160> 48

<170> PatentIn Ver. 2.1

<210> 1

<211> 954

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially
modified (mutated) Dehalogenase

<220>

<221> CDS

<222> (1)..(954)

<400> 1

atg ggg ggt tct cat cat cat cat cat cat ggt atg tct gaa ata ggt	48
Met Gly Gly Ser His His His His His His Gly Met Ser Glu Ile Gly	
1 5 10 15	
acc ggt ttt ccc ttc gac cct cat tat gtg gaa gtc ctg ggc gag cgt	96
Thr Gly Phe Pro Phe Asp Pro His Tyr Val Glu Val Leu Gly Glu Arg	
20 25 30	
atg cac tac gtc gat gtt gga ccg cgg gat ggc acg cct gtg ctg ttc	144
Met His Tyr Val Asp Val Gly Pro Arg Asp Gly Thr Pro Val Leu Phe	
35 40 45	
ctg cac ggt aac ccg acc tcg tcc tac ctg tgg cgc aac atc atc ccg	192
Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg Asn Ile Ile Pro	
50 55 60	
cat gta gca ccg agt cat cgg tgc att gct cca gac ctg atc ggg atg	240
His Val Ala Pro Ser His Arg Cys Ile Ala Pro Asp Leu Ile Gly Met	
65 70 75 80	
gga aaa tcg gac aaa cca gac ctc gat tat ttc ttc gac gac cac gtc	288
Gly Lys Ser Asp Lys Pro Asp Leu Asp Tyr Phe Phe Asp Asp His Val	
85 90 95	
cgc tac ctc gat gcc ttc atc gaa gcc ttg ggt ttg gaa gag gtc gtc	336
Arg Tyr Leu Asp Ala Phe Ile Glu Ala Leu Gly Leu Glu Val Val	
100 105 110	
ctg gtc atc cac gac tgg ggc tca gct ctc gga ttc cac tgg gcc aag	384
Leu Val Ile His Asp Trp Gly Ser Ala Leu Gly Phe His Trp Ala Lys	
115 120 125	
cgc aat ccg gaa cgg gtc aaa ggt att gca tgt atg gaa ttc atc cgg	432

```

Arg Asn Pro Glu Arg Val Lys Gly Ile Ala Cys Met Glu Phe Ile Arg
130          135          140

cct atc ccg acg tgg gac gaa tgg ccg gaa ttc gcc cgt gag acc ttc 480
Pro Ile Pro Thr Trp Asp Glu Trp Pro Glu Phe Ala Arg Glu Thr Phe
145          150          155

cag gcc ttc cgg acc gcc gac gtc ggc cga gag ttg atc atc gat cag 528
Gln Ala Phe Arg Thr Ala Asp Val Gly Arg Glu Leu Ile Ile Asp Gln
165          170          175

aac gct ttc atc gag ggt gtg ctc ccg aaa tgc gtc gtc cgt ccg ctt 576
Asn Ala Phe Ile Glu Gly Val Leu Pro Lys Cys Val Val Arg Pro Leu
180          185          190

acg gag gtc gag atg gac cac tat cgc gag ccc ttc ctc aag cct gtt 624
Thr Glu Val Glu Met Asp His Tyr Arg Glu Pro Phe Leu Lys Pro Val
195          200          205

gac cga gag cca ctg tgg cga ttc ccc aac gag atc ccc atc gcc ggt 672
Asp Arg Glu Pro Leu Trp Arg Phe Pro Asn Glu Ile Pro Ile Ala Gly
210          215          220

gag ccc gcg aac atc gtc gcg ctc gtc gag gca tac atg aac tgg ctg 720
Glu Pro Ala Asn Ile Val Ala Leu Val Glu Ala Tyr Met Asn Trp Leu
225          230          235

cac cag tca cct gtc ccg aag ttg ttg ttc tgg ggc aca ccc ggc gta 768
His Gln Ser Pro Val Pro Lys Leu Leu Phe Trp Gly Thr Pro Gly Val
245          250          255

ctg atc ccc ccg gcc gaa gcc gcg aga ctt gcc gaa agc ctc ccc aac 816
Leu Ile Pro Pro Ala Glu Ala Ala Arg Leu Ala Glu Ser Leu Pro Asn
260          265          270

tgc aag aca gtg gac atc ggc ccg gga ttg cac tac ctc cag gaa gac 864
Cys Lys Thr Val Asp Ile Gly Pro Gly Leu His Tyr Leu Gln Glu Asp
275          280          285

aac ccg gac ctt atc ggc agt gag atc gcg cgc tgg ctc ccc gga ctc 912
Asn Pro Asp Leu Ile Gly Ser Glu Ile Ala Arg Trp Leu Pro Gly Leu
290          295          300

gct agc ggc cta ggt gac tac aag gac gat gat gac aaa taa 954
Ala Ser Gly Leu Gly Asp Tyr Lys Asp Asp Asp Asp Lys
305          310          315

```

<210> 2

<211> 317

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Artificially
modified (mutated) Dehalogenase

<400> 2

```

Met Gly Gly Ser His His His His His His Gly Met Ser Glu Ile Gly
1          5          10          15
Thr Gly Phe Pro Phe Asp Pro His Tyr Val Glu Val Leu Gly Glu Arg
20          25          30
Met His Tyr Val Asp Val Gly Pro Arg Asp Gly Thr Pro Val Leu Phe
35          40          45
Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg Asn Ile Ile Pro
50          55          60
His Val Ala Pro Ser His Arg Cys Ile Ala Pro Asp Leu Ile Gly Met

```

3

65					70					75					80
Gly	Lys	Ser	Asp	Lys	Pro	Asp	Leu	Asp	Tyr	Phe	Phe	Asp	Asp	His	Val
				85					90					95	
Arg	Tyr	Leu	Asp	Ala	Phe	Ile	Glu	Ala	Leu	Gly	Leu	Glu	Glu	Val	Val
			100					105					110		
Leu	Val	Ile	His	Asp	Trp	Gly	Ser	Ala	Leu	Gly	Phe	His	Trp	Ala	Lys
		115				120						125			
Arg	Asn	Pro	Glu	Arg	Val	Lys	Gly	Ile	Ala	Cys	Met	Glu	Phe	Ile	Arg
	130					135					140				
Pro	Ile	Pro	Thr	Trp	Asp	Glu	Trp	Pro	Glu	Phe	Ala	Arg	Glu	Thr	Phe
	145				150					155					160
Gln	Ala	Phe	Arg	Thr	Ala	Asp	Val	Gly	Arg	Glu	Leu	Ile	Ile	Asp	Gln
			165					170						175	
Asn	Ala	Phe	Ile	Glu	Gly	Val	Leu	Pro	Lys	Cys	Val	Val	Arg	Pro	Leu
		180						185					190		
Thr	Glu	Val	Glu	Met	Asp	His	Tyr	Arg	Glu	Pro	Phe	Leu	Lys	Pro	Val
	195						200					205			
Asp	Arg	Glu	Pro	Leu	Trp	Arg	Phe	Pro	Asn	Glu	Ile	Pro	Ile	Ala	Gly
	210					215					220				
Glu	Pro	Ala	Asn	Ile	Val	Ala	Leu	Val	Glu	Ala	Tyr	Met	Asn	Trp	Leu
	225				230					235					240
His	Gln	Ser	Pro	Val	Pro	Lys	Leu	Leu	Phe	Trp	Gly	Thr	Pro	Gly	Val
			245						250					255	
Leu	Ile	Pro	Pro	Ala	Glu	Ala	Ala	Arg	Leu	Ala	Glu	Ser	Leu	Pro	Asn
		260					265						270		
Cys	Lys	Thr	Val	Asp	Ile	Gly	Pro	Gly	Leu	His	Tyr	Leu	Gln	Glu	Asp
	275					280					285				
Asn	Pro	Asp	Leu	Ile	Gly	Ser	Glu	Ile	Ala	Arg	Trp	Leu	Pro	Gly	Leu
	290					295					300				
Ala	Ser	Gly	Leu	Gly	Asp	Tyr	Lys	Asp	Asp	Asp	Asp	Lys			
	305				310					315					

<210> 3

<211> 954

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially modified (mutated) Dehalogenase

<220>

<221> CDS

<222> (1)..(954)

<400> 3

atg	ggg	gat	tct	cat	cat	cat	cat	cat	cat	ggg	atg	tct	gaa	ata	ggg	48
Met	Gly	Asp	Ser	His	His	His	His	His	His	Gly	Met	Ser	Glu	Ile	Gly	
1				5					10					15		
acc	ggg	ttt	ccc	ttc	gac	cct	cat	tat	gtg	gaa	gtc	ctg	ggc	gag	cgt	96
Thr	Gly	Phe	Pro	Phe	Asp	Pro	His	Tyr	Val	Glu	Val	Leu	Gly	Glu	Arg	
			20					25					30			
atg	cac	tac	gtc	gat	gtt	gga	ccg	cgg	gat	ggc	acg	cct	gtg	ctg	ttc	144
Met	His	Tyr	Val	Asp	Val	Gly	Pro	Arg	Asp	Gly	Thr	Pro	Val	Leu	Phe	
		35				40					45					
ctg	cac	ggg	aac	ccg	acc	tcg	tcc	tac	ctg	tgg	cgc	aac	atc	atc	ccg	192
Leu	His	Gly	Asn	Pro	Thr	Ser	Ser	Tyr	Leu	Trp	Arg	Asn	Ile	Ile	Pro	
	50					55				60						
cat	gta	gca	ccg	agt	cat	cgg	tgc	att	gct	cca	gac	ctg	atc	ggg	atg	240

His 65	Val	Ala	Pro	Ser	His 70	Arg	Cys	Ile	Ala	Pro 75	Asp	Leu	Ile	Gly	Met 80	
gga Gly	aaa Lys	tcg Ser	gac Asp	aaa Lys	cca Pro	gac Asp	ctc Leu	gat Asp	tat Tyr	ttc Phe	ttc Phe	gac Asp	gac Asp	cac His	gtc Val	288
cg Arg	tac Tyr	ctc Leu	gat Asp	gcc Ala	ttc Phe	atc Ile	gaa Glu	gcc Ala	ttg Leu	gg Gly	ttg Leu	gaa Glu	gag Glu	gtc Val	gtc Val	336
ctg Leu	gtc Val	atc Ile	cac His	gac Asp	tgg Trp	ggc Gly	tca Ser	gct Ala	ctc Leu	gga Gly	ttc Phe	cac His	tgg Trp	gcc Ala	aag Lys	384
cg Arg	aat Asn	ccg Pro	gaa Glu	cg Arg	gtc Val	aaa Lys	gg Gly	att Ile	gca Ala	tgt Cys	atg Met	gaa Glu	ttc Phe	atc Ile	cg Arg	432
cct Pro	atc Ile	ccg Pro	acg Thr	tgg Trp	gac Asp	gaa Glu	tgg Trp	ccg Pro	gaa Glu	ttc Phe	gcc Ala	cgt Arg	gag Glu	acc Thr	ttc Phe	480
cag Gln	gcc Ala	ttc Phe	cg Arg	acc Thr	gcc Ala	gac Asp	gtc Val	ggc Gly	cga Arg	gag Glu	ttg Leu	atc Ile	atc Ile	gat Asp	cag Gln	528
aac Asn	gct Ala	ttc Phe	atc Ile	gag Glu	gg Gly	gtg Val	ctc Leu	ccg Pro	aaa Lys	ttc Phe	gtc Val	gtc Val	cgt Arg	ccg Pro	ctt Leu	576
acg Thr	gag Glu	gtc Val	gag Glu	atg Met	gac Asp	cac His	tat Tyr	cg Arg	gag Glu	ccc Pro	ttc Phe	ctc Leu	aag Lys	cct Pro	gtt Val	624
gac Asp	cga Arg	gag Glu	cca Pro	ctg Leu	tgg Trp	cga Arg	ttc Phe	ccc Pro	aac Asn	gag Glu	atc Ile	ccc Pro	atc Ile	gcc Ala	gg Gly	672
gag Glu	ccc Pro	gcg Ala	aac Asn	atc Ile	gtc Val	gcg Ala	ctc Leu	gtc Val	gag Glu	gca Ala	tac Tyr	atg Met	aac Asn	tgg Trp	ctg Leu	720
cac His	cag Gln	tca Ser	cct Pro	gtc Val	ccg Pro	aag Lys	ttg Leu	ttg Leu	ttc Phe	tgg Trp	ggc Gly	aca Thr	ccc Pro	ggc Gly	gta Val	768
ctg Leu	atc Ile	ccc Pro	ccg Pro	gcc Ala	gaa Glu	gcc Ala	gcg Ala	aga Arg	ctt Leu	gcc Ala	gaa Glu	agc Ser	ctc Leu	ccc Pro	aac Asn	816
tgc Cys	aag Lys	aca Thr	gtg Val	gac Asp	atc Ile	ggc Gly	ccg Pro	gga Gly	ttg Leu	cac His	tac Tyr	ctc Leu	cag Gln	gaa Glu	gac Asp	864
aac Asn	ccg Pro	gac Asp	ctt Leu	atc Ile	ggc Gly	agt Ser	gag Glu	atc Ile	gcg Ala	cg Arg	tgg Trp	ctc Leu	ccc Pro	gga Gly	ctc Leu	912
gct Ala	agc Ser	ggc Gly	cta Leu	gg Gly	gac Asp	tac Tyr	aag Lys	gac Asp	gat Asp	gat Asp	gac Asp	aaa Lys	taa			954

5

<211> 317

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Artificially modified (mutated) Dehalogenase

<400> 4

```

Met Gly Asp Ser His His His His His His Gly Met Ser Glu Ile Gly
 1           5           10           15
Thr Gly Phe Pro Phe Asp Pro His Tyr Val Glu Val Leu Gly Glu Arg
          20           25           30
Met His Tyr Val Asp Val Gly Pro Arg Asp Gly Thr Pro Val Leu Phe
          35           40           45
Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg Asn Ile Ile Pro
          50           55           60
His Val Ala Pro Ser His Arg Cys Ile Ala Pro Asp Leu Ile Gly Met
          65           70           75           80
Gly Lys Ser Asp Lys Pro Asp Leu Asp Tyr Phe Phe Asp Asp His Val
          85           90           95
Arg Tyr Leu Asp Ala Phe Ile Glu Ala Leu Gly Leu Glu Glu Val Val
          100          105          110
Leu Val Ile His Asp Trp Gly Ser Ala Leu Gly Phe His Trp Ala Lys
          115          120          125
Arg Asn Pro Glu Arg Val Lys Gly Ile Ala Cys Met Glu Phe Ile Arg
          130          135          140
Pro Ile Pro Thr Trp Asp Glu Trp Pro Glu Phe Ala Arg Glu Thr Phe
          145          150          155          160
Gln Ala Phe Arg Thr Ala Asp Val Gly Arg Glu Leu Ile Ile Asp Gln
          165          170          175
Asn Ala Phe Ile Glu Gly Val Leu Pro Lys Phe Val Val Arg Pro Leu
          180          185          190
Thr Glu Val Glu Met Asp His Tyr Arg Glu Pro Phe Leu Lys Pro Val
          195          200          205
Asp Arg Glu Pro Leu Trp Arg Phe Pro Asn Glu Ile Pro Ile Ala Gly
          210          215          220
Glu Pro Ala Asn Ile Val Ala Leu Val Glu Ala Tyr Met Asn Trp Leu
          225          230          235          240
His Gln Ser Pro Val Pro Lys Leu Leu Phe Trp Gly Thr Pro Gly Val
          245          250          255
Leu Ile Pro Pro Ala Glu Ala Ala Arg Leu Ala Glu Ser Leu Pro Asn
          260          265          270
Cys Lys Thr Val Asp Ile Gly Pro Gly Leu His Tyr Leu Gln Glu Asp
          275          280          285
Asn Pro Asp Leu Ile Gly Ser Glu Ile Ala Arg Trp Leu Pro Gly Leu
          290          295          300
Ala Ser Gly Leu Gly Asp Tyr Lys Asp Asp Asp Asp Lys
          305          310          315

```

<210> 5

<211> 954

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially modified (mutated) Dehalogenase

<220>

<221> CDS

<222> (1)..(954)

<400> 5

atg ggg gat tct cat cat cat cat cat cat ggt atg tct gaa ata ggt 48

Met	Gly	Asp	Ser	His	His	His	His	His	His	Gly	Met	Ser	Glu	Ile	Gly	
1				5					10					15		
acc	ggt	ttt	ccc	ttc	gac	cct	cat	tat	gtg	gaa	gtc	ctg	ggc	gag	cgt	96
Thr	Gly	Phe	Pro	Phe	Asp	Pro	His	Tyr	Val	Glu	Val	Leu	Gly	Glu	Arg	
			20					25					30			
atg	cac	tac	gtc	gat	gtt	gga	ccg	cgg	gat	ggc	acg	cct	gtg	ctg	ttc	144
Met	His	Tyr	Val	Asp	Val	Gly	Pro	Arg	Asp	Gly	Thr	Pro	Val	Leu	Phe	
		35					40					45				
ctg	cac	ggt	aac	ccg	acc	tcg	tcc	tac	ctg	tgg	cgc	aac	atc	atc	ccg	192
Leu	His	Gly	Asn	Pro	Thr	Ser	Ser	Tyr	Leu	Trp	Arg	Asn	Ile	Ile	Pro	
	50					55					60					
cat	gta	gca	ccg	agt	cat	cgg	tgc	att	gct	cca	gac	ctg	atc	ggg	atg	240
His	Val	Ala	Pro	Ser	His	Arg	Cys	Ile	Ala	Pro	Asp	Leu	Ile	Gly	Met	
	65				70				75						80	
gga	aaa	tcg	gac	aaa	cca	gac	ctc	ggt	tat	tcc	ttc	gac	gac	cac	gtc	288
Gly	Lys	Ser	Asp	Lys	Pro	Asp	Leu	Gly	Tyr	Ser	Phe	Asp	Asp	His	Val	
				85				90						95		
cgc	tac	ctc	gat	gcc	ttc	atc	gaa	gcc	ttg	ggt	ttg	gaa	gag	gtc	gtc	336
Arg	Tyr	Leu	Asp	Ala	Phe	Ile	Glu	Ala	Leu	Gly	Leu	Glu	Glu	Val	Val	
			100					105					110			
ctg	gtc	atc	cac	gac	tgg	ggc	tca	gct	ctc	gga	ttc	cac	tgg	gcc	aag	384
Leu	Val	Ile	His	Asp	Trp	Gly	Ser	Ala	Leu	Gly	Phe	His	Trp	Ala	Lys	
		115				120						125				
cgc	aat	ccg	gaa	cgg	gtc	aaa	ggt	att	gca	tgt	atg	gaa	ttc	atc	cgg	432
Arg	Asn	Pro	Glu	Arg	Val	Lys	Gly	Ile	Ala	Cys	Met	Glu	Phe	Ile	Arg	
	130					135					140					
cct	atc	ccg	acg	tgg	gac	gaa	tgg	ccg	gaa	ttc	gcc	cgt	gag	ctc	ttc	480
Pro	Ile	Pro	Thr	Trp	Asp	Glu	Trp	Pro	Glu	Phe	Ala	Arg	Glu	Leu	Phe	
	145				150				155						160	
cag	gcc	ttc	cgg	acc	gcc	gac	gtc	ggc	cga	gag	ttg	atc	atc	gat	cag	528
Gln	Ala	Phe	Arg	Thr	Ala	Asp	Val	Gly	Arg	Glu	Leu	Ile	Ile	Asp	Gln	
				165				170						175		
aac	gct	ttc	atc	gag	cag	gtg	ctc	ccg	aaa	ttc	gtc	gtc	cgt	ccg	ctt	576
Asn	Ala	Phe	Ile	Glu	Gln	Val	Leu	Pro	Lys	Phe	Val	Val	Arg	Pro	Leu	
			180				185						190			
acg	gag	gtc	gag	atg	gac	cac	tat	cgc	gag	ccc	ttc	ctc	aag	cct	gtt	624
Thr	Glu	Val	Glu	Met	Asp	His	Tyr	Arg	Glu	Pro	Phe	Leu	Lys	Pro	Val	
		195					200					205				
gac	cga	gag	cca	ctg	tgg	cga	ttc	ccc	aac	gag	ctc	ccc	atc	gcc	ggt	672
Asp	Arg	Glu	Pro	Leu	Trp	Arg	Phe	Pro	Asn	Glu	Leu	Pro	Ile	Ala	Gly	
	210				215						220					
gag	ccc	gcg	aac	atc	gtc	gcg	ctc	gtc	gag	gca	tac	atg	acc	tgg	ctg	720
Glu	Pro	Ala	Asn	Ile	Val	Ala	Leu	Val	Glu	Ala	Tyr	Met	Thr	Trp	Leu	
	225				230				235						240	
cac	cag	tca	cct	gtc	ccg	aag	ttg	ttg	ttc	tat	ggc	aca	ccc	ggc	gta	768
His	Gln	Ser	Pro	Val	Pro	Lys	Leu	Leu	Phe	Tyr	Gly	Thr	Pro	Gly	Val	
				245				250						255		
ctg	atc	ccc	ccg	gcc	gaa	gcc	gcg	aga	ctt	gcc	gaa	agc	ctc	ccc	aac	816
Leu	Ile	Pro	Pro	Ala	Glu	Ala	Ala	Arg	Leu	Ala	Glu	Ser	Leu	Pro	Asn	

```
<210> 6
<211> 317
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Artificially
        modified (mutated) Dehalogenase
```

<400>	6															
Met	Gly	Asp	Ser	His	His	His	His	His	His	Gly	Met	Ser	Glu	Ile	Gly	
1				5				10					15			
Thr	Gly	Phe	Pro	Phe	Asp	Pro	His	Tyr	Val	Glu	Val	Leu	Gly	Glu	Arg	
			20					25					30			
Met	His	Tyr	Val	Asp	Val	Gly	Pro	Arg	Asp	Gly	Thr	Pro	Val	Leu	Phe	
			35				40					45				
Leu	His	Gly	Asn	Pro	Thr	Ser	Ser	Tyr	Leu	Trp	Arg	Asn	Ile	Ile	Pro	
	50					55					60					
His	Val	Ala	Pro	Ser	His	Arg	Cys	Ile	Ala	Pro	Asp	Leu	Ile	Gly	Met	
65					70				75					80		
Gly	Lys	Ser	Asp	Lys	Pro	Asp	Leu	Gly	Tyr	Ser	Phe	Asp	Asp	His	Val	
				85				90						95		
Arg	Tyr	Leu	Asp	Ala	Phe	Ile	Glu	Ala	Leu	Gly	Leu	Glu	Glu	Val	Val	
			100					105					110			
Leu	Val	Ile	His	Asp	Trp	Gly	Ser	Ala	Leu	Gly	Phe	His	Trp	Ala	Lys	
		115				120						125				
Arg	Asn	Pro	Glu	Arg	Val	Lys	Gly	Ile	Ala	Cys	Met	Glu	Phe	Ile	Arg	
	130					135					140					
Pro	Ile	Pro	Thr	Trp	Asp	Glu	Trp	Pro	Glu	Phe	Ala	Arg	Glu	Leu	Phe	
145					150				155						160	
Gln	Ala	Phe	Arg	Thr	Ala	Asp	Val	Gly	Arg	Glu	Leu	Ile	Ile	Asp	Gln	
				165				170						175		
Asn	Ala	Phe	Ile	Glu	Gln	Val	Leu	Pro	Lys	Phe	Val	Val	Arg	Pro	Leu	
			180					185					190			
Thr	Glu	Val	Glu	Met	Asp	His	Tyr	Arg	Glu	Pro	Phe	Leu	Lys	Pro	Val	
		195				200					205					
Asp	Arg	Glu	Pro	Leu	Trp	Arg	Phe	Pro	Asn	Glu	Leu	Pro	Ile	Ala	Gly	
	210					215					220					
Glu	Pro	Ala	Asn	Ile	Val	Ala	Leu	Val	Glu	Ala	Tyr	Met	Thr	Trp	Leu	
225					230				235					240		
His	Gln	Ser	Pro	Val	Pro	Lys	Leu	Leu	Phe	Tyr	Gly	Thr	Pro	Gly	Val	
				245					250					255		
Leu	Ile	Pro	Pro	Ala	Glu	Ala	Ala	Arg	Leu	Ala	Glu	Ser	Leu	Pro	Asn	
			260					265					270			
Cys	Lys	Thr	Val	Asp	Ile	Gly	Pro	Gly	Leu	His	Tyr	Leu	Gln	Glu	Asp	
	275					280					285					
Asn	Pro	Asp	Leu	Ile	Gly	Ser	Glu	Ile	Ala	Arg	Trp	Leu	Ala	Gly	Leu	
	290					295					300					
Ala	Ser	Gly	Leu	Gly	Asp	Tyr	Lys	Asp	Asp	Asp	Lys					
305					310					315						

<210> 7
 <211> 954
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially
 modified (mutated) Dehalogenase

<220>

<221> CDS

<222> (1)..(954)

<400> 7

atg ggg gat tct cat cat cat cat cat cat ggt atg tct gaa ata ggt	48
Met Gly Asp Ser His His His His His His Gly Met Ser Glu Ile Gly	
1 5 10 15	
acc ggt ttt ccc ttc gac cct cat tat gtg gaa gtc ctg ggc gag cgt	96
Thr Gly Phe Pro Phe Asp Pro His Tyr Val Glu Val Leu Gly Glu Arg	
20 25 30	
atg cac tac gtc gat gtt gga ccg cgg gat ggc acg cct gtg ctg ttc	144
Met His Tyr Val Asp Val Gly Pro Arg Asp Gly Thr Pro Val Leu Phe	
35 40 45	
ctg cac ggt aac ccg acc tcg tcc tac ctg tgg cgc aac atc atc ccg	192
Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg Asn Ile Ile Pro	
50 55 60	
cat gta gca ccg agt cat cgg tgc att gct cca gac ctg atc ggg atg	240
His Val Ala Pro Ser His Arg Cys Ile Ala Pro Asp Leu Ile Gly Met	
65 70 75 80	
gga aaa tcg gac aaa cca gac ctc ggt tat tcc ttc gac gac cac gtc	288
Gly Lys Ser Asp Lys Pro Asp Leu Gly Tyr Ser Phe Asp Asp His Val	
85 90 95	
cgc tac ctc gat gcc ttc atc gaa gcc ttg ggt ttg gaa gag gtc gtc	336
Arg Tyr Leu Asp Ala Phe Ile Glu Ala Leu Gly Leu Glu Glu Val Val	
100 105 110	
ctg gtc atc cac gac tgg ggc tca gct ctc gga ttc cac tgg gcc aag	384
Leu Val Ile His Asp Trp Gly Ser Ala Leu Gly Phe His Trp Ala Lys	
115 120 125	
cgc aat ccg gaa cgg gtc aaa ggt att gca tgt atg gaa ttc atc cgg	432
Arg Asn Pro Glu Arg Val Lys Gly Ile Ala Cys Met Glu Phe Ile Arg	
130 135 140	
agt atc ccg acg tgg gac gaa tgg ccg gaa ttc gcc cgt gag ctc ttc	480
Ser Ile Pro Thr Trp Asp Glu Trp Pro Glu Phe Ala Arg Glu Leu Phe	
145 150 155 160	
cag ctt ttc cgg acc gcc gac gtc ggc cga gag ttg atc atc gat cag	528
Gln Leu Phe Arg Thr Ala Asp Val Gly Arg Glu Leu Ile Ile Asp Gln	
165 170 175	
aac gct ttc atc gag cag gtg ctc ccg aaa ttc gtc gtc cgt ccg ctt	576
Asn Ala Phe Ile Glu Gln Val Leu Pro Lys Phe Val Val Arg Pro Leu	
180 185 190	
acg gag gtc gag atg gac cac tat cgc gag ccc ttc ctc aag cct gtt	624
Thr Glu Val Glu Met Asp His Tyr Arg Glu Pro Phe Leu Lys Pro Val	

195	200	205	
gac cga gag cca ctg tgg cga ttc ccc aac gag ctc ccc atc gcc ggt Asp Arg Glu Pro Leu Trp Arg Phe Pro Asn Glu Leu Pro Ile Ala Gly 210 215 220			672
gag ccc gcg aac atc gtc gcg ctc gtc gag gca tac atg acc tgg ctg Glu Pro Ala Asn Ile Val Ala Leu Val Glu Ala Tyr Met Thr Trp Leu 225 230 235 240			720
cac cag tca cct gtc ccg aag ttg ttg ttc tat ggc aca ccc ggc gta His Gln Ser Pro Val Pro Lys Leu Leu Phe Tyr Gly Thr Pro Gly Val 245 250 255			768
ctg atc ccc ccg gcc gaa gcc tcg aga ctt gcc gaa agc ctc ccc aac Leu Ile Pro Pro Ala Glu Ala Ser Arg Leu Ala Glu Ser Leu Pro Asn 260 265 270			816
tgc aag aca gtg gac atc ggc ccg gga ttg cac tac ctc cag gaa gac Cys Lys Thr Val Asp Ile Gly Pro Gly Leu His Tyr Leu Gln Glu Asp 275 280 285			864
aac ccg gac ctt atc ggc agt gag atc gcg ctg tgg ctc gcc gga ctc Asn Pro Asp Leu Ile Gly Ser Glu Ile Ala Leu Trp Leu Ala Gly Leu 290 295 300			912
gct agc ggc cta ggt gac tac aag gac gat gat gac aaa taa Ala Ser Gly Leu Gly Asp Tyr Lys Asp Asp Asp Asp Lys 305 310 315			954

<210> 8

<211> 317

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Artificially
modified (mutated) Dehalogenase

<400> 8

Met Gly Asp Ser His His His His His His Gly Met Ser Glu Ile Gly 1 5 10 15	
Thr Gly Phe Pro Phe Asp Pro His Tyr Val Glu Val Leu Gly Glu Arg 20 25 30	
Met His Tyr Val Asp Val Gly Pro Arg Asp Gly Thr Pro Val Leu Phe 35 40 45	
Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg Asn Ile Ile Pro 50 55 60	
His Val Ala Pro Ser His Arg Cys Ile Ala Pro Asp Leu Ile Gly Met 65 70 75 80	
Gly Lys Ser Asp Lys Pro Asp Leu Gly Tyr Ser Phe Asp Asp His Val 85 90 95	
Arg Tyr Leu Asp Ala Phe Ile Glu Ala Leu Gly Leu Glu Glu Val Val 100 105 110	
Leu Val Ile His Asp Trp Gly Ser Ala Leu Gly Phe His Trp Ala Lys 115 120 125	
Arg Asn Pro Glu Arg Val Lys Gly Ile Ala Cys Met Glu Phe Ile Arg 130 135 140	
Ser Ile Pro Thr Trp Asp Glu Trp Pro Glu Phe Ala Arg Glu Leu Phe 145 150 155 160	
Gln Leu Phe Arg Thr Ala Asp Val Gly Arg Glu Leu Ile Ile Asp Gln 165 170 175	
Asn Ala Phe Ile Glu Gln Val Leu Pro Lys Phe Val Val Arg Pro Leu 180 185 190	
Thr Glu Val Glu Met Asp His Tyr Arg Glu Pro Phe Leu Lys Pro Val 195 200 205	

```

Asp Arg Glu Pro Leu Trp Arg Phe Pro Asn Glu Leu Pro Ile Ala Gly
 210          215          220
Glu Pro Ala Asn Ile Val Ala Leu Val Glu Ala Tyr Met Thr Trp Leu
225          230          235          240
His Gln Ser Pro Val Pro Lys Leu Leu Phe Tyr Gly Thr Pro Gly Val
          245          250          255
Leu Ile Pro Pro Ala Glu Ala Ser Arg Leu Ala Glu Ser Leu Pro Asn
          260          265          270
Cys Lys Thr Val Asp Ile Gly Pro Gly Leu His Tyr Leu Gln Glu Asp
          275          280          285
Asn Pro Asp Leu Ile Gly Ser Glu Ile Ala Leu Trp Leu Ala Gly Leu
          290          295          300
Ala Ser Gly Leu Gly Asp Tyr Lys Asp Asp Asp Asp Lys
305          310          315

```

<210> 9

<211> 870

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially
modified (mutated) Dehalogenase

<220>

<221> CDS

<222> (1)..(870)

<400> 9

```

atg aac gca acg gaa cac gac aag cgc tac atc gag gtg ctg ggt aag      48
Met Asn Ala Thr Glu His Asp Lys Arg Tyr Ile Glu Val Leu Gly Lys
 1          5          10          15

cga atg gcc tat gtc gag atg ggc gag ggt gat ccc atc att ttc caa      96
Arg Met Ala Tyr Val Glu Met Gly Glu Gly Asp Pro Ile Ile Phe Gln
          20          25          30

cac ggc aat ccg acc tca tcg tac ctg tgg cgc aac atc atg ccc cat     144
His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg Asn Ile Met Pro His
          35          40          45

gtg caa cag ctc ggt cgc tgc ata gcg ctc gac ctg atc ggc atg ggc     192
Val Gln Gln Leu Gly Arg Cys Ile Ala Leu Asp Leu Ile Gly Met Gly
          50          55          60

gat tca gaa aaa ctc gag gac tcc gga ccc gag cgc tac acg ttc gtc     240
Asp Ser Glu Lys Leu Glu Asp Ser Gly Pro Glu Arg Tyr Thr Phe Val
          65          70          75          80

gag cac agc cgg tat ttt gat gcc gcg ctc gaa gcc ctg ggt gtg acg     288
Glu His Ser Arg Tyr Phe Asp Ala Ala Leu Glu Ala Leu Gly Val Thr
          85          90          95

agc aac gtg acg ctg gtg atc cac gat tgg ggt tca gcg ctg ggc ttc     336
Ser Asn Val Thr Leu Val Ile His Asp Trp Gly Ser Ala Leu Gly Phe
          100          105          110

cac tgg gct aac cgc tat cgt gat gac gta aaa ggt atc tgc tac atg     384
His Trp Ala Asn Arg Tyr Arg Asp Asp Val Lys Gly Ile Cys Tyr Met
          115          120          125

gaa gcc atc gtg tcg ccg ctg acc tgg gat acg ttt ccg gaa ggt gcg     432
Glu Ala Ile Val Ser Pro Leu Thr Trp Asp Thr Phe Pro Glu Gly Ala

```

130	135	140	
cgt ggt gtt ttc	cag ggg ttt	cgt tca ccg gct ggc gaa gca atg gtg	480
Arg Gly Val Phe	Gln Gly Phe	Arg Ser Pro Ala Gly Glu Ala Met Val	
145	150	155	160
ctt gag aac aat	gtg ttc gtc gaa aac	gta ctt ccc ggg tcg ata ctc	528
Leu Glu Asn Asn	Val Phe Val Glu Asn	Val Leu Pro Gly Ser Ile Leu	
	165	170	175
aga gac ctc agc	gag gaa gaa atg aac	gtc tac cgg cgc cct ttc acg	576
Arg Asp Leu Ser	Glu Glu Glu Met Asn	Val Tyr Arg Pro Phe Thr	
	180	185	190
gag cct ggc gaa ggt	cgg cgt ccg acg ctc acc	tgg cca cgg cag att	624
Glu Pro Gly Glu Gly	Arg Arg Pro Thr Leu Thr	Trp Pro Arg Gln Ile	
	195	200	205
ccg atc gat ggc	gaa cct gca gac gtc gtc gcc	ctg gta gcc gag tac	672
Pro Ile Asp Gly	Glu Pro Ala Asp Val Val Ala	Leu Val Ala Glu Tyr	
	210	215	220
gcc gcc tgg ttg	cag agt gcg gaa gta ccg aag	ttg ttt gtg aat gct	720
Ala Ala Trp Leu	Gln Ser Ala Glu Val Pro Lys	Leu Phe Val Asn Ala	
	230	235	240
gaa cca ggg gcg	ttg ctc acg gga ccg cag cgc	gag ttc tgc cgg agt	768
Glu Pro Gly Ala	Leu Leu Thr Gly Pro Gln Arg	Glu Phe Cys Arg Ser	
	245	250	255
tgg acc aat cag	agc gag gtc acc	gtg tca ggt agc cac ttc atc cag	816
Trp Thr Asn Gln	Ser Glu Val Thr Val Ser Gly	Ser His Phe Ile Gln	
	260	265	270
gaa gat tca ccg	gat gag atc ggt	gaa gca ttg aaa gtg tgg atg act	864
Glu Asp Ser Pro	Asp Glu Ile Gly Glu Ala Leu Lys	Val Trp Met Thr	
	275	280	285
gga tag			870
Gly			
290			

<210> 10

<211> 289

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Artificially modified (mutated) Dehalogenase

<400> 10

Met Asn Ala Thr	Glu His Asp Lys Arg Tyr Ile	Glu Val Leu Gly Lys
1	5	10
Arg Met Ala Tyr	Val Glu Met Gly Glu Gly Asp Pro	Ile Ile Phe Gln
	20	25
His Gly Asn Pro	Thr Ser Ser Tyr Leu Trp Arg Asn	Ile Met Pro His
	35	40
Val Gln Gln Leu	Gly Arg Cys Ile Ala Leu Asp Leu	Ile Gly Met Gly
	50	55
Asp Ser Glu Lys	Leu Glu Asp Ser Gly Pro Glu Arg Tyr	Thr Phe Val
	65	70
Glu His Ser Arg	Tyr Phe Asp Ala Ala Leu Glu Ala Leu	Gly Val Thr
	85	90
Ser Asn Val Thr	Leu Val Ile His Asp Trp Gly Ser Ala	Leu Gly Phe
	100	105
		110

His Trp Ala Asn Arg Tyr Arg Asp Asp Val Lys Gly Ile Cys Tyr Met
 115 120 125
 Glu Ala Ile Val Ser Pro Leu Thr Trp Asp Thr Phe Pro Glu Gly Ala
 130 135 140
 Arg Gly Val Phe Gln Gly Phe Arg Ser Pro Ala Gly Glu Ala Met Val
 145 150 155 160
 Leu Glu Asn Asn Val Phe Val Glu Asn Val Leu Pro Gly Ser Ile Leu
 165 170 175
 Arg Asp Leu Ser Glu Glu Glu Met Asn Val Tyr Arg Arg Pro Phe Thr
 180 185 190
 Glu Pro Gly Glu Gly Arg Arg Pro Thr Leu Thr Trp Pro Arg Gln Ile
 195 200 205
 Pro Ile Asp Gly Glu Pro Ala Asp Val Val Ala Leu Val Ala Glu Tyr
 210 215 220
 Ala Ala Trp Leu Gln Ser Ala Glu Val Pro Lys Leu Phe Val Asn Ala
 225 230 235 240
 Glu Pro Gly Ala Leu Leu Thr Gly Pro Gln Arg Glu Phe Cys Arg Ser
 245 250 255
 Trp Thr Asn Gln Ser Glu Val Thr Val Ser Gly Ser His Phe Ile Gln
 260 265 270
 Glu Asp Ser Pro Asp Glu Ile Gly Glu Ala Leu Lys Val Trp Met Thr
 275 280 285
 Gly

<210> 11

<211> 882

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially modified (mutated) Dehalogenase

<220>

<221> CDS

<222> (1)..(882)

<400> 11

atg cag gtg ggg atc gcc gct acg ctc gcc gaa atg gac aag aaa cgt 48
 Met Gln Val Gly Ile Ala Ala Thr Leu Ala Glu Met Asp Lys Lys Arg
 1 5 10 15

gtc cgt gtg tac aac gcg gag atg gcc tat gtc gac acg ggc cag ggt 96
 Val Arg Val Tyr Asn Ala Glu Met Ala Tyr Val Asp Thr Gly Gln Gly
 20 25 30

gat tcc gtt ctg ttt ctt cac ggc aac ccg acg tcg tcg tat ctg tgg 144
 Asp Ser Val Leu Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp
 35 40 45

agg ggc gta atg cct ttt gtg acg gac gtc gcc cga tgt gtg gct ccg 192
 Arg Gly Val Met Pro Phe Val Thr Asp Val Ala Arg Cys Val Ala Pro
 50 55 60

gac ctg atc ggt atg ggc gat tcc gac aag ctc gag tcg tcg atg tac 240
 Asp Leu Ile Gly Met Gly Asp Ser Asp Lys Leu Glu Ser Ser Met Tyr
 65 70 75 80

cgc ttc gag gat cac cgg cgg tac ctg gat ggt ttc ctc gat gcg gtg 288
 Arg Phe Glu Asp His Arg Arg Tyr Leu Asp Gly Phe Leu Asp Ala Val
 85 90 95

gac atc gga gac gat gtg acg gtt gtg gtg cac gac tgg ggc tct gca 336

```

Asp Ile Gly Asp Asp Val Thr Val Val Val His Asp Trp Gly Ser Ala
      100      105      110
ctc ggc ttc gac tgg gcg aac cgg cac cgc gac cgg gtc aaa gga atc 384
Leu Gly Phe Asp Trp Ala Asn Arg His Arg Asp Arg Val Lys Gly Ile
      115      120      125

gca tac atg gaa gcg atc gtt cgt cca ttg agc tgg gag gag tgg ccg 432
Ala Tyr Met Glu Ala Ile Val Arg Pro Leu Ser Trp Glu Glu Trp Pro
      130      135      140

gac gca tct cgc cgc ctg ttc gag gca atg cgc tca gac gcg ggg gag 480
Asp Ala Ser Arg Arg Leu Phe Glu Ala Met Arg Ser Asp Ala Gly Glu
      145      150      155      160

gag atc gtt ctc gaa aag aat gtc ttc gtc gag cgg att ctg ctc ggc 528
Glu Ile Val Leu Leu Lys Asn Val Phe Val Glu Arg Ile Leu Leu Gly
      165      170      175

tcg gtc ctt tgt gat ctg acc gag gag gaa atg gcg gag tac cgg cgc 576
Ser Val Leu Cys Asp Leu Thr Glu Glu Met Ala Glu Tyr Arg Arg
      180      185      190

ccg tac ctc gag ccg ggt gag tca cgg cgc ccg atg ctg aca tgg cca 624
Pro Tyr Leu Glu Pro Gly Glu Ser Arg Arg Pro Met Leu Thr Trp Pro
      195      200      205

cgc gag atc ccg atc gac ggc cac ccc gcc gac gtt gcg aag atc gtc 672
Arg Glu Ile Pro Ile Asp Gly His Pro Ala Asp Val Ala Lys Ile Val
      210      215      220

gcg gag tac tcg tcg tgg ctc tcc ggg tcg gag gtg ccg aag ctc ttc 720
Ala Glu Tyr Ser Ser Trp Leu Ser Gly Ser Glu Val Pro Lys Leu Phe
      225      230      235      240

gtc gat gcc gac ccg ggc gcc atc ctg aca ggt ccg aag cga gac ttc 768
Val Asp Ala Asp Pro Gly Ala Ile Leu Thr Gly Pro Lys Arg Asp Phe
      245      250      255

tgc agg gcg tgg ccg aac cag gtc gag acg acc gtg gca gga atc cac 816
Cys Arg Ala Trp Pro Asn Gln Val Glu Thr Thr Val Ala Gly Ile His
      260      265      270

ttc ata cag gag gat tcc tcc gcc gag atc gga gcc gcg atc agg acc 864
Phe Ile Gln Glu Asp Ser Ser Ala Glu Ile Gly Ala Ala Ile Arg Thr
      275      280      285

tgg tac ctg gga ctc tga
Trp Tyr Leu Gly Leu
      290

```

<210> 12

<211> 293

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Artificially
modified (mutated) Dehalogenase

<400> 12

```

Met Gln Val Gly Ile Ala Ala Thr Leu Ala Glu Met Asp Lys Lys Arg
  1           5           10           15
Val Arg Val Tyr Asn Ala Glu Met Ala Tyr Val Asp Thr Gly Gln Gly
      20           25           30
Asp Ser Val Leu Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp

```

14

```

      35      40      45
Arg Gly Val Met Pro Phe Val Thr Asp Val Ala Arg Cys Val Ala Pro
  50      55      60
Asp Leu Ile Gly Met Gly Asp Ser Asp Lys Leu Glu Ser Ser Met Tyr
  65      70      75      80
Arg Phe Glu Asp His Arg Arg Tyr Leu Asp Gly Phe Leu Asp Ala Val
      85      90      95
Asp Ile Gly Asp Asp Val Thr Val Val Val His Asp Trp Gly Ser Ala
      100      105      110
Leu Gly Phe Asp Trp Ala Asn Arg His Arg Asp Arg Val Lys Gly Ile
      115      120      125
Ala Tyr Met Glu Ala Ile Val Arg Pro Leu Ser Trp Glu Glu Trp Pro
      130      135      140
Asp Ala Ser Arg Arg Leu Phe Glu Ala Met Arg Ser Asp Ala Gly Glu
      145      150      155      160
Glu Ile Val Leu Glu Lys Asn Val Phe Val Glu Arg Ile Leu Leu Gly
      165      170      175
Ser Val Leu Cys Asp Leu Thr Glu Glu Glu Met Ala Glu Tyr Arg Arg
      180      185      190
Pro Tyr Leu Glu Pro Gly Glu Ser Arg Arg Pro Met Leu Thr Trp Pro
      195      200      205
Arg Glu Ile Pro Ile Asp Gly His Pro Ala Asp Val Ala Lys Ile Val
      210      215      220
Ala Glu Tyr Ser Ser Trp Leu Ser Gly Ser Glu Val Pro Lys Leu Phe
      225      230      235      240
Val Asp Ala Asp Pro Gly Ala Ile Leu Thr Gly Pro Lys Arg Asp Phe
      245      250      255
Cys Arg Ala Trp Pro Asn Gln Val Glu Thr Thr Val Ala Gly Ile His
      260      265      270
Phe Ile Gln Glu Asp Ser Ser Ala Glu Ile Gly Ala Ala Ile Arg Thr
      275      280      285
Trp Tyr Leu Gly Leu
      290

```

<210> 13
 <211> 849
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Artificially
 modified (mutated) Dehalogenase

<220>
 <221> CDS
 <222> (1)..(849)

```

<400> 13
atg gag aaa cac cgc gta gaa gtt ctc ggt tcg gag atg gcc tac atc 48
Met Glu Lys His Arg Val Glu Val Leu Gly Ser Glu Met Ala Tyr Ile
  1      5      10      15

gac gtg gga gag ggc gac ccg atc gtg ttc ctc cac gga .aat ccc acg 96
Asp Val Gly Glu Gly Asp Pro Ile Val Phe Leu His Gly Asn Pro Thr
      20      25      30

tcg tcg tac ctg tgg cgg aac gtg att ccc cac gtt gcc ggc ttg gga 144
Ser Ser Tyr Leu Trp Arg Asn Val Ile Pro His Val Ala Gly Leu Gly
      35      40      45

cgc tgc atc gcc ccg gat ctg atc ggc atg gga gac tcg gat aag gtc 192
Arg Cys Ile Ala Pro Asp Leu Ile Gly Met Gly Asp Ser Asp Lys Val
      50      55      60

```

15

```

cat ggt ctc gag tac cgc ttc gtt gat cac cgc cgg tac ctc gac gcc 240
His Gly Leu Glu Tyr Arg Phe Val Asp His Arg Arg Tyr Leu Asp Ala
65 70 75 80

ttc ctt gaa gcg gtc ggc gtt gag gat gct gtg aca ttc atc gta cac 288
Phe Leu Glu Ala Val Gly Val Glu Asp Ala Val Thr Phe Ile Val His
85 90 95

gac tgg ggc tcg gct ctc gga ttc gac tgg gcg aac cgt cac cgt gaa 336
Asp Trp Gly Ser Ala Leu Gly Phe Asp Trp Ala Asn Arg His Arg Glu
100 105 110

gcg gtc gaa ggc atc gca tac atg gag gcg atc gtg cac ccg gtt gct 384
Ala Val Glu Gly Ile Ala Tyr Met Glu Ala Ile Val His Pro Val Ala
115 120 125

tgg aac gac tgg ccg gag ctc tct cga ccg ata ttt cag gcg atg agg 432
Trp Asn Asp Trp Pro Glu Leu Ser Arg Pro Ile Phe Gln Ala Met Arg
130 135 140

tcc tcg tcc ggt gag aag atc gtg ctt gag aag aac gtg ttc gtg gag 480
Ser Ser Ser Gly Glu Lys Ile Val Leu Glu Lys Asn Val Phe Val Glu
145 150 155 160

cga atc ctg ccc gct tcc gtg atg cgc gat ctg agc gac gac gag atg 528
Arg Ile Leu Pro Ala Ser Val Met Arg Asp Leu Ser Asp Asp Glu Met
165 170 175

gat gag tac cgt cga ccg ttc cag aac ccg gga gag gat cga aga ccc 576
Asp Glu Tyr Arg Arg Pro Phe Gln Asn Pro Gly Glu Asp Arg Arg Pro
180 185 190

acg ctg acg tgg cca cgg gag atc ccg atc gat gga gaa ccg ggg gac 624
Thr Leu Thr Trp Pro Arg Glu Ile Pro Ile Asp Gly Glu Pro Gly Asp
195 200 205

gtc gcc gcc atc gtc gat gac tac ggg cga tgg ctc tcg gag agc gat 672
Val Ala Ala Ile Val Asp Asp Tyr Gly Arg Trp Leu Ser Glu Ser Asp
210 215 220

gtc cca aag ctc ttc atc gac gcg gat ccg gga gcg atc ctc gtg ggt 720
Val Pro Lys Leu Phe Ile Asp Ala Asp Pro Gly Ala Ile Leu Val Gly
225 230 235 240

cca gcg cgt ggg ttc tgc cgc ggc tgg cgg aac cag acc gaa gtg agc 768
Pro Ala Arg Gly Phe Cys Arg Gly Trp Arg Asn Gln Thr Glu Val Ser
245 250 255

gtc aca gga acc cac ttc atc cag gaa gac tct ccc gac gag atc ggc 816
Val Thr Gly Thr His Phe Ile Gln Glu Asp Ser Pro Asp Glu Ile Gly
260 265 270

gct gcg ctg gct cga tgg atc gag aac cgg taa 849
Ala Ala Leu Ala Arg Trp Ile Glu Asn Arg
275 280

```

<210> 14

<211> 282

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Artificially
modified (mutated) Dehalogenase

16

<400> 14
Met Glu Lys His Arg Val Glu Val Leu Gly Ser Glu Met Ala Tyr Ile
1 5 10 15
Asp Val Gly Glu Gly Asp Pro Ile Val Phe Leu His Gly Asn Pro Thr
20 25 30
Ser Ser Tyr Leu Trp Arg Asn Val Ile Pro His Val Ala Gly Leu Gly
35 40 45
Arg Cys Ile Ala Pro Asp Leu Ile Gly Met Gly Asp Ser Asp Lys Val
50 55 60
His Gly Leu Glu Tyr Arg Phe Val Asp His Arg Arg Tyr Leu Asp Ala
65 70 75 80
Phe Leu Glu Ala Val Gly Val Glu Asp Ala Val Thr Phe Ile Val His
85 90 95
Asp Trp Gly Ser Ala Leu Gly Phe Asp Trp Ala Asn Arg His Arg Glu
100 105 110
Ala Val Glu Gly Ile Ala Tyr Met Glu Ala Ile Val His Pro Val Ala
115 120 125
Trp Asn Asp Trp Pro Glu Leu Ser Arg Pro Ile Phe Gln Ala Met Arg
130 135 140
Ser Ser Ser Gly Glu Lys Ile Val Leu Glu Lys Asn Val Phe Val Glu
145 150 155 160
Arg Ile Leu Pro Ala Ser Val Met Arg Asp Leu Ser Asp Asp Glu Met
165 170 175
Asp Glu Tyr Arg Arg Pro Phe Gln Asn Pro Gly Glu Asp Arg Arg Pro
180 185 190
Thr Leu Thr Trp Pro Arg Glu Ile Pro Ile Asp Gly Glu Pro Gly Asp
195 200 205
Val Ala Ala Ile Val Asp Asp Tyr Gly Arg Trp Leu Ser Glu Ser Asp
210 215 220
Val Pro Lys Leu Phe Ile Asp Ala Asp Pro Gly Ala Ile Leu Val Gly
225 230 235 240
Pro Ala Arg Gly Phe Cys Arg Gly Trp Arg Asn Gln Thr Glu Val Ser
245 250 255
Val Thr Gly Thr His Phe Ile Gln Glu Asp Ser Pro Asp Glu Ile Gly
260 265 270
Ala Ala Leu Ala Arg Trp Ile Glu Asn Arg
275 280

<210> 15

<211> 876

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially
modified (mutated) Dehalogenase

<220>

<221> CDS

<222> (1)..(876)

<400> 15

atg gct agc gcg cct atc gac ccg acc gac ccg cat ccg aga aag cgg 48
Met Ala Ser Ala Pro Ile Asp Pro Thr Asp Pro His Pro Arg Lys Arg
1 5 10 15
atc gcc gtg ctc gat tgc gag atg agc tac gtc gat acc ggc gag gga 96
Ile Ala Val Leu Asp Ser Glu Met Ser Tyr Val Asp Thr Gly Glu Gly
20 25 30
gcg ccg atc gtg ttc ctt cac ggc aac ccg act tcc tcc tat ctt tgg 144
Ala Pro Ile Val Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp
35 40 45

cgc aac atc atc ccc tat ctc gcg gat cac ggc aga tgc ctc gca ccg	192
Arg Asn Ile Ile Pro Tyr Leu Ala Asp His Gly Arg Cys Leu Ala Pro	
50 55 60	
gat ctg gtc ggg atg ggc cgc tcc gga aaa tcg ccg acc cgg tcc tat	240
Asp Leu Val Gly Met Gly Arg Ser Gly Lys Ser Pro Thr Arg Ser Tyr	
65 70 75 80	
ggc ttt acc gat cac gcg cgc tat ttg gac gca tgg ttc gac gcc ctg	288
Gly Phe Thr Asp His Ala Arg Tyr Leu Asp Ala Trp Phe Asp Ala Leu	
85 90 95	
gac ctg acc cgc gac gtg acc ctg gtg att cat gac tgg gga tcg gcg	336
Asp Leu Thr Arg Asp Val Thr Leu Val Ile His Asp Trp Gly Ser Ala	
100 105 110	
ctg ggc ttc cac cgt gcc ttt cgc ttc ccc gaa cag atc aag gcg atc	384
Leu Gly Phe His Arg Ala Phe Arg Phe Pro Glu Gln Ile Lys Ala Ile	
115 120 125	
gcc tat atg gag gcc atc gtc cgg ccg ctc gtc tgg gcc gac atc gcc	432
Ala Tyr Met Glu Ala Ile Val Arg Pro Leu Val Trp Ala Asp Ile Ala	
130 135 140	
ggc gcc gag cag gcg ttt cgc gcg atc cga tcc gag gcc ggc gaa cac	480
Gly Ala Glu Gln Ala Phe Arg Ala Ile Arg Ser Glu Ala Gly Glu His	
145 150 155 160	
atg att ctg gac gag aac ttt ttc gtc gaa gtg ctc ctt ccg gcg agc	528
Met Ile Leu Asp Glu Asn Phe Phe Val Glu Val Leu Leu Pro Ala Ser	
165 170 175	
atc ctg cgc aga ttg agc gat ctg gag atg gcc gcc tac cgc gca ccg	576
Ile Leu Arg Arg Leu Ser Asp Leu Glu Met Ala Ala Tyr Arg Ala Pro	
180 185 190	
ttc ctc gac cgg gag tcg cga tgg ccg acc ctg cgc tgg ccg cgc gag	624
Phe Leu Asp Arg Glu Ser Arg Trp Pro Thr Leu Arg Trp Pro Arg Glu	
195 200 205	
gtt ccg atc gag ggg gag ccg gcc gac gtg acc gcc atc gtc gag gcc	672
Val Pro Ile Glu Gly Glu Pro Ala Asp Val Thr Ala Ile Val Glu Ala	
210 215 220	
tac gga cga tgg atg gcc gag aac acg ctg ccg aag ctg ctg gtc ttg	720
Tyr Gly Arg Trp Met Ala Glu Asn Thr Leu Pro Lys Leu Leu Val Leu	
225 230 235 240	
ggt gat ccg gga gtg atc gct acc ggc cgc acg cgc gac ttc tgt cga	768
Gly Asp Pro Gly Val Ile Ala Thr Gly Arg Thr Arg Asp Phe Cys Arg	
245 250 255	
agc tgg aag aat cag ccg gag gtc acc gta tcc ggc agc cac ttc ctt	816
Ser Trp Lys Asn Gln Arg Glu Val Thr Val Ser Gly Ser His Phe Leu	
260 265 270	
cag gaa gac tcg ccg cac gag atc ggc ctc gcg ctc ccg gat ttc gtg	864
Gln Glu Asp Ser Pro His Glu Ile Gly Leu Ala Leu Arg Asp Phe Val	
275 280 285	
cgg tcg gcg taa	876
Arg Ser Ala	
290	

18

<210> 16

<211> 291

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Artificially
modified (mutated) Dehalogenase

<400> 16

```

Met Ala Ser Ala Pro Ile Asp Pro Thr Asp Pro His Pro Arg Lys Arg
 1           5           10           15
Ile Ala Val Leu Asp Ser Glu Met Ser Tyr Val Asp Thr Gly Glu Gly
      20           25           30
Ala Pro Ile Val Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp
      35           40           45
Arg Asn Ile Ile Pro Tyr Leu Ala Asp His Gly Arg Cys Leu Ala Pro
      50           55           60
Asp Leu Val Gly Met Gly Arg Ser Gly Lys Ser Pro Thr Arg Ser Tyr
      65           70           75           80
Gly Phe Thr Asp His Ala Arg Tyr Leu Asp Ala Trp Phe Asp Ala Leu
      85           90           95
Asp Leu Thr Arg Asp Val Thr Leu Val Ile His Asp Trp Gly Ser Ala
      100          105          110
Leu Gly Phe His Arg Ala Phe Arg Phe Pro Glu Gln Ile Lys Ala Ile
      115          120          125
Ala Tyr Met Glu Ala Ile Val Arg Pro Leu Val Trp Ala Asp Ile Ala
      130          135          140
Gly Ala Glu Gln Ala Phe Arg Ala Ile Arg Ser Glu Ala Gly Glu His
      145          150          155          160
Met Ile Leu Asp Glu Asn Phe Phe Val Glu Val Leu Leu Pro Ala Ser
      165          170          175
Ile Leu Arg Arg Leu Ser Asp Leu Glu Met Ala Ala Tyr Arg Ala Pro
      180          185          190
Phe Leu Asp Arg Glu Ser Arg Trp Pro Thr Leu Arg Trp Pro Arg Glu
      195          200          205
Val Pro Ile Glu Gly Glu Pro Ala Asp Val Thr Ala Ile Val Glu Ala
      210          215          220
Tyr Gly Arg Trp Met Ala Glu Asn Thr Leu Pro Lys Leu Leu Val Leu
      225          230          235          240
Gly Asp Pro Gly Val Ile Ala Thr Gly Arg Thr Arg Asp Phe Cys Arg
      245          250          255
Ser Trp Lys Asn Gln Arg Glu Val Thr Val Ser Gly Ser His Phe Leu
      260          265          270
Gln Glu Asp Ser Pro His Glu Ile Gly Leu Ala Leu Arg Asp Phe Val
      275          280          285
Arg Ser Ala
      290

```

<210> 17

<211> 918

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially
modified (mutated) Dehalogenase

<220>

<221> CDS

<222> (1) .. (918)

<400> 17

atg caa tta acg aat gaa aca gaa gcc aac gcg atc tct gcg aca agt 48

19

Met	Gln	Leu	Thr	Asn	Glu	Thr	Glu	Ala	Asn	Ala	Ile	Ser	Ala	Thr	Ser	
1				5					10					15		
ccc	tac	cca	aaa	ttt	cgg	cgg	tcg	gtc	ttc	ggc	cgc	gag	atg	gcg	tac	96
Pro	Tyr	Pro	Lys	Phe	Arg	Arg	Ser	Val	Phe	Gly	Arg	Glu	Met	Ala	Tyr	
			20					25					30			
gtg	gaa	gtg	gga	cgg	ggc	gac	ccc	atc	gta	ctc	ttg	cac	ggc	aac	ccc	144
Val	Glu	Val	Gly	Arg	Gly	Asp	Pro	Ile	Val	Leu	Leu	His	Gly	Asn	Pro	
		35					40					45				
acc	tcg	tcg	tac	ctc	tgg	cgc	aac	gtg	ttg	ccg	cac	ctg	gcg	ccg	tta	192
Thr	Ser	Ser	Tyr	Leu	Trp	Arg	Asn	Val	Leu	Pro	His	Leu	Ala	Pro	Leu	
			50			55					60					
ggc	cgc	tgt	atc	gct	cca	gac	ctg	att	ggt	atg	gga	gac	tca	gac	aaa	240
Gly	Arg	Cys	Ile	Ala	Pro	Asp	Leu	Ile	Gly	Met	Gly	Asp	Ser	Asp	Lys	
					70					75					80	
ctg	cgt	gac	agt	ggg	ccg	ggc	tca	tat	cgc	ttc	gtc	gag	cag	cgc	cgt	288
Leu	Arg	Asp	Ser	Gly	Pro	Gly	Ser	Tyr	Arg	Phe	Val	Glu	Gln	Arg	Arg	
				85					90					95		
tac	ctc	gac	gcc	ctg	ctc	gag	gct	ctg	gac	gtg	cac	gag	cga	gtc	acg	336
Tyr	Leu	Asp	Ala	Leu	Leu	Glu	Ala	Leu	Asp	Val	His	Glu	Arg	Val	Thr	
			100					105					110			
ttt	gtc	atc	cat	gac	tgg	ggc	tcg	gcc	ctc	gga	ttt	gat	tgg	gcc	aac	384
Phe	Val	Ile	His	Asp	Trp	Gly	Ser	Ala	Leu	Gly	Phe	Asp	Trp	Ala	Asn	
		115					120					125				
cgc	cac	cgc	gaa	gca	atg	agg	ggt	atc	gcg	tac	atg	gag	gcg	att	gtg	432
Arg	His	Arg	Glu	Ala	Met	Arg	Gly	Ile	Ala	Tyr	Met	Glu	Ala	Ile	Val	
			130			135					140					
cgg	ccg	cag	ggc	ggg	gac	cac	tgg	gac	aac	atc	aac	atg	cgt	cca	ccc	480
Arg	Pro	Gln	Gly	Gly	Asp	His	Trp	Asp	Asn	Ile	Asn	Met	Arg	Pro	Pro	
				150					155					160		
ttg	cag	gcg	ctg	cgt	tca	tgg	gcc	ggc	gag	gtg	atg	gtc	ctg	caa	gac	528
Leu	Gln	Ala	Leu	Arg	Ser	Trp	Ala	Gly	Glu	Val	Met	Val	Leu	Gln	Asp	
				165					170					175		
aac	ttc	ttt	atc	gag	aag	atg	ctg	cca	ggg	ggc	atc	ctg	cgc	gcc	ctc	576
Asn	Phe	Phe	Ile	Glu	Lys	Met	Leu	Pro	Gly	Gly	Ile	Leu	Arg	Ala	Leu	
			180					185					190			
tcc	gca	ggg	gag	atg	gca	gaa	tac	cgg	cgg	ccg	ttt	gcc	gag	ccc	ggc	624
Ser	Ala	Gly	Glu	Met	Ala	Glu	Tyr	Arg	Arg	Pro	Phe	Ala	Glu	Pro	Gly	
			195				200					205				
gag	ggg	cga	cga	ccg	acg	ctg	aca	tgg	ccc	cgg	gaa	ctc	ccc	ata	gaa	672
Glu	Gly	Arg	Arg	Pro	Thr	Leu	Thr	Trp	Pro	Arg	Glu	Leu	Pro	Ile	Glu	
		210				215					220					
ggc	gac	ccc	gcc	gaa	gtg	gct	gcg	atc	gtg	gcc	gcc	tac	gcg	gac	tgg	720
Gly	Asp	Pro	Ala	Glu	Val	Ala	Ala	Ile	Val	Ala	Ala	Tyr	Ala	Asp	Trp	
					230					235					240	
tta	gcg	aca	agt	gat	gtg	ccc	aag	ctt	ttc	ctg	aag	gcc	gag	ccc	ggg	768
Leu	Ala	Thr	Ser	Asp	Val	Pro	Lys	Leu	Phe	Leu	Lys	Ala	Glu	Pro	Gly	
				245					250					255		
gcg	ctc	atc	gcc	ggc	gga	gcg	aat	ctc	gag	acc	gtc	cgc	aaa	tgg	ccg	816
Ala	Leu	Ile	Ala	Gly	Gly	Ala	Asn	Leu	Glu	Thr	Val	Arg	Lys	Trp	Pro	

260						265						270						
gcg	cag	acc	gag	gta	acg	gtc	gcg	ggg	atc	cat	ttc	atc	cag	gaa	gat	864		
Ala	Gln	Thr	Glu	Val	Thr	Val	Ala	Gly	Ile	His	Phe	Ile	Gln	Glu	Asp			
275						280						285						
tcg	ccg	gac	gag	atc	ggc	cgg	gcg	atc	gcc	gat	tgg	atg	agg	gcg	ttg	912		
Ser	Pro	Asp	Glu	Ile	Gly	Arg	Ala	Ile	Ala	Asp	Trp	Met	Arg	Ala	Leu			
290						295						300						
agc	tga															918		
Ser																		
305																		

```
<210> 18
<211> 305
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Artificially
        modified (mutated) Dehalogenase
```

[illegible]

<210> 19
 <211> 912
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Artificially
 modified (mutated) Dehalogenase

<220>
 <221> CDS
 <222> (1)..(912)

<400> 19
 atg ctc gtt gcg cag aca agg aag cat cca atg act gaa acg ccg ctg 48
 Met Leu Val Ala Gln Thr Arg Lys His Pro Met Thr Glu Thr Pro Leu
 1 5 10 15
 aca aaa aac acc gtc gat gtg ctg ggc acg tcg atg gcc tat cac gcg 96
 Thr Lys Asn Thr Val Asp Val Leu Gly Thr Ser Met Ala Tyr His Ala
 20 25 30
 cgc ggc gag ggt gcg cca ata ttg ttt ctg cac ggc aac ccg acc tcg 144
 Arg Gly Glu Gly Ala Pro Ile Leu Phe Leu His Gly Asn Pro Thr Ser
 35 40 45
 tcc tat ctg tgg cgc gac gtc att ccc gaa ctg gag gga cgc gcc cgg 192
 Ser Tyr Leu Trp Arg Asp Val Ile Pro Glu Leu Glu Gly Arg Gly Arg
 50 55 60
 ctg atc gcg ccg gat ctg atc ggg atg ggc gat tcc gcc aaa ttg cca 240
 Leu Ile Ala Pro Asp Leu Ile Gly Met Gly Asp Ser Ala Lys Leu Pro
 65 70 75 80
 gat ccc ggt gcg gac acc tat cgc ttc acg act cat cgc aaa tat ctc 288
 Asp Pro Gly Ala Asp Thr Tyr Arg Phe Thr Thr His Arg Lys Tyr Leu
 85 90 95
 gat gcc ttc gtc gat gcg gtg atc ggc ccg gcg caa tcc atc gtg atg 336
 Asp Ala Phe Val Asp Ala Val Ile Gly Pro Ala Gln Ser Ile Val Met
 100 105 110
 gtg gtg cac gac tgg ggc tcg gcg ctc ggt ttc gac tgg gcc aac cgt 384
 Val Val His Asp Trp Gly Ser Ala Leu Gly Phe Asp Trp Ala Asn Arg
 115 120 125
 cac cgc aac cgt atc cgt ggt atc gcc tat atg gag ggg atc gtg cgc 432
 His Arg Asn Arg Ile Arg Gly Ile Ala Tyr Met Glu Gly Ile Val Arg
 130 135 140
 ccg atc gcc tcc tgg gat gaa tgg agc gcg tcg gcc acg ccg atc ttc 480
 Pro Ile Ala Ser Trp Asp Glu Trp Ser Ala Ser Ala Thr Pro Ile Phe
 145 150 155 160
 cag gga ttt cgc tcc gac aag ggc gag acc atg atc ctg gag cgc aac 528
 Gln Gly Phe Arg Trp Asp Lys Gly Glu Thr Met Ile Leu Glu Arg Asn
 165 170 175
 atg ttc gtc gag cgg gtg ctg ccg ggg tcg gtg ttg cgg aaa ctg acc 576
 Met Phe Val Glu Arg Val Leu Pro Gly Ser Val Leu Arg Lys Leu Thr
 180 185 190
 gag gcc gag atg gcg gaa tac cgc cgg ccc tat ccg aaa gcc gag gac 624
 Glu Ala Glu Met Ala Glu Tyr Arg Arg Pro Tyr Pro Lys Ala Glu Asp

195					200					205						
cgc	tgg	ccg	acg	ctg	acc	tgg	ccg	cgc	cag	atc	ccg	atc	gcc	ggc	gaa	672
Arg	Trp	Pro	Thr	Leu	Thr	Trp	Pro	Arg	Gln	Ile	Pro	Ile	Ala	Gly	Glu	
	210					215					220					
ccc	gcc	gat	gtg	gtg	cag	atc	gcg	gcg	gag	tat	tca	cga	tgg	atg	gcg	720
Pro	Ala	Asp	Val	Val	Gln	Ile	Ala	Ala	Glu	Tyr	Ser	Arg	Trp	Met	Ala	
225					230					235					240	
gag	aac	gac	atc	cca	aaa	ctg	ttc	gtc	aac	gcc	gag	ccc	ggg	gcg	atc	768
Glu	Asn	Asp	Ile		Lys	Leu	Phe	Val	Asn	Ala	Glu	Pro	Gly	Ala	Ile	
				245					250					255		
ctg	acc	ggc	gcg	ccc	cgg	gat	ttc	tgc	cga	agc	tgg	aaa	agc	cag	acc	816
Leu	Thr	Gly	Ala	Pro	Arg	Asp	Phe	Cys	Arg	Ser	Trp	Lys	Ser	Gln	Thr	
			260					265					270			
gaa	gtc	acc	gtc	gcg	ggc	tcg	cat	ttc	atc	cag	gaa	gac	tcc	gga	ccg	864
Glu	Val	Thr	Val	Ala	Gly	Ser	His	Phe	Ile	Gln	Glu	Asp	Ser	Gly	Pro	
	275						280					285				
gcg	atc	ggc	cgg	gcg	gta	gcc	gcc	tgg	atg	acg	gcg	aat	ggg	cta	tag	912
Ala	Ile	Gly	Arg	Ala	Val	Ala	Ala	Trp	Met	Thr	Ala	Asn	Gly	Leu		
	290					295					300					

<210> 20

<211> 303

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Artificially modified (mutated) Dehalogenase

<400> 20

Met	Leu	Val	Ala	Gln	Thr	Arg	Lys	His	Pro	Met	Thr	Glu	Thr	Pro	Leu	
1				5					10					15		
Thr	Lys	Asn	Thr	Val	Asp	Val	Leu	Gly	Thr	Ser	Met	Ala	Tyr	His	Ala	
		20						25					30			
Arg	Gly	Glu	Gly	Ala	Pro	Ile	Leu	Phe	Leu	His	Gly	Asn	Pro	Thr	Ser	
		35				40						45				
Ser	Tyr	Leu	Trp	Arg	Asp	Val	Ile	Pro	Glu	Leu	Glu	Gly	Arg	Gly	Arg	
	50				55				60							
Leu	Ile	Ala	Pro	Asp	Leu	Ile	Gly	Met	Gly	Asp	Ser	Ala	Lys	Leu	Pro	
	65				70				75					80		
Asp	Pro	Gly	Ala	Asp	Thr	Tyr	Arg	Phe	Thr	Thr	His	Arg	Lys	Tyr	Leu	
				85					90					95		
Asp	Ala	Phe	Val	Asp	Ala	Val	Ile	Gly	Pro	Ala	Gln	Ser	Ile	Val	Met	
		100						105					110			
Val	Val	His	Asp	Trp	Gly	Ser	Ala	Leu	Gly	Phe	Asp	Trp	Ala	Asn	Arg	
		115				120						125				
His	Arg	Asn	Arg	Ile	Arg	Gly	Ile	Ala	Tyr	Met	Glu	Gly	Ile	Val	Arg	
	130				135						140					
Pro	Ile	Ala	Ser	Trp	Asp	Glu	Trp	Ser	Ala	Ser	Ala	Thr	Pro	Ile	Phe	
	145				150				155					160		
Gln	Gly	Phe	Arg	Ser	Asp	Lys	Gly	Glu	Thr	Met	Ile	Leu	Glu	Arg	Asn	
				165				170						175		
Met	Phe	Val	Glu	Arg	Val	Leu	Pro	Gly	Ser	Val	Leu	Arg	Lys	Leu	Thr	
		180						185					190			
Glu	Ala	Glu	Met	Ala	Glu	Tyr	Arg	Arg	Pro	Tyr	Pro	Lys	Ala	Glu	Asp	
	195						200					205				
Arg	Trp	Pro	Thr	Leu	Thr	Trp	Pro	Arg	Gln	Ile	Pro	Ile	Ala	Gly	Glu	
	210					215					220					
Pro	Ala	Asp	Val	Val	Gln	Ile	Ala	Ala	Glu	Tyr	Ser	Arg	Trp	Met	Ala	
	225				230					235					240	

Glu	Asn	Asp	Ile	Pro	Lys	Leu	Phe	Val	Asn	Ala	Glu	Pro	Gly	Ala	Ile
				245					250					255	
Leu	Thr	Gly	Ala	Pro	Arg	Asp	Phe	Cys	Arg	Ser	Trp	Lys	Ser	Gln	Thr
			260					265						270	
Glu	Val	Thr	Val	Ala	Gly	Ser	His	Phe	Ile	Gln	Glu	Asp	Ser	Gly	Pro
			275				280					285			
Ala	Ile	Gly	Arg	Ala	Val	Ala	Ala	Trp	Met	Thr	Ala	Asn	Gly	Leu	
	290					295					300				

```
<210> 21
<211> 894
<212> DNA
<213> Artificial Sequence
```

<223> Description of Artificial Sequence: Artificially modified (mutated) Dehalogenase

```
<220>
<221> CDS
<222> (1)..(894)
```

<400> 21																	
atg	gct	agc	atg	acc	cag	gtt	tcc	atc	tcg	acc	gag	gac	gct	tcc	tac		
Met	Ala	Ser	Met	Thr	Gln	Val	Ser	Ile	Ser	Thr	Glu	Asp	Ala	Ser	Tyr		
1				5					10					15			
cgg	aag	cgg	gtc	cgc	gtg	ctc	gat	acc	gac	atg	gcc	tat	gtc	gac	gtg		
Arg	Lys	Arg	Val	Arg	Val	Leu	Asp	Thr	Asp	Met	Ala	Tyr	Val	Asp	Val		
			20					25					30				
ggc	gaa	ggc	gat	ccg	atc	gtg	ttc	ctg	cac	ggc	aac	ccg	acg	ccg	tcg		
Gly	Glu	Gly	Asp	Pro	Ile	Val	Phe	Leu	His	Gly	Asn	Pro	Thr	Pro	Ser		
		35					40					45					
ttc	ctg	tgg	cgc	aac	atc	atc	ccc	tac	gcc	ctg	ccc	ttc	ggc	cgc	tgc		
Phe	Leu	Trp	Arg	Asn	Ile	Ile	Pro	Tyr	Ala	Leu	Pro	Phe	Gly	Arg	Cys		
	50					55					60						
ctc	gcg	ccc	gac	tac	gtg	ggg	atg	ggc	aat	tcc	ggg	ccg	gcg	ccg	ggc		
Leu	Ala	Pro	Asp	Tyr	Val	Gly	Met	Gly	Asn	Ser	Gly	Pro	Ala	Pro	Gly		
65					70					75					80		
ggg	tcg	tat	cga	ttc	gtc	gat	cac	cgg	cgc	tat	ctc	gac	gcc	tgg	ttc		
Gly	Ser	Tyr	Arg	Phe	Val	Asp	His	Arg	Arg	Tyr	Leu	Asp	Ala	Trp	Phe		
				85					90					95			
gag	gcc	atg	ggc	ctg	acg	gag	aac	gtc	atc	ctc	gtg	gtg	cac	gac	tgg		
Glu	Ala	Met	Gly	Leu	Thr	Glu	Asn	Val	Ile	Leu	Val	Val	His	Asp	Trp		
			100					105					110				
ggc	tcg	gcg	ctc	ggc	ttc	gac	tgg	gcg	cgg	cgt	cac	ccc	gat	cgg	gtc		
Gly	Ser	Ala	Leu	Gly	Phe	Asp	Trp	Ala	Arg	Arg	His	Pro	Asp	Arg	Val		
		115					120					125					
aag	gcc	atc	gtc	tat	atg	gaa	ggg	atc	gtc	cgg	ccg	ttc	ctg	tcc	tgg		
Lys	Ala	Ile	Val	Tyr	Met	Glu	Gly	Ile	Val	Arg	Pro	Phe	Leu	Ser	Trp		
	130					135					140						
gac	gaa	tgg	ccg	gcc	gtc	acg	cgc	gcc	ttc	ttc	cag	ggc	cag	cgc	acg		
Asp	Glu	Trp	Pro	Ala	Val	Thr	Arg	Ala	Phe	Phe	Gln	Gly	Gln	Arg	Thr		
145					150					155					160		

24

```

gcg gcg ggc gag gac ctg att ctc cag aag aac ctg ttc atc gag tat 528
Ala Ala Gly Glu Asp Leu Ile Leu Gln Lys Asn Leu Phe Ile Glu Tyr
165 170 175

ctc ctg ccg ctg cgc ggc atc ccc aag gag gcg atc gag gtc tac cgc 576
Leu Leu Pro Leu Arg Gly Ile Pro Lys Glu Ala Ile Glu Val Tyr Arg
180 185 190

cgt ccc ttc cgg aac ccc ggt gcc tcg cgc cag ccg atg ctg acc tgg 624
Arg Pro Phe Arg Asn Pro Gly Ala Ser Arg Gln Pro Met Leu Thr Trp
195 200 205

acc cgc gaa ctg ccg atc gcc ggc gag ccc gcc gac gtc gtg gcc atc 672
Thr Arg Glu Leu Pro Ile Ala Gly Glu Pro Ala Asp Val Val Ala Ile
210 215 220

gtc gag gac tac gcc cgc ttc ctc tcc acc agc ccg atc ccc aag ctg 720
Val Glu Asp Tyr Ala Arg Phe Leu Ser Thr Ser Pro Ile Pro Lys Leu
225 230 235 240

ttc atc gac gcc gag ccc ggc ggc ttc ctg atc ggc gcc cag cgc gaa 768
Phe Ile Asp Ala Glu Pro Gly Gly Phe Leu Ile Gly Ala Gln Arg Glu
245 250 255

ttc tgc cgc gcc tgg ccc aac cag acc gag gtg acg gtc cca ggc gtc 816
Phe Cys Arg Ala Trp Pro Asn Gln Thr Glu Val Thr Val Pro Gly Val
260 265 270

cat ttc gtc cag gag gac agt ccg agg gcg atc ggc gag gca gtg tcc 864
His Phe Val Gln Glu Asp Ser Pro Arg Ala Ile Gly Glu Ala Val Ser
275 280 285

gcc ttc gtt gtt tcg ttg cgg ggc gcg tag 894
Ala Phe Val Val Ser Leu Arg Gly Ala
290 295

```

<210> 22

<211> 297

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Artificially modified (mutated) Dehalogenase

<400> 22

```

Met Ala Ser Met Thr Gln Val Ser Ile Ser Thr Glu Asp Ala Ser Tyr
1 5 10 15
Arg Lys Arg Val Arg Val Leu Asp Thr Asp Met Ala Tyr Val Asp Val
20 25 30
Gly Glu Gly Asp Pro Ile Val Phe Leu His Gly Asn Pro Thr Pro Ser
35 40 45
Phe Leu Trp Arg Asn Ile Ile Pro Tyr Ala Leu Pro Phe Gly Arg Cys
50 55 60
Leu Ala Pro Asp Tyr Val Gly Met Gly Asn Ser Gly Pro Ala Pro Gly
65 70 75 80
Gly Ser Tyr Arg Phe Val Asp His Arg Arg Tyr Leu Asp Ala Trp Phe
85 90 95
Glu Ala Met Gly Leu Thr Glu Asn Val Ile Leu Val Val His Asp Trp
100 105 110
Gly Ser Ala Leu Gly Phe Asp Trp Ala Arg Arg His Pro Asp Arg Val
115 120 125
Lys Ala Ile Val Tyr Met Glu Gly Ile Val Arg Pro Phe Leu Ser Trp
130 135 140
Asp Glu Trp Pro Ala Val Thr Arg Ala Phe Phe Gly Gln Arg Thr
145 150 155 160

```

25

Ala	Ala	Gly	Glu	Asp	Leu	Ile	Leu	Gln	Lys	Asn	Leu	Phe	Ile	Glu	Tyr
				165					170					175	
Leu	Leu	Pro	Leu	Arg	Gly	Ile	Pro	Lys	Glu	Ala	Ile	Glu	Val	Tyr	Arg
			180					185					190		
Arg	Pro	Phe	Arg	Asn	Pro	Gly	Ala	Ser	Arg	Gln	Pro	Met	Leu	Thr	Trp
		195					200					205			
Thr	Arg	Glu	Leu	Pro	Ile	Ala	Gly	Glu	Pro	Ala	Asp	Val	Val	Ala	Ile
		210				215					220				
Val	Glu	Asp	Tyr	Ala	Arg	Phe	Leu	Ser	Thr	Ser	Pro	Ile	Pro	Lys	Leu
		225			230					235					240
Phe	Ile	Asp	Ala	Glu	Pro	Gly	Gly	Phe	Leu	Ile	Gly	Ala	Gln	Arg	Glu
			245						250				255		
Phe	Cys	Arg	Ala	Trp	Pro	Asn	Gln	Thr	Glu	Val	Thr	Val	Pro	Gly	Val
			260					265					270		
His	Phe	Val	Gln	Glu	Asp	Ser	Pro	Arg	Ala	Ile	Gly	Glu	Ala	Val	Ser
		275					280					285			
Ala	Phe	Val	Val	Ser	Leu	Arg	Gly	Ala							
		290				295									

<210> 23

<211> 915

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially modified (mutated) Dehalogenase

<220>

<221> CDS

<222> (1) .. (915)

<400> 23

atg	aat	gtg	gcg	cga	ggc	gac	acg	gtc	gtc	acc	gcc	gcg	gag	cct	gat	48
Met	Asn	Val	Ala	Arg	Gly	Asp	Thr	Val	Val	Thr	Ala	Ala	Glu	Pro	Asp	
1				5					10					15		
ggc	ccg	gac	cac	ctg	cct	cgg	cgt	cgc	gtg	aag	gtg	atg	gat	acc	gaa	96
Gly	Pro	Asp	His	Leu	Pro	Arg	Arg	Arg	Val	Lys	Val	Met	Asp	Thr	Glu	
			20					25					30			
atc	agc	tat	gtc	gat	gtc	ggg	gaa	ggg	gag	ccc	gtc	gtc	ttt	ctg	cac	144
Ile	Ser	Tyr	Val	Asp	Val	Gly	Glu	Gly	Glu	Pro	Val	Val	Phe	Leu	His	
		35				40						45				
ggc	aat	ccc	acg	tgg	tcc	tat	caa	tgg	cgc	aat	atc	att	cct	tac	atc	192
Gly	Asn	Pro	Thr	Trp	Ser	Tyr	Gln	Trp	Arg	Asn	Ile	Ile	Pro	Tyr	Ile	
	50					55					60					
agc	ccc	gtt	cgc	cgc	tgt	ctc	gcg	ccc	gat	ctt	gtc	ggc	atg	ggg	tgg	240
Ser	Pro	Val	Arg	Arg	Cys	Leu	Ala	Pro	Asp	Leu	Val	Gly	Met	Gly	Trp	
	65				70				75					80		
tcc	ggc	aag	tgc	ccg	ggc	aaa	gcc	tat	cgt	ttc	gtc	gat	cag	gcc	cgc	288
Ser	Gly	Lys	Ser	Pro	Gly	Lys	Ala	Tyr	Arg	Phe	Val	Asp	Gln	Ala	Arg	
			85					90					95			
tac	atg	gat	gcc	tgg	ttc	gag	gcg	ttg	cag	ctg	acc	cgg	aac	gtt	acg	336
Tyr	Met	Asp	Ala	Trp	Phe	Glu	Ala	Leu	Gln	Leu	Thr	Arg	Asn	Val	Thr	
			100					105					110			
ttg	gtg	ttg	cac	gac	tgg	ggc	gcg	gcc	atc	ggc	ttc	tat	cgc	gcc	cgg	384
Leu	Val	Leu	His	Asp	Trp	Gly	Ala	Ala	Ile	Gly	Phe	Tyr	Arg	Ala	Arg	

26

115	120	125	
cgc cat cct gag cag ata aag gcg att gcc tat tat gaa gct gtc gct Arg His Pro Glu Gln Ile Lys Ala Ile Ala Tyr Tyr Glu Ala Val Ala 130 135 140			432
cac tcg cgc cga tgg gac gac ttc tct ggc ggc cgc gac cgc caa ttc His Ser Arg Arg Trp Asp Asp Phe Ser Gly Gly Arg Asp Arg Gln Phe 145 150 155 160			480
cgc cta tta cgc tcg ccc gac gga gaa cgc ctc gtc ctc gac gag aac Arg Leu Leu Arg Ser Pro Asp Gly Glu Arg Leu Val Leu Asp Glu Asn 165 170 175			528
atg ttc gtg gaa gtc gtc ctg ccg cgc ggc att ttg cgc aag cta acc Met Phe Val Glu Val Val Leu Pro Arg Gly Ile Leu Arg Lys Leu Thr 180 185 190			576
gat gac gag atg gaa gcc tac cga gct cct tat cgc gat cgc gag cgg Asp Asp Glu Met Glu Ala Tyr Arg Ala Pro Tyr Arg Asp Arg Glu Arg 195 200 205			624
cgc ctg ccg acc ctg att tgg ccg cgc gag gtg ccg atc gaa gga gag Arg Leu Pro Thr Leu Ile Trp Pro Arg Glu Val Pro Ile Glu Gly Glu 210 215 220			672
ccc gcg gac gtc gtg gcc att gtc gat gag aat gcg cga tgg ctt gcg Pro Ala Asp Val Val Ala Ile Val Asp Glu Asn Ala Arg Trp Leu Ala 225 230 235 240			720
gcc agc gat cgg ctg ccg aag ctg ttc atc aag ggc gat ccc gga gca Ala Ser Asp Arg Leu Pro Lys Leu Phe Ile Lys Gly Asp Pro Gly Ala 245 250 255			768
atc cat acc gga cgc ttg ctc gat ctg gtt cgc gcg ttt ccc aat cag Ile His Thr Gly Arg Leu Leu Asp Leu Val Arg Ala Phe Pro Asn Gln 260 265 270			816
cgc gag gtg acc gtc aag ggg ctg cac cac ctg cag gac gat tcg cca Arg Glu Val Thr Val Lys Gly Leu His His Leu Gln Asp Asp Ser Pro 275 280 285			864
gac gaa atc ggc gct gcg ctg cgg gca ttc gtg ctc cgc aaa ggg att Asp Glu Ile Gly Ala Ala Leu Arg Ala Phe Val Leu Arg Lys Gly Ile 290 295 300			912
tga			915

305

<210> 24

<211> 304

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Artificially
modified (mutated) Dehalogenase

<400> 24

Met	Asn	Val	Ala	Arg	Gly	Asp	Thr	Val	Val	Thr	Ala	Ala	Glu	Pro	Asp
1				5					10					15	
Gly	Pro	Asp	His	Leu	Pro	Arg	Arg	Arg	Val	Lys	Val	Met	Asp	Thr	Glu
			20					25					30		
Ile	Ser	Tyr	Val	Asp	Val	Gly	Glu	Gly	Glu	Pro	Val	Val	Phe	Leu	His
		35					40					45			

```

Gly Asn Pro Thr Trp Ser Tyr Gln Trp Arg Asn Ile Ile Pro Tyr Ile
  50      55      60
Ser Pro Val Arg Arg Cys Leu Ala Pro Asp Leu Val Gly Met Gly Trp
  65      70      75      80
Ser Gly Lys Ser Pro Gly Lys Ala Tyr Arg Phe Val Asp Gln Ala Arg
      85      90      95
Tyr Met Asp Ala Trp Phe Glu Ala Leu Gln Leu Thr Arg Asn Val Thr
      100      105      110
Leu Val Leu His Asp Trp Gly Ala Ile Gly Phe Tyr Arg Ala Arg
      115      120      125
Arg His Pro Glu Gln Ile Lys Ala Ile Ala Tyr Tyr Glu Ala Val Ala
      130      135      140
His Ser Arg Arg Trp Asp Asp Phe Ser Gly Gly Arg Asp Arg Gln Phe
      145      150      155      160
Arg Leu Leu Arg Ser Pro Asp Gly Glu Arg Leu Val Leu Asp Glu Asn
      165      170      175
Met Phe Val Glu Val Val Leu Pro Arg Gly Ile Leu Arg Lys Leu Thr
      180      185      190
Asp Asp Glu Met Glu Ala Tyr Arg Ala Pro Tyr Arg Asp Arg Glu Arg
      195      200      205
Arg Leu Pro Thr Leu Ile Trp Pro Arg Glu Val Pro Ile Glu Gly Glu
      210      215      220
Pro Ala Asp Val Val Ala Ile Val Asp Glu Asn Ala Arg Trp Leu Ala
      225      230      235      240
Ala Ser Asp Arg Leu Pro Lys Leu Phe Ile Lys Gly Asp Pro Gly Ala
      245      250      255
Ile His Thr Gly Arg Leu Leu Asp Leu Val Arg Ala Phe Pro Asn Gln
      260      265      270
Arg Glu Val Thr Val Lys Gly Leu His His Leu Gln Asp Ser Pro
      275      280      285
Asp Glu Ile Gly Ala Ala Leu Arg Ala Phe Val Leu Arg Lys Gly Ile
      290      295      300

```

<210> 25

<211> 900

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially modified (mutated) Dehalogenase

<220>

<221> CDS

<222> (1)..(900)

<400> 25

```

atg ctg gac agg att tct gcc aaa ggc aat ctt act cgt agc tgc gta 48
Met Leu Asp Arg Ile Ser Ala Lys Gly Asn Leu Thr Arg Ser Cys Val
  1      5      10      15

```

```

agc gtc ctt gac agc gag atg agt tac gtc gcg act ggt cgg ggg cac 96
Ser Val Leu Asp Ser Glu Met Ser Tyr Val Ala Thr Gly Arg Gly His
      20      25      30

```

```

cca atc gtt ttc ctg cac ggg aac ccg acc tca tct tat ctt tgg cgt 144
Pro Ile Val Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg
      35      40      45

```

```

aac gtc atc ccc cac gtc agc aac ctt ggc cgg tgc ctc gcg ccg gac 192
Asn Val Ile Pro His Val Ser Asn Leu Gly Arg Cys Leu Ala Pro Asp
      50      55      60

```

```

ctc gtt ggt atg ggc cag ccg gcc gcc tct cca cgg ggc gcc tat cgc 240
Leu Val Gly Met Gly Gln Pro Ala Ala Ser Pro Arg Gly Ala Tyr Arg
65 70 75 80

ttt gtg gac cat tca cgt tat ctc gac gca tgg ttt gag gcc ctg gac 288
Phe Val Asp His Ser Arg Tyr Leu Asp Ala Trp Phe Glu Ala Leu Asp
85 90 95

ttg cgt aga aac gtt acc ctg gtg gtg cac gat tgg gga tcg gcg ctc 336
Leu Arg Arg Asn Val Thr Leu Val Val His Asp Trp Gly Ser Ala Leu
100 105 110

ggc ttt cat tgg gct tcc agg cat ccc gag cgg gtg cgg gcc atc gct 384
Gly Phe His Trp Ala Ser Arg His Pro Glu Arg Val Arg Ala Ile Ala
115 120 125

tac atg gag tcg atc gtt cag ccg cgc gac tgg gaa gac ctc ccc cca 432
Tyr Met Glu Ser Ile Val Gln Pro Arg Asp Trp Glu Asp Leu Pro Pro
130 135 140

agt cgg gcg ccg atc ttt cgc gac ctg cgg tcc aat aaa ggt gag cgc 480
Ser Arg Ala Pro Ile Phe Arg Asp Leu Arg Ser Asn Lys Gly Glu Arg
145 150 155 160

atg atc ctc gac gaa aat gcc ttc att gag att ctc ttg ccg aag ctc 528
Met Ile Leu Asp Glu Asn Ala Phe Ile Glu Ile Leu Leu Pro Lys Leu
165 170 175

gtc atc cgg act ctg acc agc gct gag atg gat gca tat cgt cgt cca 576
Val Ile Arg Thr Leu Thr Ser Ala Glu Met Asp Ala Tyr Arg Arg Pro
180 185 190

ttt att gaa ccg aac tcg cgc tgg cct aca ctt atc tgg ccg cgc gag 624
Phe Ile Glu Pro Asn Ser Arg Trp Pro Thr Leu Ile Trp Pro Arg Glu
195 200 205

cta ccg atc ggt ggc gaa cct gcc gac gtg gtg aaa att gtc gaa gat 672
Leu Pro Ile Gly Gly Glu Pro Ala Asp Val Val Lys Ile Val Glu Asp
210 215 220

tac ggg caa tgg ctt ctc aag acc ccg ttg ccg aag ttg ttt atc aac 720
Tyr Gly Gln Trp Leu Leu Lys Thr Pro Leu Pro Lys Leu Phe Ile Asn
225 230 235 240

gcc gag cca ggg tcg ctg ttg atc gga cgg gca cgt gaa ttc tgc cgc 768
Ala Glu Pro Gly Ser Leu Leu Ile Gly Arg Ala Arg Glu Phe Cys Arg
245 250 255

tcc tgg cca aat caa gag gaa gtg acg gtt cgg ggt atc cat ttt att 816
Ser Trp Pro Asn Gln Glu Glu Val Thr Val Arg Gly Ile His Phe Ile
260 265 270

cag gaa gac agt ccc gat gag att ggc gct gcg ctt acg cgc ttc atg 864
Gln Glu Asp Ser Pro Asp Glu Ile Gly Ala Ala Leu Thr Arg Phe Met
275 280 285

agg caa ata agt cca gat tcc gtg atc cga aac taa 900
Arg Gln Ile Ser Pro Asp Ser Val Ile Arg Asn
290 295 300

```

<210> 26

<211> 299

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Artificially
modified (mutated) Dehalogenase

<400> 26

```

Met Leu Asp Arg Ile Ser Ala Lys Gly Asn Leu Thr Arg Ser Cys Val
 1           5           10           15
Ser Val Leu Asp Ser Glu Met Ser Tyr Val Ala Thr Gly Arg Gly His
           20           25           30
Pro Ile Val Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg
           35           40           45
Asn Val Ile Pro His Val Ser Asn Leu Gly Arg Cys Leu Ala Pro Asp
           50           55           60
Leu Val Gly Met Gly Gln Pro Ala Ala Ser Pro Arg Gly Ala Tyr Arg
           65           70           75           80
Phe Val Asp His Ser Arg Tyr Leu Asp Ala Trp Phe Glu Ala Leu Asp
           85           90           95
Leu Arg Arg Asn Val Thr Leu Val Val His Asp Trp Gly Ser Ala Leu
           100          105          110
Gly Phe His Trp Ala Ser Arg His Pro Glu Arg Val Arg Ala Ile Ala
           115          120          125
Tyr Met Glu Ser Ile Val Gln Pro Arg Asp Trp Glu Asp Leu Pro Pro
           130          135          140
Ser Arg Ala Pro Ile Phe Arg Asp Leu Arg Ser Asn Lys Gly Glu Arg
           145          150          155          160
Met Ile Leu Asp Glu Asn Ala Phe Ile Glu Ile Leu Leu Pro Lys Leu
           165          170          175
Val Ile Arg Thr Leu Thr Ser Ala Glu Met Asp Ala Tyr Arg Arg Pro
           180          185          190
Phe Ile Glu Pro Asn Ser Arg Trp Pro Thr Leu Ile Trp Pro Arg Glu
           195          200          205
Leu Pro Ile Gly Gly Glu Pro Ala Asp Val Val Lys Ile Val Glu Asp
           210          215          220
Tyr Gly Gln Trp Leu Leu Lys Thr Pro Leu Pro Lys Leu Phe Ile Asn
           225          230          235          240
Ala Glu Pro Gly Ser Leu Leu Ile Gly Arg Ala Arg Glu Phe Cys Arg
           245          250          255
Ser Trp Pro Asn Gln Glu Glu Val Thr Val Arg Gly Ile His Phe Ile
           260          265          270
Gln Glu Asp Ser Pro Asp Glu Ile Gly Ala Ala Leu Thr Arg Phe Met
           275          280          285
Arg Gln Ile Ser Pro Asp Ser Val Ile Arg Asn
           290          295

```

<210> 27

<211> 888

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially
modified (mutated) Dehalogenase

<220>

<221> CDS

<222> (1) .. (888)

<400> 27

```

atg atc tct gca gca ttt ccg tac caa aag aag cgg cgg cag gtc ctc   48
Met Ile Ser Ala Ala Phe Pro Tyr Gln Lys Lys Arg Arg Gln Val Leu
 1           5           10           15

ggc agc gag atg gca tac gtc gag gta gga gag ggc gac ccc atc gtg   96
Gly Ser Glu Met Ala Tyr Val Glu Val Gly Glu Gly Asp Pro Ile Val

```

20							25							30							
tcg Ser	ctg Leu	cac His 35	ggg Gly	aat Asn	ccc Pro	acc Thr	tcg Ser 40	tcc Ser	tac Tyr	ctc Leu	tgg Trp	cgc Arg 45	aac Asn	aca Thr	tgt Leu	144					
ccc Pro	tac Tyr 50	ctg Leu	cag Gln	cca Pro	cta Leu	ggc Gly 55	cgc Arg	tgc Cys	atc Ile	gcc Ala 60	ccc Pro	gac Asp	ctg Leu	atc Ile	ggc Gly	192					
atg Met 65	ggc Gly	gac Asp	tcc Ser	gcc Ala	aag Lys 70	ctg Leu	cct Pro	aac Asn	agt Ser	ggc Gly 75	ccc Pro	ggc Gly	tcg Ser	tat Tyr	cga Arg 80	240					
ttc Phe	gtc Val	gag Glu	cac His	cgc Arg 85	cgc Arg	tac Tyr	ctc Leu	gac Asp	acc Thr 90	ctg Leu	ctc Leu	gag Glu	gcc Ala	tta Leu 95	aat Asn	288					
atg Met	cgc Arg	gag Glu	cgg Arg 100	gtc Val	acc Thr	ttc Phe	gtc Val	gcc Ala 105	cat His	gac Asp	tgg Trp	ggc Gly	tcg Ser 110	gcc Ala	ctc Leu	336					
gcc Ala	ttc Phe	gat Asp 115	tgg Trp	gcc Ala	aat Asn	cgc Arg	cac His 120	cgc Arg	gag Glu	gca Ala	gtg Val	aag Lys 125	ggg Gly	atc Ile	cgc Ala	384					
cac His	atg Met 130	gag Glu	cgc Ala	atc Ile	gtg Val	cgg Arg 135	ccg Pro	cag Gln	gac Asp	tgg Trp	acc Thr 140	cac His	tgg Trp	gac Asp	acg Thr	432					
atg Met 145	ggg Gly	cgc Ala	cgt Arg	cca Pro	atc Ile 150	ttg Leu	cag Gln	cag Gln	ttg Leu	cgt Arg 155	tcc Ser	gag Glu	gct Ala	ggc Gly	gag Glu 160	480					
aag Lys	ttg Leu	atg Met	ctg Leu	caa Gln 165	gaa Glu	aac Asn	ctc Leu	ttc Phe	atc Ile 170	gag Glu	acg Thr	ttc Phe	ctg Leu	cct Pro 175	aag Lys	528					
gcc Ala	atc Ile	aag Lys 180	cga Arg	acc Thr	ctc Leu	tcc Ser	gcc Ala	gag Glu 185	gag Glu	aag Lys	cgc Ala	gag Glu	tat Tyr 190	aga Arg	cgg Arg	576					
ccg Pro	ttc Phe	gcc Ala 195	gag Glu	ccg Pro	ggc Gly	gag Glu	ggg Gly 200	cga Arg	cgc Arg	ccg Pro	acg Thr	ctg Leu 205	acg Thr	tgg Trp	gtc Val	624					
cgc Arg	cag Gln 210	atc Ile	ccc Pro	atc Ile	gac Asp	ggc Gly 215	gag Glu	ccc Pro	gcc Ala	gac Asp	gtg Val 220	act Thr	tgc Ser	atc Ile	gta Val	672					
tcc Ser 225	gcc Ala	tat Tyr	ggg Gly	gag Glu	tgg Trp 230	ctg Leu	cgc Ala	aaa Lys	agc Ser	aat Asn 235	gtg Val	ccc Pro	aag Lys	ctg Leu	ttc Phe 240	720					
gtg Val	aag Lys	gct Ala	gag Glu	ccg Pro 245	ggc Gly	gtc Val	ctc Leu	gtt Val	gct Ala 250	ggg Gly	ggc Gly	cgc Ala	aac Asn	ctt Leu 255	gac Asp	768					
gcc Ala	gtc Val	cgc Arg	tca Ser 260	tgg Trp	cca Pro	gca Ala	cag Gln	acc Thr 265	gag Glu	gtg Val	acg Thr	gtc Val	ccg Pro 270	gga Gly	atc Ile	816					
cat His	ttc Phe	atc Ile 275	cag Gln	gaa Glu	gat Asp	tcg Ser	ccg Pro 280	gac Asp	gag Glu	att Ile	ggg Gly 285	cgc Arg 285	gcc Ala	atc Ile	gcc Ala	864					

ggc tgg att aag acg ttg ggc taa
 Gly Trp Ile Lys Thr Leu Gly
 290 295

888

<210> 28
 <211> 295
 <212> PRT
 <213> Artificial Sequence
 <223> Description of Artificial Sequence: Artificially
 modified (mutated) Dehalogenase

<400> 28
 Met Ile Ser Ala Ala Phe Pro Tyr Gln Lys Lys Arg Arg Gln Val Leu
 1 5 10 15
 Gly Ser Glu Met Ala Tyr Val Glu Val Gly Glu Gly Asp Pro Ile Val
 20 25 30
 Ser Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg Asn Thr Leu
 35 40 45
 Pro Tyr Leu Gln Pro Leu Gly Arg Cys Ile Ala Pro Asp Leu Ile Gly
 50 55 60
 Met Gly Asp Ser Ala Lys Leu Pro Asn Ser Gly Pro Gly Ser Tyr Arg
 65 70 75 80
 Phe Val Glu His Arg Arg Tyr Leu Asp Thr Leu Leu Glu Ala Leu Asn
 85 90 95
 Met Arg Glu Arg Val Thr Phe Val Ala His Asp Trp Gly Ser Ala Leu
 100 105 110
 Ala Phe Asp Trp Ala Asn Arg His Arg Glu Ala Val Lys Gly Ile Ala
 115 120 125
 His Met Glu Ala Ile Val Arg Pro Gln Asp Trp Thr His Trp Asp Thr
 130 135 140
 Met Gly Ala Arg Pro Ile Leu Gln Gln Leu Arg Ser Glu Ala Gly Glu
 145 150 155 160
 Lys Leu Met Leu Gln Glu Asn Leu Phe Ile Glu Thr Phe Leu Pro Lys
 165 170 175
 Ala Ile Lys Arg Thr Leu Ser Ala Glu Glu Lys Ala Glu Tyr Arg Arg
 180 185 190
 Pro Phe Ala Glu Pro Gly Glu Gly Arg Arg Pro Thr Leu Thr Trp Val
 195 200 205
 Arg Gln Ile Pro Ile Asp Gly Glu Pro Ala Asp Val Thr Ser Ile Val
 210 215 220
 Ser Ala Tyr Gly Glu Trp Leu Ala Lys Ser Asn Val Pro Lys Leu Phe
 225 230 235 240
 Val Lys Ala Glu Pro Gly Val Leu Val Ala Gly Gly Ala Asn Leu Asp
 245 250 255
 Ala Val Arg Ser Trp Pro Ala Gln Thr Glu Val Thr Val Pro Gly Ile
 260 265 270
 His Phe Ile Gln Glu Asp Ser Pro Asp Glu Ile Gly Arg Ala Ile Ala
 275 280 285
 Gly Trp Ile Lys Thr Leu Gly
 290 295

<210> 29
 <211> 882
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Artificially
 modified (mutated) Dehalogenase
 <220>

<221> CDS

<222> (1)..(882)

<400> 29

atg acg gag cag gag ata tca gcg gcg ttt ccc ttc gag tcg aag ttc	48
Met Thr Glu Gln Glu Ile Ser Ala Ala Phe Pro Phe Glu Ser Lys Phe	
1 5 10 15	
gtg gat gtg caa ggc tcc cgc atg cac tac gtg gag gag ggc tcg ggc	96
Val Asp Val Gln Gly Ser Arg Met His Tyr Val Glu Glu Gly Ser Gly	
20 25 30	
gac ccg gtg gtg ttc ctc cac ggc aac ccg acc tcg tcc tac ctg tgg	144
Asp Pro Val Val Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp	
35 40 45	
cgg aac gtc atc cct cac gtg tcc ccg ctt gcg agg tgc atc gcg ccg	192
Arg Asn Val Ile Pro His Val Ser Pro Leu Ala Arg Cys Ile Ala Pro	
50 55 60	
gac ctc atc ggc atg ggg aag tcg gac aaa ccg gat atc gag tac cgc	240
Asp Leu Ile Gly Met Gly Lys Ser Asp Lys Pro Asp Ile Glu Tyr Arg	
65 70 75 80	
ttc ttc gac cac gcc ggg tac gtt gac ggg ttc atc gag gca ctg gga	288
Phe Phe Asp His Ala Gly Tyr Val Asp Gly Phe Ile Glu Ala Leu Gly	
85 90 95	
ctg cgg aac atc acc ttc gtc gcc tac gac tgg ggc tcc gcg ctg gcg	336
Leu Arg Asn Ile Thr Phe Val Ala Tyr Asp Trp Gly Ser Ala Leu Ala	
100 105 110	
ttc cac tac gcg cga cgg cac gag gat aac gta aag ggg ttg gcg ttc	384
Phe His Tyr Ala Arg Arg His Glu Asp Asn Val Lys Gly Leu Ala Phe	
115 120 125	
atg gag gcc atc gtg cga ccg ctc acc tgg gac gag tgg ccg gag cag	432
Met Glu Ala Ile Val Arg Pro Leu Thr Trp Asp Glu Trp Pro Glu Gln	
130 135 140	
gca agg cag atg ttc cag gcg ttc cgg acg ccg ggc gtc ggg gag aag	480
Ala Arg Gln Met Phe Gln Ala Phe Arg Thr Pro Gly Val Gly Glu Lys	
145 150 155 160	
atg atc ctg gag gaa aac gcc ttc gtg gag cag gtg ttg ccg gga gcg	528
Met Ile Leu Glu Glu Asn Ala Phe Val Glu Gln Val Leu Pro Gly Ala	
165 170 175	
atc ctc cgc aag ctg tcc gac gag gag atg gac cgc tac cgg gag ccg	576
Ile Leu Arg Lys Leu Ser Asp Glu Glu Met Asp Arg Tyr Arg Glu Pro	
180 185 190	
ttc ccc gac ccc acc agc cgg agg ccg acg tgg cgc tgg ccc aac gag	624
Phe Pro Asp Pro Thr Ser Arg Arg Pro Thr Trp Arg Trp Pro Asn Glu	
195 200 205	
ata cct gtc gag ggg aag ccg ccg gac gtg gtt gag gca gtg cag gcc	672
Ile Pro Val Glu Gly Lys Pro Pro Asp Val Val Glu Ala Val Gln Ala	
210 215 220	
tac gcc gat tgg atg ggc gag tcg gat gtg ccc aag ctc ctc ctg tac	720
Tyr Ala Asp Trp Met Gly Glu Ser Asp Val Pro Lys Leu Leu Leu Tyr	
225 230 235 240	
gct cac cca ggc gcg atc ctc cga gag ccg ctg ctg gag tgg tgc cgc	768

[illegible]

```
<210> 30
<211> 293
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Artificially
modified (mutated) Dehalogenase
```

[illegible]

<210> 31

<211> 885

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially modified (mutated) Dehalogenase

<220>

<221> CDS

<222> (1)..(885)

<400> 31

gtg agc gag atc tcc ccg aaa gag ccc atg gac aag aag cac atc ccc	48
Val Ser Glu Ile Ser Pro Lys Glu Pro Met Asp Lys Lys His Ile Pro	
1 5 10 15	
gta ctc gga aaa tcg atg gcg tac cgg gac gta ggt gag gga gac ccg	96
Val Leu Gly Lys Ser Met Ala Tyr Arg Asp Val Gly Glu Gly Asp Pro	
20 25 30	
atc gtc ttc ctg cac ggc aac ccc acc tcg tcg tat ctc tgg cgc aac	144
Ile Val Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg Asn	
35 40 45	
atc atc ccc cac ctc gag ccg cat gca cgc tgc atc gcg ccg gat ctc	192
Ile Ile Pro His Leu Glu Pro His Ala Arg Cys Ile Ala Pro Asp Leu	
50 55 60	
atc gga atg gga gat tcg gag aag ctc gag ccg agc gga ccg gac cgc	240
Ile Gly Met Gly Asp Ser Glu Lys Leu Glu Pro Ser Gly Pro Asp Arg	
65 70 75 80	
tat cgc ttc atc gaa cat cgc gaa tat ctc gat ggt ttc ttc gag gct	288
Tyr Arg Phe Ile Glu His Arg Glu Tyr Leu Asp Gly Phe Phe Glu Ala	
85 90 95	
ctg gcc ctg caa cag aac gtc acc ctc gtc gtc cac gac tgg ggc tcc	336
Leu Ala Leu Gln Gln Asn Val Thr Leu Val Val His Asp Trp Gly Ser	
100 105 110	
ggg ctg ggc ttc gat tgg gcc aac cgg aat cgg gag cgc atc aag ggg	384
Gly Leu Gly Phe Asp Trp Ala Asn Arg Asn Arg Glu Arg Ile Lys Gly	
115 120 125	
atc gct tat atg gag gcc atc gtt cgc ccg ctc agc tgg caa gac tgg	432
Ile Ala Tyr Met Glu Ala Ile Val Arg Pro Leu Ser Trp Gln Asp Trp	
130 135 140	
ccc gac gac gcc cgc gcg gtc ttt cag ggt ttt cgc tcc gaa gca gga	480
Pro Asp Asp Ala Arg Ala Val Phe Gln Gly Phe Arg Ser Glu Ala Gly	
145 150 155 160	
gag tcg atg gtg atc gag aag aac gtc ttc gtc gaa cgg gtc ctg ccc	528
Glu Ser Met Val Ile Glu Lys Asn Val Phe Val Glu Arg Val Leu Pro	
165 170 175	
agc tcg gtc ctg cgg acg ctc cgt gac gag gag atg gag gtc tat cgc	576
Ser Ser Val Leu Arg Thr Leu Arg Asp Glu Glu Met Glu Val Tyr Arg	
180 185 190	
aga ccg ttt caa gac gcc gga gaa tca agg cgc ccg acc ctc acc tgg	624
Arg Pro Phe Gln Asp Ala Gly Glu Ser Arg Arg Pro Thr Leu Thr Trp	
195 200 205	

```

ccc cgc cag atc ccg atc gag ggg gag ccg gag gat gtg acc gag atc 672
Pro Arg Gln Ile Pro Ile Glu Gly Glu Pro Glu Asp Val Thr Glu Ile
210 215 220

gcg agc gcg tac agc gcg tgg atg gcc gag aac gat ctc ccc aag ctc 720
Ala Ser Ala Tyr Ser Ala Trp Met Ala Glu Asn Asp Leu Pro Lys Leu
225 230 235 240

ttc gtt aac gcc gag ccg ggc gcg atc ctg atc ggt ccg cag cgc gag 768
Phe Val Asn Ala Glu Pro Gly Ala Ile Leu Ile Gly Pro Gln Arg Glu
245 250 255

ttc tgc cgc acg tgg aag aat caa cgc gaa gtc acg gta agc ggt agc 816
Phe Cys Arg Thr Trp Lys Asn Gln Arg Glu Val Thr Val Ser Gly Ser
260 265 270

cac ttc atc cag gag gac tct ccg cac gaa atc ggc gac gcg att gca 864
His Phe Ile Gln Glu Asp Ser Pro His Glu Ile Gly Asp Ala Ile Ala
275 280 285

ggc tgg tac gcg gat ctc tag 885
Gly Trp Tyr Ala Asp Leu
290 295

```

<210> 32

<211> 294

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Artificially modified (mutated) Dehalogenase

<400> 32

```

Val Ser Glu Ile Ser Pro Lys Glu Pro Met Asp Lys Lys His Ile Pro
1 5 10 15
Val Leu Gly Lys Ser Met Ala Tyr Arg Asp Val Gly Glu Gly Asp Pro
20 25 30
Ile Val Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg Asn
35 40 45
Ile Ile Pro His Leu Glu Pro His Ala Arg Cys Ile Ala Pro Asp Leu
50 55 60
Ile Gly Met Gly Asp Ser Glu Lys Leu Glu Pro Ser Gly Pro Asp Arg
65 70 75 80
Tyr Arg Phe Ile Glu His Arg Glu Tyr Leu Asp Gly Phe Phe Glu Ala
85 90 95
Leu Ala Leu Gln Gln Asn Val Thr Leu Val Val His Asp Trp Gly Ser
100 105 110
Gly Leu Gly Phe Asp Trp Ala Asn Arg Asn Arg Glu Arg Ile Lys Gly
115 120 125
Ile Ala Tyr Met Glu Ala Ile Val Arg Pro Leu Ser Trp Gln Asp Trp
130 135 140
Pro Asp Asp Ala Arg Ala Val Phe Gln Gly Phe Arg Ser Glu Ala Gly
145 150 155 160
Glu Ser Met Val Ile Glu Lys Asn Val Phe Val Glu Arg Val Leu Pro
165 170 175
Ser Ser Val Leu Arg Thr Leu Arg Asp Glu Glu Met Glu Val Tyr Arg
180 185 190
Arg Pro Phe Gln Asp Ala Gly Glu Ser Arg Arg Pro Thr Leu Thr Trp
195 200 205
Pro Arg Gln Ile Pro Ile Glu Gly Glu Pro Glu Asp Val Thr Glu Ile
210 215 220
Ala Ser Ala Tyr Ser Ala Trp Met Ala Glu Asn Asp Leu Pro Lys Leu
225 230 235 240
Phe Val Asn Ala Glu Pro Gly Ala Ile Leu Ile Gly Pro Gln Arg Glu

```

36

Phe Cys Arg Thr Trp Lys Asn Gln Arg Glu Val Thr Val Ser Gly Ser
 245 260 265 270
 His Phe Ile Gln Glu Asp Ser Pro His Glu Ile Gly Asp Ala Ile Ala
 275 280 285
 Gly Trp Tyr Ala Asp Leu
 290

<210> 33
 <211> 888
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Artificially
 modified (mutated) Dehalogenase

<220>
 <221> CDS
 <222> (1)..(888)

<400> 33
 atg acc acc gaa atc tcg gca gcc gac ccc ttc gag cgg cac cgg gtc 48
 Met Thr Thr Glu Ile Ser Ala Ala Asp Pro Phe Glu Arg His Arg Val
 1 5 10 15
 acc gtg ctc gac tca gag atg tcg tac atc gac acc ggc ccc ggc gcc 96
 Thr Val Leu Asp Ser Glu Met Ser Tyr Ile Asp Thr Gly Pro Gly Ala
 20 25 30
 gca ggc agt gag ccg atc gtg ttt ctc cac ggg aac cca acc tcg tcc 144
 Ala Gly Ser Glu Pro Ile Val Phe Leu His Gly Asn Pro Thr Ser Ser
 35 40 45
 tac ctc tgg cgc aac atc att ccc cac gtc cag cac ctc ggg cgc tgc 192
 Tyr Leu Trp Arg Asn Ile Ile Pro His Val Gln His Leu Gly Arg Cys
 50 55 60
 ctc gca ccg gat ctg atc ggg atg ggc aac tcg gac cct tcc cct aac 240
 Leu Ala Pro Asp Leu Ile Gly Met Gly Asn Ser Asp Pro Ser Pro Asn
 65 70 75 80
 ggc agc tac cgc ttc gtc gac cac gtg aag tac ctc gac gcc tgg ttg 288
 Gly Ser Tyr Arg Phe Val Asp His Val Lys Tyr Leu Asp Ala Trp Leu
 85 90 95
 gac gcc gtc ggc gtg acc gac cag gtg acg ttc gtg gtg cat gac tgg 336
 Asp Ala Val Gly Val Thr Asp Gln Val Thr Phe Val Val His Asp Trp
 100 105 110
 gga tcg gcg ctc ggc ttc cac tgg gca gac cgc cat cgc gac gcc atc 384
 Gly Ser Ala Leu Gly Phe His Trp Ala Asp Arg His Arg Asp Ala Ile
 115 120 125
 cga ggc ttc gcc tac atg gag gcg atc gtg cgc ccc gtc gag tgg gag 432
 Arg Gly Phe Ala Tyr Met Glu Ala Ile Val Arg Pro Val Glu Trp Glu
 130 135 140
 gac tgg ccg cct gcg gac gtc ttc cga cgg atg cga tcc gag gag ggc 480
 Asp Trp Pro Pro Ala Asp Val Phe Arg Arg Met Arg Ser Glu Glu Gly
 145 150 155 160
 gac gag atg atg ctc gag ggc aac ttc ttc gtc gag gtg atc ctg ccc 528

Asp	Glu	Met	Met	Leu	Glu	Gly	Asn	Phe	Phe	Val	Glu	Val	Ile	Leu	Pro		
				165					170					175			
cgc	agc	gtc	ctc	cgc	ggg	ctc	act	gac	gaa	gag	atg	gag	gta	tac	cgg	576	
Arg	Ser	Val	Leu	Arg	Gly	Leu	Thr	Asp	Glu	Glu	Met	Glu	Val	Tyr	Arg		
			180					185					190				
cga	ccc	tac	ctc	gag	cgc	ggc	gag	tcg	cgg	cgt	ccg	acg	ctg	acc	tgg	624	
Arg	Pro	Tyr	Leu	Glu	Arg	Gly	Glu	Ser	Arg	Arg	Pro	Thr	Leu	Thr	Trp		
			195				200					205					
ccg	cgg	gag	atc	ccg	ctg	tca	ggc	gag	ccg	gcg	gat	gtc	gtc	gag	atc	672	
Pro	Arg	Glu	Ile	Pro	Leu	Ser	Gly	Glu	Pro	Ala	Asp	Val	Val	Glu	Ile		
		210				215					220						
gtc	agc	gcc	tac	agc	aaa	tgg	ctg	tcc	gag	acg	acc	gtg	ccg	aag	ctc	720	
Val	Ser	Ala	Tyr	Ser	Lys	Trp	Leu	Ser	Glu	Thr	Thr	Val	Pro	Lys	Leu		
					230					235					240		
ctc	gtc	act	gcc	gag	ccg	ggg	gcg	atc	ctg	aac	ggg	ccg	cag	ctg	gag	768	
Leu	Val	Thr	Ala	Glu	Pro	Gly	Ala	Ile	Leu	Asn	Gly	Pro	Gln	Leu	Glu		
				245					250					255			
ttc	gct	cgc	ggg	ttt	gcc	aac	cag	acc	gag	gtc	cga	gtc	gcc	ggc	tcg	816	
Phe	Ala	Arg	Gly	Phe	Ala	Asn	Gln	Thr	Glu	Val	Arg	Val	Ala	Gly	Ser		
			260					265					270				
cac	ttc	atc	cag	gag	gac	tcg	cca	cac	gag	atc	ggc	gcc	gcc	ctc	gcc	864	
His	Phe	Ile	Gln	Glu	Asp	Ser	Pro	His	Glu	Ile	Gly	Ala	Ala	Leu	Ala		
		275					280					285					
gag	tgg	tac	ccg	acg	acg	acc	tga									888	
Glu	Trp	Tyr	Pro	Thr	Thr												
		290				295											

<210> 34

<211> 295

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Artificially modified (mutated) Dehalogenase

<400> 34

Met	Thr	Thr	Glu	Ile	Ser	Ala	Ala	Asp	Pro	Phe	Glu	Arg	His	Arg	Val		
1				5					10					15			
Thr	Val	Leu	Asp	Ser	Glu	Met	Ser	Tyr	Ile	Asp	Thr	Gly	Pro	Gly	Ala		
			20					25					30				
Ala	Gly	Ser	Glu	Pro	Ile	Val	Phe	Leu	His	Gly	Asn	Pro	Thr	Ser	Ser		
		35					40					45					
Tyr	Leu	Trp	Arg	Asn	Ile	Ile	Pro	His	Val	Gln	His	Leu	Gly	Arg	Cys		
		50			55					60							
Leu	Ala	Pro	Asp	Leu	Ile	Gly	Met	Gly	Asn	Ser	Asp	Pro	Ser	Pro	Asn		
		65			70				75						80		
Gly	Ser	Tyr	Arg	Phe	Val	Asp	His	Val	Lys	Tyr	Leu	Asp	Ala	Trp	Leu		
			85					90					95				
Asp	Ala	Val	Gly	Val	Thr	Asp	Gln	Val	Thr	Phe	Val	Val	His	Asp	Trp		
			100					105					110				
Gly	Ser	Ala	Leu	Gly	Phe	His	Trp	Ala	Asp	Arg	His	Arg	Asp	Ala	Ile		
		115					120					125					
Arg	Gly	Phe	Ala	Tyr	Met	Glu	Ala	Ile	Val	Arg	Pro	Val	Glu	Trp	Glu		
		130				135					140						
Asp	Trp	Pro	Pro	Ala	Asp	Val	Phe	Arg	Arg	Met	Arg	Ser	Glu	Glu	Gly		
		145			150					155					160		
Asp	Glu	Met	Met	Leu	Glu	Gly	Asn	Phe	Phe	Val	Glu	Val	Ile	Leu	Pro		

Arg	Ser	Val	Leu	165	Arg	Gly	Leu	Thr	Asp	170	Glu	Glu	Met	Glu	175	Val	Tyr	Arg
			180						185						190			
Arg	Pro	Tyr	Leu	Glu	Arg	Gly	Glu	Ser	Arg	Arg	Pro	Thr	Leu	Thr	Trp			
		195					200					205						
Pro	Arg	Glu	Ile	Pro	Leu	Ser	Gly	Glu	Pro	Ala	Asp	Val	Val	Glu	Ile			
	210					215					220							
Val	Ser	Ala	Tyr	Ser	Lys	Trp	Leu	Ser	Glu	Thr	Thr	Val	Pro	Lys	Leu			
225					230					235					240			
Leu	Val	Thr	Ala	Glu	Pro	Gly	Ala	Ile	Leu	Asn	Gly	Pro	Gln	Leu	Glu			
				245					250					255				
Phe	Ala	Arg	Gly	Phe	Ala	Asn	Gln	Thr	Glu	Val	Arg	Val	Ala	Gly	Ser			
		260						265					270					
His	Phe	Ile	Gln	Glu	Asp	Ser	Pro	His	Glu	Ile	Gly	Ala	Ala	Leu	Ala			
		275					280					285						
Glu	Trp	Tyr	Pro	Thr	Thr	Thr												
	290					295												

<210> 35

<211> 861

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially modified (mutated) Dehalogenase

<220>

<221> CDS

<222> (1)..(861)

<400> 35

atg	tac	gag	aaa	cgg	ttc	gta	tct	gtc	ctc	ggg	cac	cgg	atg	gca	tac	48
Met	Tyr	Glu	Lys	Arg	Phe	Val	Ser	Val	Leu	Gly	His	Arg	Met	Ala	Tyr	
1				5				10					15			
gtc	gag	caa	gga	gcc	ggg	gac	ccg	atc	gtg	ttc	cta	cat	ggc	aac	ccc	96
Val	Glu	Gln	Gly	Ala	Gly	Asp	Pro	Ile	Val	Phe	Leu	His	Gly	Asn	Pro	
			20				25						30			
acc	tgc	tcc	tac	ctg	tgg	cgg	aag	gtc	atc	ccc	gcg	cta	acg	gag	cag	144
Thr	Ser	Ser	Tyr	Leu	Trp	Arg	Lys	Val	Ile	Pro	Ala	Leu	Thr	Glu	Gln	
			35				40					45				
gga	cga	tgc	atc	gct	ccc	gac	ttg	atc	ggc	atg	ggc	gac	tcc	gag	aag	192
Gly	Arg	Cys	Ile	Ala	Pro	Asp	Leu	Ile	Gly	Met	Gly	Asp	Ser	Glu	Lys	
		50				55				60						
ctg	gct	gac	agc	ggc	ccc	ggg	agc	tac	cgc	ttc	gtg	gaa	cat	cgg	cgt	240
Leu	Ala	Asp	Ser	Gly	Pro	Gly	Ser	Tyr	Arg	Phe	Val	Glu	His	Arg	Arg	
				70					75					80		
ttc	ctc	gat	gcc	ttc	ctc	gaa	agg	gtt	ggg	atc	agc	gag	tgc	gtg	gtc	288
Phe	Leu	Asp	Ala	Phe	Leu	Glu	Arg	Val	Gly	Ile	Ser	Glu	Ser	Val	Val	
				85				90						95		
ctg	gtg	atc	cac	gac	tgg	ggg	tcg	gcc	ctc	ggc	ttc	gac	tgg	gcc	tac	336
Leu	Val	Ile	His	Asp	Trp	Gly	Ser	Ala	Leu	Gly	Phe	Asp	Trp	Ala	Tyr	
			100					105					110			
cgc	cac	caa	aac	gcc	gtc	aag	ggg	atc	gca	tat	atg	gaa	gcg	ctg	gtc	384
Arg	His	Gln	Asn	Ala	Val	Lys	Gly	Ile	Ala	Tyr	Met	Glu	Ala	Leu	Val	
		115					120					125				

```

ggg cct gta ggt tgg agc gac tgg ccg gag tcg gcc cgg tcc atc ttc 432
Gly Pro Val Gly Trp Ser Asp Trp Pro Glu Ser Ala Arg Ser Ile Phe
130 135 140

cag gct ttc cgc tcc gaa gcc ggg gac agc ctc atc ctc gag aag aac 480
Gln Ala Phe Arg Ser Glu Ala Gly Asp Ser Leu Ile Leu Glu Lys Asn
145 150 155 160

ttc ttc gtc gag cgg gtg ctg ccc gca tcg gtg ctc gat ccc ctg cca 528
Phe Phe Val Glu Arg Val Leu Pro Ala Ser Val Leu Asp Pro Leu Pro
165 170 175

gaa gaa gtg ctc gac gag tat cga cag ccg ttt ctc gaa ccg ggc gag 576
Glu Glu Val Leu Asp Glu Tyr Arg Gln Pro Phe Leu Glu Pro Gly Glu
180 185 190

tct cgc cga ccc acc ctc acc tgg cct agg gag atc ccc atc gac ggt 624
Ser Arg Arg Pro Thr Leu Thr Trp Pro Arg Glu Ile Pro Ile Asp Gly
195 200 205

gag ccg gcc gac gtc cac gag atc gtg tcc gcg tac aac cgc tgg att 672
Glu Pro Ala Asp Val His Glu Ile Val Ser Ala Tyr Asn Arg Trp Ile
210 215 220

gga tcc tct ccg gtg ccc aag ctg tac gtc aac gcc gat ccc ggc ttc 720
Gly Ser Ser Pro Val Pro Lys Leu Tyr Val Asn Ala Asp Pro Gly Phe
225 230 235 240

ttc agc cct ggc atc gtc gag gcc acg gcc gcc tgg ccc aac cag gaa 768
Phe Ser Pro Gly Ile Val Glu Ala Thr Ala Ala Trp Pro Asn Gln Glu
245 250 255

aca gtc acg gtc cgt ggc cac cat ttc ttg cag gaa gac tct ggt gaa 816
Thr Val Thr Val Arg Gly His His Phe Leu Gln Glu Asp Ser Gly Glu
260 265 270

gcg atc ggt gat gcc atc gcc gac tgg tac cgg cgt gtc tcg tga 861
Ala Ile Gly Asp Ala Ile Ala Asp Trp Tyr Arg Arg Val Ser
275 280 285

```

<210> 36

<211> 286

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Artificially modified (mutated) Dehalogenase

<400> 36

```

Met Tyr Glu Lys Arg Phe Val Ser Val Leu Gly His Arg Met Ala Tyr
1 5 10 15
Val Glu Gln Gly Ala Gly Asp Pro Ile Val Phe Leu His Gly Asn Pro
20 25 30
Thr Ser Ser Tyr Leu Trp Arg Lys Val Ile Pro Ala Leu Thr Glu Gln
35 40 45
Gly Arg Cys Ile Ala Pro Asp Leu Ile Gly Met Gly Asp Ser Glu Lys
50 55 60
Leu Ala Asp Ser Gly Pro Gly Ser Tyr Arg Phe Val Glu His Arg Arg
65 70 75 80
Phe Leu Asp Ala Phe Leu Glu Arg Val Gly Ile Ser Glu Ser Val Val
85 90 95
Leu Val Ile His Asp Trp Gly Ser Ala Leu Gly Phe Asp Trp Ala Tyr
100 105 110
Arg His Gln Asn Ala Val Lys Gly Ile Ala Tyr Met Glu Ala Leu Val

```



```

      115      120      125
Gly Pro Val Gly Trp Ser Asp Trp Pro Glu Ser Ala Arg Ser Ile Phe
   130   135   140
Gln Ala Phe Arg Ser Glu Ala Gly Asp Ser Leu Ile Leu Glu Lys Asn
   145   150   155   160
Phe Phe Val Glu Arg Val Leu Pro Ala Ser Val Leu Asp Pro Leu Pro
      165   170   175
Glu Glu Val Leu Asp Glu Tyr Arg Gln Pro Phe Leu Glu Pro Gly Glu
      180   185   190
Ser Arg Arg Pro Thr Leu Thr Trp Pro Arg Glu Ile Pro Ile Asp Gly
      195   200   205
Glu Pro Ala Asp Val His Glu Ile Val Ser Ala Tyr Asn Arg Trp Ile
      210   215   220
Gly Ser Ser Pro Val Pro Lys Leu Tyr Val Asn Ala Asp Pro Gly Phe
   225   230   235   240
Phe Ser Pro Gly Ile Val Glu Ala Thr Ala Ala Trp Pro Asn Gln Glu
      245   250   255
Thr Val Thr Val Arg Gly His His Phe Leu Gln Glu Asp Ser Gly Glu
      260   265   270
Ala Ile Gly Asp Ala Ile Ala Asp Trp Tyr Arg Arg Val Ser
      275   280   285

```

<210> 37

<211> 891

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially
modified (mutated) Dehalogenase

<220>

<221> CDS

<222> (1)..(891)

<400> 37

```

atg aat gca atc gcc agt gag ccc tat ggg caa ctg agg ttc caa gag 48
Met Asn Ala Ile Ala Ser Glu Pro Tyr Gly Gln Leu Arg Phe Gln Glu
   1       5       10
atc gcc ggc aag caa atg gcg tac atc gac gag ggc gtc ggt gat gcc 96
Ile Ala Gly Lys Gln Met Ala Tyr Ile Asp Glu Gly Val Gly Asp Ala
      20      25      30
atc gtt ttc cag cac ggc aac ccc acg tcg tcc tac ctg tgg cgc aac 144
Ile Val Phe Gln His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg Asn
      35      40      45
gtt atg ccg cac ctg gaa ggg ctg ggc cgg ctg gtg gcg tgc gat ctg 192
Val Met Pro His Leu Glu Gly Leu Gly Arg Leu Val Ala Cys Asp Leu
      50      55      60
atc ggg atg ggg gcg tcg gag aag ctc agc cca tcg ggc ccc gac cgc 240
Ile Gly Met Gly Ala Ser Glu Lys Leu Ser Pro Ser Gly Pro Asp Arg
      65      70      75      80
tat aac tat gcc gag cag cgc gac tat ctg ttc gcg ctc tgg gat gcg 288
Tyr Asn Tyr Ala Glu Gln Arg Asp Tyr Leu Phe Ala Leu Trp Asp Ala
      85      90      95
ctc gac ctt ggc gat cac gtg gtg ctg gtg ctg cat gac tgg ggc tca 336
Leu Asp Leu Gly Asp His Val Val Leu Val Leu His Asp Trp Gly Ser
      100      105      110

```

```

gca ttg ggc ttc gac tgg gcc aac cag cat cgc gac cga gtg cag ggc 384
Ala Leu Gly Phe Asp Trp Ala Asn Gln His Arg Asp Arg Val Gln Gly
115 120 125

atc gca ttc atg gag gcg atc gtc agc ccg atc aca tgg gcc gac ttc 432
Ile Ala Phe Met Glu Ala Ile Val Ser Pro Ile Thr Trp Ala Asp Phe
130 135 140

cat ccc agc gtg cga ggc gtg ttc cag ggg ttc cgg tcg ccc gag ggt 480
His Pro Ser Val Arg Gly Val Phe Gln Gly Phe Arg Ser Pro Glu Gly
145 150 155 160

gag cgg atg gtg ttg gag cag aac atc ttt gtc gaa ggg gta ctg ccc 528
Glu Arg Met Val Leu Glu Gln Asn Ile Phe Val Glu Gly Val Leu Pro
165 170 175

ggg gcg atc cag cgc cga ctg tct gac gag gag atg ggc cat tac cgg 576
Gly Ala Ile Gln Arg Arg Leu Ser Asp Glu Glu Met Gly His Tyr Arg
180 185 190

cag cca ttc gtc gaa ccc ggc gag gac cgg cga ccg acc ttg tcg tgg 624
Gln Pro Phe Val Glu Pro Gly Glu Asp Arg Arg Pro Thr Leu Ser Trp
195 200 205

cca cgg aac atc ccc atc gac ggc gag ccg gcc gag gtc gtc gcg gtc 672
Pro Arg Asn Ile Pro Ile Asp Gly Glu Pro Ala Glu Val Val Ala Val
210 215 220

gtc gac gag tac cgt agc tgg ctc gag aag agc gac att cca aag ctg 720
Val Asp Glu Tyr Arg Ser Trp Leu Glu Lys Ser Asp Ile Pro Lys Leu
225 230 235 240

ttc gtg aac gcc gag ccg ggc gcg atc gtc acc ggc cgc atc cgc gac 768
Phe Val Asn Ala Glu Pro Gly Ala Ile Val Thr Gly Arg Ile Arg Asp
245 250 255

tat atc cgg acg tgg gcg aac ctc agc gaa atc acg gtt ccc gga gtg 816
Tyr Ile Arg Thr Trp Ala Asn Leu Ser Glu Ile Thr Val Pro Gly Val
260 265 270

cat ttc atc caa gaa gac agc cca gac gga atc ggc tcg gcc gtg gca 864
His Phe Ile Gln Glu Asp Ser Pro Asp Gly Ile Gly Ser Ala Val Ala
275 280 285

cag ttc ctg cag cag cta cgc gcc taa 891
Gln Phe Leu Gln Gln Leu Arg Ala
290 295

```

<210> 38

<211> 296

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Artificially modified (mutated) Dehalogenase

<400> 38

```

Met Asn Ala Ile Ala Ser Glu Pro Tyr Gly Gln Leu Arg Phe Gln Glu
1 5 10 15
Ile Ala Gly Lys Gln Met Ala Tyr Ile Asp Glu Gly Val Gly Asp Ala
20 25 30
Ile Val Phe Gln His Gly Asn Pro Thr Ser Ser Tyr Leu Trp Arg Asn
35 40 45
Val Met Pro His Leu Glu Gly Leu Gly Arg Leu Val Ala Cys Asp Leu

```

```

      50      55      60
Ile Gly Met Gly Ala Ser Glu Lys Leu Ser Pro Ser Gly Pro Asp Arg
65      70      75      80
Tyr Asn Tyr Ala Glu Gln Arg Asp Tyr Leu Phe Ala Leu Trp Asp Ala
      85      90      95
Leu Asp Leu Gly Asp His Val Val Leu Val Leu His Asp Trp Gly Ser
100      105      110
Ala Leu Gly Phe Asp Trp Ala Asn Gln His Arg Asp Arg Val Gln Gly
115      120      125
Ile Ala Phe Met Glu Ala Ile Val Ser Pro Ile Thr Trp Ala Asp Phe
130      135      140
His Pro Ser Val Arg Gly Val Phe Gln Gly Phe Arg Ser Pro Glu Gly
145      150      155      160
Glu Arg Met Val Leu Glu Gln Asn Ile Phe Val Glu Gly Val Leu Pro
165      170      175
Gly Ala Ile Gln Arg Arg Leu Ser Asp Glu Glu Met Gly His Tyr Arg
180      185      190
Gln Pro Phe Val Glu Pro Gly Glu Asp Arg Arg Pro Thr Leu Ser Trp
195      200      205
Pro Arg Asn Ile Pro Ile Asp Gly Glu Pro Ala Glu Val Val Ala Val
210      215      220
Val Asp Glu Tyr Arg Ser Trp Leu Glu Lys Ser Asp Ile Pro Lys Leu
225      230      235      240
Phe Val Asn Ala Glu Pro Gly Ala Ile Val Thr Gly Arg Ile Arg Asp
245      250      255
Tyr Ile Arg Thr Trp Ala Asn Leu Ser Glu Ile Thr Val Pro Gly Val
260      265      270
His Phe Ile Gln Glu Asp Ser Pro Asp Gly Ile Gly Ser Ala Val Ala
275      280      285
Gln Phe Leu Gln Gln Leu Arg Ala
290      295

```

<210> 39
 <211> 882
 <212> DNA
 <213> Rhodococcus rhodochrous

<220>
 <221> CDS
 <222> (1)..(882)

```

<400> 39
atg tca gaa atc ggt aca ggc ttc ccc ttc gac ccc cat tat gtg gaa 48
Met Ser Glu Ile Gly Thr Gly Phe Pro Phe Asp Pro His Tyr Val Glu
1      5      10      15

gtc ctg ggc gag cgt atg cac tac gtc gat gtt gga ccg cgg gat ggc 96
Val Leu Gly Glu Arg Met His Tyr Val Asp Val Gly Pro Arg Asp Gly
20      25      30

acg cct gtg ctg ttc ctg cac ggt aac ccg acc tcg tcc tac ctg tgg 144
Thr Pro Val Leu Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp
35      40      45

cgc aac atc atc ccg cat gta gca ccg agt cat cgg tgc att gct cca 192
Arg Asn Ile Ile Pro His Val Ala Pro Ser His Arg Cys Ile Ala Pro
50      55      60

gac ctg atc ggg atg gga aaa tcg gac aaa cca gac ctc gat tat ttc 240
Asp Leu Ile Gly Met Gly Lys Ser Asp Lys Pro Asp Leu Asp Tyr Phe
65      70      75      80

ttc gac gac cac gtc cgc tac ctc gat gcc ttc atc gaa gcc ttg ggt 288

```

Phe	Asp	Asp	His	Val	Arg	Tyr	Leu	Asp	Ala	Phe	Ile	Glu	Ala	Leu	Gly		
				85					90						95		
ttg	gaa	gag	gtc	gtc	ctg	gtc	atc	cac	gac	tgg	ggc	tca	gct	ctc	gga	336	
Leu	Glu	Glu	Val	Val	Leu	Val	Ile	His	Asp	Trp	Gly	Ser	Ala	Leu	Gly		
			100					105					110				
ttc	cac	tgg	gcc	aag	cgc	aat	ccg	gaa	cgg	gtc	aaa	ggg	att	gca	tgt	384	
Phe	His	Trp	Ala	Lys	Arg	Asn	Pro	Glu	Arg	Val	Lys	Gly	Ile	Ala	Cys		
		115					120					125					
atg	gaa	ttc	atc	cgg	cct	atc	ccg	acg	tgg	gac	gaa	tgg	ccg	gaa	ttc	432	
Met	Glu	Phe	Ile	Arg	Pro	Ile	Pro	Thr	Trp	Asp	Glu	Trp	Pro	Glu	Phe		
	130					135					140						
gcc	cgt	gag	acc	ttc	cag	gcc	ttc	cgg	acc	gcc	gac	gtc	ggc	cga	gag	480	
Ala	Arg	Glu	Thr	Phe	Gln	Ala	Phe	Arg	Thr	Ala	Asp	Val	Gly	Arg	Glu		
	145				150					155					160		
ttg	atc	atc	gat	cag	aac	gct	ttc	atc	gag	ggg	gcg	ctc	ccg	aaa	tgc	528	
Leu	Ile	Ile	Asp	Gln	Asn	Ala	Phe	Ile	Glu	Gly	Ala	Leu	Pro	Lys	Cys		
			165						170					175			
gtc	gtc	cgt	ccg	ctt	acg	gag	gtc	gag	atg	gac	cac	tat	cgc	gag	ccc	576	
Val	Val	Arg	Pro	Leu	Thr	Glu	Val	Glu	Met	Asp	His	Tyr	Arg	Glu	Pro		
			180					185					190				
ttc	ctc	aag	cct	ggt	gac	cga	gag	cca	ctg	tgg	cga	ttc	ccc	aac	gag	624	
Phe	Leu	Lys	Pro	Val	Asp	Arg	Glu	Pro	Leu	Trp	Arg	Phe	Pro	Asn	Glu		
		195					200					205					
ctg	ccc	atc	gcc	ggg	gag	ccc	gcg	aac	atc	gtc	gcg	ctc	gtc	gag	gca	672	
Leu	Pro	Ile	Ala	Gly	Glu	Pro	Ala	Asn	Ile	Val	Ala	Leu	Val	Glu	Ala		
	210					215					220						
tac	atg	aac	tgg	ctg	cac	cag	tca	cct	gtc	ccg	aag	ttg	ttg	ttc	tgg	720	
Tyr	Met	Asn	Trp	Leu	His	Gln	Ser	Pro	Val	Pro	Lys	Leu	Leu	Phe	Trp		
	225				230					235					240		
ggc	aca	ccc	ggc	gta	ctg	atc	ccc	ccg	gcc	gaa	gcc	gcg	aga	ctt	gcc	768	
Gly	Thr	Pro	Gly	Val	Leu	Ile	Pro	Pro	Ala	Glu	Ala	Ala	Arg	Leu	Ala		
			245					250						255			
gaa	agc	ctc	ccc	aac	tgc	aag	aca	gtg	gac	atc	ggc	ccg	gga	ttg	cac	816	
Glu	Ser	Leu	Pro	Asn	Cys	Lys	Thr	Val	Asp	Ile	Gly	Pro	Gly	Leu	His		
			260					265					270				
tac	ctc	cag	gaa	gac	aac	ccg	gac	ctt	atc	ggc	agt	gag	atc	gcg	cgc	864	
Tyr	Leu	Gln	Glu	Asp	Asn	Pro	Asp	Leu	Ile	Gly	Ser	Glu	Ile	Ala	Arg		
		275					280					285					
tgg	ctc	ccc	gca	ctc	tag											882	
Trp	Leu	Pro	Ala	Leu													
	290																

<210> 40

<211> 293

<212> PRT

<213> Rhodococcus rhodochrous

<400> 40

Met Ser Glu Ile Gly Thr Gly Phe Pro Phe Asp Pro His Tyr Val Glu

1 5 10 15

Val Leu Gly Glu Arg Met His Tyr Val Asp Val Gly Pro Arg Asp Gly

[illegible]

```
<210> 41
<211> 924
<212> DNA
<213> Mycobacterium sp.
```

```
<220>
<221> CDS
<222> (1) .. (924)
```

<400> 41																
atg	tca	gaa	atc	ggg	aca	ggc	ttc	ccc	ttc	gac	ccc	cat	tat	gtg	gaa	48
Met	Ser	Glu	Ile	Gly	Thr	Gly	Phe	Pro	Phe	Asp	Pro	His	Tyr	Val	Glu	
1				5					10					15		
gtc	ctg	ggc	gag	cgt	atg	cac	tac	gtc	gat	gtt	gga	ccg	cgg	gat	ggc	96
Val	Leu	Gly	Glu	Arg	Met	His	Tyr	Val	Asp	Val	Gly	Pro	Arg	Asp	Gly	
			20					25					30			
acg	cct	gtg	ctg	ttc	ctg	cac	ggg	aac	ccg	acc	tcg	tcc	tac	ctg	tgg	144
Thr	Pro	Val	Leu	Phe	Leu	His	Gly	Asn	Pro	Thr	Ser	Ser	Tyr	Leu	Trp	
		35					40					45				
cgc	aac	atc	atc	ccg	cat	gta	gca	ccg	agt	cat	cgg	tgc	att	gct	cca	192
Arg	Asn	Ile	Ile	Pro	His	Val	Ala	Pro	Ser	His	Arg	Cys	Ile	Ala	Pro	
	50					55					60					
gac	ctg	atc	ggg	atg	gga	aaa	tcg	gac	aaa	cca	gac	ctc	gat	tat	ttc	240

Asp 65	Leu	Ile	Gly	Met	Gly 70	Lys	Ser	Asp	Lys	Pro 75	Asp	Leu	Asp	Tyr	Phe 80	
ttc gac gac cac gtc cgc tac ctc gat gcc ttc atc gaa gcc ttg ggt	288															
Phe Asp Asp His Val Arg Tyr Leu Asp Ala Phe Ile Glu Ala Leu Gly																
85	90	95														
ttg gaa gag gtc gtc ctg gtc atc cac gac tgg ggc tca gct ctc gga	336															
Leu Glu Glu Val Val Leu Val Ile His Asp Trp Gly Ser Ala Leu Gly																
100	105	110														
ttc cac tgg gcc aag cgc aat ccg gaa cgg gtc aaa ggt att gca tgt	384															
Phe His Trp Ala Lys Arg Asn Pro Glu Arg Val Lys Gly Ile Ala Cys																
115	120	125														
atg gaa ttc atc cgg cct atc ccg acg tgg gac gaa tgg ccg gaa ttc	432															
Met Glu Phe Ile Arg Pro Ile Pro Thr Trp Asp Glu Trp Pro Glu Phe																
130	135	140														
gcc cgt gag acc ttc cag gcc ttc cgg acc gcc gac gtc ggc cga gag	480															
Ala Arg Glu Thr Phe Gln Ala Phe Arg Thr Ala Asp Val Gly Arg Glu																
145	150	155	160													
ttg atc atc gat cag aac gct ttc atc gag ggt gcg ctc ccg aaa ttc	528															
Leu Ile Ile Asp Gln Asn Ala Phe Ile Glu Gly Ala Leu Pro Lys Phe																
165	170	175														
gtc gtc cgt ccg ctt acg gag gtc gag atg gac cac tat cgc gag ccc	576															
Val Val Arg Pro Leu Thr Glu Val Glu Met Asp His Tyr Arg Glu Pro																
180	185	190														
ttc ctc aag cct gtt gac cga gag cca ctg tgg cga ttc ccc aac gag	624															
Phe Leu Lys Pro Val Asp Arg Glu Pro Leu Trp Arg Phe Pro Asn Glu																
195	200	205														
ctg ccc atc gcc ggt gag ccc gcg aac atc gtc gcg ctc gtc gag gca	672															
Leu Pro Ile Ala Gly Glu Pro Ala Asn Ile Val Ala Leu Val Glu Ala																
210	215	220														
tac atg aac tgg ctg cac cag tca cct gtc ccg aag ttg ttg ttc tgg	720															
Tyr Met Asn Trp Leu His Gln Ser Pro Val Pro Lys Leu Leu Phe Trp																
225	230	235	240													
ggc aca ccc ggc gta ctg atc tcc ccg gcc gaa gcc gcg aga ctt gcc	768															
Gly Thr Pro Gly Val Leu Ile Ser Pro Ala Glu Ala Ala Arg Leu Ala																
245	250	255														
gaa agc ctc ccc aac tgc aag aca gtg gac atc ggc ccg gga ttg cac	816															
Glu Ser Leu Pro Asn Cys Lys Thr Val Asp Ile Gly Pro Gly Leu His																
260	265	270														
ttc ctc cag gaa gac aac ccg gac ctt atc ggc agt gag atc gcg cgc	864															
Phe Leu Gln Glu Asp Asn Pro Asp Leu Ile Gly Ser Glu Ile Ala Arg																
275	280	285														
tgg ctc ccc gca ctc atc gtc ggc aag tcg atc gag ttc gac ggc ggc	912															
Trp Leu Pro Ala Leu Ile Val Gly Lys Ser Ile Glu Phe Asp Gly Gly																
290	295	300														
tgg gcc acc tga	924															
Trp Ala Thr																
305																

<211> 307

<212> PRT

<213> Mycobacterium sp.

<400> 42

```

Met Ser Glu Ile Gly Thr Gly Phe Pro Phe Asp Pro His Tyr Val Glu
 1          5          10          15
Val Leu Gly Glu Arg Met His Tyr Val Asp Val Gly Pro Arg Asp Gly
          20          25          30
Thr Pro Val Leu Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp
          35          40          45
Arg Asn Ile Ile Pro His Val Ala Pro Ser His Arg Cys Ile Ala Pro
          50          55          60
Asp Leu Ile Gly Met Gly Lys Ser Asp Lys Pro Asp Leu Asp Tyr Phe
65          70          75          80
Phe Asp Asp His Val Arg Tyr Leu Asp Ala Phe Ile Glu Ala Leu Gly
          85          90          95
Leu Glu Glu Val Val Leu Val Ile His Asp Trp Gly Ser Ala Leu Gly
          100          105          110
Phe His Trp Ala Lys Arg Asn Pro Glu Arg Val Lys Gly Ile Ala Cys
          115          120          125
Met Glu Phe Ile Arg Pro Ile Pro Thr Trp Asp Glu Trp Pro Glu Phe
130          135          140          145
Ala Arg Glu Thr Phe Gln Ala Phe Arg Thr Ala Asp Val Gly Arg Glu
145          150          155          160
Leu Ile Ile Asp Gln Asn Ala Phe Ile Glu Gly Ala Leu Pro Lys Phe
          165          170          175
Val Val Arg Pro Leu Thr Glu Val Glu Met Asp His Tyr Arg Glu Pro
          180          185          190
Phe Leu Lys Pro Val Asp Arg Glu Pro Leu Trp Arg Phe Pro Asn Glu
          195          200          205
Leu Pro Ile Ala Gly Glu Pro Ala Asn Ile Val Ala Leu Val Glu Ala
210          215          220          225
Tyr Met Asn Trp Leu His Gln Ser Pro Val Pro Lys Leu Leu Phe Trp
225          230          235          240
Gly Thr Pro Gly Val Leu Ile Ser Pro Ala Glu Ala Ala Arg Leu Ala
          245          250          255
Glu Ser Leu Pro Asn Cys Lys Thr Val Asp Ile Gly Pro Gly Leu His
          260          265          270
Phe Leu Gln Glu Asp Asn Pro Asp Leu Ile Gly Ser Glu Ile Ala Arg
          275          280          285
Trp Leu Pro Ala Leu Ile Val Gly Lys Ser Ile Glu Phe Asp Gly Gly
          290          295          300
Trp Ala Thr
305

```

<210> 43

<211> 921

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Artificially modified (mutated) Dehalogenase

<220>

<221> CDS

<222> (1)..(921)

<400> 43

```

atg tca gaa atc ggt aca ggc ttc ccc ttc gac ccc cat tat gtg gaa 48
Met Ser Glu Ile Gly Thr Gly Phe Pro Phe Asp Pro His Tyr Val Glu
 1          5          10          15

```

gtc ctg ggc gag cgt atg cac tac gtc gat gtt gga ccg cgg gat ggc	96
Val Leu Gly Glu Arg Met His Tyr Val Asp Val Gly Pro Arg Asp Gly	
20 25 30	
acg cct gtg ctg ttc ctg cac ggt aac ccg acc tcg tcc tac ctg tgg	144
Thr Pro Val Leu Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp	
35 40 45	
cgc aac atc atc ccg cat gta gca ccg agt cat ccg tgc att gct cca	192
Arg Asn Ile Ile Pro His Val Ala Pro Ser His Arg Cys Ile Ala Pro	
50 55 60	
gac ctg atc ggg atg gga aaa tcg gac aaa cca gac ctc ggt tat ttc	240
Asp Leu Ile Gly Met Gly Lys Ser Asp Lys Pro Asp Leu Gly Tyr Phe	
65 70 75 80	
ttc gac gac cac gtc cgc tac ctc gat gcc ttc atc gaa gcc ttg ggt	288
Phe Asp Asp His Val Arg Tyr Leu Asp Ala Phe Ile Glu Ala Leu Gly	
85 90 95	
ttg gaa gag gtc gtc ttg gtc atc cac gac tgg ggc tca gct ctc gga	336
Leu Glu Glu Val Val Leu Val Ile His Asp Trp Gly Ser Ala Leu Gly	
100 105 110	
ttc cac tgg gcc aag cgc aat ccg gaa cgg gtc aaa ggt att gca tgt	384
Phe His Trp Ala Lys Arg Asn Pro Glu Arg Val Lys Gly Ile Ala Cys	
115 120 125	
atg gaa ttc atc ccg tct atc ccg acg tgg gac gaa tgg ccg gaa ttc	432
Met Glu Phe Ile Arg Ser Ile Pro Thr Trp Asp Glu Trp Pro Glu Phe	
130 135 140	
gcc cgt gag acc ttc cag gcc ttc ccg acc gcc gac gtc ggc cga gag	480
Ala Arg Glu Thr Phe Gln Ala Phe Arg Thr Ala Asp Val Gly Arg Glu	
145 150 155 160	
ttg atc atc gat cag aac gct ttc atc gag cat gtg ctc ccg aaa tac	528
Leu Ile Ile Asp Gln Asn Ala Phe Ile Glu His Val Leu Pro Lys Tyr	
165 170 175	
gtc gtc cgt ccg ctt acg gag gtc gag atg gac cac tat cgc gag ccc	576
Val Val Arg Pro Leu Thr Glu Val Glu Met Asp His Tyr Arg Glu Pro	
180 185 190	
ttc ctc aag cct gct gac cga gag cca ctg tgg cga ttc ccc aac gag	624
Phe Leu Lys Pro Ala Asp Arg Glu Pro Leu Trp Arg Phe Pro Asn Glu	
195 200 205	
ctc ccc atc gcc ggt gag ccc gcg aac atc gtc gcg ctc gtc gag gca	672
Leu Pro Ile Ala Gly Glu Pro Ala Asn Ile Val Ala Leu Val Glu Ala	
210 215 220	
tac atg aac tgg ctg cac cag tca cct gtc ccg aag ttg ttg ttc tgg	720
Tyr Met Asn Trp Leu His Gln Ser Pro Val Pro Lys Leu Leu Phe Trp	
225 230 235 240	
ggc aca ccc ggc cta ctg atc ccc ccg gcc gaa gcc tcg aga ctt gcc	768
Gly Thr Pro Gly Leu Leu Ile Pro Pro Ala Glu Ala Ser Arg Leu Ala	
245 250 255	
gaa agc ctc ccc aac tgc aag aca gtg gac atc ggc ccg gga ctg cac	816
Glu Ser Leu Pro Asn Cys Lys Thr Val Asp Ile Gly Pro Gly Leu His	
260 265 270	


```

ttc ctc cag gaa gac aac ccg gac ctt atc ggc agt gag atc gcg cgc 864
Phe Leu Gln Glu Asp Asn Pro Asp Leu Ile Gly Ser Glu Ile Ala Arg
      275                      280                      285

tgg ctc gcc gga ctc gcg agc ggc ctc ggc gac tac cat cat cat cat 912
Trp Leu Ala Gly Leu Ala Ser Gly Leu Gly Asp Tyr His His His His
      290                      295                      300

cat cat taa 921
His His
305

```

```

<210> 44
<211> 306
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence:Artificially
      modified (mutated) Dehalogenase

```

```

<400> 44
Met Ser Glu Ile Gly Thr Gly Phe Pro Phe Asp Pro His Tyr Val Glu
  1      5      10      15
Val Leu Gly Glu Arg Met His Tyr Val Asp Val Gly Pro Arg Asp Gly
      20      25      30
Thr Pro Val Leu Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp
      35      40      45
Arg Asn Ile Ile Pro His Val Ala Pro Ser His Arg Cys Ile Ala Pro
      50      55      60
Asp Leu Ile Gly Met Gly Lys Ser Asp Lys Pro Asp Leu Gly Tyr Phe
      65      70      75      80
Phe Asp Asp His Val Arg Tyr Leu Asp Ala Phe Ile Glu Ala Leu Gly
      85      90      95
Leu Glu Glu Val Val Leu Val Ile His Asp Trp Gly Ser Ala Leu Gly
      100     105     110
Phe His Trp Ala Lys Arg Asn Pro Glu Arg Val Lys Gly Ile Ala Cys
      115     120     125
Met Glu Phe Ile Arg Ser Ile Pro Thr Trp Asp Glu Trp Pro Glu Phe
      130     135     140
Ala Arg Glu Thr Phe Gln Ala Phe Arg Thr Ala Asp Val Gly Arg Glu
      145     150     155     160
Leu Ile Ile Asp Gln Asn Ala Phe Ile Glu His Val Leu Pro Lys Tyr
      165     170     175
Val Val Arg Pro Leu Thr Glu Val Glu Met Asp His Tyr Arg Glu Pro
      180     185     190
Phe Leu Lys Pro Ala Asp Arg Glu Pro Leu Trp Arg Phe Pro Asn Glu
      195     200     205
Leu Pro Ile Ala Gly Glu Pro Ala Asn Ile Val Ala Leu Val Glu Ala
      210     215     220
Tyr Met Asn Trp Leu His Gln Ser Pro Val Pro Lys Leu Leu Phe Trp
      225     230     235     240
Gly Thr Pro Gly Leu Leu Ile Pro Pro Ala Glu Ala Ser Arg Leu Ala
      245     250     255
Glu Ser Leu Pro Asn Cys Lys Thr Val Asp Ile Gly Pro Gly Leu His
      260     265     270
Phe Leu Gln Glu Asp Asn Pro Asp Leu Ile Gly Ser Glu Ile Ala Arg
      275     280     285
Trp Leu Ala Gly Leu Ala Ser Gly Leu Gly Asp Tyr His His His His
      290     295     300
His His
305

```

```

<210> 45

```

<211> 882

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Artificially modified (mutated) Dehalogenase

<220>

<221> CDS

<222> (1)..(882)

<400> 45

atg agc gaa gaa gcg atc tcg gcc ctc gac ccg cat cca cgc aag aaa	48
Met Ser Glu Glu Ala Ile Ser Ala Leu Asp Pro His Pro Arg Lys Lys	
1 5 10 15	
cag gaa ctg ctc ggc acc tcg atg tct tat gtc gat acc ggg act ggc	96
Gln Glu Leu Leu Gly Thr Ser Met Ser Tyr Val Asp Thr Gly Thr Gly	
20 25 30	
gag ccg gtg gtg ttc ctg cac ggc aat cca acc tcc tcg tac ttg tgg	144
Glu Pro Val Val Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp	
35 40 45	
cgg aac gtg att cca cat gtc gcg ccg gtc gcc agg tgc atc gct ccc	192
Arg Asn Val Ile Pro His Val Ala Pro Val Ala Arg Cys Ile Ala Pro	
50 55 60	
gac ctg atc ggg atg gga gcg tca ggg cct tcc tct agc ggc aac tac	240
Asp Leu Ile Gly Met Gly Ala Ser Gly Pro Ser Ser Ser Gly Asn Tyr	
65 70 75 80	
acg ttc gcc gat cat gcg cga cat ctc gat gcg ctc ctc gac gcg att	288
Thr Phe Ala Asp His Ala Arg His Leu Asp Ala Leu Leu Asp Ala Ile	
85 90 95	
ttg cca aag ggc cag ctc agc ttg gtg gtg cac gac tgg gga tcg gcg	336
Leu Pro Lys Gly Gln Leu Ser Leu Val Val His Asp Trp Gly Ser Ala	
100 105 110	
ctg ggc ttc cac tgg gcc aat cgc aat cgg gat cgg gta agg gga atc	384
Leu Gly Phe His Trp Ala Asn Arg Asn Arg Asp Arg Val Arg Gly Ile	
115 120 125	
gcc tac atg gaa gcg att gtg cga ccg gtg ctg tgg tcg gag tgg ccc	432
Ala Tyr Met Glu Ala Ile Val Arg Pro Val Leu Trp Ser Glu Trp Pro	
130 135 140	
gaa cgt gcc cga gac att ttc aag acg ctg cga act ccg gcc ggc gaa	480
Glu Arg Ala Arg Asp Ile Phe Lys Thr Leu Arg Thr Pro Ala Gly Glu	
145 150 155 160	
gag atg att ctc aaa aac aac gta ttc gtg gag cgg atc ctg ccc ggc	528
Glu Met Ile Leu Lys Asn Asn Val Phe Val Glu Arg Ile Leu Pro Gly	
165 170 175	
agc gtc ttg cgc aaa ttg agc tcc gaa gaa atg gac aat tat cgc cgg	576
Ser Val Leu Arg Lys Leu Ser Ser Glu Glu Met Asp Asn Tyr Arg Arg	
180 185 190	
ccc ttt cgc gac gca gga gaa tcg cgg cgg cca aca ctc acg tgg ccg	624
Pro Phe Arg Asp Ala Gly Glu Ser Arg Arg Pro Thr Leu Thr Trp Pro	
195 200 205	

```

cgt cag att ccg atc gag ggt gag ccg gcc gac gtg gtg gaa atc gtg 672
Arg Gln Ile Pro Ile Glu Gly Glu Pro Ala Asp Val Val Glu Ile Val
210 215 220

cag aaa tat tcc gag tgg ctg gca cag agc gcg gtg ccc aaa ctg ctc 720
Gln Lys Tyr Ser Glu Trp Leu Ala Gln Ser Ala Val Pro Lys Leu Leu
225 230 235

gtg aat gcg gag ccg gga gcg att ttg ata ggc gcg cag cgc gag ttt 768
Val Asn Ala Glu Pro Gly Ala Ile Leu Ile Gly Ala Gln Arg Glu Phe
245 250 255

tgc cac caa tgg ccg aat cag cgc gaa gtc acg gtc aag ggc gta cac 816
Cys His Gln Trp Pro Asn Gln Arg Glu Val Thr Val Lys Gly Val His
260 265 270

ttc atc cag gaa gat tcc ccg cac gag atc ggg cga gcg atc gca gac 864
Phe Ile Gln Glu Asp Ser Pro His Glu Ile Gly Arg Ala Ile Ala Asp
275 280 285

tgg tac cga gga atc tga 882
Trp Tyr Arg Gly Ile
290

```

<210> 46

<211> 293

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:Artificially
modified (mutated) Dehalogenase

<400> 46

```

Met Ser Glu Glu Ala Ile Ser Ala Leu Asp Pro His Pro Arg Lys Lys
1 5 10
Gln Glu Leu Leu Gly Thr Ser Met Ser Tyr Val Asp Thr Gly Thr Gly
20 25 30
Glu Pro Val Val Phe Leu His Gly Asn Pro Thr Ser Ser Tyr Leu Trp
35 40 45
Arg Asn Val Ile Pro His Val Ala Pro Val Ala Arg Cys Ile Ala Pro
50 55 60
Asp Leu Ile Gly Met Gly Ala Ser Gly Pro Ser Ser Ser Gly Asn Tyr
65 70 75 80
Thr Phe Ala Asp His Ala Arg His Leu Asp Ala Leu Leu Asp Ala Ile
85 90 95
Leu Pro Lys Gly Gln Leu Ser Leu Val Val His Asp Trp Gly Ser Ala
100 105 110
Leu Gly Phe His Trp Ala Asn Arg Asn Arg Asp Arg Val Arg Gly Ile
115 120 125
Ala Tyr Met Glu Ala Ile Val Arg Pro Val Leu Trp Ser Glu Trp Pro
130 135 140
Glu Arg Ala Arg Asp Ile Phe Lys Thr Leu Arg Thr Pro Ala Gly Glu
145 150 155 160
Glu Met Ile Leu Lys Asn Asn Val Phe Val Glu Arg Ile Leu Pro Gly
165 170 175
Ser Val Leu Arg Lys Leu Ser Ser Glu Met Asp Asn Tyr Arg Arg
180 185 190
Pro Phe Arg Asp Ala Gly Glu Ser Arg Arg Pro Thr Leu Thr Trp Pro
195 200 205
Arg Gln Ile Pro Ile Glu Gly Glu Pro Ala Asp Val Val Glu Ile Val
210 215 220
Gln Lys Tyr Ser Glu Trp Leu Ala Gln Ser Ala Val Pro Lys Leu Leu
225 230 235 240
Val Asn Ala Glu Pro Gly Ala Ile Leu Ile Gly Ala Gln Arg Glu Phe
245 250 255

```

Cys His Gln Trp Pro Asn Gln Arg Glu Val Thr Val Lys Gly Val His
 260 265 270
 Phe Ile Gln Glu Asp Ser Pro His Glu Ile Gly Arg Ala Ile Ala Asp
 275 280 285
 Trp Tyr Arg Gly Ile
 290

<210> 47

<211> 1032

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Artificially
 modified (mutated) Dehalogenase

<220>

<221> CDS

<222> (1)..(1032)

<400> 47

atg gct act act gga gaa gcg ata tct tct gca ttt ccg tac gag aag	48
Met Ala Thr Thr Gly Glu Ala Ile Ser Ser Ala Phe Pro Tyr Glu Lys	
1 5 10 15	
cag cgc cgg cgg gtt ctg ggg aga gag atg gcc tat gtg gaa gtg ggg	96
Gln Arg Arg Arg Val Leu Gly Arg Glu Met Ala Tyr Val Glu Val Gly	
20 25 30	
gcc ggc gac ccg atc gtg ctg ctg cac ggc aat ccg acc tca tcc tac	144
Ala Gly Asp Pro Ile Val Leu His Gly Asn Pro Thr Ser Ser Tyr	
35 40 45	
ctc tgg cgc aat gtc ctg ccg cat ctc caa cta cga ggc cga tgc atc	192
Leu Trp Arg Asn Val Leu Pro His Leu Gln Leu Arg Gly Arg Cys Ile	
50 55 60	
gcg ccc gac ctg att ggc atg ggc gac tcc gat aag cta cct gac agc	240
Ala Pro Asp Leu Ile Gly Met Gly Asp Ser Asp Lys Leu Pro Asp Ser	
65 70 75 80	
ggc ccg agc tcg tat cgc ttc gta gat cag cgc cgc tac ctc gat gcg	288
Gly Pro Ser Ser Tyr Arg Phe Val Asp Gln Arg Arg Tyr Leu Asp Ala	
85 90 95	
ctg ctg gag gca ttg gac gta cgt gag cgt gtg acg ctc gtc att cat	336
Leu Leu Glu Ala Leu Asp Val Arg Glu Arg Val Thr Leu Val Ile His	
100 105 110	
gac tgg ggc tcg gga ctt ggc ttt gac tgg gcc aac cga cac cgc gac	384
Asp Trp Gly Ser Gly Leu Gly Phe Asp Trp Ala Asn Arg His Arg Asp	
115 120 125	
gcc gta aag ggc atc gca tac atg gag gcg atc gtg cgc ccg cag gga	432
Ala Val Lys Gly Ile Ala Tyr Met Glu Ala Ile Val Arg Pro Gln Gly	
130 135 140	
tgg gac cac tgg gac gta atg aat atg cgt cca ttc cta gag gcg ctg	480
Trp Asp His Trp Asp Val Met Asn Met Arg Pro Phe Leu Glu Ala Leu	
145 150 155 160	
cgt tcc gag gcc ggc gag aag atg gtc ctt gaa gac aac ttt ttc atc	528
Arg Ser Glu Ala Gly Glu Lys Met Val Leu Glu Asp Asn Phe Phe Ile	

52

165										170										175										
gag aag att tta cca ggc gct gtt ctc cgc aag ctc acc gcg gat gaa	576																													
Glu Lys Ile Leu Pro Gly Ala Val Leu Arg Lys Leu Thr Ala Asp Glu																														
180	185	190																												
atg gcg gag tat cgt cgg ccg ttc gct gaa ccc ggc gag gcg cga cga	624																													
Met Ala Glu Tyr Arg Arg Pro Phe Ala Glu Pro Gly Glu Ala Arg Arg																														
195	200	205																												
ccg act ctg act tgg cca cgg gag att cct atc gat ggc aaa ccc gcc	672																													
Pro Thr Leu Thr Trp Pro Arg Glu Ile Pro Ile Asp Gly Lys Pro Ala																														
210	215	220																												
gac gtg aat acg att gtg gcg gcc tat tcg gag tgg ctt gcg acg agc	720																													
Asp Val Asn Thr Ile Val Ala Ala Tyr Ser Glu Trp Leu Ala Thr Ser																														
225	230	235	240																											
gat gtg ccc aag cta ttc ata aaa gcc gag ccc ggc gca ctc ctt ggc	768																													
Asp Val Pro Lys Leu Phe Ile Lys Ala Glu Pro Gly Ala Leu Leu Gly																														
245	250	255																												
agc ggg att aac ctt gaa acc gct cgc tcc tgg cct gcg cag acg gaa	816																													
Ser Gly Ile Asn Leu Glu Thr Ala Arg Ser Trp Pro Ala Gln Thr Glu																														
260	265	270																												
gta acc gtg gcc gga gtt cat ttt gtg caa gag gat tcg cca gat gag	864																													
Val Thr Val Ala Gly Val His Phe Val Gln Glu Asp Ser Pro Asp Glu																														
275	280	285																												
att ggg cgc tcg gat tct ggc gac cct tgg ccc gct ggc gga cga aat	912																													
Ile Gly Arg Ser Asp Ser Gly Asp Pro Trp Pro Ala Gly Gly Arg Asn																														
290	295	300																												
cgc cgt cta ctc gcc ccg tct ggc gca gca tct cga tca cta cag tcc	960																													
Arg Arg Leu Leu Ala Pro Ser Gly Ala Ala Ser Arg Ser Leu Gln Ser																														
305	310	315	320																											
gtt cgc gct cag ctt cgc act gcc ctg caa tac ccc cgg cct gcg gtt	1008																													
Val Arg Ala Gln Leu Arg Thr Ala Leu Gln Tyr Pro Arg Pro Ala Val																														
325	330	335																												
cct gtg ccg cga cag ctt cga tga	1032																													
Pro Val Pro Arg Gln Leu Arg																														
340																														

<210> 48

<211> 343

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:Artificially
modified (mutated) Dehalogenase

<400> 48

Met Ala Thr Thr Gly Glu Ala Ile Ser Ser Ala Phe Pro Tyr Glu Lys	
1 5 10 15	
Gln Arg Arg Arg Val Leu Gly Arg Glu Met Ala Tyr Val Glu Val Gly	
20 25 30	
Ala Gly Asp Pro Ile Val Leu Leu His Gly Asn Pro Thr Ser Ser Tyr	
35 40 45	
Leu Trp Arg Asn Val Leu Pro His Leu Gln Leu Arg Gly Arg Cys Ile	
50 55 60	
Ala Pro Asp Leu Ile Gly Met Gly Asp Ser Asp Lys Leu Pro Asp Ser	
65 70 75 80	

